

**Funding Opportunities Monthly Edition  
June 2024 Due Dates**

## Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in June 2024. The opportunities are organized in the following order:

1. [National Institutes of Health \(NIH\)](#)
2. [National Science Foundation \(NSF\)](#)
3. [Other Federal](#)
4. [Non Federal](#)

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

109720	<a href="#">International Bioethics Research Training Program (D43 Clinical Trial Optional)</a>	Fogarty International Center/NIH/DHHS	PAR-22-116	06-Jun-2024	1,150,000 USD
--------	---	---------------------------------------	------------	-------------	---------------

Contact Name	Barbara Sina, Ph.D.
Contact Telephone	301-402-9467
Contact Email	<a href="mailto:sinab@mail.nih.gov">sinab@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	06-Jun-2024
Synopsis	The overall goal of this initiative is to support the mentored training of a sustainable critical mass of bioethics scholars in low and middle-income country (LMIC) research intensive institutions with the capabilities to conduct original empirical or conceptual ethics research that addresses challenging issues in health research and research policy in these countries as well as provide research ethics leadership to their institutions, governments and international research organizations. FIC will support LMIC-U.S. collaborative institutional bioethics doctoral and postdoctoral research training programs that incorporate mentored research, advanced theoretical didactic courses and ethics career skills training components to prepare multiple individuals for positions of ethics scholarship and leadership in health research institutions in LMICs. This Funding Opportunity Announcement (FOA) allows appointment of Trainees (D43) proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

110400	<a href="#">Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-136	17-Jun-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Mark Damico, Ph.D.
Contact Telephone	240-276-5639
Contact Email	<a href="mailto:damicomw@mail.nih.gov">damicomw@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	17-Jun-2024
Synopsis	The purpose of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
106440	<a href="#">Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-21-334	11-Jun-2024	3,000,000 USD

clinician-scientists (M.D.s, D.O.s, Pharm.D.s, nurses with Ph.D.s, or equivalent) trained in clinical and translational cancer research, and to promote their career development as cancer researchers. This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

Contact Name | Sudhir Srivastava, Ph.D., M.P.H.  
 Contact Telephone | 240-276-7028  
 Contact Email | [srivasts@mail.nih.gov](mailto:srivasts@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 11-Jun-2024

Synopsis | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) is soliciting applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify those patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the NCI's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma (PDAC). The PCDC will support research for the development and testing of new molecular and imaging biomarkers for detecting PDAC early and for identifying those patients at high risk of PDAC (because of genetic factors or presence of precursor lesions) who could be candidates for early intervention. The PCDC-RUs will consist of multi-disciplinary teams and will undertake studies to: identify and test biomarkers measurable in bodily fluids for early detection of PDAC and/or its precursor lesions; develop molecular- and/or imaging-based markers of pancreatic cysts and determine which ones are likely to progress to cancer; develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC; use machine learning and computational approaches towards biomarker discovery and/or validation; and conduct biomarker validation studies. The PCDC-RUs will also collect longitudinal biospecimens for building a biorepository. Each PCDC-RU is expected to participate in collaborative activities with other PCDC-RUs and share ideas, biospecimens, and data within the Consortium. The other scientific component of the PCDC will be the Management and Data Coordination Unit (MDCU; see companion PAR-21-335). The PCDC-MDCU will provide support toward study design, protocol development, statistical analysis, coordination, harmonization, data management and stewardship for the trans-PCDC collaborative projects, including biorepository building effort. The PCDC-MDCU will also support the coordination and organization of Consortium-



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, interventions, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical).			
122289	<a href="#">Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-24-039	18-Jun-2024	275,000 USD
	Contact Name	Laritza M. Rodriguez, M.D., Ph.D.			
	Contact Telephone	240-477-9376			
	Contact Email	<a href="mailto:laritza.rodriguez@nih.gov">laritza.rodriguez@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	18-Jun-2024 , 19-Nov-2024 , 17-Jun-2025 , 18-Nov-2025 , 15-Jun-2026 , 17-Nov-2026			
	Synopsis	This notice of funding opportunity (NOFO) is a continuation of an NCI program to enhance the diversity of the pool of the cancer research workforce by recruiting and supporting eligible New Investigators and Early Stage Investigators from diverse backgrounds, including from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, clinical and social sciences. This NOFO will fund investigators to develop a larger research project grant application.			
117092	<a href="#">RFA-CA-23-028 -- Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-23-028	14-May-2024 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Altaf Mohammed, PhD			
	Contact Telephone	240-276-6082			
	Contact Email	<a href="mailto:wynne.norton@nih.gov">wynne.norton@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	14-May-2024 [Optional][LOI/Pre-App], 13-Jun-2024 , 13-Jun-2025 , 14-Jun-2025 [Optional][LOI/Pre-App]			
	Synopsis	Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support the discovery and development of novel natural products that are safe, non-toxic, and efficacious for cancer interception and prevention. The UG3 phase will provide up to three years of support for milestone-driven initial target selection, verification of the target in clinical samples and preclinical in vivo studies, assay development, and/or assay validation for target activity, as well as on-			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					target toxicity screening, and pilot screening of natural agents. If UG3 milestones are met, support may be provided for a full-scale screening, identification of active natural compounds, full-scale evaluation of screened individual agents, assessment of the natural product's effect in vitro and in vivo, and determining the optimal dose for subsequent studies and safety testing in the UH3 phase.
123579	<a href="#">Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-24-122	05-Jun-2024	1,250,000 USD
	Contact Name	Scott Rogers, MPH			
	Contact Telephone	240-276-6932			
	Contact Email	<a href="mailto:rogerssc@mail.nih.gov">rogerssc@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024			
	Synopsis	This notice of funding opportunity (NOFO) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, digital health and data science, and implementation science.			
123027	<a href="#">RFA-CA-24-016 -- Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-24-016	12-May-2024 [Optional][LOI/Pre-App]	275,000 USD
	Contact Name	Juli Klemm, Ph.D.			
	Contact Telephone	202-853-7889			
	Contact Email	<a href="mailto:juli.klemm@nih.gov">juli.klemm@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	12-May-2024 [Optional][LOI/Pre-App], 11-Jun-2024 , 16-Oct-2024 [Optional][LOI/Pre-App], 15-Nov-2024			
	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to invite exploratory/developmental research grant applications (R21) for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, the emphasis of this NOFO is on supporting the development of novel informatics capabilities that involve a high degree of innovation that have the potential to accelerate or enhance research. To be successful, there must be a clear rationale for how the proposed informatics method or algorithm is novel and how it will benefit the cancer research field. Projects with a significant level of data generation and/or data analysis will not be considered responsive to this funding opportunity.

123030	<a href="#">RFA-CA-24-017 -- Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-24-017	12-May-2024 [Optional][LOI/Pre-App]	900,000 USD
--------	---	------------------------------------	---------------	-------------------------------------	-------------

Contact Name	Juli Klemm, Ph.D.
Contact Telephone	202-853-7889
Contact Email	<a href="mailto:juli.klemm@nih.gov">juli.klemm@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	12-May-2024 [Optional][LOI/Pre-App], 11-Jun-2024 , 16-Oct-2024 [Optional][LOI/Pre-App], 15-Nov-2024
Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this NOFO focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this NOFO as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.

123041	<a href="#">RFA-CA-24-019 -- Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-24-019	12-May-2024 [Optional][LOI/Pre-App]	Not Specified
--------	--	------------------------------------	---------------	-------------------------------------	---------------

Contact Name	Juli Klemm, Ph.D.
Contact Telephone	202-853-7889



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:juli.klemm@nih.gov">juli.klemm@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 12-May-2024 [Optional][LOI/Pre-App], 11-Jun-2024 , 16-Oct-2024 [Optional][LOI/Pre-App], 15-Nov-2024</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this NOFO focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR NOFOs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justification for why the research resource should be maintained and how it has benefited and will continue to benefit the cancer research field. In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and deep engagement between the resource and the targeted research community should be described.</p>				
123034	<a href="#">RFA-CA-24-018 -- Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-24-018	12-May-2024 [Optional][LOI/Pre-App]	3,000,000 USD
	<p>Contact Name Juli Klemm, Ph.D.</p> <p>Contact Telephone 202-853-7889</p> <p>Contact Email <a href="mailto:juli.klemm@nih.gov">juli.klemm@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 12-May-2024 [Optional][LOI/Pre-App], 11-Jun-2024 , 16-Oct-2024 [Optional][LOI/Pre-App], 15-Nov-2024</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this NOFO focuses</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	<p>on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. To be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult the companion NOFOs listed above.</p>																		
107027	<a href="#">Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-22-049	07-Jun-2024	1,250,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Abhi Rao, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-276-5715</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:abhi.rao@nih.gov">abhi.rao@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-Jun-2024 , 13-Sep-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td> <p>This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as “liquid biopsies, or other biospecimens as described in this FOA. Extramural research funded under this FOA may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for liquid biopsies, tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.</p> </td> </tr> </table>					Contact Name	Abhi Rao, Ph.D.	Contact Telephone	240-276-5715	Contact Email	<a href="mailto:abhi.rao@nih.gov">abhi.rao@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	07-Jun-2024 , 13-Sep-2024	Synopsis	<p>This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as “liquid biopsies, or other biospecimens as described in this FOA. Extramural research funded under this FOA may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for liquid biopsies, tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.</p>
Contact Name	Abhi Rao, Ph.D.																		
Contact Telephone	240-276-5715																		
Contact Email	<a href="mailto:abhi.rao@nih.gov">abhi.rao@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	07-Jun-2024 , 13-Sep-2024																		
Synopsis	<p>This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as “liquid biopsies, or other biospecimens as described in this FOA. Extramural research funded under this FOA may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for liquid biopsies, tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.</p>																		
108548	<a href="#">Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-22-083	05-Jun-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Tram Kim Lam, Ph.D., MPH</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-276-6967</td> </tr> </table>					Contact Name	Tram Kim Lam, Ph.D., MPH	Contact Telephone	240-276-6967										
Contact Name	Tram Kim Lam, Ph.D., MPH																		
Contact Telephone	240-276-6967																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:Tram.Lam@nih.gov">Tram.Lam@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.</p>				
108551	<a href="#">Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-099	05-Jun-2024	2,000,000 USD
	<p>Contact Name Steven Becker, Ph.D.</p> <p>Contact Telephone 240-276-6210</p> <p>Contact Email <a href="mailto:steven.becker@nih.gov">steven.becker@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology in the context of a testable cancer research hypothesis. The projects supported by this FOA will collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program. The Cancer TEC Program will (1) catalyze the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, (2) expand the breadth of these systems to several cancer types, and (3) promote the exploration of cancer phenomena with biomimetic tissue-engineered systems.</p>				
107221	<a href="#">Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-22-061	05-Jun-2024	Not Specified
	<p>Contact Name Phillip J. Daschner, M.Sc.</p> <p>Contact Telephone 240-276-6227</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:PD93u@nih.gov">PD93u@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2024 , 05-Oct-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies. Applications should be focused on delineating how host interactions with specific microbes (or consortia) or their metabolites target immune responses that enhance or prevent inflammation-associated or sporadic tumor formation. Concentration, timing, and duration of administered beneficial microbes may alter its effectiveness and thus those parameters should be rigorously addressed in the application.</p>				
123053	<a href="#">National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)</a>	National Cancer Institute/NIH/DHHS	PAR-24-085	07-May-2024	2,499,995 USD
	<p>Contact Name Lori A. Henderson, Ph.D.</p> <p>Contact Telephone 240-276-5930</p> <p>Contact Email <a href="mailto:hendersonlori@mail.nih.gov">hendersonlori@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) is soliciting research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of DCTD and OHAM. The proposed project must involve at least 1 clinical trial related to the scientific interests of one or more of the following research programs: Cancer Therapy Evaluation Program, Cancer Imaging Program, Cancer Diagnosis Program, Radiation Research Program, Complementary and Alternative Medicine Program and/or the HIV and AIDS Malignancies Research Programs. Applicants may propose to conduct an early phase trial by itself, or in combination with another research aim(s) as appropriate. This NOFO does not accept Phase III clinical trials.</p>				
123051	<a href="#">Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)</a>	National Cancer Institute/NIH/DHHS	PAR-24-072	07-May-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Brandy Heckman-Stoddard, Ph.D., M.P.H.
Contact Telephone	240-276-7048
Contact Email	<a href="mailto:heckmanbm@mail.nih.gov">heckmanbm@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 05-Jan-2027
Synopsis	Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this NOFO must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this NOFO and the application instructions. This NOFO does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients.

111847	<a href="#">Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-164	05-Jun-2024	2,500,000 USD
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Kelly D. Blake, ScD
Contact Telephone	240-281-5934
Contact Email	<a href="mailto:kelly.blake@nih.gov">kelly.blake@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025
Synopsis	Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.
111859	<a href="#">Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-198	05-Jun-2024	Not Specified
	Contact Name	Michael Graham Espey, Ph.D.			
	Contact Telephone	240-276-5609			
	Contact Email	<a href="mailto:SP@nih.gov">SP@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025			
	Synopsis	Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits R01 research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.			
120897	<a href="#">Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-23-281	05-Jun-2024	2,495,000 USD
	Contact Name	Joanna Watson, Ph.D.			
	Contact Telephone	240-276-6206			
	Contact Email	<a href="mailto:Joanna.Watson@nih.gov">Joanna.Watson@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026			
	Synopsis	Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. The NCI, through this NOFO encourages submission of projects devoted to demonstrating that mammalian models, including organoids, tumoroids and cell models, used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patient benefit. These practical goals			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this NOFO could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.</p>			
120973	<a href="#">Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-23-279	05-Jun-2024	Not Specified
	Contact Name	Edward R. Sauter, MD, PhD			
	Contact Telephone	240-276-7657			
	Contact Email	<a href="mailto:edward.sauter@nih.gov">edward.sauter@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026			
	Synopsis	<p>Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer. Investigators wishing to study incretin mimetics other than GLP-1 RAs or GLP-1/GIP-1 RAs, such as dipeptidyl peptidase (DPP)-4 inhibitors, must justify why the agent(s) they propose to study are more effective and/or have a more favorable side effect profile than GLP-1 or GLP-1/GIP-1 RAs. Route of agent administration (oral vs. other) is, by itself, not an adequate justification.</p>			
109909	<a href="#">Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-22-139	05-Jun-2024	2,500,000 USD
	Contact Name	Michael Graham Espey, Ph.D.			
	Contact Telephone	240-276-7619			
	Contact Email	<a href="mailto:SP@nih.gov">SP@nih.gov</a>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to solicit R01 research projects utilizing state-of-the-art cancer biology methods and model systems to study effects of different types of radiation used in radionuclide-based therapeutics (e.g., radiopharmaceutical therapy) on normal tissue, tumor cells and the tumor microenvironment.			
120755	<a href="#">Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators (R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-23-264	05-Jun-2024	Not Specified
	Contact Name	Suzanne Forry, Ph.D.			
	Contact Telephone	240-276-5922			
	Contact Email	<a href="mailto:forryscs@mail.nih.gov">forryscs@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026			
	Synopsis	Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate research in discovery and development of novel, small molecules for cancer. Molecules discovered through this NOFO may be used to probe cancer biology, to validate cancer targets, or as the basis for optimized drugs. Stages of discovery research covered by this NOFO include: 1) development of the primary screen assay(s) and testing in an initial pilot screen; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.			
120756	<a href="#">Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)</a>	National Cancer Institute/NIH/DHHS	PAR-23-273	05-Jun-2024	Not Specified
	Contact Name	Rebecca Ferrer			
	Contact Telephone	240-276-6914			
	Contact Email	<a href="mailto:ferrerra@mail.nih.gov">ferrerra@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	<p>Synopsis</p>	<p>This Notice of Funding Opportunity (NOFO) will solicit mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. Expectancies are defined in this context as beliefs about future outcomes, including one's response to cancer or cancer treatment. Expectancies can be evoked by social, psychological, environmental, and systemic factors. Expectancy effects are the cognitive, behavioral, and biological outcomes caused by expectancies. Expectancy effects can be generated by expectancies held by patients, clinicians, family members, caregivers, and/or dyadic/social networks. Program is particularly interested in applications that enroll individuals and groups from populations historically underrepresented or excluded from biomedical and behavioral research.</p>			
--	-----------------	--	--	--	--

110471	<a href="#">Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-131	05-Jun-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Sudhir Srivastava, Ph.D., MPH</p> <p>240-276-7028</p> <p><a href="mailto:srivasts@mail.nih.gov">srivasts@mail.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</p> <p>This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that include imaging, biomarkers, digital pathomic and other -omic integration strategies for improving current approaches for the earliest detection of premetastatic aggressive cancer as well as identifying precancerous lesions that will subsequently demonstrate an aggressive phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions in a technology agnostic manner by improving sensitivity and specificity of applied tests. N-dimensional co-registered, cross-correlated imaging results integrated with multiplexed biomarker data and digital pathomics using analytic strategies such as artificial intelligence and virtual reality visualization for improving discovery are encouraged. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of lethal cancer versus non-lethal disease, (2) to minimize/better manage overdiagnosis and (3) to reduce false positives and false negatives.</p>
---	--

106546	<a href="#">Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and</a>	National Cancer	PAR-21-	05-Jun-2024	Not
--------	--	-----------------	---------	-------------	-----

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)</a>	Institute/NIH/DHHS	329		Specified
	<p>Contact Name   Kelly Filipski PhD, MPH</p> <p>Contact Telephone   240-276-6841</p> <p>Contact Email   <a href="mailto:Filipskikk@mail.nih.gov">Filipskikk@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2024 , 05-Oct-2024</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and/or clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on 1) mechanistic studies with translational endpoints; and/or 2) longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.</p>				
117334	<a href="#">Impacts of Climate Change Across the Cancer Control Continuum (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-23-153	05-Jun-2024	Not Specified
	<p>Contact Name   Curt DellaValle, Ph.D., MPH</p> <p>Contact Telephone   240-276-7225</p> <p>Contact Email   <a href="mailto:curt.dellavalle@nih.gov">curt.dellavalle@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026</p> <p>Synopsis   This notice of funding opportunity (NOFO) aims to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. This includes, but is not limited to, studies to improve knowledge of the impact of climate change related environmental effects on cancer risks, control and behaviors.</p>				
106356	<a href="#">NCI Transition Career Development Award to Promote Diversity (K22 Independent Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-21-301	12-Jun-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Mulualem E. Tilahun, D.V.M., Ph.D
Contact Telephone	240-276-7360
Contact Email	<a href="mailto:mulualem.tilahun@nih.gov">mulualem.tilahun@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	12-Jun-2024
Synopsis	The purpose of the NCI Transition Career Development Award to Promote Diversity (K22) is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. This Funding Opportunity Announcement (FOA) is a continuation of the NCI Transition Career Development Award to Promote Diversity (K22) to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This award will provide "protected time" through salary and research support for 3 years beginning at the time when the candidate starts a tenure-track faculty position. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or a separate ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-21-302).

106358	<a href="#">NCI Transition Career Development Award to Promote Diversity (K22 Clinical Trial Required)</a>	National Cancer Institute/NIH/DHHS	PAR-21-302	12-Jun-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Mulualem E. Tilahun, D.V.M., Ph.D
Contact Telephone	240-276-7360
Contact Email	<a href="mailto:mulualem.tilahun@nih.gov">mulualem.tilahun@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	12-Jun-2024
Synopsis	The purpose of the NCI Transition Career Development Award to Promote Diversity (K22) is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. This Funding Opportunity Announcement (FOA) is a continuation of the NCI Transition Career Development Award to Promote Diversity (K22) to enhance the diversity in the NCI-funded cancer

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
106354	<a href="#">NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Clinical Trial Required)</a>	National Cancer Institute/NIH/DHHS	PAR-21-299	12-Jun-2024	Not Specified

research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This award will provide "protected time" through salary and research support for 3 years beginning at the time when the candidate starts a tenure-track faculty position. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-21-301).

Contact Name  
Contact Telephone  
Contact Email  
Sponsor Website  
Program URL  
Deadline Dates (ALL)

Mulualem E. Tilahun, D.V.M., Ph.D  
240-276-7360  
[mulualem.tilahun@nih.gov](mailto:mulualem.tilahun@nih.gov)  
  
[Link to program URL](#)  
12-Jun-2024

Synopsis

The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree or a health professional doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This NCI-sponsored K08 award is specifically designed to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible clinical scientists from diverse backgrounds, including groups that have been shown to be nationally underrepresented in health-related sciences and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-21-300).

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
106355	<a href="#">NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 - Independent Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-21-300	12-Jun-2024	Not Specified
	<p>Contact Name   Mulualem E. Tilahun, D.V.M., Ph.D</p> <p>Contact Telephone   240-276-7360</p> <p>Contact Email   <a href="mailto:mulualem.tilahun@nih.gov">mulualem.tilahun@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Jun-2024</p> <p>Synopsis   The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree or a health professional doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This NCI-sponsored K08 award is specifically designed to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible clinical scientists from diverse backgrounds, including groups that have been shown to be nationally underrepresented in health-related sciences and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or a separate ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-21-299).</p>				
106228	<a href="#">NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-21-295	12-Jun-2024	Not Specified
	<p>Contact Name   Mulualem E. Tilahun, D.V.M., Ph.D</p> <p>Contact Telephone   240-276-7360</p> <p>Contact Email   <a href="mailto:mulualem.tilahun@nih.gov">mulualem.tilahun@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 12-Jun-2024 , 12-Oct-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or a separate ancillary clinical trial as lead investigator, should apply to the companion FOA.</p>				
106230	<a href="#">NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Clinical Trial Required)</a>	National Cancer Institute/NIH/DHHS	PAR-21-296	12-Jun-2024	Not Specified
	<p>Contact Name Mulualem E. Tilahun, D.V.M., Ph.D</p> <p>Contact Telephone 240-276-7360</p> <p>Contact Email <a href="mailto:mulualem.tilahun@nih.gov">mulualem.tilahun@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 12-Jun-2024 , 12-Oct-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA.</p>				
115286	<a href="#">Notice of Special Interest (NOSI): Career Development Opportunities for Research Within the Mission of the Division of Cancer Prevention at the National Cancer Institute</a>	National Cancer Institute/NIH/DHHS	NOT-CA-23-035	07-May-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Jessica Faupel-Badger</p> <p>Contact Telephone   240-276-7296</p> <p>Contact Email   <a href="mailto:Jessica.Faupel-Badger@nih.gov">Jessica.Faupel-Badger@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024</p> <p>Synopsis   This NOSI from the NCI expresses continued interest in receiving Career Development Award applications from early career scientists conducting research within the mission of the Division of Cancer Prevention.</p>				
106733	<a href="#">Notice of Special Interest (NOSI): Dietary Effects on Nutrient Sensing Pathways in Tumor Etiology and Prevention</a>	National Cancer Institute/NIH/DHHS	NOT-CA-21-121	07-May-2024	Not Specified
	<p>Contact Name   Phillip J. Daschner, MSc</p> <p>Contact Telephone   240-276-6227</p> <p>Contact Email   <a href="mailto:pd93u@nih.gov">pd93u@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 25-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   This Notice of Special Interest (NOSI) seeks to support new and ongoing basic research that provides a deeper understanding of the biology and molecular mechanisms that determine the outcome of key diet/nutrient/cell interactions during early tumor development. Specifically, studies that examine the tumor preventive or tumor-promoting effects of dietary modulation of nutrient sensor signaling pathways during early tumor formation (initiation and malignant progression from early lesions) in preclinical cell, organoid, and animal models, with the goal of identifying and testing potential molecular intervention targets.</p>				
106036	<a href="#">Notice of Special Interest (NOSI): Advancing the Development of Tumor Site-Activated Small Molecules</a>	National Cancer Institute/NIH/DHHS	NOT-CA-21-101	07-May-2024	Not Specified
	<p>Contact Name   Sharad K. Verma, PhD</p> <p>Contact Telephone   202-657-3694</p> <p>Contact Email   <a href="mailto:sharad.verma@nih.gov">sharad.verma@nih.gov</a></p> <p>Sponsor Website  </p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis This Notice of Special Interest (NOSI) seeks to highlight the interest of NCI’s Division of Cancer Treatment and Diagnosis (DCTD) to support investigation of the development of novel therapies for cancer-applied research encompassing chemistry and biology disciplines to support the discovery and testing of novel therapeutics offering improved safety and efficacy profiles for eventual translation to the clinic.</p>				
114550	<a href="#">NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-23-058	07-May-2024	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 20-Jun-2024 , 07-Sep-2024 , 17-Oct-2024 , 07-Jan-2025 , 24-Feb-2025 , 07-May-2025 , 20-Jun-2025 , 07-Sep-2025 , 17-Oct-2025 , 07-Jan-2026</p> <p>Synopsis This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.</p>				
122281	<a href="#">Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-23-313	10-Jun-2024	Not Specified
	<p>Contact Name Tracy G. Lively, Ph.D.</p> <p>Contact Telephone 240-276-5944</p> <p>Contact Email <a href="mailto:livelyt@mail.nih.gov">livelyt@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 10-Jun-2024 , 08-Oct-2024 , 14-Feb-2025 , 11-Jun-2025 , 15-Oct-2025 , 13-Feb-2026 , 10-Jun-2026 , 14-Oct-2026</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this NOFO supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this NOFO supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays. Investigators responding to this NOFO must address both UH2 and UH3 phases. Milestones to be accomplished in the UH2 phase for transition to the UH3 phase must be proposed by the investigators.

122288	<a href="#">Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-23-314	10-Jun-2024	750,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name	Tracy G. Lively, Ph.D.
Contact Telephone	240-276-5944
Contact Email	<a href="mailto:livelyt@mail.nih.gov">livelyt@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	10-Jun-2024 , 08-Oct-2024 , 14-Feb-2025 , 11-Jun-2025 , 15-Oct-2025 , 13-Feb-2026 , 10-Jun-2026 , 14-Oct-2026
Synopsis	Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multidisciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays.

112021	<a href="#">Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-174	07-May-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Brandy Heckman-Stoddard, Ph.D., M.P.H.
Contact Telephone	240-276-7048
Contact Email	<a href="mailto:heckmanbm@mail.nih.gov">heckmanbm@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 25-Jun-2024 , 07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025 , 25-Feb-2025 , 07-May-2025 , 25-Jun-2025
Synopsis	Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns this can include a pilot/feasibility clinical trial if necessary, improving trial design and rigor.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
112019	<a href="#">Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-173	07-May-2024	Not Specified
	<p>Contact Name   Brandy Heckman-Stoddard, Ph.D., M.P.H.</p> <p>Contact Telephone   240-276-7048</p> <p>Contact Email   <a href="mailto:heckmanbm@mail.nih.gov">heckmanbm@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 25-Jun-2024 , 07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025 , 25-Feb-2025 , 07-May-2025 , 25-Jun-2025</p> <p>Synopsis   Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns this can include a pilot/feasibility clinical trial if necessary, improving trial design and rigor.</p>				
123943	<a href="#">The NCI Transition Career Development Award (K22 - Independent Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-24-117	12-Jun-2024	450,000 USD
	<p>Contact Name   Sonia B. Jakowlew, Ph.D.</p> <p>Contact Telephone   240-276-5630</p> <p>Contact Email   <a href="mailto:jakowles@mail.nih.gov">jakowles@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Jun-2024 , 12-Oct-2024 , 12-Nov-2024 , 12-Feb-2025 , 12-Mar-2025 , 12-Jun-2025 , 12-Jul-2025 , 12-Oct-2025 , 12-Nov-2025 , 12-Feb-2026 , 12-Mar-2026 , 12-Jun-2026 , 12-Jul-2026 , 12-Oct-2026 , 12-Nov-2026 , 12-Feb-2027 , 12-Mar-2027</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position. This FOA is designed specifically for candidates proposing research in which leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial is optional and replaces both PAR-21-128 and PAR-21-111.			
112622	<a href="#">Biology of Bladder Cancer (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-219	16-Jun-2024	275,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Ron Johnson, Ph. D. 240-276-6250 <a href="mailto:rjohnso2@mail.nih.gov">rjohnso2@mail.nih.gov</a>  <a href="#">Link to program URL</a> 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 This Funding Opportunity Announcement (FOA) encourages applications that investigate the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression and malignancy of bladder cancer. Furthermore, our understanding of the biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and contribute to the future development of new interventions.			
106319	<a href="#">Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-21-330	11-Jun-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Claire Zhu, Ph.D. 240-276-7013 <a href="mailto:zhucla@mail.nih.gov">zhucla@mail.nih.gov</a>  <a href="#">Link to program URL</a> 11-Jun-2024 , 11-Oct-2024			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from both the screened and the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and other clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens and may include other resources; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research on non-cancer outcomes, especially those related to aging (e.g., Alzheimer's, depression, hip fracture, osteoporosis and rheumatoid arthritis) may also be supported. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.</p>				
109910	<a href="#">Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-22-140	16-Jun-2024	275,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Michael Graham Espey, Ph.D.</p> <p>240-276-7619</p> <p><a href="mailto:SP@nih.gov">SP@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to solicit R21 research projects utilizing state-of-the-art cancer biology methods and model systems to study effects of different types of radiation used in radionuclide-based therapeutics (e.g., radiopharmaceutical therapy) on normal tissue, tumor cells and the tumor microenvironment.</p>			
114679	<a href="#">Co-infection and Cancer (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-23-056	16-Jun-2024	275,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p>	<p>Tram Kim Lam, Ph.D., MPH</p> <p>240-276-6967</p> <p><a href="mailto:lamt@mail.nih.gov">lamt@mail.nih.gov</a></p> <p></p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.</p>				
121014	<a href="#">Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-23-280	16-Jun-2024	275,000 USD
	<p>Contact Name Edward R. Sauter, MD, PhD</p> <p>Contact Telephone 240-276-7657</p> <p>Contact Email <a href="mailto:edward.sauter@nih.gov">edward.sauter@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026</p> <p>Synopsis Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer.</p>				
111848	<a href="#">Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-165	16-Jun-2024	275,000 USD
	<p>Contact Name Kelly D. Blake, ScD</p> <p>Contact Telephone 240-281-5934</p> <p>Contact Email <a href="mailto:kelly.blake@nih.gov">kelly.blake@nih.gov</a></p> <p>Sponsor Website</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication pilot interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.</p>				
111860	<a href="#">Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-199	16-Jun-2024	275,000 USD
	<p>Contact Name Michael Graham Espey, Ph.D.</p> <p>Contact Telephone 240-276-5609</p> <p>Contact Email <a href="mailto:SP@nih.gov">SP@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits R21 research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.</p>				
122437	<a href="#">NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)</a>	National Cancer Institute/NIH/DHHS	PAR-23-288	14-Jun-2024	Not Specified
	<p>Contact Name Sergey Radaev, PhD</p> <p>Contact Telephone 240-276-5630</p> <p>Contact Email <a href="mailto:sradaev@mail.nih.gov">sradaev@mail.nih.gov</a></p> <p>Sponsor Website</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 14-Jun-2024 , 15-Oct-2024 , 14-Feb-2025 , 16-Jun-2025 , 14-Oct-2025 , 17-Feb-2026 , 15-Jun-2026 , 14-Oct-2026</p> <p>Synopsis The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-23-286). This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>				
122436	<p><a href="#">NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)</a></p>	National Cancer Institute/NIH/DHHS	PAR-23-287	14-Jun-2024	Not Specified
	<p>Contact Name Sergey Radaev, PhD</p> <p>Contact Telephone 240-276-5630</p> <p>Contact Email <a href="mailto:sradaev@mail.nih.gov">sradaev@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 14-Jun-2024 , 15-Oct-2024 , 14-Feb-2025 , 16-Jun-2025 , 14-Oct-2025 , 17-Feb-2026 , 15-Jun-2026 , 14-Oct-2026</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This notice of funding opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-23-286).</p>			
122435	<a href="#">NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-23-286	14-Jun-2024	Not Specified
	Contact Name	Sergey Radaev, PhD			
	Contact Telephone	240-276-5630			
	Contact Email	<a href="mailto:sradaev@mail.nih.gov">sradaev@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	14-Jun-2024 , 15-Oct-2024 , 14-Feb-2025 , 16-Jun-2025 , 14-Oct-2025 , 17-Feb-2026 , 15-Jun-2026 , 14-Oct-2026			
	Synopsis	<p>The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		investigator, should apply to the companion NOFOs (PAR-23-287 or PAR-23-288).			
108550	<a href="#">Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-22-084	16-Jun-2024	275,000 USD
	Contact Name	Tram Kim Lam, Ph.D., MPH			
	Contact Telephone	240-276-6967			
	Contact Email	<a href="mailto:Tram.Lam@nih.gov">Tram.Lam@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.			
108359	<a href="#">Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-091	16-Jun-2024	275,000 USD
	Contact Name	Miguel R. Ossandon, Ph.D.			
	Contact Telephone	240-276-5714			
	Contact Email	<a href="mailto:ossandom@mail.nih.gov">ossandom@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024			
	Synopsis	The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA			
110931	<a href="#">Notice of Special Interest (NOSI): Basic Mechanisms of Cannabis and</a>	National Cancer	NOT-CA-	07-May-2024	Not

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Cannabinoid Action in Cancer</a>	Institute/NIH/DHHS	22-085		Specified
	<p>Contact Name Ron Johnson, Ph.D.</p> <p>Contact Telephone 240-276-6250</p> <p>Contact Email <a href="mailto:rjohnso2@mail.nih.gov">rjohnso2@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 12-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 12-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 12-Oct-2026 , 16-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 12-Feb-2027 , 16-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to promote research in understanding the mechanisms by which cannabis and cannabinoids affect cancer biology, cancer interception, cancer treatment and resistance, and management of cancer symptoms.</p>				
115117	<a href="#">Notice of Special Interest (NOSI): Adaptive Biomaterials for Cancer Biology</a>	National Cancer Institute/NIH/DHHS	NOT-CA-23-030	07-May-2024	Not Specified
	<p>Contact Name Eric M. Johnson Chavarria, Ph.D.</p> <p>Contact Telephone 240-276-7416</p> <p>Contact Email <a href="mailto:eric.johnsonchavarria@nih.gov">eric.johnsonchavarria@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to promote research focused on the development, adaptation, or integration of innovative biomaterials for cancer biology. The applications of these new materials are expected to enable new insights into basic cancer research.</p>				
107222	<a href="#">Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-22-062	16-Jun-2024	275,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Phillip J. Daschner, M.Sc. 240-276-6227 <a href="mailto:PD93u@nih.gov">PD93u@nih.gov</a>  <a href="#">Link to program URL</a> 16-Jun-2024 , 16-Oct-2024 The purpose of this Funding Opportunity Announcement (FOA) is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies. Applications should be focused on delineating how host interactions with specific microbes (or consortia) or their metabolites target immune responses that enhance or prevent inflammation-associated or sporadic tumor formation. Concentration, timing, and duration of administered beneficial microbes may alter their effectiveness and thus those parameters should be rigorously addressed in the application.
--	---

117338	<a href="#">Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-23-152	16-Jun-2024	275,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Curt DellaValle, Ph.D., MPH 240-276-7225 <a href="mailto:curt.dellavalle@nih.gov">curt.dellavalle@nih.gov</a>  <a href="#">Link to program URL</a> 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 This Notice of Funding Opportunity (NOFO) aims to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. This includes, but is not limited to, studies to improve knowledge of the impact of climate change related environmental effects on cancer risks, control and behaviors.
--	--

117714	<a href="#">Notice of Special Interest (NOSI): RNA Modifications in Cancer Biology</a>	National Cancer Institute/NIH/DHHS	NOT-CA-23-060	07-May-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name Contact Telephone	Stefan Maas, Ph.D. 240-276-6230
-----------------------------------	------------------------------------

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:stefan.maas@nih.gov">stefan.maas@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis Through this Notice of Scientific Interest (NOSI), the National Cancer Institute intends to stimulate research on the role of RNA modifications in the area of cancer biology. Despite the recognition that RNA modifications and editing exert a substantial impact on gene expression and function, there is a lack of mechanistic insights into the dynamic regulation of RNA modifications and their de-regulation as drivers of cancer formation. A better understanding of the extent, diversity, and crosstalk between different types of RNA modification, and the elucidation of the molecular players that read and interpret the modification code are needed to reveal the mechanisms of RNA modifications that underlie cancer formation and the cancer phenotype.</p>				
114360	<a href="#">Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)</a>	National Cancer Institute/NIH/DHHS	PAR-22-256	14-Jun-2024	Not Specified
	<p>Contact Name Wynne E. Norton, PhD</p> <p>Contact Telephone 240-276-6875</p> <p>Contact Email <a href="mailto:wynne.norton@nih.gov">wynne.norton@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 14-Jun-2024 , 17-Oct-2024 , 14-Feb-2025 , 14-Jun-2025 , 17-Oct-2025</p> <p>Synopsis Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) intends to accelerate the development of evidence-based cancer-related interventions that reflect the diversity of people, places, contexts, and settings in the United States. Specifically, this FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design. This FOA will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support refining the cancer-related intervention and finalizing study-related activities in preparation for conducting the pragmatic trial during the UH3 phase.</p>				
103024	<a href="#">Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-21-206	05-Jun-2024	2,495,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Miguel Ossandon MS 240-276-5714 <a href="mailto:ossandom@mail.nih.gov">ossandom@mail.nih.gov</a>  <a href="#">Link to program URL</a> 05-Jun-2024  Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines "innovation" as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. This FOA is not intended to support straight clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA. This FOA does not propose to support commercial production or basic research projects.
--	---

114678	<a href="#">Co-infection and Cancer (R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-23-055	05-Jun-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website	Tram Kim Lam, Ph.D., MPH 240-276-6967 <a href="mailto:lamt@mail.nih.gov">lamt@mail.nih.gov</a>  
---	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.</p>				
112619	<a href="#">Biology of Bladder Cancer (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-218	05-Jun-2024	Not Specified
	<p>Contact Name Ron Johnson, Ph. D.</p> <p>Contact Telephone 240-276-6250</p> <p>Contact Email <a href="mailto:rjohnso2@mail.nih.gov">rjohnso2@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications that investigate the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression and malignancy of bladder cancer. Furthermore, our understanding of the biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and contribute to the future development of new interventions.</p>				
106261	<a href="#">Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-21-322	05-Jun-2024	Not Specified
	<p>Contact Name Anu Sharman, Ph.D.</p> <p>Contact Telephone 240-276-6250</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:sharmananu@nih.gov">sharmananu@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2024 , 05-Jul-2024</p> <p>Synopsis National Cancer Institute (NCI) invites applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
106282	<a href="#">Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-21-331	05-Jun-2024	2,500,000 USD
	<p>Contact Name Edward R. Sauter, M.D., Ph.D.</p> <p>Contact Telephone 240-276-7657</p> <p>Contact Email <a href="mailto:edward.sauter@nih.gov">edward.sauter@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2024 , 05-Jul-2024</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter term outcomes such as weight loss and diabetes.</p>				
105645	<a href="#">Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-21-290	07-May-2024	499,999 USD
	<p>Contact Name Shane Woodward</p> <p>Contact Telephone 240-276-6624</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:woodwars@mail.nih.gov">woodwars@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 05-Jul-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025</p> <p>Synopsis National Cancer Institute (NCI) invites applications for research projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
107760	<a href="#">Notice of Special Interest (NOSI): Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment</a>	National Cancer Institute/NIH/DHHS	NOT-CA-22-014	07-May-2024	Not Specified
	<p>Contact Name Sallie J. Weaver, PhD, MHS</p> <p>Contact Telephone 240-276-6254</p> <p>Contact Email <a href="mailto:sallie.weaver@nih.gov">sallie.weaver@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 25-Sep-2024 , 05-Oct-2024 , 08-Oct-2024</p> <p>Synopsis This Notice of Special Interest (NOSI) highlights the NCI Healthcare Delivery Research Program's interest in receiving applications focused on understanding and improving interprofessional teamwork and coordination during cancer diagnosis and treatment.</p>				
113232	<a href="#">Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-22-242	07-May-2024	Not Specified
	<p>Contact Name Rao Divi, Ph.D.</p> <p>Contact Telephone 240-276-6913</p> <p>Contact Email <a href="mailto:divir@mail.nih.gov">divir@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 05-Jul-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 05-Mar-</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p>	<p>2025 , 07-May-2025 , 05-Jun-2025 , 05-Jul-2025 , 07-Sep-2025</p> <p>The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) develop, integrate, optimize, validate, translate or accelerate adoption of promising tools, methods and techniques: a) that fulfill an unmet need and address specific research or clinical problem in basic, translational, and/or clinical science and practice, b) capable of enhancing our understanding of health and disease, and/or c) improve practice of medicine. Applications may propose design-directed, developmental, discovery-driven, or hypothesis-driven research, and this FOA is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.</p>			
113233	<a href="#">Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-243	07-May-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Rao Divi, Ph.D.</p> <p>240-276-6913</p> <p><a href="mailto:divir@mail.nih.gov">divir@mail.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-May-2024 , 05-Jun-2024 , 05-Jul-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 05-Mar-2025 , 07-May-2025 , 05-Jun-2025 , 05-Jul-2025 , 07-Sep-2025</p> <p>The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods, and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical, or translational science. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. This FOA is not intended to support conventional clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of research are not sought by and will not be supported through this FOA. This FOA does not propose to support commercial production.</p>			
108323	<a href="#">Notice of Special Interest (NOSI): Disparities Affecting Healthcare Utilization and Health Outcomes Among Childhood Cancer Survivors</a>	National Cancer Institute/NIH/DHHS	NOT-CA-22-029	07-May-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Veronica Chollette, RN, MS</p> <p>Contact Telephone   240-276-6969</p> <p>Contact Email   <a href="mailto:cholletv@mail.nih.gov">cholletv@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 25-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 25-Sep-2024 , 08-Oct-2024</p> <p>Synopsis   The purpose of this Notice is to highlight the interest of the National Cancer Institute (NCI) Division of Cancer Control and Population Sciences (DCCPS) in receiving applications to understand and address the full spectrum of factors that contribute to disparities in survivorship care, healthcare utilization, and health outcomes among childhood cancer survivors. Studies that focus on factors that extend beyond the individual (e.g., survivor, caregiver, clinician) to include an examination or intervention that involves healthcare teams, healthcare system, community, payer, and/or policy-level factors that contribute to disparities in health outcomes and result in inequitable survivorship care are strongly encouraged.</p>				
112442	<a href="#">NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-216	12-Jun-2024	275,000 USD
	<p>Contact Name   William C. Timmer, Ph.D</p> <p>Contact Telephone   240-276-6130</p> <p>Contact Email   <a href="mailto:william.timmer@nih.gov">william.timmer@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Jun-2024 , 01-Jul-2024 , 10-Oct-2024 , 01-Nov-2024 , 13-Feb-2025 , 01-Mar-2025 , 12-Jun-2025 , 01-Jul-2025</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among underserved populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>on established mechanisms of action. Comparative correlative studies in cancer patients with age, gender, racial/ethnic, or health disparities are encouraged to explore mechanisms underlying their differential responses (efficacy and toxicity) and resistance to therapeutic interventions. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well. This FOA does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways, molecular mechanisms, or mechanisms of metastasis), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. These applications will be deemed not responsive to this FOA and will not be reviewed (see below for a more detailed description of studies that are not responsive for this FOA). The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to breakthroughs in particular areas, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research (preclinical or clinical).</p>				
115306	<a href="#">Notice of Special Interest (NOSI): Research on the Etiology, Early Detection, Screening and Prevention of Early-Onset Colorectal Cancer</a>	National Cancer Institute/NIH/DHHS	NOT-CA-23-018	07-May-2024	Not Specified
	<p>Contact Name   Gary Della’Zanna            Contact Telephone   240-276-7042            Contact Email   <a href="mailto:Gary.DellaZanna@nih.gov">Gary.DellaZanna@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   07-May-2024 , 25-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024 , 25-Sep-2024 , 08-Oct-2024 , 10-Oct-2024 , 12-Oct-2024 , 25-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025            Synopsis   The purpose of this Notice of Special Interest (NOSI) is to solicit applications directed toward identifying, characterizing, and mitigating risk factors, identifying biomarkers for early detection, best screening modalities, and preventive interventions for early-onset colorectal cancer (EOCRC), defined as occurring before 50 years of age.</p>				
106264	<a href="#">Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-21-323	16-Jun-2024	400,000 USD
	<p>Contact Name   Anu Sharman, Ph.D.            Contact Telephone   240-276-6250            Contact Email   <a href="mailto:sharmananu@nih.gov">sharmananu@nih.gov</a>            Sponsor Website  </p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2024 , 16-Jul-2024</p> <p>Synopsis National Cancer Institute (NCI) invites applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.</p>				
106265	<a href="#">Basic Research in Cancer Health Disparities (R03 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-21-324	16-Jun-2024	100,000 USD
	<p>Contact Name Anu Sharman, Ph.D.</p> <p>Contact Telephone 240-276-6250</p> <p>Contact Email <a href="mailto:sharmananu@nih.gov">sharmananu@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2024 , 16-Jul-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These small research grants (R03) will support projects on cancer health disparities that can be carried out in a short period of time with limited resources. The projects should propose innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses.</p>				
106283	<a href="#">Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-21-332	16-Jun-2024	550,000 USD
	<p>Contact Name Edward R. Sauter, M.D., Ph.D.</p> <p>Contact Telephone 240-276-7657</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:edward.sauter@nih.gov">edward.sauter@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2024 , 16-Jul-2024</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter term outcomes such as weight loss and diabetes.</p>				
125154	<a href="#">Notice of Special Interest (NOSI): Administrative Supplements for Assessing and Enhancing Survivorship Care</a>	National Cancer Institute/NIH/DHHS	NOT-CA-24-041	04-Jun-2024	100,000 USD
	<p>Contact Name Michelle Mollica, PhD, MPH, RN, OCN</p> <p>Contact Telephone 240-276-7621</p> <p>Contact Email <a href="mailto:michelle.mollica@nih.gov">michelle.mollica@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 04-Jun-2024</p> <p>Synopsis The Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI) announces this Notice of Special Interest (NOSI) to encourage current grant or cooperative agreement awardees to apply for administrative supplement funds to support research with an overall goal of examining and improving survivorship care to align with recently developed national survivorship standards. Please note that this NOSI is a reissuance of NOT-CA-24-035.</p>				
113746	<a href="#">Notice of Special Interest (NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers</a>	National Cancer Institute/NIH/DHHS	NOT-CA-23-004	07-May-2024	Not Specified
	<p>Contact Name Matthew Young, Ph.D.</p> <p>Contact Telephone 240-276-5846</p> <p>Contact Email <a href="mailto:matthew.young@nih.gov">matthew.young@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 11-Jun-2024 , 12-Jun-2024 , 01-Jul-2024 , 05-Sep-2024 , 07-Sep-2024 , 01-Oct-2024 , 05-Oct-2024 , 10-Oct-2024 , 11-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 13-Feb-2025 , 01-Mar-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 01-Jul-2025</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to encourage research studies leveraging partnerships between biomarker technology developers with assays for early cancer detection, and population-based researchers, including cohort and biorepository researchers. Proposals that facilitate early cancer biomarker assay development, verification, qualification, and validation utilizing statistically powered retrospective cohorts and/or through prospective studies in the appropriate populations with a sound study design are responsive to this NOSI.</p>				
102903	<a href="#">Notice of Special Interest (NOSI): Fundamental Science Research on Complementary and Integrative Health Approaches</a>	National Center for Complementary and Integrative Health/NIH/DHHS	NOT-AT-21-006	07-May-2024	Not Specified
	<p>Contact Name Wen Chen, M.M.Sc., Ph.D.</p> <p>Contact Telephone 301-451-3989</p> <p>Contact Email <a href="mailto:chenw@mail.nih.gov">chenw@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to describe NCCIH priorities in innovative basic and mechanistic research or technology/method development research relevant to complementary and integrative health approaches.</p>				
124471	<a href="#">RFA-AT-24-008 -- Leveraging Data at Scale to Understand Natural Product Impacts on Whole Person Health (R01 Clinical Trial Not Allowed)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	RFA-AT-24-008	28-May-2024 [Optional][LOI/Pre-App]	499,999 USD
	<p>Contact Name D. Craig Hopp, Ph.D.</p> <p>Contact Telephone 301-496-5825</p> <p>Contact Email <a href="mailto:hoppdc@nih.gov">hoppdc@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 28-May-2024 [Optional][LOI/Pre-App], 28-Jun-2024</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that seek to identify natural products with the potential to inhibit or induce Phase I and Phase II drug metabolizing enzymes and drug transporters, thereby possibly contributing to pharmacokinetic interactions with other medications. These in vitro studies may include screening libraries of complex extracts and/or purified natural products in suitable medium to high throughput assays to identify potential interactions. They may also include isolation and identification of novel, or not commercially available, natural products within complex mixtures that exhibit pharmacokinetic interactions. This FOA is part of a larger investment from NCCIH that includes a U54 Center of Excellence for Natural Product Drug Interaction Research. It is expected that data generated in projects supported under this FOA will be uploaded and made publicly available through the data repository maintained by the U54 Center.</p>			
--	----------	--	--	--	--

123152	<a href="#">Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24-084	20-Jun-2024	450,000 USD
--------	--	---	------------	-------------	-------------

	Contact Name	Jennifer N. Baumgartner, Ph.D.			
	Contact Telephone	301-402-4084			
	Contact Email	<a href="mailto:jennifer.baumgartner@nih.gov">jennifer.baumgartner@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	20-Jun-2024 , 15-Jul-2024 , 21-Oct-2024 , 13-Nov-2024 , 20-Feb-2025 , 10-Mar-2025 , 20-Jun-2025 , 14-Jul-2025 , 20-Oct-2025 , 17-Nov-2025 , 20-Feb-2026 , 17-Mar-2026 , 22-Jun-2026 , 13-Jul-2026 , 20-Oct-2026 , 13-Nov-2026			
	Synopsis	<p>The goal of this notice of funding opportunity (NOFO) is to support feasibility trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) for conditions that have been identified by NCCIH as high-priority research topics. This funding opportunity is intended to support feasibility clinical trials that provide new information that are scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial within NCCIH’s mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent competitive full-scale clinical trial. Under this R34, the data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the following: examining feasibility and acceptability of interventions lacking published data; tailoring or adapting the content or structure of an intervention to a specific population, modality, or setting; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention, and data collection procedures; refining and assessing the feasibility of protocolized multi-component</p>			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>interventions; or examining acceptability and adherence of control conditions. The subsequent full-scale clinical trial should have the potential to make a significant impact on public health. Prior to submitting to this NOFO, applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact person for the science area of the planned application. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>			
123153	<a href="#">Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24-086	20-Jun-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Beda Jean-Francois, Ph.D.</p> <p>202-313-2144</p> <p><a href="mailto:beda.jean-francois@nih.govr01">beda.jean-francois@nih.govr01</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>20-Jun-2024 , 15-Jul-2024 , 21-Oct-2024 , 13-Nov-2024 , 20-Feb-2025 , 10-Mar-2025 , 20-Jun-2025 , 14-Jul-2025 , 20-Oct-2025 , 17-Nov-2025 , 20-Feb-2026 , 17-Mar-2026 , 22-Jun-2026 , 13-Jul-2026 , 20-Oct-2026 , 13-Nov-2026</p> <p>This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy or effectiveness of complementary and integrative health interventions in NCCIH- designated areas of high research priority. Applications submitted under this NOFO are expected to propose a remotely delivered and conducted fully powered clinical trial with no in-person contact between research staff and study participants and may utilize mHealth tools or technologies. Applicants must provide justification for the remotely delivered approach and provide preliminary data on the feasibility and safety of the approach, along with evidence that the intervention has promise of clinical benefit. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>			
123147	<a href="#">NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions</a>	National Center for	PAR-24-	20-Jun-2024	Not

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">(R01 Clinical Trial Required)</a>		Complementary and Integrative Health/NIH/DHHS 083		Specified
	Contact Name	Pete Murray, Ph.D.			
	Contact Telephone	301-496-4054			
	Contact Email	<a href="mailto:peter.murray@nih.gov">peter.murray@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	20-Jun-2024 , 15-Jul-2024 , 21-Oct-2024 , 13-Nov-2024 , 20-Feb-2025 , 20-Jun-2025 , 15-Jul-2025 , 20-Oct-2025 , 18-Nov-2025 , 20-Feb-2026 , 17-Mar-2026 , 22-Jun-2026 , 14-Jul-2026 , 20-Oct-2026 , 17-Nov-2026			
	Synopsis	<p>This notice of funding opportunity (NOFO) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH-designated areas of high research priority. Applications submitted under this NOFO are expected to propose a multisite feasibility clinical trial that will provide new information that is scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial within NCCIH’s mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R01) research is scientifically necessary to design or plan the subsequent fully powered, full-scale clinical trial. Under this R01, the data collected should be used to fill gaps in scientific knowledge, including, but not limited to the following: assessing whether the intervention can be delivered with fidelity across sites; demonstrating feasibility of recruitment, accrual, and randomization of participants across sites; demonstrating participant adherence to the intervention, as well as retention of participants throughout the study across sites; refining and assessing the feasibility of protocolized multimodal interventions, and/or demonstrating feasibility of data collection across sites in preparation for a future fully powered, multisite efficacy or effectiveness trial. The need for multisite feasibility trials is expected to be justified by sufficient preliminary data from previous single site feasibility or acceptability trial(s) or the published literature. The data collected should be used to fill gaps in scientific knowledge and be necessary to develop a competitive fully powered multisite clinical trial that has the potential to make a significant impact on public health. Prior to submitting to this NOFO, applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact person for the science area of the planned application. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>			
123160	<a href="#">Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated</a>	National Center for	PAR-24-	20-Jun-2024	Not

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required)</a>		Complementary and Integrative Health/NIH/DHHS 090		Specified
	<p>Contact Name Elizabeth Ginexi, Ph.D.</p> <p>Contact Telephone 301-827-0160</p> <p>Contact Email <a href="mailto:elizabeth.ginexi@nih.gov">elizabeth.ginexi@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 20-Jun-2024 , 15-Jul-2024 , 20-Feb-2025 , 10-Mar-2025 , 20-Jun-2025 , 14-Jul-2025 , 20-Feb-2026 , 17-Mar-2026 , 22-Jun-2026 , 13-Jul-2026</p> <p>Synopsis This notice of funding opportunity (NOFO), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi site clinical trial (Phase III and beyond) application submitted under companion PAR-24-090. The DCC application must be specific to the companion Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this NOFO applies must be relevant to the research mission of NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of NCCIH, applicants are encouraged to consult the NCCIH website (<a href="http://www.nccih.nih.gov">http://www.nccih.nih.gov</a>). Applicants are encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>				
123155	<a href="#">Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required)</a>		National Center for Complementary and Integrative Health/NIH/DHHS PAR-24-087	20-Jun-2024	Not Specified
	<p>Contact Name Elizabeth Ginexi, Ph.D.</p> <p>Contact Telephone 301-827-0160</p> <p>Contact Email <a href="mailto:elizabeth.ginexi@nih.gov">elizabeth.ginexi@nih.gov</a></p> <p>Sponsor Website</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 20-Jun-2024 , 15-Jul-2024 , 20-Feb-2025 , 10-Mar-2025 , 20-Jun-2025 , 14-Jul-2025 , 20-Feb-2026 , 17-Mar-2026 , 22-Jun-2026 , 13-Jul-2026</p> <p>Synopsis This notice of funding opportunity (NOFO), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi site clinical trial (Phase III and beyond) application submitted under companion PAR-24-090. The DCC application must be specific to the companion Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this NOFO applies must be relevant to the research mission of NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of NCCIH, applicants are encouraged to consult the NCCIH website (<a href="http://www.nccih.nih.gov">http://www.nccih.nih.gov</a>). Applicants are encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>				
123823	<p><a href="#">Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required)</a></p>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24-123	21-Jun-2024	Not Specified
	<p>Contact Name Wendy Weber, N.D., Ph.D, M.P.H.</p> <p>Contact Telephone 301-402-1272</p> <p>Contact Email <a href="mailto:weberwj@mail.nih.gov">weberwj@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 21-Jun-2024 , 15-Jul-2024 , 20-Feb-2025 , 10-Mar-2025 , 23-Jun-2025 , 17-Jul-2025 , 23-Feb-2026 , 17-Mar-2026 , 22-Jun-2026 , 14-Jul-2026</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for investigator-initiated, multi-site, clinical trials (Phase III and beyond) to study the effects of natural products in NCCIH designated areas of high research priority. Applicants should describe plans for a Clinical Coordinating Center to develop and implement the proposed</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

multi-site clinical trial. The objective of the Clinical Coordinating Center is to provide the design scientific rationale and a comprehensive scientific and operational plan for the clinical trial. The Clinical Coordinating Center is expected to be responsible for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. Clinical Coordinating Center applications submitted under this FOA will utilize a two-phase, milestone-driven, cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanying Data Coordinating Center application, submitted under PAR-24-125, proposing a data analysis and data management plan for the clinical project is required. Both a Clinical Coordinating Center application and a corresponding Data Coordinating Center (DCC) application need to be submitted simultaneously for consideration by NCCIH.

123835	<a href="#">Notice of Special Interest (NOSI): National Center for Complementary and Integrative Health (NCCIH) T32 Complementary and Integrative Health Practitioner Supplement Program for Pre- and Postdoctoral Candidates</a>	National Center for Complementary and Integrative Health/NIH/DHHS	NOT-AT-24-033	03-Jun-2024	Not Specified
--------	---	---	---------------	-------------	---------------

Contact Name	Jennifer N. Baumgartner, Ph.D.
Contact Telephone	301-402-4084
Contact Email	<a href="mailto:jennifer.baumgartner@nih.gov">jennifer.baumgartner@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	03-Jun-2024 , 01-Nov-2024 , 03-Mar-2025 , 02-Jun-2025 , 03-Nov-2025 , 02-Mar-2026 , 01-Jun-2026 , 02-Nov-2026
Synopsis	NCCIH announces an opportunity to allow existing NCCIH-funded Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (T32) programs to apply for an administrative supplement to support an additional training slot for predoctoral and postdoctoral candidates with professional clinical complementary and integrative health degrees.

124673	<a href="#">RFA-AT-24-007 -- Limited Competition: Research Resource for Natural Product Nuclear Magnetic Resonance Data (R24 Clinical Trial Not Allowed)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	RFA-AT-24-007	10-Jun-2024 [Optional][LOI/Pre-App]	Not Specified
--------	--	---	---------------	--	---------------

Contact Name	Patrick C. Still, Ph.D.
Contact Telephone	
Contact Email	<a href="mailto:patrick.still@nih.gov">patrick.still@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   10-Jun-2024 [Optional][LOI/Pre-App], 08-Jul-2024</p> <p>Synopsis   The National Center for Complementary and Integrative Health (NCCIH) with the Office of Dietary Supplements (ODS) solicit applications for continuation of an established nuclear magnetic resonance (NMR) research resource consisting of raw and meta-data from natural products ranging from crude extracts to purified substances; with the capacity to upload, download, store, search and analyze raw NMR data. The purpose of this limited competition is to promote sustainability, scaling and wider community inclusiveness of the established NMR research resource. This notice of funding opportunity (NOFO) is part of the Consortium Advancing Research on Botanicals and Other Natural Products (CARBON) Program. Other elements of this Program include the RFA-OD-24-014 Botanical Dietary Supplements Translational Research Teams (RM1) and RFA-AT-24-008Leveraging Big Data to Understand Natural Product Impacts on Whole Person Health (R01).</p>				
123623	<p><a href="#">Notice of Special Interest (NOSI): Administrative Supplements for Complementary Health Practitioner Research Experience (Admin Supplements)</a></p>	National Center for Complementary and Integrative Health/NIH/DHHS	NOT-AT-24-032	03-Jun-2024	200,000 USD
	<p>Contact Name   Lanay M. Mudd, Ph.D., FACSM</p> <p>Contact Telephone   301-594-9346</p> <p>Contact Email   <a href="mailto:lanay.mudd@nih.gov">lanay.mudd@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   03-Jun-2024 , 01-Nov-2024 , 03-Mar-2025 , 02-Jun-2025 , 03-Nov-2025 , 02-Mar-2026 , 01-Jun-2026 , 02-Nov-2026</p> <p>Synopsis   The National Center for Complementary and Integrative Health (NCCIH) encourages applications for administrative supplements to NCCIH-supported awards to support complementary health practitioners in an intensive, supervised research experience that will lead to a better understanding of, and practical experience in, complementary and integrative health research.</p>				
123858	<p><a href="#">Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Required)</a></p>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24-125	21-Jun-2024	Not Specified
	<p>Contact Name   Wendy Weber, N.D., Ph.D., M.P.H.</p> <p>Contact Telephone   301-402-1272</p> <p>Contact Email   <a href="mailto:weberwj@mail.nih.gov">weberwj@mail.nih.gov</a></p> <p>Sponsor Website  </p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 21-Jun-2024 , 15-Jul-2024 , 20-Feb-2025 , 10-Mar-2025 , 23-Jun-2025 , 15-Jul-2025 , 20-Feb-2026 , 17-Mar-2026 , 22-Jun-2026 , 14-Jul-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under PAR-24-123. The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this NOFO applies must be relevant to the research mission of the NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: (<a href="http://www.nccih.nih.gov">http://www.nccih.nih.gov</a>).</p>				
124534	<a href="#">Notice of Special Interest (NOSI): National Center for Complementary and Integrative Health (NCCIH) T32 Supplement Program to Promote Diversity in Health Research</a>	National Center for Complementary and Integrative Health/NIH/DHHS	NOT-AT-24-034	03-Jun-2024	Not Specified
	<p>Contact Name Jennifer N. Baumgartner, Ph.D.</p> <p>Contact Telephone 301-402-4084</p> <p>Contact Email <a href="mailto:jennifer.baumgartner@nih.gov">jennifer.baumgartner@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 03-Jun-2024 , 01-Nov-2024 , 03-Mar-2025 , 02-Jun-2025 , 03-Nov-2025 , 02-Mar-2026 , 01-Jun-2026 , 02-Nov-2026</p> <p>Synopsis NCCIH announces an opportunity to allow institutions with existing NCCIH-funded Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (T32) programs to apply for an administrative supplement to promote diversity in health research. A very limited number of supplementary slots will be available in each fiscal year and the number awarded will depend on the number and merit of applications received and the availability of funds.</p>				
119247	<a href="#">NEI Institutional Mentored Physician Scientist Award (K12 Clinical Trial Optional)</a>	National Eye Institute/NIH/DHHS	PAR-23-197	09-Jun-2024	Not Specified
	<p>Contact Name Neeraj Agarwal, Ph.D.</p> <p>Contact Telephone 301-435-8155</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:agarwalnee@nei.nih.gov">agarwalnee@nei.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 09-Jun-2024 , 09-Jun-2025 , 09-Jun-2026</p> <p>Synopsis                      The purpose of this Notice of Funding Opportunity (NOFO) is to encourage institutions to propose creative and innovative institutional research career development programs which will prepare clinically trained vision scientists for independent research careers. This NOFO is intended to expand and strengthen the community of clinician investigators engaged in vision research. This Notice of Funding Opportunity (NOFO) allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development program. For this career development program scholars are limited to clinical trials that are minimal risk. The existing clinical trial must be a NIH-defined clinical trial that fulfills the NIH requirement for minimal risk trial. A minimal risk trial is one in which the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity. For the purposes of this announcement, institutions are highly encouraged to recruit prospective PIs/PDs, mentors, and scholars from diverse backgrounds, including individuals from underrepresented racial and ethnic groups and individuals with disabilities as described in the NOT-OD-22-019 in all of its programs.</p>				
109678	<a href="#">NEI Regenerative Medicine Clinical Trial Planning Grant (R34 - Clinical Trials Not Allowed)</a>	National Eye Institute/NIH/DHHS	PAR-22-135	07-May-2024	300,000 USD
	<p>Contact Name Donald Everett, MA</p> <p>Contact Telephone 301-435-8181</p> <p>Contact Email <a href="mailto:everettd@mail.nih.gov">everettd@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis                      The National Eye Institute (NEI) supports regenerative medicine clinical trials. Before a research team undertakes a clinical trial, it is critical to have clear delineation and documentation of the trial's rationale, design, analytic techniques, protocols, and procedures in a Manual of Procedures (MOP). Additionally, there are other elements essential to the launching of a trial, such as obtaining regulatory authorizations or approvals and establishing agreements with requisite partners including cell</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

manufacturing and production facilities, assay or cell analysis centers, and data coordinating centers. These activities are often costly and time-consuming, and they may involve collection of preliminary data to assess feasibility. The Regenerative Medicine Clinical Trial Planning Grant may be used by applicants to support the preparation of a clinical trial MOP and procedures necessary for implementing a clinical trial to evaluate interventions (or new treatments) that restore vision in humans through regeneration of cells.

109530	<a href="#">NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)</a>	National Eye Institute/NIH/DHHS	PAR-22-128	07-May-2024	300,000 USD
--------	---	---------------------------------	------------	-------------	-------------

Contact Name	Donald Everett, MA
Contact Telephone	301-435-8181
Contact Email	<a href="mailto:everettd@mail.nih.gov">everettd@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025
Synopsis	The NEI supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies on eye/vision conditions. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. This clinical research planning grant funding opportunity supports applicants in their planning efforts to conduct collaborative clinical research. The grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical trial research studies.

109824	<a href="#">NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)</a>	National Eye Institute/NIH/DHHS	PAR-22-141	07-May-2024	275,000 USD
--------	--	---------------------------------	------------	-------------	-------------

Contact Name	Donald Everett, M.A.
Contact Telephone	301-435-8181
Contact Email	<a href="mailto:everettd@mail.nih.gov">everettd@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL) | 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025

Synopsis | This FOA encourages applications from institutions/organizations that propose to conduct vision-related secondary data analyses utilizing existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic research projects wherein numerous data collection activities are required to meet each project's specific aims. The resultant wealth of data generated by these studies often provides unique, cost-effective opportunities to investigate additional research questions or develop new analytical approaches secondary to a project's originally-intended purpose. Data are not limited to those collected under NEI support, but such data are of the highest programmatic interest. The purpose of this FOA is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This FOA may be used to develop new statistical methodologies or test hypotheses using existing data, but this FOA must not be used to support the collection of new data.

117409	<a href="#">Notice of Special Interest (NOSI): Development of Innovative Informatics and Data Science Technologies, Tools, and Methods for Vision Research</a>	National Eye Institute/NIH/DHHS	NOT-EY-23-005	07-May-2024	Not Specified
--------	--	---------------------------------	---------------	-------------	---------------

Contact Name | James Gao, Ph.D.  
 Contact Telephone | 301-594-6074  
 Contact Email | [james.gao@nih.gov](mailto:james.gao@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 07-May-2024 , 16-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 16-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026 , 16-Feb-2026  
 Synopsis | The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants that the National Eye Institute (NEI) is interested in supporting research to develop innovative informatics and data science methods, algorithms, and tools to improve data acquisition, analysis, visualization, annotation, integration, and interpretation. The emphasis will be on innovation and its potential impact on vision research, including discovery biology, population studies, as well as clinical and translational research.

109308	<a href="#">RFA-HL-23-018 -- Maximizing the Scientific Value of the NHLBI Biologic Biospecimen Repository: Scientific Opportunities for Exploratory Research (R21)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-018	20-Jun-2024	150,000 USD
--------	--	--	---------------	-------------	-------------

Contact Name | Margaret Ochocinska, PhD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-827-8285</p> <p>Contact Email   <a href="mailto:ochocinm@mail.nih.gov">ochocinm@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   20-Jun-2024 , 09-Aug-2024 , 21-Oct-2024 , 10-Dec-2024</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) will support meritorious exploratory research relevant to the NHLBI mission (<a href="http://www.nhlbi.nih.gov/about/org/mission">http://www.nhlbi.nih.gov/about/org/mission</a>) using the existing biospecimen collections that are stored in the NHLBI Biologic Specimen Repository (Biorepository), thereby maximizing the scientific value of the stored collections and providing researchers with an opportunity to generate preliminary data for subsequent research proposals.</p>				
107287	<p><a href="#">Notice of Special Interest (NOSI): Heart, Lung, Blood and Sleep Focused Ancillary Studies to Large Ongoing Clinical Studies (Revised)</a></p>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-21-030	07-May-2024	Not Specified
	<p>Contact Name   Jue Chen, Ph.D.</p> <p>Contact Telephone   301-435-0550</p> <p>Contact Email   <a href="mailto:jue.chen@nih.gov">jue.chen@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis   This Notice of Special Interest (NOSI) seeks to expand the breadth of scientific research on the clinical course, prevention and treatment of diseases within the mission of the National Heart, Lung, and Blood Institute (NHLBI) by leveraging ongoing clinical research studies through ancillary studies. The purpose of this NOSI is to invite research project applications to conduct focused ancillary studies to large ongoing clinical trials (including late-stage T4 implementation clinical trials), observational studies, and registries. This NOSI also serves as a replacement for NOT-HL-20-755 (expired as of November 6, 2021).</p>				
107093	<p><a href="#">Notice of Special Interest (NOSI): DEA2Health: Innovative Data Evaluation and Analysis to Health</a></p>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-001	07-May-2024	Not Specified
	<p>Contact Name   Lucy L. Hsu, M.P.H.</p> <p>Contact Telephone   301-402-3276</p> <p>Contact Email   <a href="mailto:lucy.hsu@nih.gov">lucy.hsu@nih.gov</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025  
 Synopsis | The purpose of this Notice of Special Interest (NOSI) is to stimulate research and advancement of methodologies in data science in heart, lung, blood, or sleep (HLBS) biomedical research, and ultimately translate new insights into decision-making to improve health.

114141	<a href="#">Notice of Special Interest (NOSI): Advancing Research in Lipoprotein(a) and Cardiovascular Disease (R01 Clinical Trials Allowed) and (R01 No Clinical Trials Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-052	07-May-2024	Not Specified
--------	---	--	---------------	-------------	---------------

Contact Name | Lijuan Liu, PhD  
 Contact Telephone | 301-435-0582  
 Contact Email | [liu@nhlbi.nih.gov](mailto:liu@nhlbi.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026  
 Synopsis | The purpose of this NOSI is to stimulate research on lipoprotein(a) [Lp(a)] and its role in cardiovascular disease (CVD). We encourage multidisciplinary collaborations to conduct basic, preclinical, and mechanistic clinical studies on Lp(a) and CVD.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

116586	<a href="#">Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-23-067	07-May-2024	Not Specified
--------	--	--	---------------	-------------	---------------

Contact Name | James Luo, Ph.D.  
 Contact Telephone | 301-435-0533  
 Contact Email | [luoja@nih.gov](mailto:luoja@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis   The symptom-based diagnosis and treatment of heart, lung, blood, and sleep (HLBS) diseases has vastly improved in recent years, yet an understanding of the molecular mechanisms underlying many of these diseases has remained elusive. Furthermore, in most cases the impact of genetic variation on severity of disease and treatment outcomes remains unknown. Therefore, the NHLBI has created the Trans-omics for Precision Medicine (TOPMed) program, which aims to utilize genomics data to characterize a variety of HLBS diseases. TOPMed is well on its way to collecting whole genome sequence (WGS) from over 194,270 well-phenotyped individuals and is currently generating multi-omics data (e.g., over 31,852 RNA sequences, over 44,342 DNA methylation profiles, and 26,124 metabolomics profiles) from many of these individuals to complement whole genome sequence information. Having produced an unprecedented volume of high-throughput data, TOPMed now seeks to turn its attention to effectively leveraging this resource to uncover biological function and disease pathobiology through novel systems biology analyses and the power of artificial intelligence (AI) and Machine Learning (ML). Although lower costs and technological improvements in sequencing technology have vastly expanded our ability to generate large volumes of omics data, the ability to analyze such large datasets to extract biologically meaningful insights remains challenging. Systems level models incorporating trans-omics analyses will be an important step in uncovering the underlying biological networks and the gene-gene and gene-environment interactions influencing disease and treatment outcomes. Thus, advanced analyses that incorporate genotype and phenotype datasets from thousands to tens of thousands of individuals are essential to move TOPMed to the next phase of discovery.</p>				
112260	<p><a href="#">Notice of Special Interest (NOSI): Studies of Cellular/Molecular Pathobiological Mechanisms of Lung Diseases Using Human 3-Dimensional Cellular Systems (R01)</a></p>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-030	07-May-2024	Not Specified
	<p>Contact Name   Qing Lu, Ph.D.</p> <p>Contact Telephone   301-480-9158</p> <p>Contact Email   <a href="mailto:qing.lu@nih.gov">qing.lu@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</p> <p>Synopsis   The purpose of this NOSI is to promote research characterizing the pathobiological processes and mechanisms that drive the onset and progression of lung diseases at a molecular/cellular level, providing a systems-level understanding by studying experimental systems with cellular heterogeneity and 3-D architecture. It is expected that projects supported by this NOSI</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		will utilize ex vivo preparations (e.g., thin human lung slices) or 3-D multi-cellular in vitro systems (e.g., organoids) of human lung cells and will employ state-of-art multi-omics measures (e.g., spatial or single cell/nucleus omics) to better understand specific pathobiological processes in systems of interacting cell types.			
106202	<a href="#">Notice of Special Interest (NOSI): Promoting Cardiovascular and Cardiometabolic Health in Early Stages of the Lifecourse: Pre-adolescence Through Adolescence to Young Adulthood</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-21-015	07-May-2024	Not Specified
	Contact Name	Alison G.M. Brown, PhD, MS, RDN			
	Contact Telephone	301-435-0583			
	Contact Email	<a href="mailto:Alison.brown@nih.gov">Alison.brown@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026			
	Synopsis	This Notice of Special Interest (NOSI) calls for research to understand and promote cardiovascular and cardiometabolic health during transitional phases across the lifecourse, from pre-adolescence (6-10 years) through adolescence (11-18 years) to young adulthood (19-39 years). This initiative would support research to: 1) understand the mechanisms and the pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitional phases from pre-adolescence into adolescence and adolescence into young adulthood, and 2) develop precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitional phases.			
113286	<a href="#">Notice of Special Interest (NOSI): Basic and Translational Research on Circadian Regulation of Heart, Lung, Blood, and Sleep Disorders (R01)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-043	07-May-2024	Not Specified
	Contact Name	Ravi Balijepalli, Ph.D.			
	Contact Telephone	301-435-0504			
	Contact Email	<a href="mailto:ravi.balijepalli@nih.gov">ravi.balijepalli@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</p> <p>This NOSI aims to stimulate research on understanding how circadian rhythms regulate cell function and metabolism of peripheral tissues, and to find new avenues for the investigation of heart, lung, and blood disease risk, pathogenesis, diagnosis, treatment, and prevention. Basic, translational, and clinical research applications to elucidate circadian-dependent mechanisms contributing to the pathophysiology of HLBS disorders are invited. This NOSI encourages multidisciplinary and multiple investigator teams of experts in heart, lung, and blood research fields to synergistically work with circadian biologists and sleep researchers to provide a comprehensive understanding of the circadian biology in relation to HLBS conditions. The purpose is to facilitate translational research to identify potential applications of circadian science to the diagnosis, prevention and treatment of HLBS conditions. Mechanism-based studies investigating the circadian rhythm dysregulation, clinical markers, and/or therapeutic targets of HLBS conditions are encouraged. Behavioral, physiological, pharmacological, molecular, and genomic studies aimed at elucidating the relationship between circadian-dependent mechanisms and disease are appropriate. Studies to delineate circadian-based mechanisms, therapeutic targets, epidemiological risk and clinical trials to assess therapeutic safety, efficacy, effectiveness, or implementation may be proposed.</p>			
106893	<a href="#">NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-034	12-Jun-2024	Not Specified
	Contact Name	Shawn Bediako, Ph.D.			
	Contact Telephone	301-827-5163			
	Contact Email	<a href="mailto:direducation@nhlbi.nih.gov">direducation@nhlbi.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	12-Jun-2024			
	Synopsis	<p>The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows and other doctoral-level researchers currently in training in the NHLBI Division of Intramural Research with the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA, PAR-22-040 "NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22- Clinical Trial Required)".

106898	<a href="#">NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Clinical Trial Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-040	12-Jun-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Shawn Bediako, Ph.D.
Contact Telephone	301-827-5163
Contact Email	<a href="mailto:direducation@nhlbi.nih.gov">direducation@nhlbi.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	12-Jun-2024
Synopsis	The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows and other doctoral-level researchers currently in training in the NHLBI Division of Intramural Research with the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not proposing to serve as lead investigator of an independent clinical trial must apply to the companion FOA (PAR-22-034).

112358	<a href="#">Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-193	10-May-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Nancy DiFronzo, PhD
Contact Telephone	301-435-0065
Contact Email	<a href="mailto:difronzon@nhlbi.nih.gov">difronzon@nhlbi.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>10-May-2024 , 11-Jun-2024 , 11-Sep-2024 , 11-Oct-2024 , 10-Jan-2025 , 11-Feb-2025 , 12-May-2025 , 11-Jun-2025 , 11-Sep-2025</p> <p>This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA PAR-22-192() that encourages applications for a collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial proposed in the collaborating CCC application. The application should also describe its approaches to collaborate with the CCC on implementation of the clinical trial community engagement and diversity plans. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.</p>			
112357	<p><a href="#">Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)</a></p>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-192	10-May-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Nancy DiFronzo, PhD</p> <p>301-435-0065</p> <p><a href="mailto:difronzon@nhlbi.nih.gov">difronzon@nhlbi.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>10-May-2024 , 11-Jun-2024 , 11-Sep-2024 , 11-Oct-2024 , 10-Jan-2025 , 11-Feb-2025 , 12-May-2025 , 11-Jun-2025 , 11-Sep-2025</p> <p>This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (PAR-22-193). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The application should also describe its approaches to increasing community engagement and diversity as well as reducing health inequities and disparities. Both a CCC application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.

112356	<a href="#">Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-189	10-May-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Nahed El Kassar, MD
Contact Telephone	301-435-0065
Contact Email	<a href="mailto:nahed.elkassar@nih.gov">nahed.elkassar@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	10-May-2024 , 11-Jun-2024 , 11-Sep-2024 , 11-Oct-2024 , 11-Jan-2025 , 11-Feb-2025 , 11-May-2025 , 11-Jun-2025 , 11-Sep-2025
Synopsis	<p>This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. The application should also describe its approaches to increasing community engagement, reducing health inequities and disparities, and include a Plan for Increasing Diverse Perspectives (PDEP).</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
113729	<a href="#">RFA-HL-24-005 -- Limited Competition: Small Grant Program for NHLBI K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-24-005	07-May-2024	150,000 USD
	<p>Contact Name: Qing Lu, Ph.D.</p> <p>Contact Telephone: 301-480-9158</p> <p>Contact Email: <a href="mailto:Qing.Lu@nih.gov">Qing.Lu@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 07-May-2024 , 13-Jun-2024 , 07-Sep-2024 , 17-Oct-2024 , 07-Jan-2025 , 13-Feb-2025 , 07-May-2025 , 13-Jun-2025 , 07-Sep-2025 , 13-Oct-2025 , 07-Jan-2026</p> <p>Synopsis: The purpose of this funding opportunity announcement (FOA) is to solicit current or recently completed NHLBI K01, K08, K23, and K25 recipients for small grant support to expand their current research objectives or to branch out to a new study that resulted from the research conducted under the K award. Active NHLBI K01, K08, K23, and K25 recipients may apply for R03 support after the notice of award (NoA) for their first type-5 K awards has been issued. Recently completed NHLBI K01, K08, K23, and K25 recipients are eligible to apply for the R03 if the earliest possible R03 start date falls within 2 years of their prior NHLBI K award Project Period end date. This FOA is intended to enhance the capability of NHLBI K01, K08, K23, and K25 recipients to conduct research as they complete their transition to fully independent investigator status. This R03 program is intended to support research projects that can be carried out and completed within a short period of time (no more than two years) with limited resources and that may generate preliminary data to support a subsequent R01-equivalent application. These studies include, but are not limited to, pilot or feasibility studies; proof of concept studies; secondary analysis of existing data; small, self-contained research projects; development of new research methodologies or technologies, or development of novel experimental models. A minimum of 40% protected overall research effort, not necessarily limited to the proposed R03 project, is required from applicants. For current and previous K23 recipients, research proposed in the R03 application may or may not include patient-oriented research.</p>				
122332	<a href="#">NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-24-049	07-May-2024	450,000 USD
	<p>Contact Name: Patrice Desvigne-Nickens, MD</p> <p>Contact Telephone: 301-435-0504</p> <p>Contact Email: <a href="mailto:desvignp@mail.nih.gov">desvignp@mail.nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	<p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027</p> <p>This Notice of Funding Opportunity (NOFO) supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, or sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at Clinical Trial Development Continuum   NHLBI, NIH), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application. Plan for Enhancing Diverse Perspectives The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: -Transdisciplinary research projects and collaborations among neuroscientists and researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. - Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). - Individual applications and partnerships that enhance geographic and regional heterogeneity. - Investigators and teams composed of researchers at different career stages. - Participation of individuals from diverse backgrounds, including groups historically underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. - Opportunities to enhance the research environment to benefit early- and mid-career investigators. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>				
111425	<a href="#">Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-189	10-May-2024	Not Specified	

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Nahed El Kassar, MD</p> <p>Contact Telephone   301-435-0065</p> <p>Contact Email   <a href="mailto:nahed.elkassar@nih.gov">nahed.elkassar@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   10-May-2024 , 11-Jun-2024 , 11-Sep-2024 , 11-Oct-2024 , 11-Jan-2025 , 11-Feb-2025 , 11-May-2025 , 11-Jun-2025 , 11-Sep-2025</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. The application should also describe its approaches to increasing community engagement, reducing health inequities and disparities, and include a Plan for Increasing Diverse Perspectives (PDEP),.</p>				
106072	<p><a href="#">Notice of Special Interest (NOSI): Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases (Reissue)</a></p>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-21-024	07-May-2024	Not Specified
	<p>Contact Name   Narasimhan Danthi, Ph.D.</p> <p>Contact Telephone   301-435-5170</p> <p>Contact Email   <a href="mailto:ndanthi@mail.nih.gov">ndanthi@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis   This Notice of Special Interest is a reissue of NOT-HL-20-796. The purpose of this NOSI is to advise potential applicants to the</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>National Heart, Lung and Blood Institute (NHLBI) of an area of special interest to support early phases of innovative bioengineering projects which are expected to transition their research into future follow-on funding, technologies, or commercial products. Please note that this R21 program does not overlap with projects which are expected to transition their research into future follow-on funding, technologies, or commercial products. Please note that this R21 program does not overlap with the NHLBI Catalyze Program, and it does focus on new investigator-initiated ideas that will feed into the Catalyze pipeline.</p>			
108068	<a href="#">Notice of Special Interest (NOSI): Diagnostics and Disease Management Tools for Use in Underserved Populations</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-024	07-May-2024	Not Specified
	Contact Name	Bishow Adhikari, Ph.D.			
	Contact Telephone	301-594-2791			
	Contact Email	<a href="mailto:adhikarb@nhlbi.nih.gov">adhikarb@nhlbi.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025			
	Synopsis	<p>The purpose of this NOSI is to stimulate research focused on the development of transformative diagnostics and disease management tools for heart, lung, blood, or sleep (HLBS) disorders that are designed to meet the needs of the underserved populations. Underserved populations, for the purpose of this NOSI, can include racial and ethnic minorities, immigrants, the homeless, low-income individuals, the uninsured and people who live in communities that are socioeconomically disadvantaged, rural or have few health care resources. Please see NOT-OD-20-031 for NIH definitions. Special consideration will be given to technology solutions that are accessible and feasible in these communities. Working with community partners is required throughout the project to ensure successful development and implementation.</p>			
108064	<a href="#">Notice of Special Interest (NOSI): Promoting Fundamental Research on Mitochondrial Involvement in Lung Diseases and Sleep Disorders</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-003	07-May-2024	Not Specified
	Contact Name	Jining Lu			
	Contact Telephone	301-827-2807			
	Contact Email	<a href="mailto:jining.lu@nih.gov">jining.lu@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The purpose of this NOSI is to stimulate research focused on cell-type-specific signatures of mitochondrial behavior in healthy and diseased lungs. Multidisciplinary collaboration among experts in recently developed technologies, such as iPSC cell and lung progenitor/organoid culture systems, advanced single cell-and “-omic” technologies, and lung cell biology is encouraged. We encourage investigators to Utilization of lung cells from human donors and animal models with respiratory diseases and/or well-defined congenital mitochondrial diseases is also encouraged.</p>			
125065	<a href="#">NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-24-172	05-May-2024 [Optional][LOI/Pre-App]	4,545,000 USD
	Contact Name	Sumita Khatri, MD			
	Contact Telephone	301-402-9673			
	Contact Email	<a href="mailto:sumita.khatri@nih.gov">sumita.khatri@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-May-2024 [Optional][LOI/Pre-App], 04-Jun-2024 , 03-Sep-2024 [Optional][LOI/Pre-App], 07-Sep-2024 , 02-Oct-2024 , 04-Jan-2025 [Optional][LOI/Pre-App], 03-Feb-2025 , 05-May-2025 [Optional][LOI/Pre-App], 07-May-2025 , 04-Jun-2025 , 03-Sep-2025 [Optional][LOI/Pre-App], 07-Sep-2025 , 02-Oct-2025 , 04-Jan-2026 [Optional][LOI/Pre-App], 07-Jan-2026 , 03-Feb-2026 , 05-May-2026 [Optional][LOI/Pre-App], 07-May-2026 , 04-Jun-2026 , 03-Sep-2026 [Optional][LOI/Pre-App], 07-Sep-2026 , 02-Oct-2026 , 07-Jan-2027			
	Synopsis	<p>The objective of this Notice of Funding Opportunity (NOFO) is to support investigator-initiated, Phase 1 clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multi-site. Applicants applying for funding under this NOFO should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. If time and support for these and other pre-clinical and/or trial readiness activities are desired, applicants should consider the companion NOFO PAR-24-173, which utilizes an R61/R33 phased approach.</p>			
125098	<a href="#">NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R61/R33 Clinical Trial Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-24-173	05-May-2024 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Sumita Khatri, MD			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-402-9673</p> <p>Contact Email   <a href="mailto:sumita.khatri@nih.gov">sumita.khatri@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-May-2024 [Optional][LOI/Pre-App], 04-Jun-2024 , 03-Sep-2024 [Optional][LOI/Pre-App], 07-Sep-2024 , 02-Oct-2024 , 04-Jan-2025 [Optional][LOI/Pre-App], 07-Jan-2025 , 03-Feb-2025 , 05-May-2025 [Optional][LOI/Pre-App], 07-May-2025 , 04-Jun-2025 , 03-Sep-2025 [Optional][LOI/Pre-App], 07-Sep-2025 , 02-Oct-2025 , 04-Jan-2026 [Optional][LOI/Pre-App], 07-Jan-2026 , 03-Feb-2026 , 05-May-2026 [Optional][LOI/Pre-App], 07-May-2026 , 04-Jun-2026 , 03-Sep-2026 [Optional][LOI/Pre-App], 07-Sep-2026 , 02-Oct-2026 , 07-Jan-2027</p> <p>Synopsis   The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This FOA will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.</p>				
115585	<p><a href="#">Notice of Special Interest (NOSI): Development of Functional Assay Sites to Evaluate Candidate -Omics Variants Associated with Heart, Lung, Blood, or Sleep Disease (R01, R41, R42, R43, R44)</a></p>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-23-066	07-May-2024	Not Specified
	<p>Contact Name   Charlene Schramm, Ph.D.</p> <p>Contact Telephone   301-402-3793</p> <p>Contact Email   <a href="mailto:schrammc@nih.gov">schrammc@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 07-May-2025 , 05-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 05-Jan-2026 , 07-Jan-2026 , 05-Feb-2026 , 05-Apr-2026 , 07-May-2026 , 05-Jun-2026 , 05-Sep-2026 , 07-Sep-2026</p> <p>Synopsis   The NHLBI is issuing this Notice of Special Interest (NOSI) to highlight interest in receiving grant applications focused on HLBS disorders in the following area(s): Development and/or application of moderate- or high-throughput functional assays to provide biological validation of candidate human variants associated with HLBS disorders Defining causal relationships</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| between genotypes and phenotypes Development and validation of functionally informed risk predictions

108514	<a href="#">RFA-HG-22-004 -- Genome Research Experiences to Attract Talented Undergraduates into Genomic Fields to Enhance Diversity (R25 Clinical Trial Not Allowed)</a>	National Human Genome Research Institute/NIH/DHHS	RFA-HG-22-004	01-Jun-2024 [Optional][LOI/Pre-App]	1,750,000 USD
--------	---	---	---------------	-------------------------------------	---------------

Contact Name	Tina Gatlin, Ph.D.
Contact Telephone	301-480-2280
Contact Email	<a href="mailto:gatlincl@nih.gov">gatlincl@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-Jun-2024 [Optional][LOI/Pre-App], 01-Jul-2024

Synopsis

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support educational activities that encourage undergraduates from diverse backgrounds, including those from groups underrepresented in the biomedical workforce, to pursue further training and careers in the scientific, medical, ethical, social and/or legal areas of genomics research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences Courses for Skills Development This Genome Research Experiences to Attract Talented Undergraduates into the Genomic Field to Promote Diversity (GREAT) Program will support collaborative institutional partnerships that provide research education programs for undergraduates enrolled at minority-serving institutions (MSIs) or Institutional Development Award (IDeA)-eligible institutions. A partnership will include a MSI or IDeA-eligible institution, and one or more research-intensive institutions or organizations with a suitable research base for graduate-level training in scientific areas of interest to NHGRI.

108325	<a href="#">Notice of Special Interest (NOSI): Development and Implementation of Clinical Informatics Tools to Enhance Patients' Use of Genomic Information</a>	National Human Genome Research Institute/NIH/DHHS	NOT-HG-22-011	07-May-2024	Not Specified
--------	---	---	---------------	-------------	---------------

Contact Name	Ken Wiley, Jr., Ph.D.
Contact Telephone	301-435-5540

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:ken.wiley@nih.gov">ken.wiley@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The National Human Genome Research Institute (NHGRI) is issuing a Notice of Special Interest (NOSI) to encourage applications to develop and implement patient-facing genomic-based clinical informatics tools that facilitate or enhance patient-provider electronic communication, patient tracking and registry functions, patient self-management and support, provider electronic prescribing, test tracking, referral tracking, and health care decision-making.</p>				
107786	<a href="#">Notice of Special Interest (NOSI): Methods Development for Genomic Studies of Genetic Variation, Function, and Disease</a>	National Human Genome Research Institute/NIH/DHHS	NOT-HG-22-007	07-May-2024	Not Specified
	<p>Contact Name Lisa D. Brooks, Ph.D.</p> <p>Contact Telephone 301-547-1387</p> <p>Contact Email <a href="mailto:lisa.brooks@nih.gov">lisa.brooks@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024</p> <p>Synopsis The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications that develop novel computational or experimental approaches for genomic studies of how genetic variants relate to genomic function, phenotype, and disease.</p>				
113281	<a href="#">NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-22-225	07-May-2024	Not Specified
	<p>Contact Name Mr. Martin Gutierrez, B.S.</p> <p>Contact Telephone 240-292-4844</p> <p>Contact Email <a href="mailto:mgutierrez@niaid.nih.gov">mgutierrez@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 11-Jun-2024 , 07-Sep-2024 , 10-Jan-2025 , 07-May-2025 , 11-Jun-2025 , 07-Sep-2025</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs should address scientific areas relevant to the NIAID mission including: biology and pathogenesis of infectious microbes, including HIV; host-microbe interactions; mechanisms regulating immune system development and function across the lifespan, and in response to infectious pathogens; immune dysfunction resulting in allergy, asthma, autoimmunity, immunodeficiency, or transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious and immune-mediated diseases. Each P01 application submitted to this FOA must include at least two related, synergistic research projects that share a common central theme, focus, and/or overall objective; and an administrative core. A P01 may include scientific cores, if needed for the proposed research.</p>			
123129	<a href="#">RFA-AI-24-002 -- Research Initiative for Vaccine and Antibiotic Allergy (UG3/UH3 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-24-002	22-May-2024 [Optional][LOI/Pre-App]	1,250,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	<p>Patricia Fulkerson, MD, PhD                      202-641-4535  <a href="mailto:patricia.fulkerson@nih.gov">patricia.fulkerson@nih.gov</a>    <a href="#">Link to program URL</a>                      22-May-2024 [Optional][LOI/Pre-App], 21-Jun-2024                      The purpose of this notice of funding opportunity (NOFO) is to support research that enhances understanding of the mechanisms and management of vaccine and antibiotic drug allergy.</p>			
108513	<a href="#">NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-22-075	07-May-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	<p>    <a href="mailto:AITrainingHelpDesk@niaid.nih.gov">AITrainingHelpDesk@niaid.nih.gov</a>    <a href="#">Link to program URL</a>                      07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025                      The purpose of the NIAID Career Transition Award program is to assist postdoctoral fellows' transition to positions of</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by another investigator.			
115066	<a href="#">NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-23-071	07-May-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	301-594-5945 <a href="mailto:AITrainingHelpDesk@niaid.nih.gov">AITrainingHelpDesk@niaid.nih.gov</a> <a href="#">Link to program URL</a> 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-23-070).			
115065	<a href="#">NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-23-070	07-May-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	301-594-5945 <a href="mailto:AITrainingHelpDesk@niaid.nih.gov">AITrainingHelpDesk@niaid.nih.gov</a>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 12-Jun-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-23-071)</p>				
113372	<a href="#">Notice of Special Interest (NOSI): Halting Tuberculosis (TB) Transmission</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-22-064	07-May-2024	Not Specified
	<p>Contact Name Karen Lacourciere, Ph.D.</p> <p>Contact Telephone 240-627-3297</p> <p>Contact Email <a href="mailto:lacourcierek@niaid.nih.gov">lacourcierek@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID's interest in accepting applications that aim to understand the critical drivers of Tuberculosis (TB) transmission at the individual and population levels in high-burden settings. Applicants are encouraged to develop effective methods to measure rates of TB transmission that rely on an increased understanding of the biomedical basis of transmission and related risk factors and to develop and assess potential interventions, including low-cost and low-tech options, to prevent TB transmission.</p>				
113565	<a href="#">Notice of Special Interest (NOSI): argeting the Pathogen within the Arthropod Vector</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-22-074	07-May-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Adriana Costero-Saint Denis, Ph.D.</p> <p>Contact Telephone   240-292-4184</p> <p>Contact Email   <a href="mailto:acostero@niaid.nih.gov">acostero@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis   This Notice of Special Interest (NOSI) invites applications to stimulate multidisciplinary research to better understand pathogen/vector interactions to identify approaches to prevent pathogen transmission to the vertebrate host.</p>				
114374	<a href="#">Notice of Special Interest (NOSI): Complement in Fundamental Immunology</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-23-012	07-May-2024	Not Specified
	<p>Contact Name   Ari Joffe, PhD</p> <p>Contact Telephone   240-669-5084</p> <p>Contact Email   <a href="mailto:ari.joffe@nih.gov">ari.joffe@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis   The main objective of this program is to support studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses involved in pathogenic infections, vaccination, post-infection sequelae, autoimmunity, allergy, or transplantation. The results of such studies will inform the development of vaccines or therapeutics that target complement components.</p>				
105630	<a href="#">Notice of Special Interest (NOSI): Understanding the Immune Functions of DEAD/H-box Helicases</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-21-066	07-May-2024	Not Specified
	<p>Contact Name   Qian "Joy" Liu, M.D., M.Sc.</p> <p>Contact Telephone   301-761-6621</p> <p>Contact Email   <a href="mailto:liujoy@niaid.nih.gov">liujoy@niaid.nih.gov</a></p> <p>Sponsor Website  </p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis This Notice of Special Interest (NOSI) supports research aimed at gaining a comprehensive understanding of the expression, function, and regulation of DEAD/H-box helicases in immune homeostasis, activation, and/or function. Knowledge obtained from such studies may be applied to the design of improved vaccines and immunotherapies to combat pathogenic infections or treat/prevent immune-mediated diseases.</p>				
105735	<a href="#">Notice of Special Interest (NOSI): Using the Collaborative Cross (CC) Mouse Model for Immunoregulatory and Infectious Disease Research</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-21-071	07-May-2024	Not Specified
	<p>Contact Name Qian “Joy” Liu, M.D., M.Sc.</p> <p>Contact Telephone 301-761-6621</p> <p>Contact Email <a href="mailto:liujoy@niaid.nih.gov">liujoy@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The National Institute of Allergy and Immunology (NIAID) is issuing this Notice of Special Interest (NOSI) to highlight interest in receiving grant applications focusing on the following area(s): Use mouse lines from the Collaborative Cross (CC) and recombinant inbred intercrosses of CC lines (CC-RIX) to more faithfully reproduce human immune responses and to advance understanding of the host genetics involved in immune regulation and function Screen CC mouse lines to identify and characterize lines suitable for specific studies and disease models within the mission of NIAID (e.g., fundamental immunology, immune-mediated diseases, infectious diseases).</p>				
106991	<a href="#">Notice of Special Interest (NOSI): Leveraging Microbial Exposure for Improving Mouse Models of Human Immunity</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-21-072	07-May-2024	Not Specified
	<p>Contact Name Qian “Joy” Liu, M.D., M.Sc.</p> <p>Contact Telephone 301-761-6621</p> <p>Contact Email <a href="mailto:niaidmousemodelnosi@nih.gov">niaidmousemodelnosi@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This Notice of Special Interest (NOSI) solicits research on immunologic characterization of mice with diverse microbial exposures (commonly referred to as “dirty mice”) to determine their usefulness as research tools to advance understanding of human immune function in homeostasis and in response to infectious or immune-mediated diseases.			
107851	<a href="#">Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Universal Influenza Vaccine</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-22-013	07-May-2024	Not Specified
	Contact Name	Jennifer L. Gordon, Ph.D.			
	Contact Telephone	301-761-6805			
	Contact Email	<a href="mailto:Jennifer.gordon2@nih.gov">Jennifer.gordon2@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025			
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to support research that contributes to the areas of interest outlined in “A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.”			
123682	<a href="#">Understanding Mechanisms and Outcomes of Trained Immunity (R21 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-24-111	16-Jun-2024	275,000 USD
	Contact Name	Ari Joffe, Ph.D.			
	Contact Telephone	240-669-5084			
	Contact Email	<a href="mailto:ari.joffe@nih.gov">ari.joffe@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026			
	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to support research that improves understanding of basic mechanisms and biomarkers of trained immunity (i.e., innate immune memory), plus the functional implications of trained immunity, related to 1) immune system development and function, 2) immunity to vaccines or natural infections, or 3) allergic diseases, autoimmunity, or rejection of organ/tissue/cell transplantation.			
107638	<a href="#">Notice of Special Interest (NOSI): Accelerating Malaria Vaccine Discovery</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-22-014	07-May-2024	Not Specified



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Annie Mo, Ph.D.</p> <p>Contact Telephone   240-627-3320</p> <p>Contact Email   <a href="mailto:moa@niaid.nih.gov">moa@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025</p> <p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants about an area of special interest to NIAID on early phase translational research that will generate new malaria vaccine candidates with desirable features suitable for further downstream development and clinical evaluation. This NOSI encourages studies that will lead to discovery of new vaccine candidates that prevent infection, ameliorate disease, and/or interrupt transmission caused by human malaria parasites, especially Plasmodium falciparum and Plasmodium vivax.</p>				
123681	<a href="#">Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-24-112	05-Jun-2024	Not Specified
	<p>Contact Name   Ari Joffe, Ph.D.</p> <p>Contact Telephone   240-669-5084</p> <p>Contact Email   <a href="mailto:ari.joffe@nih.gov">ari.joffe@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis   The purpose of this Notice of Funding Opportunity (NOFO) is to support research that improves understanding of basic mechanisms and biomarkers of trained immunity (i.e., innate immune memory), plus the functional implications of trained immunity, related to 1) immune system development and function, 2) immunity to vaccines or natural infections, or 3) allergic diseases, autoimmunity, or rejection of organ/tissue/cell transplantation.</p>				
113395	<a href="#">NIAID Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-22-241	07-May-2024	Not Specified
	<p>Contact Name   Diane Adger-Johnson, MPH</p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:AITrainingHelpDesk@niaid.nih.gov">AITrainingHelpDesk@niaid.nih.gov</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 05-Jul-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 05-Mar-2025 , 07-May-2025 , 05-Jun-2025 , 05-Jul-2025 , 07-Sep-2025			
	Synopsis	The purpose of this funding opportunity announcement is to encourage applications for research projects within the NIAID mission. This FOA seeks to support either (a) a New Investigator (NI), an individual who has not previously competed successfully for substantial, independent funding from NIH, or (b) are an 'At-Risk' investigator, an individual who had prior support as a PD/PI on a substantial independent research award and unless successful in securing a substantial research grant award in the current fiscal year, will have no substantial research grant funding in the following fiscal year, from diverse backgrounds, including those from groups underrepresented in the health-related sciences.			
124616	<a href="#">RFA-AI-23-077 -- Center of Excellence for Systems Modeling of Infection and Immunity across Biological Scales (U54 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-23-077	05-May-2024 [Optional][LOI/Pre-App]	15,625,000 USD
	Contact Name	Jason Lundgren			
	Contact Telephone	240-669-2973			
	Contact Email	<a href="mailto:lundgrenj@mail.nih.gov">lundgrenj@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-May-2024 [Optional][LOI/Pre-App], 04-Jun-2024			
	Synopsis	The purpose of this notice of funding opportunity (NOFO) is to support the establishment of one (1) Center of Excellence (CoE) to coordinate the research community of infectious and immune-mediated disease (IID) computational modelers and advance IID modeling research across biological scales. The CoE must include three (3) Coordinating Cores and two (2) Research Projects to advance and integrate bridge models across scales in the context of IID, including HIV/AIDS. The CoE will accelerate multi-scale model development, sharing and re-use, and support collaboration to benefit the entire IID research community. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.			
124850	<a href="#">RFA-RM-24-007 -- Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-RM-24-007	26-Jun-2024 [Optional][LOI/Pre-App]	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
App]					
	<p>Contact Name   Betty Poon, Ph.D.</p> <p>Contact Telephone   240-669-5024</p> <p>Contact Email   <a href="mailto:poonb@mail.nih.gov">poonb@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   26-Jun-2024 [Optional][LOI/Pre-App], 26-Jul-2024</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications on the optimization and characterization of technologies and assays with the potential for utilization and adoption in regulatory submissions of genome editing therapeutics. This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (<a href="https://commonfund.nih.gov/">https://commonfund.nih.gov/</a>) through the NIH Office of the NIH Director, Office of Strategic Coordination (<a href="https://dpcpsi.nih.gov/">https://dpcpsi.nih.gov/</a>). All NIH Institutes and Centers participate in Common Fund initiatives. The FOA will be administered by the National Institute of Allergy and Infectious Diseases (NIAID) on behalf of the NIH.</p>				
124938	<a href="#">RFA-AI-24-010 -- Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-24-010	29-May-2024 [Optional][LOI/Pre-App]	3,500,000 USD
	<p>Contact Name   Karen Lacourciere, PhD</p> <p>Contact Telephone   240-627-3297</p> <p>Contact Email   <a href="mailto:lacourcierek@niaid.nih.gov">lacourcierek@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   29-May-2024 [Optional][LOI/Pre-App], 28-Jun-2024</p> <p>Synopsis   The purpose of this notice of funding opportunity (NOFO) is to support the evaluation of early-stage diagnostics and novel diagnostic strategies for Tuberculosis (TB) in the context of existing clinical algorithms in TB endemic countries. Evaluation studies should: 1) perform proof-of principle studies of novel diagnostic tests and strategies for TB, including among people living with HIV (PLWH) and 2) provide feedback to diagnostic developers and policy makers on the performance of the technologies and most effective strategies for use of the diagnostic technologies in an endemic setting.</p>				
124966	<a href="#">RFA-AI-24-009 -- Limited Interaction Targeted Epidemiology: Epidemiology of Transmission and Treatment of HIV Among People Who</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-24-009	30-Jun-2024 [Optional][LOI/Pre-App]	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[Are at Increased Risk for HIV Infection in Latin America \(LITE-LA\) \(UG3/UH3 Clinical Trial Optional\)](#)

App]

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)  Synopsis	Gerald B. Sharp, Dr.P.H. 240-627-3217 <a href="mailto:GSharp@niaid.nih.gov">GSharp@niaid.nih.gov</a>  <a href="#">Link to program URL</a> 30-Jun-2024 [Optional][LOI/Pre-App], 30-Jul-2024  The purpose of this notice of funding opportunity (NOFO) is to support investigators who will form large, electronically-generated cohorts in Latin America of HIV-negative men who have sex with men (MSM), transgender women (TGW), people who inject drugs (PWID), and/or female sex-workers and follow them to study the epidemiology of HIV incidence. Continued follow-up of those persons who acquire HIV will be required to study the epidemiology of viral suppression. Descriptions of these groups and comparisons of participants by seroconversion status will provide information on geographic and socially defined areas of high HIV incidence as well as on both personal and structural vulnerabilities to HIV infection. Studies of participants who seroconvert and comparisons of those becoming rapidly engaged in care and who reach non-detectable HIV levels to those whose virus remains detectable will inform on the treatment of HIV in Latin American countries. This NOFO will allow digital trials to determine optimal study approaches, or to pilot evidence-based digital (mHealth and online) HIV prevention and treatment interventions to both reduce HIV incidence and improve treatment in Latin America.
--	---

124968	<a href="#">RFA-AI-24-018 -- Interaction between ARVs and Hormones in HIV and Coinfections (R01 Clinical Trial Optional)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-24-018	30-Jun-2024 [Optional][LOI/Pre-App]	Not Specified
--------	--	--	---------------	-------------------------------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)  Synopsis	Cherlynn Mathias 240-292-4791 <a href="mailto:cmathias@mail.nih.gov">cmathias@mail.nih.gov</a>  <a href="#">Link to program URL</a> 30-Jun-2024 [Optional][LOI/Pre-App], 30-Jul-2024  The purpose of this Notice of Funding Opportunity (NOFO) is to support research to identify and characterize the interaction between hormone therapy and antiretroviral drugs (ARVs) used for treatment and prevention of HIV and co-infections.
--	---

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
124822	<a href="#">RFA-AI-24-011 -- HIV/AIDS Clinical Trials Units (UM1 Clinical Trial Required)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-24-011	30-Jun-2024 [Optional][LOI/Pre-App]	2,000,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Leia Novak, Ph.D.</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-761-7825</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;"><a href="mailto:Leia.novak@nih.gov">Leia.novak@nih.gov</a></td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;"><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">30-Jun-2024 [Optional][LOI/Pre-App], 30-Jul-2024</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;"> <p>The purpose of this Notice of Funding Opportunity (NOFO) is to support the development of clinical research platforms that will enable future clinical trials to determine whether combinations of HIV cure strategies can be effective when optimally tailored to the participants. The ultimate goal is for the results of such proof-of-concept clinical studies to inform the development and prioritization of more broad-based curative strategies that will be effective in all people living with HIV. This NOFO will support multidisciplinary teams to conduct coordinated basic and pre-clinical research to profile participants' intact, rebound-competent HIV reservoirs and immunologic backgrounds and use that information to develop and test combinations of HIV curative approaches that are specifically tailored to those participants.</p> </td> </tr> </table>					Contact Name	Leia Novak, Ph.D.	Contact Telephone	301-761-7825	Contact Email	<a href="mailto:Leia.novak@nih.gov">Leia.novak@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	30-Jun-2024 [Optional][LOI/Pre-App], 30-Jul-2024	Synopsis	<p>The purpose of this Notice of Funding Opportunity (NOFO) is to support the development of clinical research platforms that will enable future clinical trials to determine whether combinations of HIV cure strategies can be effective when optimally tailored to the participants. The ultimate goal is for the results of such proof-of-concept clinical studies to inform the development and prioritization of more broad-based curative strategies that will be effective in all people living with HIV. This NOFO will support multidisciplinary teams to conduct coordinated basic and pre-clinical research to profile participants' intact, rebound-competent HIV reservoirs and immunologic backgrounds and use that information to develop and test combinations of HIV curative approaches that are specifically tailored to those participants.</p>
Contact Name	Leia Novak, Ph.D.																		
Contact Telephone	301-761-7825																		
Contact Email	<a href="mailto:Leia.novak@nih.gov">Leia.novak@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	30-Jun-2024 [Optional][LOI/Pre-App], 30-Jul-2024																		
Synopsis	<p>The purpose of this Notice of Funding Opportunity (NOFO) is to support the development of clinical research platforms that will enable future clinical trials to determine whether combinations of HIV cure strategies can be effective when optimally tailored to the participants. The ultimate goal is for the results of such proof-of-concept clinical studies to inform the development and prioritization of more broad-based curative strategies that will be effective in all people living with HIV. This NOFO will support multidisciplinary teams to conduct coordinated basic and pre-clinical research to profile participants' intact, rebound-competent HIV reservoirs and immunologic backgrounds and use that information to develop and test combinations of HIV curative approaches that are specifically tailored to those participants.</p>																		
124947	<a href="#">RFA-AI-24-008 -- Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-24-008	30-Jun-2024 [Optional][LOI/Pre-App]	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Angela Malaspina, Ph.D.</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-825-3859</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;"><a href="mailto:angela.malaspina@nih.gov">angela.malaspina@nih.gov</a></td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;"><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">30-Jun-2024 [Optional][LOI/Pre-App], 30-Jul-2024</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;"> <p>The purpose of this Notice of Funding Opportunity (NOFO) is to support product-focused research to advance controlled release vaccine strategies to improve immune responses for HIV prevention, treatment, and cure and develop simplified or single-shot vaccination formulations. Timelines with measurable milestones are required.</p> </td> </tr> </table>					Contact Name	Angela Malaspina, Ph.D.	Contact Telephone	301-825-3859	Contact Email	<a href="mailto:angela.malaspina@nih.gov">angela.malaspina@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	30-Jun-2024 [Optional][LOI/Pre-App], 30-Jul-2024	Synopsis	<p>The purpose of this Notice of Funding Opportunity (NOFO) is to support product-focused research to advance controlled release vaccine strategies to improve immune responses for HIV prevention, treatment, and cure and develop simplified or single-shot vaccination formulations. Timelines with measurable milestones are required.</p>
Contact Name	Angela Malaspina, Ph.D.																		
Contact Telephone	301-825-3859																		
Contact Email	<a href="mailto:angela.malaspina@nih.gov">angela.malaspina@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	30-Jun-2024 [Optional][LOI/Pre-App], 30-Jul-2024																		
Synopsis	<p>The purpose of this Notice of Funding Opportunity (NOFO) is to support product-focused research to advance controlled release vaccine strategies to improve immune responses for HIV prevention, treatment, and cure and develop simplified or single-shot vaccination formulations. Timelines with measurable milestones are required.</p>																		
124933	<a href="#">RFA-AI-24-006 -- Centers for Research in Emerging Infectious Diseases</a>	National Institute of Allergy and	RFA-AI-	22-May-2024	4,250,000														

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">(CREID) Network (U01 Clinical Trial Not Allowed)</a>	Infectious Diseases/NIH/DHHS	24-006	[Optional][LOI/Pre-App]	USD
	<p>Contact Name Sara E. Woodson, PhD</p> <p>Contact Telephone 301-761-6478</p> <p>Contact Email <a href="mailto:woodsonse@niaid.nih.gov">woodsonse@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 22-May-2024 [Optional][LOI/Pre-App], 21-Jun-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Centers for Research in Emerging Infectious Diseases (CREID) Network Research Centers (RCs). The CREID Network, comprised of all recipients under this NOFO and the companion NOFO [RFA-AI-24-016], serves to expand knowledge on re-emerging and emerging infectious diseases (re/EIDs) around the globe where outbreaks are most likely to occur while developing expertise, capacity, and readiness to address outbreak-related research. Multi- and interdisciplinary teams of domestic and international investigators will conduct innovative, collaborative, hypothesis-driven One Health (approach that recognizes the health of humans is interconnected with that of animal health and the shared environment) based research, will undertake outbreak-related research when necessary in their geographical areas, and will work across the CREID Network in a coordinated, collaborative, and cooperative fashion.</p>				
124934	<a href="#">RFA-AI-24-016 -- Centers for Research in Emerging Infectious Diseases (CREID) Network Coordination Center (U01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-24-016	22-May-2024 [Optional][LOI/Pre-App]	7,500,000 USD
	<p>Contact Name Sara E. Woodson, PhD</p> <p>Contact Telephone 301-761-6478</p> <p>Contact Email <a href="mailto:woodsonse@niaid.nih.gov">woodsonse@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 22-May-2024 [Optional][LOI/Pre-App], 21-Jun-2024</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to invite applications for the Centers for Research in Emerging Infectious Diseases (CREID) Network Coordination Center (CC). The CREID Network, comprised of all recipients under this NOFO and the companion NOFO [RFA-AI-24-006], serves to expand knowledge on re-emerging and emerging infectious</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		diseases (re/EIDs) around the globe where outbreaks are most likely to occur while developing expertise, capacity, and readiness to address outbreak-related research. The CC will serve to lead, advance, facilitate, and coordinate critical and collaborative scientific, data and resource management, communication, and administrative activities during both outbreak and non-outbreak periods among the CREID Network research centers in a coordinated, collaborative and cooperative fashion.			
116360	<a href="#">Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Coccidioidomycosis (Valley fever) Vaccine</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-23-031	07-May-2024	Not Specified
	Contact Name	Dona C. Love, Ph.D.			
	Contact Telephone	301-761-7788			
	Contact Email	<a href="mailto:Dona.Love@nih.gov">Dona.Love@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026			
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID’s interest in supporting research in the areas outlined in the NIAID Strategic Plan For Research To Develop A Valley Fever Vaccine. The proposed research should have clear relevance to the strategic priorities defined in the strategic plan, which encompasses three major research areas: 1) address gaps in Coccidioides basic research to support the development of a vaccine; 2) develop tools and resources to support vaccine development; 3) develop and advance vaccines to prevent coccidioidomycosis.			
109336	<a href="#">Notice of Special Interest (NOSI): Optimizing Vascularized Composite Allograft Survival</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-22-023	07-May-2024	Not Specified
	Contact Name	Patricia Kehn, Ph.D.			
	Contact Telephone	240-627-3547			
	Contact Email	<a href="mailto:pkehr@NIAID.nih.gov">pkehr@NIAID.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

		Feb-2026 , 07-May-2026			
	Synopsis	<p>The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting preclinical studies utilizing animal models or human tissue specimens that focus on 1) optimizing treatment and graft monitoring to reduce incidence of acute rejection and maximize graft survival after vascularized composite allotransplantation (VCA) and 2) minimizing immunosuppression required for long-term VCA acceptance.</p>			

109528	<a href="#">Limited Competition: Small Grant Program for NIAMS K01, K08, K23, and K25 Recipients (R03) (Clinical Trials Not Allowed)</a>	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-22-119	19-Jun-2024	100,000 USD
--------	--	--	------------	-------------	-------------

	Contact Name	Su-Yau Mao, Ph.D.			
	Contact Telephone	301-594-5032			
	Contact Email	<a href="mailto:maos2@mail.nih.gov">maos2@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	19-Jun-2024 , 21-Oct-2024 , 19-Feb-2025			
	Synopsis	<p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) announces a program that provides NIAMS-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support at an appropriate point during the second to fourth year of their K award. Through the use of this mechanism, which allows up to \$100,000 direct costs for the entire project period of up to two years, the NIAMS is seeking to enhance the capability of its scientists to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that provide support, in addition to the career development award, for a subsequent R01, or equivalent, application. Clinical trials of any phase will not be supported by this FOA.</p>			

117716	<a href="#">Notice of Special Interest (NOSI): Supporting Exploratory/Developmental Research Focused on NIAMS Core Mission Areas</a>	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR-23-006	07-May-2024	Not Specified
--------	--	--	---------------	-------------	---------------

	Contact Name	Jana Eisenstein			
	Contact Telephone	301-594-5032			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:jana.eisenstein@nih.gov">jana.eisenstein@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 06-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 06-Dec-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 09-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 06-Aug-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Dec-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 16-Oct-2026 , 07-Jan-2027</p> <p>Synopsis The purpose of this announcement is to notify the research community that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is interested in receiving Exploratory/Developmental grant applications focused on NIAMS core mission areas. Awards will provide support for innovative projects that introduce novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential for significant impact, and to substantially advance research within the NIAMS mission. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs of high value to the NIAMS research community.</p>				
114290	<a href="#">Notice of Special Interest (NOSI): Promoting Research Opportunities on HIV/AIDS in NIAMS</a>	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR-23-004	07-May-2024	Not Specified
	<p>Contact Name Heiyoung Park, Ph.D.</p> <p>Contact Telephone 301-594-5032</p> <p>Contact Email <a href="mailto:parkh1@mail.nih.gov">parkh1@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 06-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 06-Dec-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 09-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 06-Aug-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Dec-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 16-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 16-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 16-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 16-Oct-2027 , 07-Jan-2028</p> <p>Synopsis The purpose of this announcement is to inform potential applicants to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of an area of special interest in HIV/AIDS-associated comorbidities that are within the NIAMS mission.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
117677	<a href="#">Notice of Special Interest (NOSI): Synthetic Biology for Biomedical Applications</a>	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	NOT-EB-23-002	06-May-2024	Not Specified
	<p>Contact Name: Hye-Sook Kim, Ph.D.</p> <p>Contact Telephone: 301-827-6910</p> <p>Contact Email: <a href="mailto:hye-sook.kim@nih.gov">hye-sook.kim@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 06-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 06-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 08-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 16-Oct-2025</p> <p>Synopsis: The purpose of this Notice is to announce that the National Center for Complementary and Integrative Health (NCCIH), the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), the National Institute on Aging (NIA), the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Institute of General Medical Sciences (NIGMS) are encouraging new applications to advance research activities relevant to synthetic biology.</p>				
107317	<a href="#">Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-21-353	05-Jun-2024	Not Specified
	<p>Contact Name: Mollie Minear, Ph.D.</p> <p>Contact Telephone: 301-827-9442</p> <p>Contact Email: <a href="mailto:mollie.minear@nih.gov">mollie.minear@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 05-Jun-2024 , 05-Oct-2024</p> <p>Synopsis: This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	infants with the condition would significantly benefit from early identification and treatment.				
113756	<a href="#">NCMRR Early Career Research Award (R03 Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-23-029	16-Jun-2024	200,000 USD
	Contact Name	Maria Nurminskaya, PhD			
	Contact Telephone	240-591-9986			
	Contact Email	<a href="mailto:Maria.nurminskaya@nih.gov">Maria.nurminskaya@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026			
	Synopsis	<p>The National Center for Medical Rehabilitation Research (NCMRR) Early Career Research (ECR) Award (R03) is intended to support both basic and clinical research from rehabilitation scientists who are establishing independent research careers. The research must be focused on one or more of the areas within the mission of NCMRR: Applicants are encouraged to refer to the NIH Research Plan on Rehabilitation for strategic priorities (<a href="https://www.nichd.nih.gov/newsroom/news/110121-NIH-rehab-plan">https://www.nichd.nih.gov/newsroom/news/110121-NIH-rehab-plan</a>). The NCMRR ECR Award R03 grant mechanism supports various types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new technology. Irrespective of the type of project, the intent of the NCMRR ECR Award R03 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.</p>			
113468	<a href="#">Notice of Special Interest (NOSI): High Priority Areas in Placental Research for Healthy Pregnancies (Reissue)</a>	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-22-049	07-May-2024	Not Specified
	Contact Name	John V. Ilekis, PhD			
	Contact Telephone	301-435-6895			
	Contact Email	<a href="mailto:ilekisj@nih.gov">ilekisj@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025			
	Synopsis	<p>Although the placenta is a short-lived organ limited to pregnancy, its importance is often underappreciated in being a crucial organ for the propagation of our species and future health of our progeny. Perturbations in any one of its many functions</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

may result in many common adverse pregnancy outcomes. These include early pregnancy loss, preeclampsia, fetal growth restriction, stillbirth, and preterm birth. In addition, a poorly functioning placenta can lead to aberrant programming of the fetus that can impact the health of the individual later in adult life. This includes an increased incidence of adult diseases such as obesity, cardiovascular disease, and diabetes. Thus, a more comprehensive understanding of the placenta is necessary to help address a number of major gaps in knowledge.

115063	<a href="#">Archiving and Documenting Child Health and Human Development Data Sets (R03 Clinical Trial Not Allowed)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-22-261	16-Jun-2024	100,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Rebecca L. Clark, PhD
Contact Telephone	301-496-1175
Contact Email	<a href="mailto:rclark@mail.nih.gov">rclark@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025
Synopsis	The purpose of this funding opportunity announcement (FOA) is to support the archiving and documentation of existing data sets within the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) in order to enable secondary analysis of these data by the scientific community. The highest priority is to archive original data collected with NICHD funding.

105045	<a href="#">Notice of Special Interest (NOSI): Promoting Vaccine Access, Acceptance and Uptake among Children, Adolescents, Pregnant and Lactating Women, and Persons with Disabilities</a>	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-21-038	07-May-2024	Not Specified
--------	---	---	---------------	-------------	---------------

Contact Name	Regina M. Bures, Ph.D.
Contact Telephone	301-496-9485
Contact Email	<a href="mailto:regina.bures@nih.gov">regina.bures@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 16-Jun-2024 , 07-Sep-2024
Synopsis	This NOSI encourages applications that address dimensions of access, acceptance and uptake of CDC-recommended vaccines among infants, children, adolescents, pregnant and lactating women, and persons with disabilities, especially among

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| populations who are underserved or experience health disparities.

107319	<a href="#">Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-21-355	16-Jun-2024	275,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Mollie Minear, Ph.D.
Contact Telephone	301-827-9442
Contact Email	<a href="mailto:mollie.minear@nih.gov">mollie.minear@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024
Synopsis	This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

107320	<a href="#">Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R03 - Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-21-354	16-Jun-2024	100,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Mollie Minear, Ph.D.
Contact Telephone	301-827-9442
Contact Email	<a href="mailto:mollie.minear@nih.gov">mollie.minear@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024
Synopsis	This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	infants with the condition would significantly benefit from early identification and treatment.																		
112833	<a href="#">Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-22-215	05-Jun-2024	2,499,995 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Reiko Toyama, Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-435-2723</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td><a href="mailto:toyamar@nih.gov">toyamar@nih.gov</a></td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The purpose of this funding opportunity announcement (FOA) is to support innovative research that will inform our understanding of the mechanisms underlying the formation of structural birth defects using animal models in conjunction with human translational/clinical approaches. Applicants are encouraged to take advantage of advances in genetics, 'omics methods (genomics, proteomics, metabolomics, etc.), and synthetic biology, biochemical and other approaches to developmental biology research to identify specific genetic, epigenetic, environmental, or gene/environment interactions associated with the formation of, susceptibility to, and variability of structural birth defects in human populations.</td> </tr> </table>					Contact Name	Reiko Toyama, Ph.D.	Contact Telephone	301-435-2723	Contact Email	<a href="mailto:toyamar@nih.gov">toyamar@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025	Synopsis	The purpose of this funding opportunity announcement (FOA) is to support innovative research that will inform our understanding of the mechanisms underlying the formation of structural birth defects using animal models in conjunction with human translational/clinical approaches. Applicants are encouraged to take advantage of advances in genetics, 'omics methods (genomics, proteomics, metabolomics, etc.), and synthetic biology, biochemical and other approaches to developmental biology research to identify specific genetic, epigenetic, environmental, or gene/environment interactions associated with the formation of, susceptibility to, and variability of structural birth defects in human populations.
Contact Name	Reiko Toyama, Ph.D.																		
Contact Telephone	301-435-2723																		
Contact Email	<a href="mailto:toyamar@nih.gov">toyamar@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025																		
Synopsis	The purpose of this funding opportunity announcement (FOA) is to support innovative research that will inform our understanding of the mechanisms underlying the formation of structural birth defects using animal models in conjunction with human translational/clinical approaches. Applicants are encouraged to take advantage of advances in genetics, 'omics methods (genomics, proteomics, metabolomics, etc.), and synthetic biology, biochemical and other approaches to developmental biology research to identify specific genetic, epigenetic, environmental, or gene/environment interactions associated with the formation of, susceptibility to, and variability of structural birth defects in human populations.																		
124780	<a href="#">RFA-HD-25-004--Optimizing Health of Children and Adolescents with Perinatal HIV Exposure (U19 Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-25-004	30-Jun-2024 [Optional][LOI/Pre-App]	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Allahna Esber, PhD</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-827-4560</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td><a href="mailto:allahna.esber@nih.gov">allahna.esber@nih.gov</a></td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>30-Jun-2024 [Optional][LOI/Pre-App], 30-Jul-2024</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>This Notice of Funding Opportunity (NOFO) invites applications to participate in a research program cooperative agreement to support the Optimizing Health of Children and Adolescents with Perinatal HIV Exposure Initiative. The objective of this NOFO is to generate information needed to develop and to test interventions for the early detection and reduction of long-term effects of in utero/perinatal exposure to antiretroviral therapy (ART) and/or HIV among individuals who are HIV exposed</td> </tr> </table>					Contact Name	Allahna Esber, PhD	Contact Telephone	301-827-4560	Contact Email	<a href="mailto:allahna.esber@nih.gov">allahna.esber@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	30-Jun-2024 [Optional][LOI/Pre-App], 30-Jul-2024	Synopsis	This Notice of Funding Opportunity (NOFO) invites applications to participate in a research program cooperative agreement to support the Optimizing Health of Children and Adolescents with Perinatal HIV Exposure Initiative. The objective of this NOFO is to generate information needed to develop and to test interventions for the early detection and reduction of long-term effects of in utero/perinatal exposure to antiretroviral therapy (ART) and/or HIV among individuals who are HIV exposed
Contact Name	Allahna Esber, PhD																		
Contact Telephone	301-827-4560																		
Contact Email	<a href="mailto:allahna.esber@nih.gov">allahna.esber@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	30-Jun-2024 [Optional][LOI/Pre-App], 30-Jul-2024																		
Synopsis	This Notice of Funding Opportunity (NOFO) invites applications to participate in a research program cooperative agreement to support the Optimizing Health of Children and Adolescents with Perinatal HIV Exposure Initiative. The objective of this NOFO is to generate information needed to develop and to test interventions for the early detection and reduction of long-term effects of in utero/perinatal exposure to antiretroviral therapy (ART) and/or HIV among individuals who are HIV exposed																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

but uninfected (IHEU). Investigators with innovative thinking and new approaches to address the public health issues facing IHEUs are encouraged to apply. A multi-program project grant is proposed to answer questions not easily addressed in an R01 or U01. The applications should answer important fundamental questions related to long-term health outcomes for IHEUs. Proposed projects should 1) have a scope that is well matched to the resources and the research objectives, 2) be scientifically meritorious, and 3) complement one another, be synergistic, and support the program's overall theme.

125122	<a href="#">RFA-HD-25-001 -- Medical Rehabilitation Research Resource (P50 Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-25-001	30-Jun-2024 [Optional][LOI/Pre-App]	3,750,000 USD
--------	---	---	---------------	-------------------------------------	---------------

Contact Name | Joe Bonner, PhD  
 Contact Telephone | 301-827-8303  
 Contact Email | [joe.bonner@nih.gov](mailto:joe.bonner@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 30-Jun-2024 [Optional][LOI/Pre-App], 30-Jul-2024

Synopsis | This Notice of Funding Opportunity (NOFO) invites grant applications from institutions/organizations that propose to build a Medical Rehabilitation Research Center. The centers will have a specific rehabilitation research theme and be comprised of a research project supported by 3 cores. The 3 cores will have functions within the center as well as functions nationwide. Together, the cores will support: administrative functions (including an optional pilot program), resource sharing, and community engagement and outreach. The Medical Rehabilitation Research Centers will contribute to medical rehabilitation research infrastructure by developing and disseminating techniques, data, theories, research programs, and expertise with the goal of enhancing the capability of medical rehabilitation investigators to understand mechanisms of functional recovery, develop therapeutic strategies, identify clinical care gaps, and improve the lives of people with disabilities. Applications must include a plan for inclusion of People with Lived Experience (as a required other attachment) that is relevant to the research theme of the center and increases the potential impact of the center.

110993	<a href="#">Short-term Mentored Career Enhancement Award in Dental, Oral and Craniofacial Research for Mid-Career and Senior Investigators (K18 Independent Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-121	07-May-2024	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name | Leslie A. Frieden, PhD  
 Contact Telephone | 301-496-4263

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025</p> <p>Synopsis The goal of the NIDCR Career Enhancement Award (K18) is to support mentored research experiences for established investigators who either wish to expand or augment their dental, oral, or craniofacial (DOC) research program, or to redirect their research by incorporating DOC research into their research program to advance fundamental knowledge about dental, oral, and craniofacial health and disease. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.</p>				
108355	<p><a href="#">NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Basic Experimental Studies Involving Humans Required)</a></p>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-043	07-May-2024	Not Specified
	<p>Contact Name Leslie A. Frieden, PhD</p> <p>Contact Telephone 301-496-4263</p> <p>Contact Email <a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is to develop and maintain a strong cohort of independently funded dentist scientists dedicated to improving dental, oral and craniofacial health. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. An option for five years of independent (R00) support is available to accommodate clinical training in a dental specialty program at no more than 3 person-months effort (25% full-time professional effort) in any year of the R00 phase. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

108353	<a href="#">NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-041	07-May-2024	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Leslie A. Frieden, PhD
Contact Telephone	301-496-4263
Contact Email	<a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025

Synopsis The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is to develop and maintain a strong cohort of independently funded dentist scientists dedicated to improving dental, oral and craniofacial health. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. An option for five years of independent (R00) support is available to accommodate clinical training in a dental specialty program at no more than 3 person-months (25% full-time professional effort) in any year of the R00 phase. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-22-042). Applicants proposing basic experimental studies in humans referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants” should apply to the companion Basic Experimental Studies with Humans FOA (PAR-22-043).

108354	<a href="#">NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-042	07-May-2024	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Leslie A. Frieden, PhD
--------------	------------------------

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-496-4263</p> <p>Contact Email   <a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025</p> <p>Synopsis   The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is to develop and maintain a strong cohort of independently funded dentist scientists dedicated to improving dental, oral and craniofacial health. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. An option for five years of independent (R00) support is available to accommodate clinical training in a dental specialty program at no more than 3 person-months effort (25% full-time professional effort) in any year of the R00 phase. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-22-041).</p>				
117230	<p><a href="#">NIDCR Research Grants for Analyses of Existing Genomics Data (R01)</a> <a href="#">(Clinical Trial Not Allowed)</a></p>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-23-133	07-May-2024	Not Specified
	<p>Contact Name   Noffisat Oki</p> <p>Contact Telephone   301-402-6778</p> <p>Contact Email   <a href="mailto:noffisat.oki@nih.gov">noffisat.oki@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis   The purpose of this NOFO is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) biology, and diseases and conditions, through analysis of existing and publicly available genomic data, with or without other types of complementary data, using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the proposed project(s), including methods for data and metadata mining, data integration, and Artificial Intelligence</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

(AI)/Machine Learning (ML)/Deep Learning (DL) methods. In addition to analysis of existing data, experimental or in silico work is required to validate the results of the proposed analysis, or to validate a newly developed analytic method. Projects aimed at understanding oral health disparities to inform strategies for improving health for all individuals are a priority. Projects focused on investigating and/or characterizing human biological pathways to inform identification of intervention targets or defining the pathogenicity of known genetic variants are encouraged.

117461	<a href="#">NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-23-162	07-May-2024	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Lorena Baccaglini, DDS, MS, PhD
Contact Telephone	301-435-7908
Contact Email	<a href="mailto:lorena.baccaglini@nih.gov">lorena.baccaglini@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026
Synopsis	This NOFO will support, through the cooperative agreement mechanism, investigator-initiated observational studies or biomarker validation studies that require prospective collection of data/biospecimens or continued analysis of data/biospecimens.

108981	<a href="#">NIDCR Mentored Career Development Award to Promote Diversity (K01 Independent Basic Experimental Studies with Humans Required)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-052	07-May-2024	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Leslie A. Frieden, Ph.D.
Contact Telephone	301-496-4263
Contact Email	<a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025
Synopsis	The purpose of the NIDCR Mentored Career Development Award to Promote Diversity is to support postdoctoral fellows and early career faculty from diverse backgrounds, including those from groups underrepresented in the biomedical, behavioral, and social sciences, to ensure a well-trained dental, oral, and craniofacial research workforce. This FOA provides salary and

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

research support for a sustained period of “protected time” for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA.

108979	<a href="#">NIDCR Mentored Career Development Award to Promote Diversity (K01 Clinical Trial Required)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-051	07-May-2024	Not Specified
--------	--	---	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Leslie A. Frieden, Ph.D.</p> <p>301-496-4263</p> <p><a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025</p> <p>The purpose of the NIDCR Mentored Career Development Award to Promote Diversity is to support postdoctoral fellows and early career faculty from diverse backgrounds, including those from groups underrepresented in the biomedical, behavioral, and social sciences, to ensure a well-trained dental, oral, and craniofacial research workforce. This FOA provides salary and research support for a sustained period of “protected time” for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-22-050).</p>
---	--

108980	<a href="#">NIDCR Mentored Career Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-050	07-May-2024	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name | Leslie A. Frieden, Ph.D.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-496-4263</p> <p>Contact Email   <a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025</p> <p>Synopsis   The purpose of the NIDCR Mentored Career Development Award to Promote Diversity is to support postdoctoral fellows and early career faculty from diverse backgrounds, including those from groups underrepresented in the biomedical, behavioral, and social sciences, to ensure a well-trained dental, oral, and craniofacial research workforce. This FOA provides salary and research support for a sustained period of “protected time” for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-22-051).</p>				
100931	<a href="#">NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21-084	07-May-2024	200,000 USD
	<p>Contact Name   Preethi Chander, PhD</p> <p>Contact Telephone   301-827-4620</p> <p>Contact Email   <a href="mailto:preethi.chander@nih.gov">preethi.chander@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   This NIDCR Small Grant Program for New Investigators supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This R03 program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator- initiated Research Project Grant (R01) or equivalent application.</p>				
102596	<a href="#">NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21-160	07-May-2024	Not Specified
	<p>Contact Name   Dena Fischer, DDS, MSD, MS</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-594-4876</p> <p>Contact Email   <a href="mailto:dena.fischer@nih.gov">dena.fischer@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 06-Jun-2024 , 06-Sep-2024 , 03-Oct-2024 , 08-Jan-2025</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) will support UG3/UH3 phased, cooperative agreement research applications to plan and implement clinical trials within the mission of the National Institute of Dental and Craniofacial Research (NIDCR). Studies appropriate for this FOA are those testing diagnostic, prevention or treatment approaches to test a drug, biologic, device, or procedure for dental, oral, or craniofacial diseases or conditions, including trials for any phase of testing for a Food and Drug Administration (FDA)-regulated product. Awards made under this FOA will initially support a one-year milestone-driven UG3 planning phase, with possible transition to a UH3 clinical trial implementation phase of up to five years. The UH3 phase of the award will support the conduct of one investigator-initiated clinical trial. The UG3 planning phase permits both operational and scientific planning activities. Operational planning activities include, at minimum, finalizing the protocol and preparing other documents to implement the clinical trial (e.g., data collection instruments, Manual of Procedures, data management plan). Allowable scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned intervention and associated study procedures (e.g., acceptability of mode of intervention delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures) and assessment of the subject population to determine recruitment potential for the future trial. The UG3 phase cannot be used to test for intervention safety or efficacy. If the application proposes a clinical trial with an investigational drug, biologic or device, the investigators must have submitted the appropriate investigational application to the FDA prior to the UH3 phase.</p>				
110754	<a href="#">Notice of Special Interest (NOSI): Achieving Tissue Robustness Through Harnessing Immune System Plasticity</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	NOT-DE-22-005	07-May-2024	Not Specified
	<p>Contact Name   Preethi Chander, PhD</p> <p>Contact Telephone   301-827-4620</p> <p>Contact Email   <a href="mailto:preethi.chander@nih.gov">preethi.chander@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	<p>Synopsis</p>	<p>NIDCR announces its interest in encouraging state-of-the-art, systematic research approaches to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations, and to examine immune mechanisms of protection against recurrence of chronic inflammation in response to infectious and autoimmune diseases of dental, oral, and craniofacial (DOC) tissues. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward protection against episodic recurrence and preventative disease management in a patient-specific manner across the lifespan.</p>			
--	-----------------	--	--	--	--

117231	<a href="#">NIDCR Small Research Grants for Analyses of Existing Genomics Data (R03 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-23-132	07-May-2024	200,000 USD
--------	---	---	------------	-------------	-------------

	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Noffisat Oki</p> <p>301-402-6778</p> <p><a href="mailto:noffisat.oki@nih.gov">noffisat.oki@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026</p> <p>The purpose of this NOFO is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) biology, and diseases and conditions, through analysis of existing and publicly available genomic data, with or without other types of complementary data, using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the proposed project(s), including methods for data and metadata mining, data integration, and Artificial Intelligence (AI)/Machine Learning (ML)/Deep Learning (DL) methods. Projects focused on investigating and/or characterizing human biological pathways to inform identification of intervention targets or defining the pathogenicity of known genetic variants are encouraged.</p>			
--	---	---	--	--	--

116699	<a href="#">Notice of Special Interest (NOSI): NIDCR Support for Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 (COVID-19)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	NOT-DE-23-004	07-May-2024	Not Specified
--------	--	---	---------------	-------------	---------------

	<p>Contact Name</p> <p>Contact Telephone</p>	<p>Amanda Melillo, Ph.D.</p> <p>301-529-7217</p>			
--	--	--	--	--	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:amanda.melillo@nih.gov">amanda.melillo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026</p> <p>Synopsis The National Institute of Dental and Craniofacial Research (NIDCR) is reissuing this Notice of Special Interest (NOSI) to encourage research studies focused on the physiological involvement of oral cavity and oral manifestations related to SARS-CoV-2 and/or Coronavirus Disease 2019 (COVID-19).</p>				

106245	<a href="#">NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21-317	07-May-2024	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Melissa W. Riddle, PhD
Contact Telephone	301-451-3888
Contact Email	<a href="mailto:riddleme@mail.nih.gov">riddleme@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 04-Jun-2024 , 06-Sep-2024 , 03-Oct-2024 , 07-Jan-2025
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage UG3/UH3 phased cooperative agreement research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this FOA include clinical trials to develop and test behavior change interventions related to dental, oral, or craniofacial conditions. Applications for NIDCR support of clinical trials research are expected to identify research proposals using the NIH Stage Model framework, described in detail here and incorporate an experimental medicine approach. Awards made under this FOA will initially support a milestone-driven UG3 planning phase for up to 2 years, with possible transition to a UH3 clinical trial implementation phase (UH3) of up to five years. The UG3 phase for behavioral and social intervention clinical trials will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned behavioral or social intervention and associated study procedures (e.g., acceptability of study content or mode of delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures). Operational planning activities include, at a minimum, development of: the final clinical protocol; the intervention manual or equivalent; the data management system and other



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

tools for data and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents. The UH3 phase will support the conduct of investigator-initiated intervention research at all stages, from early mechanistic research and intervention development (e.g., Stages 0/ I) through implementation and health services research (Stages IV/V). This FOA may also support basic behavioral experimental studies with humans that are considered clinical trials based on the NIH's revised clinical trial definition (please see Clinical Trial Requirements for Grants and Contracts for guidance).

125150	<a href="#">RFA-RM-24-006 -- Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-RM-24-006	27-Jun-2024	200,000 USD
--------	---	---	---------------	-------------	-------------

Contact Name | George J. Papanicolaou, Ph.D.  
 Contact Telephone | 301-480-6722  
 Contact Email | [george.papanicolaou@nih.gov](mailto:george.papanicolaou@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 27-Jun-2024

Synopsis | Many valuable and widely available data sets have been generated by multiple Common Fund programs. The purpose of this NOFO is to announce the availability of funding to demonstrate and enhance the utility of selected Common Fund (<https://commonfund.nih.gov/>) data sets, including generating hypotheses and catalyzing discoveries. Award recipients are asked to provide feedback on the utility of the Common Fund data resources.

123758	<a href="#">RFA-DK-23-011 -- Continuous Ketone Monitoring for the Safe Use of Sodium-glucose Cotransporter-2 Inhibitors in Type 1 Diabetes (R01 Clinical trial Required)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-23-011	27-May-2024 [Optional][LOI/Pre-App]	500,000 USD
--------	--	---	---------------	-------------------------------------	-------------

Contact Name | Teresa L. Z. Jones, M.D.  
 Contact Telephone | 301-435-2996  
 Contact Email | [teresa.jones@nih.gov](mailto:teresa.jones@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)

Deadline Dates (ALL) | 27-May-2024 [Optional][LOI/Pre-App], 27-Jun-2024

Synopsis | Sodium-glucose co-transporter-2 inhibitors (SGLT2i) that were developed for the treatment of type 2 diabetes (T2D) have

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>significant protective effects for cardiac and renal diseases for people with and without diabetes. However, SGLT2i are not currently approved for individuals with type 1 diabetes (T1D) and there is an increased risk of diabetic ketoacidosis (DKA) for this population. Despite this concern, these drugs are increasingly being prescribed off-label for people with T1D. Continuous ketone monitoring (CKM) is a rapidly evolving technology that could be utilized clinically to prevent DKA by an early warning of elevations in ketone levels. The purpose of this NOFO is to solicit applications for studies that will develop and test risk mitigation strategies that involve the clinical integration of CKM for the safe use of SGLT2i for people living with T1D so that they may benefit from the cardiac and renal protection and glucose-lowering effects of this drug class. The NOFO will support short-term, clinical trials to gain and disseminate knowledge on safety and glucose control with CKM and SGLT2i use. Possible topics include testing optimal insulin delivery in open and closed loop systems or multiple daily injections and developing clinical protocols to control or ameliorate elevated ketone levels in individuals with T1D who are receiving adjunct therapy with SGLT2i.</p>				
123309	<a href="#">NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-24-102	05-Jun-2024	Not Specified
	<p>Contact Name Tracy Rankin, Ph.D., M.P.H.            Contact Telephone 301-594-4748            Contact Email <a href="mailto:rankint@mail.nih.gov">rankint@mail.nih.gov</a>            Sponsor Website            Program URL <a href="#">Link to program URL</a>            Deadline Dates (ALL) 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis This NOFO invites applications for investigator-initiated, high-risk multi-center observational studies involving more than one clinical center. Proposed studies should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this NOFO. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-24-094). Consultation with NIDDK Scientific/Research Staff strongly encouraged prior to the submission of either a U34 or U01 application. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the FOA instructions carefully and view the available PEDP guidance material. (with link to <a href="https://braininitiative.nih.gov/about/plan-enhancing-diverse-perspectives-pedp">https://braininitiative.nih.gov/about/plan-enhancing-diverse-perspectives-pedp</a> for "PEDP guidance material").</p>				
105892	<a href="#">Notice of Special Interest (NOSI): Advancing Research in Gastrointestinal</a>	National Institute of Diabetes and	NOT-DK-	07-May-2024	Not

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	<a href="#">Dysfunction in People with Neurodevelopmental Disorders</a>		Digestive and Kidney Diseases/NIH/DHHS	21-024	Specified	
	<p>Contact Name   Terez Shea-Donohue, Ph.D.</p> <p>Contact Telephone   301 825-2314</p> <p>Contact Email   <a href="mailto:terez.shea-donohue@nih.gov">terez.shea-donohue@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   The National Institute of Diabetes and Digestive and Kidney Diseases is issuing this Notice to highlight interest in receiving grant applications focused in the following area(s) to support basic, translational, and/or clinical research on the causes, diagnosis, prevention, or treatment of gastrointestinal dysfunction in people with neurodevelopmental disorders. Interdisciplinary science in this area plays a pivotal role and projects are encouraged to include close collaboration between scientists with expertise in neurodevelopmental disorders and scientists with expertise in neurogastroenterology.</p>					
123312	<a href="#">NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)</a>		National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-24-103	05-Jun-2024	Not Specified
	<p>Contact Name   Tracy Rankin, Ph.D., M.P.H.</p> <p>Contact Telephone   301-594-4748</p> <p>Contact Email   <a href="mailto:rankint@mail.nih.gov">rankint@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis   This NOFO invites applications for investigator-initiated, high-risk multi-center clinical trials involving more than one clinical center. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this NOFO. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-24-094). Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP</p>					

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the FOA instructions carefully and view the available PEDP guidance material located at: <a href="https://braininitiative.nih.gov/about/plan-enhancing-diverse-perspectives-pedp">https://braininitiative.nih.gov/about/plan-enhancing-diverse-perspectives-pedp</a> attached to "PEDP guidance material".</p>					
107685	<a href="#">Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) (R01 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-22-074	05-Jun-2024	Not Specified
	<p>Contact Name   Julie Barthold, MD</p> <p>Contact Telephone   301-594-9655</p> <p>Contact Email   <a href="mailto:julia.barthold@nih.gov">julia.barthold@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025</p> <p>Synopsis   The Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) program is intended to promote innovative, high quality, interdisciplinary research relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK invites investigator-initiated research project grant applications (R01s) in specific areas of basic, translational, or clinical research in specific benign urologic conditions and diseases where needs and opportunities for progress are particularly timely. As such, research topics of interest will change over time to take advantage of emerging opportunities. The research topic area previously supported by the SUITOR program, urinary incontinence, will now transition to neurourology, as described below.</p>				
108051	<a href="#">Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-22-096	05-Jun-2024	Not Specified
	<p>Contact Name   Shilpa Hattangadi, M.D.</p> <p>Contact Telephone   301-594-7726</p> <p>Contact Email   <a href="mailto:shilpam.hattangadi@nih.gov">shilpam.hattangadi@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2024 , 05-Oct-2024</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the leading edge of the field will change over time and will be updated regularly through the NIH Guide to Grants and Contracts and hyperlinked to this FOA.			
112160	<a href="#">NIDDK Central Repository Non-renewable Sample Access (X01 Clinical Trial Not Allowed)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-22-171	27-Jun-2024	Not Specified
	Contact Name	Rebecca M. Rodriguez, Ph.D			
	Contact Telephone	301-451-0323			
	Contact Email	<a href="mailto:rebecca.rodriguez2@nih.gov">rebecca.rodriguez2@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	27-Jun-2024 , 29-Oct-2024 , 04-Mar-2025 , 25-Jun-2025			
	Synopsis	The NIDDK Central Repository houses valuable biological samples and data from numerous major clinical studies. This initiative allows investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at the Repository's website. Applicants must include a volume and impact assessment report from the NIDDK Central Repository with the X01 Application to document sample availability.			
116589	<a href="#">Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-23-086	07-May-2024	600,000 USD
	Contact Name	Aynur Unalp-Arida, M.D., M.Sc., Ph.D.			
	Contact Telephone	301-594-8879			
	Contact Email	<a href="mailto:aynur.unalp-arida@nih.gov">aynur.unalp-arida@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>This Funding Opportunity Announcement encourages the submission of pilot and feasibility clinical trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small, short-term proof-of-concept clinical trials in humans to acquire preliminary data regarding the effects of the intervention, as well as feasibility data related to recruitment and retention, and study conduct. Applications for clinical trials submitted under this FOA should have clearly described aims and objectives, and have a high likelihood that the trial findings will lead to more definitive, hypothesis-driven trials to improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health. Preliminary data regarding intervention efficacy are not required.</p>			
113279	<a href="#">Limited Competition: Small Grant Program for NIDDK K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-22-129	07-May-2024	150,000 USD
	Contact Name	Lisa M. Spain, Ph.D.			
	Contact Telephone	301-451-9871			
	Contact Email	<a href="mailto:SpainL@niddk.nih.gov">SpainL@niddk.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 16-Jun-2024 , 16-Jul-2024 , 07-Sep-2024 , 16-Oct-2024 , 16-Nov-2024 , 07-Jan-2025 , 25-Feb-2025 , 16-Mar-2025 , 07-May-2025 , 16-Jun-2025 , 16-Jul-2025 , 07-Sep-2025			
	Synopsis	<p>The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces a program that provides NIDDK-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support during the latter years of the award period of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, K23, and K25 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.</p>			
125058	<a href="#">RFA-DK-24-002 -- Adaptation of Diabetes Control Technologies for Older Adults with T1D (R01 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney	RFA-DK-24-002	17-Jun-2024 [Optional][LOI/Pre-	500,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Diseases/NIH/DHHS	App]		
	Contact Name	Guillermo Arreaza-Rubín, M.D.			
	Contact Telephone	301-594-4724			
	Contact Email	<a href="mailto:arreazag@mail.nih.gov">arreazag@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	17-Jun-2024 [Optional][LOI/Pre-App], 17-Jul-2024			
	Synopsis	<p>The main objective of this NOFO is to foster development and testing of technologies adaptable to aging-related changes in older adults (aged 65 years or older) with T1D to improve diabetes management and quality of life. Older adults may have increased vulnerability to hypoglycemia, cognitive impairment and/or multiple co-morbidities which may affect the risks and benefits of these technologies in this population. Projects will be funded to a) develop and test new technologies and b) to adapt and test existing technologies. It is expected that aging-adaptive diabetes technologies that address barriers for use among older adults with T1D will improve usability, adoption and adherence decreasing the risk of hypoglycemia (and hypoglycemia unawareness) while enhancing glycemic control, facilitating better diabetes management, and improving quality of life for these individuals and their caregivers.</p>			
124080	<a href="#">Notice of Special Interest (NOSI): Administrative Supplements to Enhance Engagement Activity with Underserved Populations Within the Type 1 Diabetes Community (Admin Supp Clinical Trial Not Allowed)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	NOT-DK-24-010	01-Jun-2024	150,000 USD
	Contact Name	Miranda M. Broadney MD, MPH			
	Contact Telephone	301-594-1176			
	Contact Email	<a href="mailto:Miranda.Broadney@nih.gov">Miranda.Broadney@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2024 , 01-Dec-2024 , 01-Mar-2025			
	Synopsis	<p>NIDDK aims to achieve equitable engagement in research across all persons impacted by type 1 diabetes (T1D). Understanding that participation in research is inequitable across many groups impacted by T1D, this supplement opportunity supports activities which enhance outreach to and engagement with underserved populations which experience diabetes-related health disparities. (ref. NIH designated health disparities populations). Improved engagement, participation, and incorporation of leadership from underserved T1D populations is deemed essential for addressing disparities and</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

advancing health equity in T1D outcomes. This supplement opportunity is available to PD(s)/PI(s) of active NIDDK research grants investigating T1D. Administrative supplements must support work within the scope of the original project and cannot be used to support planning activities for future grants.

125036	<a href="#">RFA-DK-25-008 -- Diabetes Research Centers (P30 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-25-008	20-May-2024 [Optional][LOI/Pre-App]	6,250,000 USD
--------	--	---	---------------	-------------------------------------	---------------

Contact Name | Corinne M. Silva, Ph.D.  
 Contact Telephone | 301-451-7335  
 Contact Email | [silvacm@mail.nih.gov](mailto:silvacm@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 20-May-2024 [Optional][LOI/Pre-App], 18-Jun-2024

Synopsis | This Notice of Funding Opportunity (NOFO) invites applications for Diabetes Research Centers (DRCs) that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. The purpose of this Centers program is to bring together basic and clinical investigators to enhance communication, multidisciplinary collaboration, and effectiveness of ongoing research in Diabetes Research Center topic areas. By providing shared access to specialized technical resources (research cores) and supporting a Pilot and Feasibility Program (P&F), DRCs are intended to create an environment that provides the capability for accomplishments greater than those that would be possible by individual research project grant support alone. New Center programs that bring in diverse perspectives, propose unique scientific themes, or provide innovative resources are encouraged. Emphasis will be placed on Center programs that propose enhanced synergies with other NIDDK-funded programs as well as providing a rich mentoring environment for future diabetes researchers. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

125054	<a href="#">RFA-DK-23-007 -- Discovery of Early Type 1 Diabetes Disease Processes in the Human Pancreas [HIRN Consortium on Beta Cell Death and Survival (CBDS)] (U01 Clinical Trial Not Allowed)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-23-007	10-Jun-2024 [Optional][LOI/Pre-App]	2,200,000 USD
--------	---	---	---------------	-------------------------------------	---------------

Contact Name | Olivier Blondel, Ph.D.  
 Contact Telephone | 301-263-4342



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:blondelol@niddk.nih.gov">blondelol@niddk.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 10-Jun-2024 [Optional][LOI/Pre-App], 09-Jul-2024</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) requests applications to explore human pancreatic tissues and the immune compartment for the discovery of specific signaling or processing pathways that may contribute to the asymptomatic phase of T1D, the discovery of early biomarkers of T1D pathogenesis, the development of diagnostic tools for the detection and staging of early T1D in at-risk or recently-diagnosed individuals, and/or the identification and biological validation of therapeutic targets for the development of preventative or early treatment strategies. Successful applicants will join the Consortium on Beta Cell Death and Survival (CBDS), whose mission is to better define and detect the mechanisms of beta cell stress and destruction central to the development of T1D in humans, with- the long-term goal of protecting the residual beta cell mass in T1D patients as early as possible in the disease process, and of preventing the progression to autoimmunity. The CBDS is part of a collaborative research framework, the Human Islet Research Network (HIRN, <a href="https://hirnetwork.org/">https://hirnetwork.org/</a>), whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This NOFO will only support studies with a primary focus on increasing our understanding of human disease biology (as opposed to rodent or other animal models). This NOFO will not accept applications proposing a clinical trial.</p>				
125109	<a href="#">RFA-DK-25-009 -- Kidney Technology Development Research Education Program (R25 - Independent Clinical Trial Not Allowed)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-25-009	13-May-2024 [Optional][LOI/Pre-App]	650,000 USD
	<p>Contact Name Daniel Gossett, Ph.D.</p> <p>Contact Telephone 301-594-7723</p> <p>Contact Email <a href="mailto:daniel.gossett@nih.gov">daniel.gossett@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 13-May-2024 [Optional][LOI/Pre-App], 13-Jun-2024 , 13-May-2025 [Optional][LOI/Pre-App], 13-Jun-2025</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>This NOFO encourages applications from institutions that propose to establish research experiences in kidney technology development. Successful programs should include a collaborative capstone research or design project(s), innovative and/or ground-breaking technology development, multidisciplinary/interdisciplinary teamwork, education in entrepreneurship, product development and navigating regulatory pathways, and clinical immersion. Applications must include plans to recruit undergraduate students as participants and to engage students from engineering and other quantitative scientific and technical backgrounds, but applicants may also propose the inclusion of medical students, graduate students and/or dual-degree students (e.g., M.D./Ph.D.; Pharm.D./Ph.D.) prior to their qualifying exams and selection of Ph.D. mentor.</p>				
113566	<a href="#">Notice of Special Interest (NOSI): Understanding Exposure and Health Effects of Micro and/or Nanoplastics</a>	National Institute of Environmental Health Sciences/NIH/DHHS	NOT-ES-23-002	07-May-2024	Not Specified
	<p>Contact Name   Lingamanaidu V. Ravichandran, Ph.D            Contact Telephone   984-287-3309            Contact Email   <a href="mailto:lingamanaidu.ravichandran@nih.gov">lingamanaidu.ravichandran@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 16-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 16-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 16-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 16-Oct-2027            Synopsis   The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants that the National Institute of Environmental Health Sciences (NIEHS), has special interest in applications that investigate exposure to, and health effects of, microplastics (MPs) and nanoplastics (NPs).</p>				
119809	<a href="#">RFA-ES-23-011 -- Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)</a>	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-23-011	03-Jun-2024	275,000 USD
	<p>Contact Name   Toccara Chamberlain, M.A.            Contact Telephone   984-287-4482            Contact Email   <a href="mailto:toccara.chamberlain@nih.gov">toccara.chamberlain@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   03-Jun-2024 , 01-Aug-2024 , 01-Oct-2024 , 02-Dec-2024 , 03-Mar-2025 , 02-Jun-2025 , 01-Aug-2025 , 01-Oct-2025 , 01-Dec-</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>2025</p> <p>This Notice of Funding Opportunity (NOFO) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the NOFO is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 4-6 months.</p>			
107585	<a href="#">NIGMS National and Regional Resources (R24 - Clinical Trial Not Allowed)</a>	National Institute of General Medical Sciences/NIH/DHHS	PAR-22-065	14-Jun-2024	Not Specified
	Contact Name	Christina Liu, Ph.D., PE			
	Contact Telephone				
	Contact Email	<a href="mailto:christina.liu@nih.gov">christina.liu@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	14-Jun-2024			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages applications for support of resources that will provide access to state-of-the-art equipment, technologies, research tools, materials, organisms, software, and/or services to a substantial regional (multi-state) or national user base. Only those resources with technical capabilities that fall within the NIGMS-supported program areas are eligible for awards. The resources should already be established or may be formed through consolidation of existing local or regional facilities. The intent is to provide resource access to investigators without regard to the specific biomedical focus of their research, while not duplicating or replacing resources supported by sources such as other NIH Institutes and Centers (ICs) or host institutions. The resource is expected to be maintained or upgraded to current best practices, make its capabilities and availability known to the biomedical research community through outreach activities, and provide user training and support. The FOA does not support major new research and development efforts and stand-alone data resources and databases are not eligible.</p>			
108741	<a href="#">Notice of Special Interest (NOSI): Inclusion of Economic Factors and Outcomes in Infectious Disease Modeling Studies</a>	National Institute of General Medical Sciences/NIH/DHHS	NOT-GM-22-021	08-Apr-2024	Not Specified
	Contact Name	Veerasamy (Ravi) Ravichandran, Ph.D.			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email <a href="mailto:Veerasamy.ravichandra@nih.gov">Veerasamy.ravichandra@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 08-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 08-Dec-2024 , 07-Jan-2025</p> <p>Synopsis The National Institute of General Medical Sciences (NIGMS) is issuing this Notice to highlight interest in receiving grant applications focused on infectious disease modeling research that incorporates economic factors. The Institute is particularly interested in mathematical and computational modeling studies of infectious disease spread and evolution, and of the effects of possible intervention strategies, that include consideration of economic influences and feedback.</p>				
111607	<p><a href="#">Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional)</a></p>	National Institute of Mental Health/NIH/DHHS	PAR-22-155	08-May-2024 [Optional][LOI/Pre-App]	10,000,000 USD
	<p>Contact Name Susan Koester, Ph.D.</p> <p>Contact Telephone 301-443-3563</p> <p>Contact Email <a href="mailto:koesters@mail.nih.gov">koesters@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 08-May-2024 [Optional][LOI/Pre-App], 07-Jun-2024 , 10-May-2025 [Optional][LOI/Pre-App], 09-Jun-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications for Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research. The NIMH seeks teams of researchers working at different levels of analysis and employing integrative, novel, and creative experimental approaches to address high-risk, high-impact questions with the primary objectives of: (a) advancing the state of the science in basic brain and behavior research that will uncover and dissect the underlying mechanisms that will ultimately provide the foundation for understanding mental disorders; (b) supporting the integration and translation of basic and clinical neuroscience research on severe mental illnesses; and/or (c) advancing our understanding of the neurobehavioral developmental mechanisms and trajectories of psychopathology that begin in childhood and adolescence. The Conte Centers program is intended to support interdisciplinary basic neuroscience or translational research that demonstrates an extraordinary level of synergy, integration, and potential for advancing the state of the field. This program is intended only for projects that could not be achieved using other, more standard grant mechanisms.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
112626	<a href="#">RFA-MH-22-185 -- NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	RFA-MH-22-185	21-May-2024 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name Eric R. Murphy, Ph.D.</p> <p>Contact Telephone 301-443-9230</p> <p>Contact Email <a href="mailto:eric.murphy@nih.gov">eric.murphy@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 21-May-2024 [Optional][LOI/Pre-App], 20-Jun-2024 , 21-May-2025 [Optional][LOI/Pre-App], 20-Jun-2025</p> <p>Synopsis The NIMH Biobehavioral Research Awards for Innovative New Scientists (BRAINS) award is intended to support the research and research career advancement of outstanding, exceptionally productive scientists who are in the early, formative stages of their careers and who plan to make a long-term career commitment to research in specific mission areas of the NIMH. This award seeks to assist these individuals in launching an innovative clinical, translational, basic, or services research program that holds the potential to profoundly transform the understanding, diagnosis, treatment, or prevention of mental disorders. The NIMH BRAINS program will focus on the research priorities and gap areas identified in the NIMH Strategic Plan.</p>				
114657	<a href="#">Clinical Studies of Mental Illness (Collaborative R01) (Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-050	07-May-2024	Not Specified
	<p>Contact Name Jonathan Pevsner, Ph.D</p> <p>Contact Telephone 301-728-5618</p> <p>Contact Email <a href="mailto:jonathan.pevsner@nih.gov">jonathan.pevsner@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026</p> <p>Synopsis This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, that primarily focus on mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology). Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase the inclusion of women and minorities (NOT-OD-18-014) and NIH-defined</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

health disparity populations. (see <https://www.nimhd.nih.gov/about/strategic-plan/nih-strategic-plan-definitions-and-parameters.html>). It is expected that one site will be submitted as a coordinating R01 for data management and/or other centralized administration. For a linked set of collaborative R01s, each application has its own Program Director/Principal Investigator (PD/PI). The collaborative R01 program provides a mechanism for cross-R01 coordination, quality control, database management, statistical analysis, and reporting.

117750	<a href="#">Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-168	07-May-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Enrique Michelotti, PhD
Contact Telephone	301-443-5415
Contact Email	<a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026
Synopsis	The overarching goal of this Notice of Funding Opportunity (NOFO) is to support the development and validation of screening assays for the discovery of validated hits that can be used in future drug discovery/development efforts for identifying potential drug candidates for the treatment of mental illness. For purposes of this initiative, a “hit” is defined as a compound that has the desired activity in a compound screen and whose activity is confirmed upon retesting in orthogonal assays. Stages of discovery research covered by this NOFO include 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); and 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

119663	<a href="#">Schizophrenia and Related Disorders During mid- to Late-Life (R01 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-24-023	05-Jun-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Laura M. Rowland, Ph.D.
Contact Telephone	301-480-8335
Contact Email	<a href="mailto:laura.rowland@nih.gov">laura.rowland@nih.gov</a>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications that will advance translational research to better understand the emergence, trajectory, and outcomes of schizophrenia and related psychotic disorders in mid- to late-life, and to identify targets for future development of prevention and treatment interventions. This NOFO uses the R01 grant mechanism, while the companion NOFO (PAR-24-026), uses the R21 mechanism. Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism.</p>				
118003	<a href="#">Notice of Special Interest (NOSI): NIMH Planning Grants for Natural History Studies of Rare Genetic Neurodevelopmental Disorders</a>	National Institute of Mental Health/NIH/DHHS	NOT-MH-23-235	07-May-2024	Not Specified
	<p>Contact Name Margaret Grabb, Ph.D.</p> <p>Contact Telephone 301-443-3563</p> <p>Contact Email <a href="mailto:mgrabb@mail.nih.gov">mgrabb@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026</p> <p>Synopsis The National Institute of Mental Health (NIMH) is issuing this Notice to highlight its interest in supporting planning grants to conduct retrospective natural history studies that explore the prevalence of disabling psychiatric symptoms and disruptions in function in patients (birth to 25 years of age) with rare genetic neurodevelopmental disorders (NDD). The principal goal of these studies is to assess the time of onset and severity of these symptoms, identify appropriate outcome measures, and establish potential timepoints for intervention. Additionally, the planning grants should focus on identifying potential quantitative clinical functional measures or biomarkers that could be used as prognostics and/or measures of change in future clinical trials. These retrospective natural history studies are expected to enable future prospective longitudinal studies (see Food and Drug Administration's (FDA's) guidance on natural history studies for rare disorders).</p>				
118004	<a href="#">Notice of Special Interest (NOSI): Pre-Clinical Research on Gene Therapies for Rare Genetic Neurodevelopmental Disorders</a>	National Institute of Mental Health/NIH/DHHS	NOT-MH-23-236	07-May-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-443-3563</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:NIMHgenetherapies@nih.gov">NIMHgenetherapies@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026</p> <p>Synopsis The National Institute of Mental Health (NIMH) is issuing this Notice of Special Interest (NOSI) to highlight interest in pre-clinical research aimed at developing novel approaches for somatic cell gene therapies to treat neurodevelopmental disorders with prominent cognitive, social and/or affective impairment.</p>				
123916	<p><a href="#">Advancing Learning Health Care Research in Outpatient Mental Health Treatment Settings (R34 Clinical Trial Optional)</a></p>	National Institute of Mental Health/NIH/DHHS	PAR-24-118	17-May-2024 [Optional][LOI/Pre-App]	450,000 USD
	<p>Contact Name Michael Freed, Ph.D.</p> <p>Contact Telephone 301-443-3747</p> <p>Contact Email <a href="mailto:michael.freed@nih.gov">michael.freed@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 17-May-2024 [Optional][LOI/Pre-App], 16-Jun-2024 , 17-Sep-2024 [Optional][LOI/Pre-App], 16-Oct-2024 , 17-Jan-2025 [Optional][LOI/Pre-App], 16-Feb-2025 , 17-May-2025 [Optional][LOI/Pre-App], 16-Jun-2025 , 17-Sep-2025 [Optional][LOI/Pre-App], 16-Oct-2025</p> <p>Synopsis This Notice of Funding Announcement (NOFO) solicits exploratory/developmental research applications within the learning health care framework to support adoption, implementation, sustainability, and continuous improvement of evidence-based practices in outpatient mental health and substance use treatment systems. These settings could include, but are not limited to, Certified Community Behavioral Health Clinics (CCBHCs) funded through the Substance Abuse and Mental Health Services Administration (SAMHSA) expansion grant program and CCBHCs participating in their states' Section 223 CCBHC Medicaid demonstration program, or as a part of independent state programs where the CCBHCs are meeting the federal CCBHC certification criteria. This NOFO requires active collaboration between behavioral health researchers and community behavioral health partners across all phases of the research process. Studies that are co-designed between community clinic staff/service users and health services researchers may focus on (1) identifying subgroups within the population of individuals served by CCBHCs with unique needs, including health disparities experienced by people from racial and ethnic minority groups or underserved communities; (2) workforce development strategies, including new approaches to train providers who</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

vary in terms of prior experience, expertise and skills; (3) developing and testing tools to promote measurement-based treatment; (4) hybrid effectiveness-implementation trials aimed at implementing and improving evidence-based prevention, treatment, or services delivery approaches in real-world settings; and (5) research to establish and/or expand 988 crisis response services within CCBHC settings.

105330	<a href="#">NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22 No Independent Clinical Trials)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-239	12-Jun-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name Ashlee Van't Veer, PhD  
 Contact Telephone 301-443-3107  
 Contact Email [dnbbstrainingbranch@mail.nih.gov](mailto:dnbbstrainingbranch@mail.nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 12-Jun-2024

Synopsis The primary goal of the NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22) Program (hereafter abbreviated as the NIMH Career Transition K22 Program) is to provide support for career intramural investigators at NIMH who aim to transition from the Division of Intramural Research Programs (IRP) to an independent research faculty position in the extramural community. Applicants should have a demonstrated record of meritorious research in mental health-related fields. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial.

107489	<a href="#">Basic Neurodevelopmental Biology of Circuits and Behavior (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-22-066	05-Jun-2024	2,500,000 USD
--------	--	--	------------	-------------	---------------

Contact Name Andrew Breeden, Ph.D.  
 Contact Telephone 301-451-3185  
 Contact Email [neurodevelopmentpar@mail.nih.gov](mailto:neurodevelopmentpar@mail.nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 05-Jun-2024 , 05-Oct-2025

Synopsis This Funding Opportunity Announcement (FOA) encourages research projects focused on the dynamic and mechanistic links between the maturation of brain circuits and behaviors across development in rodents and non-human primates. The goal is

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

to build a foundation for understanding how interactions within and among brain regions change over pre- and post-natal development, allowing for the emergence of cognitive, affective and social behaviors. To this end, projects supported will focus on neurodevelopmental trajectories and investigate questions using in vivo neural measures in awake, behaving animals. This FOA uses the R01 grant mechanism, whereas its companion FOA, PAR-22-067, seeks shorter, higher-risk R21 grant applications.

112309	<a href="#">Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-22-170	07-May-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Jamie Driscoll
Contact Telephone	301-443-5288
Contact Email	<a href="mailto:jdrisco1@mail.nih.gov">jdrisco1@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025

**Synopsis**

The goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. This FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as pharmacokinetic/pharmacodynamic (PK/PD) markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline in which treatment candidates and therapeutic targets can be evaluated for their ability to impact neurobiological mechanisms of potential clinical relevance to mental illnesses. The objectives of this FOA will be accomplished by supporting basic neuroscience aimed at improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivo physiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay measures that are adaptable across early therapeutic screens in animals to evaluation in humans. The FOA may be considered a prequel to build a suite of assays that are evaluated in future projects for coherence of assay performance between the preclinical species and healthy humans. In summary, this FOA will support efforts to improve the tool kit of assays available for early phase testing of novel therapeutic agents by incorporating measures proximal to neural systems that impact mental health.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
119702	<a href="#">Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-24-024	05-Jun-2024	Not Specified
	<p>Contact Name   David Panchision</p> <p>Contact Telephone   301-402-3969</p> <p>Contact Email   <a href="mailto:panchisiond@mail.nih.gov">panchisiond@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Synopsis   This Notice of Funding Opportunity (NOFO) encourages research on the biology of high-confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular, and circuit substrates of neural function. For the purposes of this NOFO , the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular, and circuit mechanisms, these are neither required nor expected. Studies should not attempt to “model” disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components, and processes. The resulting paradigms, component pathways, and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present NOFO (R01 activity code) can be used for applications to further develop lines of inquiry where feasibility or proof-of-concept has been established. Applicants proposing exploratory research at the early and conceptual stages of project development should apply to the companion R21 NOFO PAR-24-025</p>				
115061	<a href="#">Mood and Psychosis Symptoms During the Menopause Transition (R01 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-097	05-Jun-2024	Not Specified
	<p>Contact Name   Laura M. Rowland, Ph.D.</p> <p>Contact Telephone   301-480-8335</p> <p>Contact Email   <a href="mailto:laura.rowland@nih.gov">laura.rowland@nih.gov</a></p> <p>Sponsor Website  </p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2024 , 05-Oct-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause). In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts This FOA uses the R01 grant mechanism, while the companion FOA (PAR-22-036 ) uses the R21 mechanism. Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies that utilize existing data may wish to apply using the R21 mechanism, while applicants with preliminary data who seek longer-term funding may wish to apply using the R01 mechanism.</p>				
115058	<a href="#">Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-095	05-Jun-2024	Not Specified
	<p>Contact Name Michael C. Freed, Ph.D., EMT</p> <p>Contact Telephone 301-443-3747</p> <p>Contact Email <a href="mailto:michael.freed@nih.gov">michael.freed@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial R01-level projects that address NIMH strategic priorities that strengthen the public health impact of NIMH-supported research as described in Goal 4 of the NIMH Strategic Plan. Proposed research should seek to: Identify mutable factors that impact access, continuity, utilization, quality, value, and outcomes, including disparities in outcomes, or scalability of mental health services, which may serve as targets in future service delivery intervention development; Develop and test new research tools, technologies, measures, or methods and statistical approaches to study these issues; Integrate and analyze large data sets to understand factors affecting mental health services outcomes using advanced computational and predictive analytic approaches; Wherever possible, leverage existing infrastructure and partnerships to accomplish these goals.</p>				
115044	<a href="#">Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-094	05-Jun-2024	2,500,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[and Adolescents \(R01 Clinical Trial Required\)](#)

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Susan T. Azrin, Ph.D. 301-443-3267 <a href="mailto:azrinst@mail.nih.gov">azrinst@mail.nih.gov</a>  <a href="#">Link to program URL</a> 05-Jun-2024  The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to develop and test the effectiveness and implementation of family navigator models designed to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents who are experiencing early symptoms of mental health problems. For the purposes of this FOA, NIMH defines a family navigator model as a health care professional or paraprofessional whose role is to deploy a set of strategies designed to rapidly engage youth and families in needed treatment and services, work closely with the family and other involved treatment and service providers to optimize care, and through the use of technology – to monitor the trajectory of mental health symptoms and outcomes over time. Synopsis Applicants are required to develop and test the navigator model’s ability to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents as soon as symptoms are detected. Applicants are also required to identify and test components of navigator models that drive improvements in mental health care; detect and interrogate tailoring variables that optimize the ‘personalized match’ between the unique mental health needs of youth to the appropriate level of intensity and frequency of mental health services; and utilize emerging novel technologies to track and monitor the trajectory of clinical, functional and behavioral progress toward achieving intended services outcomes. This FOA is published in parallel to a companion R34 FOA, PAR-21-292 supporting pilot studies in preparation for the larger-scale studies described here.
--	---

115060	<a href="#">Laboratories to Optimize Digital Health (R01 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-096	05-Jun-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Adam Haim, Ph.D. 301-435-3593 <a href="mailto:Haima@mail.nih.gov">Haima@mail.nih.gov</a>  <a href="#">Link to program URL</a>
--	---

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL) | 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025

Synopsis | NIMH seeks applications for innovative research projects to test strategies to increase the reach, efficiency, effectiveness, and quality of digital mental health interventions which may impact mental health outcomes, including suicide behaviors and serious mental illness. This Funding Opportunity Announcement (FOA) is intended to support the development of digital health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations.

115032	<a href="#">Effectiveness of Implementing Sustainable Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Mental Health Equity for Traditionally Underserved Populations (R01 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-092	05-Jun-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name | Susan T. Azrin, Ph.D.  
 Contact Telephone | 301-443-3267  
 Contact Email | [azrinst@mail.nih.gov](mailto:azrinst@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 05-Jun-2024

Synopsis | This Funding Opportunity Announcement (FOA) encourages studies that develop and test the effectiveness of strategies for implementation and sustainable delivery of evidence-based mental health treatments and services to improve mental health outcomes for underserved populations in low-resourced settings in the United States. Studies should identify and use innovative approaches to remediate barriers to provision, receipt, and/or benefit from evidence-based practices (EBPs) and generate new information about factors integral to achieving equity in mental health outcomes for underserved populations. Research generating new information about factors causing/reducing disparities are strongly encouraged, including due consideration of the needs of individuals across the life span. This FOA is published in parallel to a companion R34, PAR-21-283, that supports pilot studies in preparation for the larger-scale studies described here.

115033	<a href="#">Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-093	05-Jun-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name | David McMullen, M.D.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-451-0180</p> <p>Contact Email   <a href="mailto:david.mcmullen@nih.gov">david.mcmullen@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2024</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This FOA aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new therapies is outside the scope of this FOA, though development of novel tools/methods to enable relevant mental health studies is encouraged. This FOA uses the R01 grant mechanism, encouraging longer-term projects, whereas its companion R21 FOA, PAR-21-288, seeks grant applications encouraging shorter, higher-risk studies.</p>				
106895	<a href="#">Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-22-039	05-Jun-2024	Not Specified
	<p>Contact Name   David McMullen, M.D.</p> <p>Contact Telephone   301-451-0180</p> <p>Contact Email   <a href="mailto:david.mcmullen@nih.gov">david.mcmullen@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2024 , 05-Oct-2024</p> <p>Synopsis   The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitting in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animal and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches.</p>			
106926	<a href="#">Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-22-039	05-Jun-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>David McMullen, M.D.</p> <p>301-451-0180</p> <p><a href="mailto:david.mcmullen@nih.gov">david.mcmullen@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>05-Jun-2024 , 05-Oct-2024</p>			
	Synopsis	<p>The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitting in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animal and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches.</p>			
108843	<a href="#">Notice of Special Interest (NOSI): NIMH Priorities on Research on Aggression</a>	National Institute of Mental	NOT-MH-	08-Apr-2024	Not



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">and Violence Against Others</a>	Health/NIH/DHHS	22-095		Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:NIMHResearchOnAggres@mail.nih.gov">NIMHResearchOnAggres@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 08-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 08-Dec-2024 , 07-Jan-2025</p> <p>Synopsis NIMH is issuing this Notice of Special Interest (NOSI) to outline priorities for research on the etiology, risks for, and prevention of interpersonal aggression and violence against others.</p>				
114549	<a href="#">Notice of Special Interest (NOSI): The Neural Mechanisms of Multi-Dimensional Emotional and Social Representation</a>	National Institute of Mental Health/NIH/DHHS	NOT-MH-23-120	07-May-2024	Not Specified
	<p>Contact Name Andrew Breeden, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:andrew.breeden@nih.gov">andrew.breeden@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis NIMH is issuing this Notice of Special Interest (NOSI) to outline priorities for research that incorporates a multi-dimensional perspective into studies of the neural mechanisms underlying emotional and/or social representations. The ability to integrate a broad array of emotional and social information is impaired in many mental disorders, yet the neural mechanisms underlying these processes are not well understood. This NOSI encourages studies in humans and animals investigating how diverse multi-dimensional emotional and/or social cues are represented across brain circuits that are important for mental health relevant cognitive, social, and affective behavioral functions. The term “multi-dimensional” refers to the consideration of multiple modalities (e.g., social, emotional, visual, and auditory), the effects of complex contexts and development, and/or dynamic processes that unfold over a variety of temporal scales.</p>				
107450	<a href="#">Notice of Special Interest (NOSI): Secondary Analysis of Posttraumatic Psychopathology Data</a>	National Institute of Mental Health/NIH/DHHS	NOT-MH-22-045	07-May-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Susan Borja, Ph.D.
Contact Telephone	310-443-1252
Contact Email	<a href="mailto:susan.borja@nih.gov">susan.borja@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024
Synopsis	NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to analyze existing and accumulating data to aid in refining phenotypes of posttraumatic psychopathology(ies), markers of onset and change, and risk detection. NIMH is also interested in research using available data to identify potential prevention and treatment targets and to advance and refine measurement and validation of potential novel targets for future development in experimental therapeutics research.

115199	<a href="#">Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-087	21-Jun-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Jamie Driscoll
Contact Telephone	301-443-5288
Contact Email	<a href="mailto:jdrisco1@mail.nih.gov">jdrisco1@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	21-Jun-2024 , 21-Oct-2024 , 21-Feb-2025 , 20-Jun-2025
Synopsis	The goal of this initiative is to identify neurophysiological measures as potential assays for treatment development research. The Funding Opportunity Announcement (FOA) will support efforts to optimize and evaluate pharmacodynamic (PD) measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data may also reveal assay measures where performance is dissimilar between preclinical animal species and humans, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate goal of this FOA is to improve the efficiency of the therapeutic development process by identifying congruent measures as well as inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates. The objectives of the FOA will be accomplished by supporting partnerships among basic and

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>translational neuroscientists who are committed to advancing the discovery of in vivo physiological measures as tools for target validation and therapeutic development. Groups will be tasked with developing and optimizing in vivo assays of brain processes in both animals and in healthy humans. Groups will evaluate assay performance across both species in response to pharmacologic manipulations. In this way, projects will reveal the potential of specific assays to translate from animals to humans, suggesting assays for further development as tools in the treatment development pipeline.</p>				
117822	<a href="#">Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Required)</a>	National Institute of Mental Health/NIH/DHHS	PA-23-150	12-Jun-2024	Not Specified
	<p>Contact Name   Ashlee Van't Veer            Contact Telephone   301-443-3107            Contact Email   <a href="mailto:dnbstrainingbranch@mail.nih.gov">dnbbstrainingbranch@mail.nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   12-Jun-2024 , 12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026            Synopsis   The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA, PAR-23-149.</p>				
103213	<a href="#">Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-210	05-Jun-2024	Not Specified
	<p>Contact Name   Adam Haim, Ph.D.            Contact Telephone   301-435-3593            Contact Email   <a href="mailto:haima@mail.nih.gov">haima@mail.nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024			
	Synopsis	<p>NIMH seeks applications for research projects to evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting youth, adults, and older adults. This Funding Opportunity Announcement (FOA) encourages clinical trials to establish the effectiveness and test hypotheses regarding moderators, mediators, and mechanisms of action of post-acute phase therapeutic and services interventions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden for promoting optimal longer-term outcomes. This FOA is intended to support trials that are statistically powered to provide a definitive answer regarding the effectiveness of the post-acute phase intervention. Support for pilot effectiveness trials designed to evaluate the initial feasibility, tolerability, acceptability, safety and preliminary indications of post-acute phase intervention approaches is provided via the R34, PAR-21-211.</p>			
119705	<a href="#">Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-24-025	16-Jun-2024	275,000 USD
	Contact Name	David Panchision			
	Contact Telephone	301-402-3969			
	Contact Email	<a href="mailto:panchisiond@mail.nih.gov">panchisiond@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026			
	Synopsis	<p>This Notice of Funding Opportunity (NOFO) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this NOFO , the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechanisms, these are neither required nor expected. Studies should not attempt to “model” disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present NOFO (R21 activity code) can be used for applications to develop early stage, high-risk, exploratory approaches or establish proof-of-concept where there is little or no preliminary data. Applicants proposing to develop lines of inquiry where feasibility or proof of concept has been established should apply to the companion R01 NOFO (PAR-24-024).</p>				
124186	<a href="#">RFA-MH-25-100 -- BRAIN Initiative: Scaled reagent resources for brain cell type-specific access across vertebrate species (U01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	RFA-MH-25-100	15-May-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name   Douglas S. Kim, Ph.D.            Contact Telephone   301-827-6463            Contact Email   <a href="mailto:douglas.kim@nih.gov">douglas.kim@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   15-May-2024 [Optional][LOI/Pre-App], 14-Jun-2024 , 18-Dec-2024 [Optional][LOI/Pre-App], 17-Jan-2025</p> <p>Synopsis   This Notice of Funding Opportunity (NOFO) from the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is intended to support the scaling up of brain cell type-specific molecular or genetic access reagents to study circuit function. Scaled engineering and validation of cell type-specific reagents are priorities to be supported. Applications are sought for Reagent Resource for Design and Development projects that scale up the creation of these tools for several vertebrate species, including in experimental animals and human ex vivo tissues or cells. Projects will integrate: scaled engineering, validation, cataloguing, and adaptation into easily disseminable formats of reagents. Scaled up projects are sought that will develop tens to hundreds of cell type-selective reagents. Validated reagents produced in these projects are intended to be distributed to neuroscience researchers via centralized Production and Distribution Facilities to be supported separately. This NOFO is part of the BRAIN Initiative Armamentarium project, whose overall goal is to generate tools to specifically access, manipulate, and monitor brain cell types across multiple vertebrate species. This NOFO will foster close interaction between technologists, disseminators, and neurobiologists in a research consortium including investigators funded by other Armamentarium NOFOs. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.</p>				
119664	<a href="#">Schizophrenia and Related Disorders During mid- to Late-Life (R21 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-24-026	16-Jun-2024	275,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Laura M. Rowland, Ph.D.</p> <p>Contact Telephone   301-480-8335</p> <p>Contact Email   <a href="mailto:laura.rowland@nih.gov">laura.rowland@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026</p> <p>Synopsis   The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications that will advance translational research to better understand the emergence, trajectory, and outcomes of schizophrenia and related psychotic disorders in mid- to late-life, and to identify targets for future development of prevention and treatment interventions. This NOFO uses the R21 grant mechanism, while the companion NOFO (PAR-24-023) uses the R01 mechanism. Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism, while applicants with preliminary data who seek longer-term funding should apply using the R01 mechanism.</p>				
117821	<a href="#">Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PA-23-149	12-Jun-2024	Not Specified
	<p>Contact Name   Ashlee Van't Veer</p> <p>Contact Telephone   301-443-3107</p> <p>Contact Email   <a href="mailto:dnbbsstrainingbranch@mail.nih.gov">dnbbstrainingbranch@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Jun-2024 , 12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026</p> <p>Synopsis   The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator should apply to the companion FOA, PAR-</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	23-150.				
108834	<a href="#">Notice of Special Interest (NOSI): Neuro-Glia Mechanisms Governing Complex Behaviors (R01 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	NOT-MH-22-090	07-May-2024	Not Specified
	Contact Name	Michele Ferrante, Ph.D.			
	Contact Telephone	301-435-6782			
	Contact Email	<a href="mailto:michele.ferrante@nih.gov">michele.ferrante@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025			
	Synopsis	This Notice of Special Interest (NOSI) encourages projects to experimentally test mechanistic hypotheses on the role of neuro-glia activity coupling in modulating complex behaviors.			
115204	<a href="#">Pilot Studies to Test the Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (R34 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-104	16-Jun-2024	450,000 USD
	Contact Name	Susan T. Azrin, Ph.D.			
	Contact Telephone	301-443-3267			
	Contact Email	<a href="mailto:azrinst@mail.nih.gov">azrinst@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2024			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to develop and pilot test the effectiveness and implementation of existing family navigator models designed to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents who are experiencing early symptoms of mental health problems. For the purposes of this FOA, NIMH defines a family navigator model as a health care professional or paraprofessional whose role is to deploy a set of strategies designed to rapidly engage youth and families in needed treatment and services, work closely with the family and other involved treatment and service providers to optimize care, and through the use of technology – to monitor the trajectory of mental health symptoms and outcomes over			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

time. Applicants are required to develop and pilot test the navigator model’s ability to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents as soon as symptoms are detected. Applicants are also required to identify and pilot test components of navigator models that drive improvements in mental health care; detect and interrogate tailoring variables that optimize the ‘personalized match’ between the unique mental health needs of youth to the appropriate level of intensity and frequency of mental health services; and utilize emerging novel technologies to track and monitor the trajectory of clinical, functional and behavioral progress toward achieving intended services outcomes. This FOA is published in parallel to a companion R01 FOA, PAR-23-094 which uses the R01 funding mechanism.

115209	<a href="#">Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-105	16-Jun-2024	450,000 USD
--------	---	--	------------	-------------	-------------

Contact Name	Susan T. Azrin, Ph.D.
Contact Telephone	301-443-3267
Contact Email	<a href="mailto:azrinst@mail.nih.gov">azrinst@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025

Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial pilot projects that address NIMH strategic priorities to strengthen the public health impact of NIMH-supported research as described in Goal 4 of the NIMH Strategic Plan. Proposed research should seek to: Identify mutable factors that impact access, continuity, utilization, quality, value, and outcomes, including disparities in outcomes, or scalability of mental health services, which may serve as targets in future service delivery intervention development; Develop and test new research tools, technologies, measures, or methods and statistical approaches to study these issues; Test the feasibility of integrating and analyzing large data sets to understand factors affecting mental health services outcomes using advanced computational and predictive analytic approaches; Wherever possible, leverage existing infrastructure and partnerships to accomplish these goals.

115201	<a href="#">Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-102	16-Jun-2024	275,000 USD
--------	---	--	------------	-------------	-------------

Contact Name	Laura M. Rowland, Ph.D.
--------------	-------------------------



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-480-8335</p> <p>Contact Email   <a href="mailto:laura.rowland@nih.gov">laura.rowland@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2024 , 16-Oct-2024</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause). In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts. This FOA uses the R21 mechanism, while the companion FOA (PAR-23-097) uses the R01 grant mechanism. Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies that utilize existing data may wish to apply using the R21 mechanism, while applicants with preliminary data who seek longer-term funding may wish to apply using the R01 mechanism.</p>				
115202	<a href="#">Implementing and Sustaining Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Equity in Outcomes (R34 Clinical Trial Required )</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-103	16-Jun-2024	450,000 USD
	<p>Contact Name   Susan T. Azrin, Ph.D.</p> <p>Contact Telephone   301-443-3267</p> <p>Contact Email   <a href="mailto:azrinst@mail.nih.gov">azrinst@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2024</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) supports pilot work for subsequent studies testing the effectiveness of strategies to deliver evidence-based mental health services, treatment interventions, and/or preventive interventions (EBPs) in low-resourced mental health specialty and non-specialty settings within the United States. The FOA targets settings where EBPs are not currently delivered or delivered with fidelity, such that there are disparities in mental health and related functional outcomes (e.g., employment, educational attainment, stable housing, integration in the community, treatment of comorbid substance use disorders) for the population(s) served. Implementation strategies should identify and use innovative approaches to remediate barriers to provision, receipt, and/or benefit from EBPs and generate new information about factors integral to achieving equity in mental health outcomes for underserved populations. Research generating new information about factors causing/reducing disparities is strongly encouraged, including due consideration for the needs of</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

individuals across the life span. Applications proposing definitive tests of an implementation strategy should respond to the companion R01 announcement PAR-23-092.

115200	<a href="#">Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-101	16-Jun-2024	275,000 USD
--------	---	--	------------	-------------	-------------

Contact Name	Lizzy Ankudowich, Ph.D.
Contact Telephone	301-480-8187
Contact Email	<a href="mailto:lizzy.ankudowich@nih.gov">lizzy.ankudowich@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2024
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This FOA aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new therapies is outside the scope of this FOA, though development of novel tools/methods to enable relevant mental health studies is encouraged. This FOA uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity, PAR-23-093, seeks R01 grant applications.

103214	<a href="#">Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-211	16-Jun-2024	450,000 USD
--------	---	--	------------	-------------	-------------

Contact Name	Adam Haim, Ph.D.
Contact Telephone	301-435-3593
Contact Email	<a href="mailto:haima@mail.nih.gov">haima@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Synopsis	<p>NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) that is/are presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitely test the effectiveness of interventions to improve post-acute outcomes. This FOA supports pilot research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials. Support for fully-powered, definitive effectiveness studies focused on post-acute phase interventions is provided via the R01, PAR-21-210.</p>			
--	----------	---	--	--	--

106896	<a href="#">Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-22-038	16-Jun-2024	275,000 USD
--------	---	--	------------	-------------	-------------

Contact Name David McMullen, M.D.  
 Contact Telephone 301-451-0180  
 Contact Email [david.mcmullen@nih.gov](mailto:david.mcmullen@nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 16-Jun-2024 , 16-Oct-2024

	Synopsis	<p>The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitted in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application</p>			
--	----------	---	--	--	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
106927	<a href="#">Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-22-038	16-Jun-2024	275,000 USD

should focus on the engineering development and bench top testing of the tool, animals and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA. This FOA uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity, PAR-22-039, seeks R01 grant applications.

Contact Name | David McMullen, M.D.  
 Contact Telephone | 301-451-0180  
 Contact Email | [david.mcmullen@nih.gov](mailto:david.mcmullen@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 16-Jun-2024 , 16-Oct-2024

Synopsis | The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitted in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animals and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA. This FOA uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity, PAR-22-039, seeks R01 grant applications.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
107491	<a href="#">Basic Neurodevelopmental Biology of Circuits and Behavior (R21 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-22-067	16-Jun-2024	275,000 USD
	<p>Contact Name   Andrew Breeden, Ph.D.</p> <p>Contact Telephone   301-451-3185</p> <p>Contact Email   <a href="mailto:neurodevelopmentpar@mail.nih.gov">neurodevelopmentpar@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2024 , 16-Oct-2025</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages research projects focused on the dynamic and mechanistic links between the maturation of brain circuits and behaviors across development in rodents and non-human primates. The goal is to build a foundation for understanding how interactions within and among brain regions change over pre- and post-natal development, allowing for the emergence of cognitive, affective and social behaviors. To this end, projects supported will focus on neurodevelopmental trajectories and investigate questions using in vivo neural measures in awake, behaving animals. This FOA seeks shorter, higher-risk R21 grant applications, whereas its companion funding opportunity PAR-22-066 seeks R01 grant applications.</p>				
102507	<a href="#">Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-131	15-Jun-2024	450,000 USD
	<p>Contact Name   Joel Sherrill, Ph.D.</p> <p>Contact Telephone   301-443-2477</p> <p>Contact Email   <a href="mailto:jsherril@mail.nih.gov">jsherril@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-Jun-2024 , 15-Oct-2024</p> <p>Synopsis   NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to encourage pilot research consistent with NIMH's priorities for: 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) research on the development and preliminary testing of innovative services interventions. Consistent with the NIMH experimental therapeutics approach, this FOA is</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

intended to support pilot studies of intervention effectiveness or service delivery approaches that explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects (i.e., the mechanism(s) that accounts for changes in clinical/functional outcomes, changes in provider behavior, improved access or continuity of services, etc.). In this pilot effectiveness phase of research, NIMH places highest priority on intervention and service delivery approaches that can be justified in terms of their potential to substantially impact practice and public health. This FOA supports pilot studies and provides resources for evaluating the feasibility, tolerability, acceptability and safety and preliminary effectiveness of approaches to improve mental health/functional outcomes, to modify risk factors, or to improve service delivery, and for obtaining the preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, pragmatic trial). Support for fully-powered effectiveness studies is provided through separate FOAs that utilize the R01 mechanism for single-site effectiveness trials (PAR-21-130; "Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01).") and collaborative R01 mechanism for multi-site effectiveness trials (PAR-21-129;"Clinical Trials to Test the Effectiveness of Treatment, Prevention, and Services Interventions (Collaborative R01 Clinical Trial Required)"). Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.

102506	<a href="#">Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-130	15-Jun-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name | Joel Sherrill, Ph.D.  
 Contact Telephone | 301-443-2477  
 Contact Email | [jsherril@mail.nih.gov](mailto:jsherril@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 15-Jun-2024 , 15-Oct-2024

Synopsis | NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. This FOA seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (e.g., psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality,

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. This FOA uses the R01 grant mechanism to support trials that are adequately powered and of sufficient scope to test effectiveness and examine mediators and moderators of response. Support for multi-site trials that require participation of two or more collaborative sites for completion of the study (e.g., in order to increase sample size, accelerate recruitment, or increase sample diversity and representation) is provided through a separate FOA, PAR-21-129 "Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01)." This FOA is designed for applicants seeking funding for single-site clinical trials to establish the effectiveness of interventions. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.

102513	<a href="#">Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-135	15-Jun-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Alexander Talkovsky, Ph.D.
Contact Telephone	301-827-7614
Contact Email	<a href="mailto:alexander.talkovsky@nih.gov">alexander.talkovsky@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	15-Jun-2024 , 15-Oct-2024

Synopsis NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH's experimental therapeutics approach, this FOA is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial interventions may be standalone interventions or augmentations to efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of a novel intervention's impact on a target process or mechanism associated mental disorder risk, causation, or maintenance (target engagement). Up to 3 years of additional support (R33 phase) will be provided for studies with findings that meet the "go/no-go" milestones embedded in the R61 phase. The R33 phase is intended to support the replication of target engagement and to test whether engaging the intervention target/mechanism mediates changes in clinical outcomes.



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development and/or testing of the intervention. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.

102530	<a href="#">Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-137	15-Jun-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name | Margaret Grabb, Ph.D.  
 Contact Telephone | 301-443-3563  
 Contact Email | [mgrabb@mail.nih.gov](mailto:mgrabb@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 15-Jun-2024 , 15-Oct-2024

Synopsis | NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase) prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. The R61/R33 FOAs are intended to support biphasic high-risk applications. Support for a single phased award that does not need the developmental (R61) phase is available in the companion R33, PAR-21-136 . Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.

102528	<a href="#">Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-136	15-Jun-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name | Margaret Grabb, Ph.D.  
 Contact Telephone | 301-443-3563  
 Contact Email | [mgrabb@mail.nih.gov](mailto:mgrabb@mail.nih.gov)



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Jun-2024 , 15-Oct-2024			
	Synopsis	<p>NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. Pediatric, adult and geriatric focused interventions are appropriate for this FOA. This R33 FOA supports single-phased clinical trial awards. Applicants proposing high risk projects are encouraged to apply to the companion FOA, PAR-21-137or PAR-21-133.</p>			
102511	<a href="#">Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-134	15-Jun-2024	Not Specified
	Contact Name	Alexander Talkovsky, Ph.D.			
	Contact Telephone	301-827-7614			
	Contact Email	<a href="mailto:alexander.talkovsky@nih.gov">alexander.talkovsky@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Jun-2024 , 15-Oct-2024			
	Synopsis	<p>NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-inhuman, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH’s experimental therapeutics approach, this FOA is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial intervention strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. They may also be standalone interventions or augmentations of efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. Support will be provided for up to 3 years for studies to replicate previous target engagement findings, and to relate change in the intervention target/mechanism to clinical benefit. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support “go/no-go” decisions about further development and/or testing of the intervention. This FOA is designed for applicants seeking to fund pilot stages of research. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.

102509	<a href="#">First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-133	15-Jun-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name | Margaret Grabb, Ph.D.  
 Contact Telephone | 301-443-3563  
 Contact Email | [mgrabb@mail.nih.gov](mailto:mgrabb@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 15-Jun-2024 , 15-Oct-2024

Synopsis | NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-inhuman, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action investigational drugs or novel neuromodulatory devices for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase Ib studies of novel agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drug’s impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to “de-risk” novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private or other public funding (when appropriate) for further clinical development as FDA-approved treatments. A key aspect of this FOA is the formation of collaborative

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development. This FOA is designed for applicants seeking funding for cooperative agreements supporting early stage clinical trials as outlined above. Applicants pursuing other stages of the clinical trial pipeline or funding for clinical research not involving cooperative agreements should consider one of the companion FOAs.

102508	<a href="#">Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-132	15-Jun-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name | Adam Haim, Ph.D.  
 Contact Telephone | 301-435-3593  
 Contact Email | [haima@mail.nih.gov](mailto:haima@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 15-Jun-2024 , 15-Oct-2024

Synopsis | NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to support confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention. Interventions to be studied include, but are not limited to behavioral, cognitive, interpersonal, and device-based (both invasive/surgically implanted as well as noninvasive/transcranial) approaches, or a combination thereof. Interventions appropriate for efficacy testing must be based on a compelling scientific rationale, previous demonstration that the intervention engages and alters the hypothesized mechanism of action, a preliminary efficacy signal, and must address an unmet therapeutic need. Support will be provided for a trial of the intervention's efficacy that includes measurement of the hypothesized mechanism of action and the relationship between change in the mechanism and change in functional or clinical effects. Ultimately, this FOA is intended to support a sufficiently-powered efficacy trial to determine the intervention's potential for significant clinical benefit. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs

115030	<a href="#">Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-091	07-May-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name | Jamie Driscoll

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-443-5288</p> <p>Contact Email   <a href="mailto:jdrisco1@mail.nih.gov">jdrisco1@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</p> <p>Synopsis   The goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. This FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as pharmacokinetic/pharmacodynamic (PK/PD) markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline in which treatment candidates and therapeutic targets can be evaluated for their ability to impact neurobiological mechanisms of potential clinical relevance to mental illnesses. The objectives of this FOA will be accomplished by supporting basic neuroscience aimed at improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivo physiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay measures that are adaptable across early therapeutic screens in animals to evaluation in humans. The FOA may be considered a prequel to build a suite of assays that are evaluated in future projects for coherence of assay performance between the preclinical species and healthy humans. In summary, this FOA will support efforts to improve the tool kit of assays available for early phase testing of novel therapeutic agents by incorporating measures proximal to neural systems that impact mental health.</p>				
123799	<p><a href="#">Notice of Special Interest (NOSI): Impact of Policy Interventions Aimed at Addressing Social Determinants of Health to Improve Functioning and Well-being for People with Serious Mental Illnesses</a></p>	National Institute of Mental Health/NIH/DHHS	NOT-MH-24-340	05-Jun-2024	Not Specified
	<p>Contact Name   Jennifer Humensky, PhD</p> <p>Contact Telephone   301-480-1265</p> <p>Contact Email   <a href="mailto:Jennifer.Humensky@nih.gov">Jennifer.Humensky@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   05-Jun-2024</p> <p>Synopsis   This Notice of Special Interest (NOSI) highlights research priorities on the impact of social and economic policy interventions that address social determinants of health (SDOH) on improvements in access and engagement with mental health treatment, mental health functioning, and quality of life for people with serious mental illnesses, with special attention to understanding the underlying mediators/change mechanisms of those policies on outcomes.</p>				
124764	<a href="#">RFA-MH-25-110 -- BRAIN Initiative: Data Archives for the BRAIN Initiative (R24 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	RFA-MH-25-110	25-May-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name   Ming Zhan, Ph.D.</p> <p>Contact Telephone   301-827-3678</p> <p>Contact Email   <a href="mailto:ming.zhan@nih.gov">ming.zhan@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   25-May-2024 [Optional][LOI/Pre-App], 24-Jun-2024 , 25-May-2025 [Optional][LOI/Pre-App], 24-Jun-2025 , 25-May-2026 [Optional][LOI/Pre-App], 24-Jun-2026</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) solicits applications to develop web-accessible data archives to capture, store, and curate data related to BRAIN Initiative activities. The data archives teams will work with the research community to incorporate software tools that allow users to analyze and visualize the data, and will use appropriate standards to describe the data, but an application with major focus on the creation of such software tools and data standards is not responsive to this NOFO. A goal of this program is to advance research by creating a data archive with appropriate standards and summary information that is broadly available and accessible to the research community for furthering research. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>				
124716	<a href="#">RFA-MH-25-120 -- Lethal Means Safety Suicide Prevention Research in Healthcare and Community Settings (R34 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	RFA-MH-25-120	15-Jun-2024 [Optional][LOI/Pre-App]	450,000 USD
	<p>Contact Name   Stephen O'Connor, Ph.D.</p> <p>Contact Telephone   301-480-8366</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email [stephen.o'connor2@nih.gov](mailto:stephen.o'connor2@nih.gov)

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 15-Jun-2024 [Optional][LOI/Pre-App], 15-Jul-2024 , 23-Jan-2025

Synopsis NIMH seeks applications to evaluate the preliminary effectiveness of therapeutic and service delivery interventions that utilize lethal means safety strategies to reduce suicide risk in healthcare and community settings. Behavioral health clinics that incorporate lethal means counseling into their programming have been associated with significant reductions in suicide attempts and death. Yet, the field is lacking strong evidence on the effectiveness of these strategies tested in healthcare and community settings. Pilot effectiveness research will advance knowledge regarding optimization strategies, therapeutic change mechanisms, and inform decisions about whether further effectiveness testing is warranted. The research will provide preliminary evidence on the extent to which lethal means safety interventions more optimally lead to improved safety (e.g., number/percent of firearms safely stored, overdose injury codes for an individual) and lower suicide risk. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) that is/are presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitively test the effectiveness of the intervention.

102910	<a href="#">Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-176	16-Jun-2024	275,000 USD
--------	--	--	------------	-------------	-------------

Contact Name Andrew Rossi, Ph.D.

Contact Telephone 301-443-1576

Contact Email [andrew.rossi@nih.gov](mailto:andrew.rossi@nih.gov)

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 16-Jun-2024 , 16-Oct-2024

Synopsis A growing body of evidence suggests that optimal cognitive, affective, and social processes are associated with highly coordinated neural activity. These findings indicate that oscillatory rhythms, their co-modulation across frequency bands, spike-phase correlations, spike population dynamics, and other patterns might be useful drivers of therapeutic development for treatment of cognitive, social, or affective symptoms in neuropsychiatric disorders. This Funding Opportunity Announcement (FOA) supports projects that test whether modifying electrophysiological patterns during behavior can

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
102908	<a href="#">Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R01 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-175	05-Jun-2024	Not Specified

improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. This FOA uses the R21 exploratory grant mechanism, whereas its companion FOA, PAR-21-175, seeks R01 grant applications for larger research applications that have an established premise.

Contact Name | Andrew Rossi, Ph.D.  
 Contact Telephone | 301-443-1576  
 Contact Email | [andrew.rossi@nih.gov](mailto:andrew.rossi@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 05-Jun-2024 , 05-Oct-2024

Synopsis | A growing body of evidence suggests that optimal cognitive, affective, and social processes are associated with highly coordinated neural activity. These findings indicate that oscillatory rhythms, their co-modulation across frequency bands, spike-phase correlations, spike population dynamics, and other patterns might be useful drivers of therapeutic development for the treatment of cognitive, social, or affective symptoms in neuropsychiatric disorders. This Funding Opportunity Announcement (FOA) supports projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. This FOA uses the R01 grant mechanism, whereas its companion FOA, PAR-21-176, seeks shorter, higher-risk R21 grant applications.			
104058	<a href="#">NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PA-21-235	07-May-2024	275,000 USD
	Contact Name	Susan Koester, Ph.D.			
	Contact Telephone	301-443-3563			
	Contact Email	<a href="mailto:koesters@mail.nih.gov">koesters@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025			
	Synopsis	The NIMH Exploratory/Developmental Grant program supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. The preliminary work from these studies could lead to a major impact on biomedical, behavioral, or clinical mental health research, or on the delivery of mental health care.			
110192	<a href="#">RFA-NS-22-038 -- Research Program Award (R35 Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-22-038	15-Jun-2024 [Optional][LOI/Pre-App]	6,000,000 USD
	Contact Name	Alisa Schaefer, Ph.D.			
	Contact Telephone				
	Contact Email	<a href="mailto:alisa.schaefer@nih.gov">alisa.schaefer@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Jun-2024 [Optional][LOI/Pre-App], 15-Jul-2024			
	Synopsis	The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support, and increased freedom and flexibility to Program Directors (PDs)/Principal Investigators (PIs), to allow them to redirect their time away from the administrative burden of writing and managing multiple grant applications and towards engaging in the lab. This RPA affords			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
104258	<a href="#">NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-237	07-May-2024	Not Specified

investigators at most career stages the opportunity to advance their long-term research goals, rigorously explore exciting research opportunities, and mentor students and postdoctorates, which support and align with the mission of NINDS. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PI's recent NINDS support (Part 2, Section II). This greater funding stability will provide eligible investigators increased security, allowing them to undertake research projects that require a longer timeframe or to embark upon research that breaks new ground. Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center, will not be considered through this program. Benefits of the RPA include: A more stable funding environment, facilitating the pursuit of longer-term research goals; Flexible funding, enabling investigators to pursue research opportunities as they arise, not tied to specific aims; Reduced time spent writing grant applications and managing multiple grant awards, allowing investigators to spend more time conducting and overseeing research; More time for PDs/Pis to mentor and foster a diverse workforce in their laboratories. The RPA is a unique program for NINDS, as such NINDS strives to ensure it reflects our commitment to enhancing the diversity and inclusiveness of the neuroscience workforce. A diverse NIH-supported scientific workforce, including individuals from underrepresented groups, fosters scientific innovation, enhances global competitiveness, contributes to robust learning environments, and improves the quality of the research (see NIH's Interest in Diversity). NINDS will work to ensure that it maintains a broad and diverse research portfolio in terms of scientific areas, approaches, regions, institutions, and individuals. Such diversity will optimize returns on the Institute's investments by maximizing the ideas explored and the chances for important breakthroughs. Note that, while this funding opportunity also accepts clinical trials, only applications proposing "mechanistic clinical trials or studies" or basic experimental studies with humans (BESH) will be accepted. For information on the types of clinical trial that are within scope of this funding opportunity announcement, refer to Funding Opportunity Description, below.

Contact Name	Jeremy Brown, MD
Contact Telephone	301-496-9135
Contact Email	<a href="mailto:Jeremy.brown@nih.gov">Jeremy.brown@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 09-Jun-2024 , 10-Sep-2024 , 09-Oct-2024 , 08-Jan-2025
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website ( <a href="https://www.ninds.nih.gov/">https://www.ninds.nih.gov/</a> ).																		
107322	<a href="#">Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-030	07-Jun-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Ann-Marie Broome, PhD, MBA</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-496-1779</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:ann-marie.broome@nih.gov">ann-marie.broome@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-Jun-2024 , 10-Oct-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this funding opportunity announcement (FOA) is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.</td> </tr> </table>					Contact Name	Ann-Marie Broome, PhD, MBA	Contact Telephone	301-496-1779	Contact Email	<a href="mailto:ann-marie.broome@nih.gov">ann-marie.broome@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	07-Jun-2024 , 10-Oct-2024	Synopsis	The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this funding opportunity announcement (FOA) is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.
Contact Name	Ann-Marie Broome, PhD, MBA																		
Contact Telephone	301-496-1779																		
Contact Email	<a href="mailto:ann-marie.broome@nih.gov">ann-marie.broome@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	07-Jun-2024 , 10-Oct-2024																		
Synopsis	The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this funding opportunity announcement (FOA) is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.																		
110549	<a href="#">NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-142	10-Jun-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Jeremy Brown MD</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:jeremy.brown@nih.gov">jeremy.brown@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>10-Jun-2024 , 08-Oct-2024 , 10-Feb-2025</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated</td> </tr> </table>					Contact Name	Jeremy Brown MD	Contact Telephone		Contact Email	<a href="mailto:jeremy.brown@nih.gov">jeremy.brown@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	10-Jun-2024 , 08-Oct-2024 , 10-Feb-2025	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated
Contact Name	Jeremy Brown MD																		
Contact Telephone																			
Contact Email	<a href="mailto:jeremy.brown@nih.gov">jeremy.brown@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	10-Jun-2024 , 08-Oct-2024 , 10-Feb-2025																		
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

exploratory Phase 1 and Phase 2 clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). These trials must address questions within the mission and research interests of the NINDS. They may include studies of drugs and biologics, feasibility or preliminary efficacy studies of devices, and early studies of surgical, behavioral or rehabilitation therapies. All Phase 1 exploratory trials must contribute to the justification for and provide some of the data required to inform a future Phase 2 trial that may also be performed as part of the current grant application, should the results of the Phase 1 studies be encouraging. This FOA uses the UG3/UH3 mechanism.

103393	<a href="#">NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-153	07-May-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name | Michelle Jones-London, Ph.D.  
 Contact Telephone | 301-451-7966  
 Contact Email | [jonesmiche@ninds.nih.gov](mailto:jonesmiche@ninds.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 07-May-2024 , 12-Jun-2024 , 07-Sep-2024

Synopsis | The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from diverse backgrounds, including those from groups underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-21-152).

103724	<a href="#">NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-234	07-May-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name | Michelle Jones-London, Ph.D.  
 Contact Telephone | 301-451-7966

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:jonesmiche@ninds.nih.gov">jonesmiche@ninds.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 12-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from diverse backgrounds, including those from groups underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-21-153).</p>				

107186	<a href="#">Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-053	05-Jun-2024	Not Specified
--------	--	--	------------	-------------	---------------

	<p>Contact Name Codrin Lungu, MD</p> <p>Contact Telephone 301-496-9135</p> <p>Contact Email <a href="mailto:lunguci@ninds.nih.gov">lunguci@ninds.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2024 , 05-Oct-2024</p> <p>Synopsis Functional Neurological Disorders (FNDs) are characterized by symptoms of altered voluntary motor or sensory function with clinical findings providing evidence of incompatibility between the symptoms and recognized neurological or medical conditions. FNDs are highly prevalent and associated with significant morbidity, health care costs, and even mortality. In some respects, this group of conditions sits at the intersection of neurology and psychiatry, but the majority of cases first come to the attention of neurologists. Management is complex and requires interdisciplinary approaches. Given the disability caused by the symptoms, and the high cost in healthcare utilization and loss of productivity, FNDs amount to a significant missed opportunity for therapeutic intervention and therefore, a healthcare crisis. Diagnosis and management of FNDs</p>				
--	---	--	--	--	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	<p>remain very challenging. Diagnostic criteria have been proposed but they are not universally agreed upon. Diagnosis is based on positive clinical findings, and can be supported by laboratory or ancillary investigation findings. Certain FND subtypes are more difficult to correctly diagnose than others. More importantly, laboratory-supported diagnosis is possible, and biomarkers can be developed, but significantly more research is needed in these areas to advance clinical management of FNDs. Therapies exist and have been studied in select populations but gathering high-level evidence through clinical trials is hampered by limitations in available outcome measures. Differential responses to treatments have been recorded, and thus, prediction of aggregate treatment response has been difficult. This FOA invites researchers to submit prospective clinical projects that address critical needs for clinical trial readiness in FNDs. Projects appropriate for this FOA include the validation of biomarkers, endpoints and clinical outcome assessments (COA) that are fit-for-purpose and have a defined context of use for clinical trials. Projects involving biomarker discovery or early validation should apply to the relevant FOAs (PAR-19-315, PAR-21-056, PAR-21-057, PAR-21-058, PAR-21-059). The initiative will promote partnerships among academic investigators, industry, and patient groups, and will encourage interactions with the Food and Drug Administration (FDA).</p>																		
106361	<a href="#">Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-328	12-Jun-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Stephen Korn, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:korns@ninds.nih.gov">korns@ninds.nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>12-Jun-2024 , 12-Oct-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-327.</td> </tr> </table>					Contact Name	Stephen Korn, Ph.D.	Contact Telephone		Contact Email	<a href="mailto:korns@ninds.nih.gov">korns@ninds.nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	12-Jun-2024 , 12-Oct-2024	Synopsis	This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-327.
Contact Name	Stephen Korn, Ph.D.																		
Contact Telephone																			
Contact Email	<a href="mailto:korns@ninds.nih.gov">korns@ninds.nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	12-Jun-2024 , 12-Oct-2024																		
Synopsis	This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-327.																		
111360	<a href="#">Notice of Special Interest (NOSI): Disease Mechanisms of Prenatal and Pediatric Hydrocephalus</a>	National Institute of Neurological Disorders and	NOT-NS-23-004	07-May-2024	Not Specified														

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Stroke/NIH/DHHS					
	<p>Contact Name Jill Morris, Ph.D.</p> <p>Contact Telephone 301-496-5754</p> <p>Contact Email <a href="mailto:jill.morris@nih.gov">jill.morris@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025</p> <p>Synopsis The purpose of this Notice is to inform potential applicants about an area of special interest to NINDS in hypothesis-driven research projects that focus on deciphering the molecular, cellular and developmental mechanisms involved in the pathogenesis of prenatal and/or pediatric hydrocephalus and to examine new approaches for treatment.</p>				
106266	<p><a href="#">NINDS Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)</a></p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-022	07-May-2024	Not Specified
	<p>Contact Name Amelie Gubitza, Ph.D.</p> <p>Contact Telephone 301-451-7966</p> <p>Contact Email <a href="mailto:gubitza@ninds.nih.gov">gubitza@ninds.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 12-Jun-2024</p> <p>Synopsis The purpose of the NINDS Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of new and talented, independent investigators from diverse backgrounds (e.g. see NOT-OD-20-031, Notice of NIH’s Interest in Diversity) conducting AD/ADRD research. The program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees establish independent research programs in the AD/ADRD field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experiences</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| in a clinical trial led by a mentor or co-mentor.

106359	<a href="#">Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-327	12-Jun-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Stephen Korn, Ph.D.
Contact Telephone	
Contact Email	<a href="mailto:korns@ninds.nih.gov">korns@ninds.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	12-Jun-2024 , 12-Oct-2024
Synopsis	This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA PAR-21-328.

102747	<a href="#">Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-122	20-Jun-2024	750,000 USD
--------	--	--	------------	-------------	-------------

Contact Name	Becky Roof, PhD
Contact Telephone	301-496-1779
Contact Email	<a href="mailto:rebecca.roof@nih.gov">rebecca.roof@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	20-Jun-2024 , 21-Oct-2024
Synopsis	This funding opportunity announcement (FOA) provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.

102739	<a href="#">Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-123	20-Jun-2024	750,000 USD
--------	--	--	------------	-------------	-------------

Contact Name | Becky Roof, PhD  
 Contact Telephone | 301-496-1779  
 Contact Email | [rebecca.roof@nih.gov](mailto:rebecca.roof@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 20-Jun-2024 , 21-Oct-2024

Synopsis | This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.

109299	<a href="#">Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-089	07-May-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name | Carol Taylor-Burds Ph.D  
 Contact Telephone | 301-496-1779  
 Contact Email | [carol.taylor-burds@nih.gov](mailto:carol.taylor-burds@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   07-May-2024 , 22-Jun-2024 , 07-Sep-2024 , 21-Feb-2025 , 07-May-2025</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to promote the development of fit-for-purpose candidate biomarkers and biomarker signatures that enable more efficient clinical trials to advance therapeutic development or be used in clinical practice to help guide clinical care decisions. Specifically, the goal of this phased funding mechanism is to first identify or confirm candidate biomarkers or biomarker signatures using human samples and/or data, followed by an independent retrospective or prospective clinical study to conduct initial clinical validation of the biomarker/signature’s clinical utility for a defined Context of Use(s). In the first phase, applicants are expected to demonstrate that the biomarker acceptably identifies or predicts the concept of interest and may include optimization of the detection method using carefully standardized human samples or datasets. The overarching purpose of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.</p>				
109940	<a href="#">Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-076	07-May-2024	Not Specified
	<p>Contact Name   Adam L. Hartman, MD</p> <p>Contact Telephone   301-496-9135</p> <p>Contact Email   <a href="mailto:adam.hartman@nih.gov">adam.hartman@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 18-Oct-2024 , 07-Jan-2025 , 19-Feb-2025 , 07-May-2025</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS) (note: only prospective observational studies will be considered). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice.</p>				
111323	<a href="#">Notice of Special Interest (NOSI): Tools to Enhance the Study of Prenatal and Pediatric Hydrocephalus</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	NOT-NS-23-003	07-May-2024	Not Specified
	Contact Name   Jill Morris, Ph.D.				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-496-5754</p> <p>Contact Email   <a href="mailto:jill.morris@nih.gov">jill.morris@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025</p> <p>Synopsis   The purpose of this Notice is to inform potential applicants about an area of special interest to NINDS in research to develop or substantially modify existing cutting-edge tools that will advance prenatal and/or pediatric hydrocephalus research. Applications should aim to transform the field of prenatal and/or pediatric hydrocephalus research by generating tools including animal and cell models, novel methods and innovative technologies that will be widely used throughout the neuroscience community to understand disease mechanisms and/or developing therapeutics.</p>				
124093	<a href="#">RFA-NS-24-032 -- Development and Validation of Human Cellular Models for Alzheimer's Disease-Related Dementias (ADRD) (R01 - Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-24-032	20-May-2024 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name   Linda McGavern, PhD</p> <p>Contact Telephone</p> <p>Contact Email   <a href="mailto:mcgavernlm@ninds.nih.gov">mcgavernlm@ninds.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   20-May-2024 [Optional][LOI/Pre-App], 20-Jun-2024 , 20-Sep-2024 [Optional][LOI/Pre-App], 21-Oct-2024</p> <p>Synopsis   This Notice of Funding Opportunity (NOFO) supports the development and validation of novel, complex, and pathophysiologically relevant human cellular models of Alzheimer's Disease Related Dementias (ADRD). The cellular model system needs to reflect multiple aspects of the human condition as much as possible, such as capturing the multiple pathologies and brain cell types observed in ADRD. Validation is required, including face and construct validity. Human cellular models could be developed and validated with the goal of supporting therapeutic development or better understanding of human disease mechanisms and mechanisms that cause predisposition or resilience to developing ADRD.</p>				
108301	<a href="#">RFA-NS-22-034 -- HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-22-034	09-Apr-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Michael L. Oshinsky, PhD 301-496-9964 <a href="mailto:michael.oshinsky@nih.gov">michael.oshinsky@nih.gov</a>  <a href="#">Link to program URL</a> 09-Apr-2024 , 04-Jun-2024 , 07-Aug-2024 , 02-Oct-2024 , 06-Dec-2024  Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices is not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery. This FOA is not specific for any one or group of pain conditions. Projects to identify novel targets for acute pain, chronic pain, migraine, other headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, post stroke pain, orofacial pain, etc. will be considered. Projects to identify novel targets for a combination of chronic overlapping pain conditions or for specific pathological conditions will be considered. Projects that seek to identify novel targets in specific populations such as women, children, older adults or other underrepresented groups will also be responsive to this FOA.
--	--

115920	<a href="#">NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-23-090	10-Jun-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Jeremy Brown, MD 301-594-4481 <a href="mailto:jeremy.brown@nih.gov">jeremy.brown@nih.gov</a>  <a href="#">Link to program URL</a> 10-Jun-2024 , 08-Oct-2024 , 07-Feb-2025 , 06-Jun-2025 , 07-Oct-2025 , 06-Feb-2026
--	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	<p>Synopsis</p>	<p>This funding opportunity announcement (FOA) encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols. Applicants do not need to be part of the existing SIREN infrastructure to apply under this FOA. The NIH SIREN Network will also be uniquely poised to collaborate with other U.S. and international consortia necessary to conduct larger, definitive trials of promising interventions for neurological emergencies. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN.</p>			
--	-----------------	---	--	--	--

100306	<a href="#">NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-032	07-May-2024	Not Specified
--------	--	--	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Stephen Korn, Ph.D.</p> <p>301-496-4188</p> <p><a href="mailto:korns@ninds.nih.gov">korns@ninds.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-May-2024 , 10-Jun-2024 , 07-Sep-2024 , 10-Oct-2024 , 07-Jan-2026</p> <p>The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in the proposed postdoctoral position. This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, this F32 seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral fellow into an outstanding scientist. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 4 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early, thoughtful planning and timely completion of “mentored training” within a particular lab or environment. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose</p>
---	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| research experience in a clinical trial led by a sponsor or co-sponsor.

124721	<a href="#">RFA-NS-25-014 -- Mechanisms of Cognitive Fluctuations in ADRD Populations (R01 - Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-25-014	24-Jun-2024	4,125,000 USD
--------	---	--	---------------	-------------	---------------

Contact Name	Debra Babcock, PhD, MD
Contact Telephone	301-496-9964
Contact Email	<a href="mailto:dbabcock@mail.nih.gov">dbabcock@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	24-Jun-2024
Synopsis	This Notice Of Funding Opportunity invites research applications focused on understanding the underlying pathophysiology of cognitive fluctuations in people diagnosed with Alzheimer’s Disease- Related Dementias (ADRD). Researchers should propose a clear hypothesis for one or more etiologies that can be measured with standardized assessments (e.g., clinical evaluations, blood tests, electrophysiology, etc.) that can be collected across multiple time points and/or diagnoses. The use of digital measures capable of capturing fluctuations in real time are highly encouraged.

124926	<a href="#">RFA-NS-25-012 -- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-25-012	18-Jun-2024	1,050,000 USD
--------	--	--	---------------	-------------	---------------

Contact Name	Julia L. Bachman, PhD
Contact Telephone	
Contact Email	<a href="mailto:julia.bachman@nih.gov">julia.bachman@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	18-Jun-2024 , 17-Sep-2024 , 28-Jan-2025 , 16-May-2025 , 17-Sep-2025 , 16-Jan-2026 , 15-May-2026 , 17-Sep-2026 , 15-Jan-2027
Synopsis	This notice of funding opportunity (NOFO) aims to encourage research grant applications for initial translational efforts that will enable a drug discovery program for novel, non-opioid, and non-addictive treatments for pain. The program provides funding to develop and validate assays to support a distinct testing funnel and conduct screening efforts to identify and

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>characterize potential therapeutic agents including small molecules, biologics, and natural products. Preliminary in vivo pharmacokinetic, pharmacodynamic, and efficacy studies may also be supported. The goal of this NOFO is to advance projects to the point where they meet the entry criteria for the Pain Therapeutics Development Program or other later-stage translational programs. This NOFO is part of the NIH Helping to End Addiction Long Term (HEAL) initiative to accelerate the discovery and preclinical development of safe and effective therapeutics to treat pain with little or no addiction liability.</p>			
123614	<a href="#">Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-098	21-Jun-2024	Not Specified
	Contact Name	Carol Taylor-Burds, PhD			
	Contact Telephone	301-496-1779			
	Contact Email	<a href="mailto:carol.taylor-burds@nih.gov">carol.taylor-burds@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	21-Jun-2024 , 21-Feb-2025 , 20-Jun-2025 , 20-Feb-2026 , 22-Jun-2026			
	Synopsis	<p>The purpose of this notice of funding opportunity (NOFO) is to support rigorous analytical validation of method(s) used for measuring biomarkers for neurological and neuromuscular disorders for use in clinical trials or clinical practice. Applicants must justify the unmet need for the biomarker(s) and measurement methods and specify one or two context(s) of use for the biomarker(s). Activities supported include optimizing and evaluating the accuracy, precision, reportable range, and analytical sensitivity and specificity of the detection method across multiple sites and operators and establishing reference intervals and quality control procedures. Multi-site applications are expected but not required. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material. The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: Transdisciplinary research projects and collaborations among neuroscientists and researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>focused, minority-serving, community-based). Individual applications and partnerships that enhance geographic and regional heterogeneity. Investigators and teams composed of researchers at different career stages. Participation of individuals from diverse backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. Opportunities to enhance the research environment to benefit early- and mid-career investigators."</p>			
123611	<a href="#">Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-096	21-Jun-2024	Not Specified
	Contact Name	Carol Taylor-Burds, PhD			
	Contact Telephone	301-496-1779			
	Contact Email	<a href="mailto:carol.taylor-burds@nih.gov">carol.taylor-burds@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	21-Jun-2024 , 21-Feb-2025 , 20-Jun-2025 , 20-Feb-2026 , 22-Jun-2026			
	Synopsis	<p>The purpose of this notice of funding opportunity (NOFO) is to enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous clinical validation of biomarker measurements within the clinical population of interest to establish the clinical sensitivity and specificity of the biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material. The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: Transdisciplinary research projects and collaborations among neuroscientists and researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. Engagement</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). Individual applications and partnerships that enhance geographic and regional heterogeneity. Investigators and teams composed of researchers at different career stages. Participation of individuals from diverse backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. Opportunities to enhance the research environment to benefit early- and mid-career investigators."

123610	<a href="#">Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-095	21-Jun-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Carol Taylor-Burds, PhD
Contact Telephone	301-496-1779
Contact Email	<a href="mailto:carol.taylor-burds@nih.gov">carol.taylor-burds@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	21-Jun-2024 , 21-Feb-2025 , 20-Jun-2025 , 20-Feb-2026 , 22-Jun-2026
Synopsis	<p>The purpose of this notice of funding opportunity (NOFO) is to support rigorous analytical validation of method(s) used for measuring biomarkers for neurological and neuromuscular disorders for use in clinical trials or clinical practice. Applicants must justify the unmet need for the biomarker(s) and measurement methods and specify one or two context(s) of use for the biomarker(s). Activities supported include optimizing and evaluating the accuracy, precision, reportable range, and analytical sensitivity and specificity of the detection method across multiple sites and operators and establishing reference intervals and quality control procedures. Multi-site applications are expected but not required. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material. The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: Transdisciplinary research projects and collaborations among neuroscientists and</p>



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). Individual applications and partnerships that enhance geographic and regional heterogeneity. Investigators and teams composed of researchers at different career stages. Participation of individuals from diverse backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. Opportunities to enhance the research environment to benefit early- and mid-career investigators.

123613	<a href="#">Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-097	21-Jun-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Carol Taylor-Burds, PhD
Contact Telephone	301-496-1779
Contact Email	<a href="mailto:carol.taylor-burds@nih.gov">carol.taylor-burds@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	21-Jun-2024 , 21-Feb-2025 , 20-Jun-2025 , 20-Feb-2026 , 22-Jun-2026

**Synopsis**

The purpose of this notice of funding opportunity (NOFO) is to enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous clinical validation of biomarker measurements within the clinical population of interest to establish the clinical sensitivity and specificity of the biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material. The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to:

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Transdisciplinary research projects and collaborations among neuroscientists and researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). Individual applications and partnerships that enhance geographic and regional heterogeneity. Investigators and teams composed of researchers at different career stages. Participation of individuals from diverse backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. Opportunities to enhance the research environment to benefit early- and mid-career investigators."

123196	<a href="#">NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24-101	20-Jun-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Scott Janis, Ph.D.
Contact Telephone	301-496-9135
Contact Email	<a href="mailto:moyc@ninds.nih.gov">moyc@ninds.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	20-Jun-2024 , 18-Oct-2024 , 19-Feb-2025 , 20-Jun-2025 , 20-Oct-2025 , 19-Feb-2026 , 18-Jun-2026 , 19-Oct-2026
Synopsis	<p>This NOFO encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. Successful applicants will collaborate and conduct the study within the NIH StrokeNet. Following peer review, NINDS will prioritize studies among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. The NIH StrokeNet network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for stroke treatment, prevention, and recovery. It is NINDS's intent that all NINDS-supported multi-center clinical trials in stroke treatment, recovery, or prevention will be conducted within the NIH StrokeNet. Only in exceptional circumstances will NINDS consider funding multi-site stroke clinical trials outside of this network. This NOFO uses the bi-phasic, milestone driven</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

UG3/UH3 cooperative agreement activity code. Awards made under this NOFO will initially support a one-year milestone-driven planning and start-up phase, with possible transition to an implementation (UH3) phase of up to 6 additional years. Only UG3 projects that meet the scientific milestones and award requirements of the UG3 phase may transition to the UH3 phase. Applications submitted in response to this FOA must address both the UG3 and UH3 phases and are expected to include plans for project management and performance milestones for each phase. Applicants do not need to be part of the existing NIH StrokeNet infrastructure to apply under this NOFO.

115793	<a href="#">Notice of Special Interest (NOSI): Advancing Research for Amyotrophic Lateral Sclerosis (ALS)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	NOT-NS-23-062	22-Jun-2024	Not Specified
--------	---	--	---------------	-------------	---------------

Contact Name	Amelie Gubitz, PhD
Contact Telephone	301-332-6453
Contact Email	<a href="mailto:gubitza@nih.gov">gubitza@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	22-Jun-2024
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to announce that the National Institute of Neurological Disorders and Stroke (NINDS) encourages applications to advance research activities relevant to strategic priorities for the ALS research community identified in a recent planning effort of NINDS.

122306	<a href="#">RFA-NR-24-002 -- Short Courses in Social Determinants of Health for Research Education in Nursing Research (R25 Independent Clinical Trial Not Allowed)</a>	National Institute of Nursing Research/NIH/DHHS	RFA-NR-24-002	01-Jun-2024 [Optional][LOI/Pre-App]	Not Specified
--------	---	---	---------------	-------------------------------------	---------------

Contact Name	Liz Perruccio, MS, PhD
Contact Telephone	301-402-8084
Contact Email	<a href="mailto:liz.perruccio@nih.gov">liz.perruccio@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-Jun-2024 [Optional][LOI/Pre-App], 01-Jul-2024
Synopsis	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on: Courses for Skills Development Develop and implement a program to prepare nurse scientists, and scientists in aligned fields, to conduct research on the social determinants of health in alignment with the NINR Strategic Plan. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

113257	<a href="#">NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-22-230	07-May-2024	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	David L. Tilley, MPH, MS, CPH
Contact Telephone	301-827-6014
Contact Email	<a href="mailto:david.tilley@nih.gov">david.tilley@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 05-Jul-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 05-Mar-2025 , 07-May-2025
Synopsis	This funding announcement solicits R01 grant applications that propose independent research projects that are consistent with the scientific framework detailed in the 2022-2026 National Institute of Nursing Research (NINR) Strategic Plan. This research will be rooted in nursing's holistic, contextualized approach to understanding people and their health, address the nation's most pressing and persistent health challenges with a solutions orientation, and employ innovative and rigorous study designs to inform practice and policy.

113258	<a href="#">NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-22-231	07-May-2024	200,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	David L. Tilley, MPH, MS, CPH
Contact Telephone	301-827-6014
Contact Email	<a href="mailto:david.tilley@nih.gov">david.tilley@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   07-May-2024 , 16-Jun-2024 , 16-Jul-2024 , 07-Sep-2024 , 16-Oct-2024 , 16-Nov-2024 , 07-Jan-2025 , 16-Feb-2025 , 16-Mar-2025 , 07-May-2025</p> <p>Synopsis   This funding announcement solicits R21 grant applications that propose exploratory/developmental research projects that are consistent with the research framework detailed in the 2022-2026 National Institute of Nursing Research (NINR) Strategic Plan. This research will be rooted in nursing's holistic, contextualized approach to understanding people and their health, address the nation's most pressing and persistent health challenges with a solutions orientation, and employ innovative and rigorous study designs to inform practice and policy.</p>				
108328	<p><a href="#">Early and Late Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)</a></p>	National Institute on Aging/NIH/DHHS	PAR-18-878	05-Jun-2024	Not Specified
	<p>Contact Name   Laurie Ryan</p> <p>Contact Telephone   301-496-9350</p> <p>Contact Email   <a href="mailto:ryanl@mail.nih.gov">ryanl@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2024 , 05-Oct-2024</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite applications that propose to develop and implement early to late stage clinical trials of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods.</p>				
114469	<p><a href="#">NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)</a></p>	National Institute on Aging/NIH/DHHS	PAR-23-057	05-Jun-2024	Not Specified
	<p>Contact Name   Sergei Romashkan, M.D., Ph.D.</p> <p>Contact Telephone   301-435-3047</p> <p>Contact Email   <a href="mailto:romashks@mail.nih.gov">romashks@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025			
	Synopsis	This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the NIA website.			
123842	<a href="#">RFA-AG-25-016 -- Multi-Scale Models Bridging Levels of Analysis in Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R01 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	RFA-AG-25-016	13-May-2024 [Optional][LOI/Pre-App]	2,500,000 USD
	Contact Name	Amanda DiBattista, Ph.D.			
	Contact Telephone	301-827-3342			
	Contact Email	<a href="mailto:amanda.dibattista@nih.gov">amanda.dibattista@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	13-May-2024 [Optional][LOI/Pre-App], 13-Jun-2024			
	Synopsis	This notice of funding opportunity (NOFO) invites applications proposing to establish multi-scale computational models recapitulating dynamic changes associated with aging and Alzheimer's disease (AD) and AD-related dementias (ADRD). This broad scope encompasses a variety of computational approaches—such as mathematical and computational modeling, image analysis, artificial intelligence, and machine learning—to better understand aging processes and AD/ADRD across molecules, cells and networks, and cognition and behavior.			
104436	<a href="#">NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-21-220	12-Jun-2024	Not Specified
	Contact Name	Yuan Luo, Ph.D.			
	Contact Telephone	301-496-9350			
	Contact Email	<a href="mailto:yuan.luo@nih.gov">yuan.luo@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	12-Jun-2024			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to promote diversity in the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This pathway to independence award will			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

emphasize the development of skills in data science and drug discovery, and their application to various aspects of AD/ADRD research (from populations studies to research that can lead to new treatments and diagnostics, including all aspects of behavioral and social research). This award will support early career investigators from diverse backgrounds to gain critical translational skills in data science and drug discovery and transition to research independence.. The long-term goal of this program is to develop a diverse translational research workforce that can effectively participate in and/or lead a team-science, precision medicine approach to studies of AD/ADRD treatment, prevention, early detection, and disease management and care. This Funding Opportunity Announcement (FOA) is designed for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor.

107419	<a href="#">Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-22-047	05-Jun-2024	5,000,000 USD
--------	--	--------------------------------------	------------	-------------	---------------

Contact Name | Lorenzo M. Refolo, Ph.D.  
 Contact Telephone | 301-594-7576  
 Contact Email | [refolol@nia.nih.gov](mailto:refolol@nia.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 05-Jun-2024 , 05-Oct-2024

Synopsis | The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this FOA include: research on basic mechanisms of disease or mechanisms of drug action; development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone clinical trials.

123977	<a href="#">NIA Career Transition Award (K22 Independent Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-24-120	12-Jun-2024	Not Specified
--------	--	--------------------------------------	------------	-------------	---------------

Contact Name | Jamie Lahvic, Ph.D.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email <a href="mailto:NIATraining@mail.nih.gov">NIATraining@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 12-Jun-2024 , 12-Jul-2024 , 12-Oct-2024 , 12-Nov-2024 , 12-Feb-2025 , 12-Mar-2025 , 12-Jun-2025 , 12-Jul-2025 , 12-Oct-2025 , 12-Nov-2025</p> <p>Synopsis The purpose of the NIA Career Transition Award (CTA) is to facilitate the transition of mentored, postdoctoral researchers to tenure-track or equivalent faculty positions conducting research that advances the mission of NIA. This award does not provide postdoctoral phase funding; therefore, candidates should be prepared to transition to tenure-track or equivalent faculty positions within 12 months after confirmation of a positive funding decision. After transition to an approved faculty position at an extramural institution/organization, the award will provide three years of protected research time through salary and research support. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial.</p>				
123983	<p><a href="#">RFA-AG-25-005 -- Open Measurement Coordinating Network for Non-Pharmacological Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Primary Prevention Trials (U24 Clinical Trail Not Allowed)</a></p>	National Institute on Aging/NIH/DHHS	RFA-AG-25-005	16-May-2024 [Optional][LOI/Pre-App]	8,000,000 USD
	<p>Contact Name Luke Stoeckel, Ph.D.</p> <p>Contact Telephone 301-529-7254</p> <p>Contact Email <a href="mailto:NIAOpenMeasure@nih.gov">NIAOpenMeasure@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-May-2024 [Optional][LOI/Pre-App], 15-Jun-2024</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) invites U24 Cooperative Agreement applications that propose to establish a national Open Measurement Coordinating Network for Non-Pharmacological Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Primary Prevention Trials. The Network will serve as a centralized hub for developing, validating, standardizing, and disseminating measures and measurement methods for AD/ADRD primary prevention trials. It will incorporate measures and measurement methods across neuropsychological, biomarker, and functional domains to meet the goal of primary prevention of AD/ADRD centered around brain health equity. Brain health equity is the fair distribution of brain health determinants, outcomes, and resources within and between segments of the population, regardless of social standing. Measures and measurement methods of interest will test outcomes and mechanisms of action (e.g., cognitive,</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

behavioral, structural/social, computational, biological) that are customized for individuals with different needs and that are linked to real-world function. Resources developed through this initiative, including measurement instruments, methods, algorithms, code, documentation, and normative data, are intended to enable future measures and measurement-methods-development projects that support AD/ADRD primary prevention research needs. The National Institute on Aging (NIA) is particularly interested in proposals that aim to advance equity for populations disproportionately impacted by AD/ADRD.

114865	<a href="#">Pilot Studies for the Spectrum of Alzheimer’s Disease/Alzheimer’s Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-23-083	18-Jun-2024	650,000 USD
--------	---	--------------------------------------	------------	-------------	-------------

Contact Name	Laurie Ryan
Contact Telephone	301-496-9350
Contact Email	<a href="mailto:ryanl@mail.nih.gov">ryanl@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	18-Jun-2024 , 18-Oct-2024
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite research grant applications that enable the collection of pilot data to support early stage testing of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods.

120970	<a href="#">Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)</a>	National Institute on Aging/NIH/DHHS	PAR-23-274	20-Jun-2024	Not Specified
--------	--	--------------------------------------	------------	-------------	---------------

Contact Name	Akanni Clarke
Contact Telephone	301-496-9350
Contact Email	<a href="mailto:akanni.clarke@nih.gov">akanni.clarke@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	20-Jun-2024 , 21-Oct-2024 , 21-Feb-2025 , 23-Jun-2025 , 20-Oct-2025 , 20-Feb-2026 , 22-Jun-2026 , 19-Oct-2026

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The purpose of this notice of funding opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and AD-related dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum, from pre-symptomatic to more severe stages of disease. This NOFO uses a phased award activity code. Applications must include prespecified, go/no-go safety and tolerability milestones that must be met to advance from phase 1 to latter stages of clinical development.</p>			
124356	<a href="#">RFA-AG-25-009 -- Research Training in Aging for Medical Students (T35)</a>	National Institute on Aging/NIH/DHHS	RFA-AG-25-009	14-May-2024 [Optional][LOI/Pre-App]	750,000 USD
	<p>Contact Name   Jessi Perez</p> <p>Contact Telephone   301-402-7739</p> <p>Contact Email   <a href="mailto:perezi@mail.nih.gov">perezi@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   14-May-2024 [Optional][LOI/Pre-App], 14-Jun-2024</p> <p>Synopsis  </p>	<p>The primary goal of this Institutional Research Training Grant is to provide a short-term training for medical students to obtain necessary aging research experiences and technical expertise and skills early during their education to encourage them to pursue careers in research. Other health professional students may also benefit from such short-term training and are eligible when research training is a minor part of, or nonexistent in, their doctoral program. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.</p>			
108329	<a href="#">Pilot Studies for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-21-360	18-Jun-2024	650,000 USD
	<p>Contact Name   Laurie Ryan</p> <p>Contact Telephone   301-496-9350</p> <p>Contact Email   <a href="mailto:ryanl@mail.nih.gov">ryanl@mail.nih.gov</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 18-Jun-2024 , 18-Oct-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite research grant applications that enable the collection of pilot data to support early stage testing of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods.</p>				
124189	<p><a href="#">Notice of Special Interest (NOSI): Administrative Supplements for NIA-VA Mentored Physician and Clinical Psychologist Scientist Award in Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)</a></p>	National Institute on Aging/NIH/DHHS	NOT-AG-23-054	10-Jun-2024	875,000 USD
	<p>Contact Name Lisa A. Opanashuk, Ph.D.</p> <p>Contact Telephone 301-827-5422</p> <p>Contact Email <a href="mailto:Lisa.Opanashuk@nih.gov">Lisa.Opanashuk@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 10-Jun-2024 , 09-Dec-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to attract early stage physician-scientists and clinical psychologist-scientists from the U.S. Department of Veterans Affairs (VA) to an Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) research career. To accomplish this goal, the VA and the National Institute on Aging (NIA) have created a two-part opportunity for eligible VA researchers to pair with both VA- and NIA-funded mentors in the AD/ADRD field through an IK2 career development award from the VA (described in VA RFAs BX-24-030, CX-24-030, HX-24-030, and RX-24-030 ) and an administrative supplement from NIA. The research can focus on any aspect of the AD/ADRD field (e.g., disease mechanisms, biomarker discovery, diagnosis/clinical assessment, therapeutics, patient care, community care/social determinants of health, caregiver issues, and models of care). The VA RFAs and NIA NOSI will also promote developing and implementing a collaborative framework to facilitate co-funding and support of shared research priorities between NIA and the VA, enabling increased coordination between the two organizations.</p>				
117878	<p><a href="#">Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)</a></p>	National Institute on Aging/NIH/DHHS	PAR-23-179	16-Jun-2024	200,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Luci Roberts, Ph.D.
Contact Telephone	301-496-9350
Contact Email	<a href="mailto:roberlu@mail.nih.gov">roberlu@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026
Synopsis	This Small Research Grant Program (R03) will support meritorious projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this NOFO will support projects covering a wide range of topics related to AD/ADRD. The overall goal of this NOFO is (i) to encourage the next generation of researchers to pursue research and academic careers in AD/ADRD research; and (ii) to stimulate established researchers who have not had a major award in AD/ADRD research to perform pilot studies to develop new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from diverse backgrounds, including those from underrepresented groups are always encouraged to apply for NIH support. Investigators who have not successfully competed for an award under this or prior versions of this announcement are specifically encouraged to apply.

114861	<a href="#">Early and Late Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-23-081	05-Jun-2024	Not Specified
--------	--	--------------------------------------	------------	-------------	---------------

Contact Name	Laurie Ryan
Contact Telephone	301-496-9350
Contact Email	<a href="mailto:ryanl@mail.nih.gov">ryanl@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite applications that propose to develop and implement early to late stage clinical trials of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
124637	<a href="#">RFA-AG-25-017 -- Exploring Proteogenomic Approaches to Unravel the Mechanisms of Mis-Folded Protein Accumulation in Tauopathies (R01 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	RFA-AG-25-017	10-May-2024 [Optional][LOI/Pre-App]	2,500,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">J. Austin Yang, Ph.D.</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-496-9350</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;"><a href="mailto:austin.yang@nih.gov">austin.yang@nih.gov</a></td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;"><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">10-May-2024 [Optional][LOI/Pre-App], 10-Jun-2024</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">This notice of funding opportunity (NOFO) invites innovative research proposals to explore the accumulation of misprocessed proteins in Tauopathies within specific brain regions and cell types. NIA encourages collaborative efforts to create advanced single-cell or single-cell type proteogenomic platforms. These platforms aim to shed light on dynamic changes in protein-misfolding responses in neuronal proteomes and their potential biological consequences during aging and the development of Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD).</td> </tr> </table>					Contact Name	J. Austin Yang, Ph.D.	Contact Telephone	301-496-9350	Contact Email	<a href="mailto:austin.yang@nih.gov">austin.yang@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	10-May-2024 [Optional][LOI/Pre-App], 10-Jun-2024	Synopsis	This notice of funding opportunity (NOFO) invites innovative research proposals to explore the accumulation of misprocessed proteins in Tauopathies within specific brain regions and cell types. NIA encourages collaborative efforts to create advanced single-cell or single-cell type proteogenomic platforms. These platforms aim to shed light on dynamic changes in protein-misfolding responses in neuronal proteomes and their potential biological consequences during aging and the development of Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD).
Contact Name	J. Austin Yang, Ph.D.																		
Contact Telephone	301-496-9350																		
Contact Email	<a href="mailto:austin.yang@nih.gov">austin.yang@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	10-May-2024 [Optional][LOI/Pre-App], 10-Jun-2024																		
Synopsis	This notice of funding opportunity (NOFO) invites innovative research proposals to explore the accumulation of misprocessed proteins in Tauopathies within specific brain regions and cell types. NIA encourages collaborative efforts to create advanced single-cell or single-cell type proteogenomic platforms. These platforms aim to shed light on dynamic changes in protein-misfolding responses in neuronal proteomes and their potential biological consequences during aging and the development of Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD).																		
124485	<a href="#">Notice of Special Interest (NOSI): U.S. Health in the International Perspective</a>	National Institute on Aging/NIH/DHHS	NOT-AG-24-004	05-Jun-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Kriti M. Jain, Ph.D.</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">202-740-6701</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;"><a href="mailto:kriti.jain@nih.gov">kriti.jain@nih.gov</a></td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;"><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">05-Jun-2024</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">This NOSI expresses NIA’s interest in research that examines mechanisms and causes behind the increasing U.S. health disadvantage, which refers to worsening life expectancies and health outcomes in the U.S. compared to other countries. Of particular interest are projects that examine cross-national and U.S. cross-regional or cross-state differences in policy context that may drive poor health outcomes.</td> </tr> </table>					Contact Name	Kriti M. Jain, Ph.D.	Contact Telephone	202-740-6701	Contact Email	<a href="mailto:kriti.jain@nih.gov">kriti.jain@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	05-Jun-2024	Synopsis	This NOSI expresses NIA’s interest in research that examines mechanisms and causes behind the increasing U.S. health disadvantage, which refers to worsening life expectancies and health outcomes in the U.S. compared to other countries. Of particular interest are projects that examine cross-national and U.S. cross-regional or cross-state differences in policy context that may drive poor health outcomes.
Contact Name	Kriti M. Jain, Ph.D.																		
Contact Telephone	202-740-6701																		
Contact Email	<a href="mailto:kriti.jain@nih.gov">kriti.jain@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	05-Jun-2024																		
Synopsis	This NOSI expresses NIA’s interest in research that examines mechanisms and causes behind the increasing U.S. health disadvantage, which refers to worsening life expectancies and health outcomes in the U.S. compared to other countries. Of particular interest are projects that examine cross-national and U.S. cross-regional or cross-state differences in policy context that may drive poor health outcomes.																		
122532	<a href="#">Aging Research Dissertation Awards to Promote Diversity (R36 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-24-052	16-Jun-2024	Not Specified														

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Jamie Lahvic, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email   <a href="mailto:NIATraining@mail.nih.gov">NIATraining@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2024 , 16-Jul-2024 , 16-Oct-2024 , 16-Nov-2024 , 16-Feb-2025 , 16-Mar-2025 , 16-Jun-2025 , 16-Jul-2025 , 16-Oct-2025 , 16-Nov-2025 , 16-Feb-2026 , 16-Mar-2026 , 16-Jun-2026 , 16-Jul-2026 , 16-Oct-2026 , 16-Nov-2026</p> <p>Synopsis   This Notice of Funding Opportunity (NOFO) invites R36 applications to promote diversity in the scientific research workforce engaged in research on aging and aging-related health conditions by providing dissertation awards in all areas of research within NIA's strategic priorities.</p>				
124720	<a href="#">RFA-AG-25-013 -- Nathan Shock Centers Coordinating Center (U24 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	RFA-AG-25-013	15-May-2024 [Optional][LOI/Pre-App]	5,000,000 USD
	<p>Contact Name   Christy S. Carter, Ph.D.</p> <p>Contact Telephone   240-687-0644</p> <p>Contact Email   <a href="mailto:christy.carter@nih.gov">christy.carter@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-May-2024 [Optional][LOI/Pre-App], 15-Jun-2024</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) invites applications to develop and maintain a Nathan Shock Centers Coordinating Center (NSC3). The goal of the NSC3 is to provide logistical and organization support of the Nathan Shock Centers of Excellence in Basic Biology of Aging (NSC). Applicants should be familiar with NSC activities, but they do not need to be part of an NSC. Major activities of the proposed NSC3 will include improving visibility of the NSC nationally and internationally, improving collaboration and coordination among NSC, enhancing NSC training activities, facilitating the sharing of resources, and interacting with NIA and NSC to develop strategies and plans for further development. The successful application will include a plan to improve transparency and the interactions of NSC with the research community. It should also leverage existing bioinformatics resources. The NSC3 director will be a participant in the NIA's Research Centers Collaborative Network (RCCN).</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

124719	<a href="#">RFA-AG-25-012 -- Nathan Shock Centers of Excellence in Basic Biology of Aging (P30 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	RFA-AG-25-012	15-May-2024 [Optional][LOI/Pre-App]	5,500,000 USD
--------	--	--------------------------------------	---------------	-------------------------------------	---------------

Contact Name	Christy Carter, Ph.D.
Contact Telephone	301-827-1382
Contact Email	<a href="mailto:christy.carter@nih.gov">christy.carter@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	15-May-2024 [Optional][LOI/Pre-App], 14-Jun-2024
Synopsis	This FOA aims to provide support, including competitive renewals, for the Centers known as the Nathan Shock Centers of Excellence in Basic Biology of Aging (NSC). These Center grants will provide funding for leadership, training, and research activities that will increase and disseminate scientific knowledge in the research areas supported by the NIA's Division of Aging Biology ( <a href="https://www.nia.nih.gov/research/dab">https://www.nia.nih.gov/research/dab</a> ). The NSC provide intellectual leadership and innovation, training, pertinent cores focused on the needs of the field and opportunities for research career development for future leaders, both within and beyond their institutions. They also collaborate substantially with other NSCs, the NSC Coordinating Center and other NIA-funded Centers. The NSC awards are intended for institutions committed to research on the basic biology of aging, but previous funding in this area is not necessary.

124752	<a href="#">New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-24-160	05-Jun-2024	Not Specified
--------	--	--------------------------------------	------------	-------------	---------------

Contact Name	Elizabeth Newman, Ph.D.
Contact Telephone	301-480-7937
Contact Email	<a href="mailto:elizabeth.newman@nih.gov">elizabeth.newman@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027
Synopsis	The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop new approaches or apply

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
124754	<a href="#">New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-24-160	16-Jun-2024	400,000 USD

existing approaches in novel ways to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease. Research can include healthy human participants of any age; specific clinical groups such as those with cognitive, motor, or affective regulation challenges; and/or animal research on these domains of function. The studies can focus on longitudinal neuroanatomical or functional changes at any level, including genetics/genomics, single cells, connectomics, neural population activity patterns, and others. This funding opportunity is intended to encourage technological and conceptual innovation to improve repeated measures across longer epochs of the lifespan, to better predict outcomes at later ages. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

Contact Name	Elizabeth Newman, Ph.D.
Contact Telephone	301-480-7937
Contact Email	<a href="mailto:elizabeth.newman@nih.gov">elizabeth.newman@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027
Synopsis	The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop exploratory, highly novel new approaches, or innovative applications of existing approaches, to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease, by improving repeated measures across longer epochs of the lifespan to better predict outcomes at later ages. Research can include healthy human participants of any age; specific clinical groups such those with cognitive, motor, or affective regulation challenges; and/or animal research on these domains of function. The studies can focus on longitudinal neuroanatomical or functional changes at any level, including genetics/genomics, single cells, connectomics, neural population activity patterns, and others. This funding opportunity is intended to encourage technological and conceptual innovation through this high risk, high reward funding mechanism to develop highly innovative ideas that either lack preliminary data or need additional preliminary data. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

115129	<a href="#">RFA-AG-24-001 -- Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	RFA-AG-24-001	15-May-2024 [Optional][LOI/Pre-App]	14,750,000 USD
--------	--	--------------------------------------	---------------	-------------------------------------	----------------

Contact Name	Cerise Elliott, Ph.D.
Contact Telephone	301-496-9350
Contact Email	<a href="mailto:elliottce@mail.nih.gov">elliottce@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	15-May-2024 [Optional][LOI/Pre-App], 14-Jun-2024 , 27-Aug-2025 [Optional][LOI/Pre-App], 26-Sep-2025
Synopsis	This Funding Opportunity Announcement (FOA) invites applications from institutions proposing to establish, or renew, an Alzheimer's Disease Research Center (ADRC). NIA-designated ADRCs serve as a national resource for research on the nature of Alzheimer's disease (AD) and AD-related dementias (ADRD) and the development of more effective approaches to prevention, diagnosis, care, and therapy. They create shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators.

108054	<a href="#">Notice of Special Interest (NOSI): Research on Pain, Pain Management, and Opioids in Aging</a>	National Institute on Aging/NIH/DHHS	NOT-AG-22-004	08-Apr-2024	Not Specified
--------	--	--------------------------------------	---------------	-------------	---------------

Contact Name	Devon Oskvig, Ph.D.
Contact Telephone	301-827-5899
Contact Email	<a href="mailto:devon.oskvig@nih.gov">devon.oskvig@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 25-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 08-Aug-2024 , 05-Sep-2024 , 07-Sep-2024 , 25-Sep-2024 , 12-Oct-2024 , 25-Oct-2024 , 05-Jan-2025 , 08-Dec-2025
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to highlight that the National Institute on Aging (NIA) is interested in receiving grant applications focused on pain, pain management, and opioids related to aging or older adults and within NIA's

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

mission areas. This NOSI invites research applications that focus on improving the understanding of mechanisms underlying pain experience with aging; enhancing assessment, prevention, and management strategies for pain in older adults; and improving health equity of aging populations suffering with pain. New applications, resubmissions, competing renewals, and competing revisions to existing awards are all encouraged through this NOSI. For administrative supplements focused on pain, pain management, and opioids related to aging or older adults and within NIA's mission areas, please see NOT-AG-22-005.

113465	<a href="#">Notice of Special Interest (NOSI): Development of Radiotracers for Diagnosis and Clinical Studies in Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)</a>	National Institute on Aging/NIH/DHHS	NOT-AG-22-032	07-May-2024	Not Specified
--------	---	--------------------------------------	---------------	-------------	---------------

Contact Name	Lorenzo M. Refolo, Ph.D.
Contact Telephone	301-594-7576
Contact Email	<a href="mailto:refolol@nia.nih.gov">refolol@nia.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 09-Jul-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 05-Sep-2025
Synopsis	This Notice of Special Interest (NOSI) invites applications for research grants that propose to develop radiotracers for Positron Emission Tomography (PET) for use in Alzheimer's disease (AD) and AD-related dementias (ADRD) research targeting new and/or emerging biological process or molecular pathways that have been shown to be relevant in the etiology and pathophysiology of neurodegeneration.

120716	<a href="#">Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23-250	05-Jun-2024	2,500,000 USD
--------	---	---	------------	-------------	---------------

Contact Name	Brett T. Hagman, Ph.D.
Contact Telephone	301-443-0638
Contact Email	<a href="mailto:brett.hagman@nih.gov">brett.hagman@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.			
120720	<a href="#">Alcohol Health Services Research (R01 Clinical Trial Optional)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23-251	05-Jun-2024	Not Specified
	Contact Name	Laura E. Kwako, Ph.D.			
	Contact Telephone	301-451-8507			
	Contact Email	<a href="mailto:laura.kwako@nih.gov">laura.kwako@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026			
	Synopsis	The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.			
120718	<a href="#">Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23-249	16-Jun-2024	450,000 USD
	Contact Name	Brett T. Hagman, Ph.D.			
	Contact Telephone	301-443-0638			
	Contact Email	<a href="mailto:brett.hagman@nih.gov">brett.hagman@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026			
	Synopsis	The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Required mechanism			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.

120721	<a href="#">Alcohol Health Services Research (R01 Clinical Trial Optional)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23-252	16-Jun-2024	450,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Laura E. Kwako, Ph.D.
Contact Telephone	301-451-8507
Contact Email	<a href="mailto:laura.kwako@nih.gov">laura.kwako@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026
Synopsis	The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.

122636	<a href="#">Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-24-068	17-Jun-2024	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	William Dunty, PhD
Contact Telephone	301-443-7351
Contact Email	<a href="mailto:duntyw@mail.nih.gov">duntyw@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	17-Jun-2024 , 16-Oct-2024 , 17-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026
Synopsis	This Notice of Funding Opportunity (NOFO) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials. Applicants interested in planning clinical trials or adding to current projects may also consider NOFO (PAR-24-067, the R34 option).

104867	<a href="#">Mechanisms of Alcohol Tolerance (R21/R33 Clinical Trial Optional)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-21-250	16-Jun-2024	1,775,000 USD
--------	---	---	------------	-------------	---------------

Contact Name | Elizabeth M Powell, PhD  
 Contact Telephone | 301-443-0786  
 Contact Email | [elizabeth.powell3@nih.gov](mailto:elizabeth.powell3@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 16-Jun-2024

Synopsis | This funding opportunity announcement (FOA) focuses on sensitivity and tolerance mechanisms underlying the development of alcohol use disorder. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol use disorder. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, clinical trial optional, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase.

105028	<a href="#">Notice of Special Interest (NOSI): Genetics of Alcohol Sensitivity and Tolerance</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-21-029	07-May-2024	Not Specified
--------	--	---	---------------	-------------	---------------

Contact Name | Hemin Chin, PhD  
 Contact Telephone | 301-443-1282  
 Contact Email | [hemin.chin@nih.gov](mailto:hemin.chin@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL) | 07-May-2024 , 05-Jun-2024

Synopsis | The purpose of this notice of special interest (NOSI) is to provide enhanced understanding of genetic, genomic, and epigenetic factors contributing to biological processes for individual variation in sensitivity, the development of tolerance, and progression to AUD. NIAAA is interested in projects that will develop innovative strategies integrating both experimental and bioinformatics approaches to establish causality for candidate genes from GWAS and linkage studies and to provide insights into genetic mechanisms of alcohol sensitivity and the development of tolerance through investigation of genomic, epigenetic, or transcriptional variation, and gene network and pathway analyses. Applicants are encouraged to consider model systems in which these complex relationships can be better studied under defined genetic backgrounds and well-controlled environmental conditions.

116584	<a href="#">Notice of Special Interest (NOSI): Advancing mHealth Interventions for Understanding and Preventing Alcohol-Related Domestic Violence</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-23-003	07-May-2024	Not Specified
--------	---	---	---------------	-------------	---------------

Contact Name | Robert Freeman, Ph.D.  
 Contact Telephone | 301-443-8820  
 Contact Email | [rfreeman@mail.nih.gov](mailto:rfreeman@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)

Deadline Dates (ALL) | 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 12-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 12-Jun-2026 , 16-Jun-2026 , 07-Sep-2026

Synopsis | In light of the documented increases in both alcohol misuse (among some individuals) and domestic violence (DV) as a result of the global COVID-19 pandemic and array of mandated restrictions enacted to mitigate COVID spread, the purpose of this grant application solicitation is to announce NIAAA’s interest in addressing the critical need for research related to developing, testing, and intervening proximal to drinking occasions, when risk of DV is elevated, to decrease the likelihood of alcohol consumption at levels sufficient to trigger DV and to provide skills shown to reduce risk of DV perpetration and victimization. In particular, this solicitation seeks to advance the development, feasibility, acceptability, pilot testing, potential efficacy, and implementation of scalable, low resource, and remotely delivered interventions via mobile devices (mHealth) that rely on communication technologies for reducing and preventing alcohol consumption and DV. For this FOA, the term “domestic violence” will extend to child maltreatment (abuse and neglect) and elder abuse, in addition to intimate partner violence (IPV).

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
122632	<a href="#">Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-24-067	16-Jun-2024	450,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>William Dunty, PhD</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-443-7351</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:duntyw@mail.nih.gov">duntyw@mail.nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>This Notice of Funding Opportunity (NOFO) for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies. Applicants interested in exploratory phased projects may consider NOFO (PAR-24-068, the R61/R33 option).</td> </tr> </table>					Contact Name	William Dunty, PhD	Contact Telephone	301-443-7351	Contact Email	<a href="mailto:duntyw@mail.nih.gov">duntyw@mail.nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026	Synopsis	This Notice of Funding Opportunity (NOFO) for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies. Applicants interested in exploratory phased projects may consider NOFO (PAR-24-068, the R61/R33 option).
Contact Name	William Dunty, PhD																		
Contact Telephone	301-443-7351																		
Contact Email	<a href="mailto:duntyw@mail.nih.gov">duntyw@mail.nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026																		
Synopsis	This Notice of Funding Opportunity (NOFO) for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies. Applicants interested in exploratory phased projects may consider NOFO (PAR-24-068, the R61/R33 option).																		
124492	<a href="#">RFA-AA-24-006--Model Continuums of Care Initiative (MCCI) to Advance Health Equity and End Health Disparities Among Women and Girls in Racial/Ethnic Minority and Other Underserved Communities (U34 Clinical Trials Required)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA-24-006	19-May-2024 [Optional][LOI/Pre-App]	600,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Deidra Roach, M.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-443-5820</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:droach@nih.gov">droach@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>19-May-2024 [Optional][LOI/Pre-App], 18-Jun-2024 , 19-Sep-2024 [Optional][LOI/Pre-App], 18-Oct-2024 , 20-Jan-2025 [Optional][LOI/Pre-App], 19-Feb-2025</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this NOFO is to support the planning phase of the Model Continuums of Care Initiative (MCCI) to Advance Health Equity and End Health Disparities Among Women and Girls in Racial/Ethnic Minority Communities. MCCI is a multi-ICO dissemination and implementation science initiative to advance racial equity and end health disparities in racial/ethnic minority women and girls of reproductive age. Specifically, the Model Continuums of Care Initiative will apply the latest</td> </tr> </table>					Contact Name	Deidra Roach, M.D.	Contact Telephone	301-443-5820	Contact Email	<a href="mailto:droach@nih.gov">droach@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	19-May-2024 [Optional][LOI/Pre-App], 18-Jun-2024 , 19-Sep-2024 [Optional][LOI/Pre-App], 18-Oct-2024 , 20-Jan-2025 [Optional][LOI/Pre-App], 19-Feb-2025	Synopsis	The purpose of this NOFO is to support the planning phase of the Model Continuums of Care Initiative (MCCI) to Advance Health Equity and End Health Disparities Among Women and Girls in Racial/Ethnic Minority Communities. MCCI is a multi-ICO dissemination and implementation science initiative to advance racial equity and end health disparities in racial/ethnic minority women and girls of reproductive age. Specifically, the Model Continuums of Care Initiative will apply the latest
Contact Name	Deidra Roach, M.D.																		
Contact Telephone	301-443-5820																		
Contact Email	<a href="mailto:droach@nih.gov">droach@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	19-May-2024 [Optional][LOI/Pre-App], 18-Jun-2024 , 19-Sep-2024 [Optional][LOI/Pre-App], 18-Oct-2024 , 20-Jan-2025 [Optional][LOI/Pre-App], 19-Feb-2025																		
Synopsis	The purpose of this NOFO is to support the planning phase of the Model Continuums of Care Initiative (MCCI) to Advance Health Equity and End Health Disparities Among Women and Girls in Racial/Ethnic Minority Communities. MCCI is a multi-ICO dissemination and implementation science initiative to advance racial equity and end health disparities in racial/ethnic minority women and girls of reproductive age. Specifically, the Model Continuums of Care Initiative will apply the latest																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

dissemination and implementation science approaches to significantly reduce the prevalence and impact of multi-morbidity among racial/ethnic minority women and girls of reproductive age at risk and living with mental health disorders, substance use disorders, chronic stress, cardiopulmonary diseases, common metabolic disorders (e.g., diabetes), cancer, and HIV/AIDS. This concept proposes a continuum of care approach that integrates preventive health services, primary care, behavioral health, integrative care, and cardiopulmonary and endocrine specialties to fully address health care needs in each of these domains, and to have maximum impact on the overall health and well-being of racial and ethnic minority and other underserved women and girls. While MCCI is not a maternal health initiative, women and girls ages 15-44 yrs. are centered because it is during the early reproductive period, i.e., adolescence, that multimorbidity typically begins and rapidly progresses, setting the stage for multiple chronic debilitating conditions in later life. Special emphasis will be placed on using stakeholder partnerships, provider training, and infrastructure changes to improve access for subgroups of racial/ethnic minority women and girls who currently have the least access to high quality health care (e.g., racial/ethnic minority women and girls living in low resource settings). Applications that include a partnership between Research Centers in Minority Institutions and other institutions with extensive programs in women's health research are strongly encouraged. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

107782	<a href="#">Notice of Special Interest (NOSI): Epidemiology and Prevention of Alcohol Misuse in Understudied Young Adult Populations; Military, Workforce, and Community College</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-22-001	07-May-2024	Not Specified
--------	--	---	---------------	-------------	---------------

Contact Name	Bradley Kerridge, Ph.D.
Contact Telephone	301-827-7493
Contact Email	<a href="mailto:bradley.kerridge@nih.gov">bradley.kerridge@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025
Synopsis	The purpose of this future grant application solicitation is to balance the NIAAA research portfolio by supporting research on alcohol misuse among persons aged 18 to 29 who are not enrolled in four-year colleges or universities. These persons are commonly in the military, workforce, or community college populations, which are understudied relative to their age peers in four-year colleges. Research on epidemiology, prevention, and screening centered on these understudied populations are all encouraged.



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
105011	<a href="#">RFA-DC-22-001 -- NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01 Clinical Trial Optional)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC-22-001	21-May-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Roger L. Miller, Ph.D.</p> <p>Contact Telephone 301-402-3458</p> <p>Contact Email <a href="mailto:millerr@nidcd.nih.gov">millerr@nidcd.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 21-May-2024 [Optional][LOI/Pre-App], 20-Jun-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is intended to provide an avenue for basic scientists, clinicians and clinical scientists to jointly initiate and conduct translational research projects which translate basic research findings into clinical tools for better human health. The scope of this FOA includes a range of activities to encourage translation of basic research findings which will impact the diagnosis, treatment and prevention of communication disorders. Connection to the clinical condition must be clearly established and the outcomes of the grant must have practical clinical impact.</p>				
123922	<a href="#">NIDCD Research Career Enhancement Award for Established Investigators (K18 Clinical Trial Required)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-140	10-Jun-2024	Not Specified
	<p>Contact Name Alberto L. Rivera-Rentas, Ph.D.</p> <p>Contact Telephone 301-496-1804</p> <p>Contact Email <a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 10-Jun-2024 , 07-Sep-2024 , 08-Oct-2024 , 07-Jan-2025 , 10-Feb-2025 , 07-May-2025 , 09-Jun-2025 , 07-Sep-2025 , 08-Oct-2025 , 07-Jan-2026 , 09-Feb-2026 , 07-May-2026 , 08-Jun-2026 , 07-Sep-2026 , 08-Oct-2026 , 07-Jan-2027 , 08-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFOs PAR-24-142 and PAR-24-143.

123925	<a href="#">NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Basic Experimental Studies with Humans Required)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-142	10-Jun-2024	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	<a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	10-Jun-2024 , 07-Sep-2024 , 08-Oct-2024 , 07-Jan-2025 , 10-Feb-2025 , 07-May-2025 , 09-Jun-2025 , 07-Sep-2025 , 08-Oct-2025 , 07-Jan-2026 , 09-Feb-2026 , 07-May-2026 , 08-Jun-2026 , 07-Sep-2026 , 08-Oct-2026 , 07-Jan-2027 , 08-Feb-2027 , 07-May-2027
Synopsis	<p>The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFOs PAR-24-140 and PAR-24-143</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
123928	<a href="#">NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Clinical Trial Not Allowed)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-143	10-Jun-2024	Not Specified
	<p>Contact Name Alberto L. Rivera-Rentas, Ph.D.</p> <p>Contact Telephone 301-496-1804</p> <p>Contact Email <a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 10-Jun-2024 , 07-Sep-2024 , 08-Oct-2024 , 07-Jan-2025 , 10-Feb-2025 , 07-May-2025 , 09-Jun-2025 , 07-Sep-2025 , 08-Oct-2025 , 07-Jan-2026 , 09-Feb-2026 , 07-May-2026 , 08-Jun-2026 , 07-Sep-2026 , 08-Oct-2026 , 07-Jan-2027 , 08-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (NOFO# PAR-24-140 and PAR-24-142).</p>				
123942	<a href="#">NIDCD's Mentored Research Pathway for Otolaryngology Residents and Medical Students (R25 - Clinical Trial Not Allowed)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-127	14-May-2024 [Optional][LOI/Pre-App]	2,499,990 USD
	<p>Contact Name Alberto L. Rivera-Rentas, Ph.D.</p> <p>Contact Telephone 301-496-1804</p> <p>Contact Email <a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 14-May-2024 [Optional][LOI/Pre-App], 14-Jun-2024 , 30-Sep-2024 , 29-Jan-2025 , 29-Sep-2025 , 29-Jan-2026 , 29-Sep-2026</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NIDCD R25 program is to support educational activities that help recruit individuals with specific</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences.

122439	<a href="#">RFA-DC-24-004 -- In Vivo High-Resolution Imaging for Inner Ear Visualization (R01 Clinical Trial optional)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC-24-004	03-Jun-2024	2,499,995 USD
--------	--	---	---------------	-------------	---------------

Contact Name | Amy Poremba, Ph.D.  
 Contact Telephone | 301-997-3152  
 Contact Email | [amy.poremba@nih.gov](mailto:amy.poremba@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 03-Jun-2024 , 01-Oct-2024 , 03-Feb-2025

Synopsis | This funding opportunity aims to support the development of in vivo high-resolution structural and functional imaging technologies for the living human inner ear. Proposed projects should focus on improving the resolution of current imaging techniques or developing new imaging techniques that can visualize inner ear structures in vivo with significantly greater detail and accuracy than currently possible. Both structural and functional aspects, including visualizing dynamic elements are important to the development of new and improved techniques. Projects may also focus on developing new imaging probes or contrast agents that can enhance visualization of the inner ear structures. Research supported in response to this funding opportunity is expected to significantly advance the ability to visualize auditory and vestibular components, such as hair cells, otoliths, membranes, ions, and vasculature, in detail in awake patients in a clinical setting using non-invasive techniques. To achieve this goal, a multidisciplinary team approach that takes advantage of the expertise of each team member is highly encouraged. Studies in humans and intermediate studies in mammalian animal models may be proposed to develop or advance the needed technology. Any intermediate studies must articulate a clear path of the proposed methodology to application in awake humans or define the limitations and the usefulness in anesthetized humans. This notice of funding opportunity announcement (NOFO) also supports investigator initiated low-risk clinical trials addressing the development or improvement of human in vivo structural and functional imaging technologies. Clinical trials must meet ALL the following criteria: meet the budget limits of this NOFO, not require FDA oversight, not be an NIH-defined Phase III Clinical Trial, have low risks to subjects, and intend to gather scientific data/evidence to inform subsequent studies. This NOFO also supports low-risk trials determined to be Basic Experimental Studies with Humans (BESH). These studies fall within the NIH definition of a clinical trial and meet the definition of basic research. It is advisable that only one clinical trial be proposed in each application. High-risk clinical trials not meeting all the criteria above are referred to the companion U01 Cooperative Agreement for In Vivo High-Resolution Imaging for Inner Ear Visualization (Clinical Trial required) NOFO RFA-DC-24-005.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
122441	<a href="#">RFA-DC-24-005 -- Cooperative Agreement for In Vivo High-Resolution Imaging for Inner Ear Visualization (U01 Clinical Trial Required)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC-24-005	03-Jun-2024	2,499,995 USD
	<p>Contact Name Amy Poremba, Ph.D.</p> <p>Contact Telephone 301-997-3152</p> <p>Contact Email <a href="mailto:amy.poremba@nih.gov">amy.poremba@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 03-Jun-2024 , 01-Oct-2024 , 03-Feb-2025</p> <p>Synopsis This funding opportunity aims to support high risk clinical trials for the development of in vivo high-resolution structural and functional imaging technologies for the living human inner ear. Proposed projects should focus on improving the resolution of current imaging techniques or developing new imaging techniques that can visualize inner ear structures in vivo with significantly greater detail and accuracy than currently possible. Structural and functional aspects, including visualizing dynamic elements, are important to developing new and improved techniques. Projects may also focus on developing new imaging probes or contrast agents that can enhance visualization of the inner ear structures. Research supported in response to this funding opportunity is expected to significantly advance the ability to visualize auditory and vestibular components, such as hair cells, otoliths, membranes, ions, and vasculature, in detail in awake patients in a clinical setting using non-invasive techniques. To achieve this goal, a multidisciplinary team approach that takes advantage of the expertise of each team member is highly encouraged. Studies in humans must be proposed to develop, advance, or test the needed technology. Any intermediate studies must articulate a clear path of the proposed methodology to application in awake humans or define the limitations and the usefulness in anesthetized humans. This funding opportunity supports a cooperative agreement between an NIDCD Project Scientist and an Investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has potentially higher risks to participants. These investigator-initiated clinical trials are perceived to benefit from close interaction, oversight, and guidance resulting from a cooperative agreement. Only one clinical trial may be proposed per application submitted to this funding opportunity. Low risk clinical trials not meeting any of the criteria above are referred to the companion In Vivo High-Resolution Imaging for Inner Ear Visualization (R01 - Clinical Trial Optional) RFA-DC-24-004. Investigators are strongly encouraged to contact the scientific/research contact, prior to submission, to ensure this is the correct NOFO for their proposed research.</p>				
114999	<a href="#">Notice of Special Interest (NOSI): Fundamental Science Research on the Neural Circuits Underlying Sensory Processing</a>	National Institute on Deafness and Other Communication	NOT-DC-23-001	07-May-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Disorders/NIH/DHHS

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Merav Sabri, Ph.D. 301-827-0908 <a href="mailto:merav.sabri@nih.gov">merav.sabri@nih.gov</a>  <a href="#">Link to program URL</a> 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 The National Institute on Deafness and Other Communication Disorders (NIDCD) is issuing this Notice to highlight priorities from its new strategic plan, in basic and mechanistic research on neural circuits underlying sensory processing in hearing, balance, taste and smell. NIDCD encourages multidisciplinary and innovative projects, from diverse teams, to advance a mechanistic understanding of the behavior of neural circuits at cellular and sub-second temporal resolution by integrating cutting-edge technologies and approaches for recording and modulation of cells and circuits (e.g., electrophysiology, optical imaging, optogenetics, chemogenetics, sonogenetics, magnetogenetics, pharmacologic modulation). Applications are expected to integrate appropriate domains of expertise, including but not limited to biological, chemical and physical sciences, engineering, computational modeling, statistical analysis, and bioethics, as appropriate. Mechanistic human studies and comparative, cross-species projects are highly encouraged.
--	--

123134	<a href="#">RFA-DC-24-007 -- NIDCD Research Opportunities for New Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC-24-007	28-Jun-2024	2,495,000 USD
--------	--	---	---------------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Kelly King, Au.D., Ph.D. 301-402-3458 <a href="mailto:kingke@nidcd.nih.gov">kingke@nidcd.nih.gov</a>  <a href="#">Link to program URL</a> 28-Jun-2024 , 28-Oct-2024 , 06-Feb-2025 This Notice of Funding Opportunity (NOFO) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the National Institute on Deafness and Other Communication Disorders (NIDCD).
--	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

This program is intended to support Early Stage and New Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences. Investigators from diverse backgrounds, including those from underrepresented groups (e.g., see NOT-OD-20-031, Notice of NIH's Interest in Diversity), are encouraged to work with their institutions to apply. Preliminary data are not required for this NOFO.

124297	<a href="#">NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Clinical Trial Required)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-149	13-Jun-2024	315,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	<a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	13-Jun-2024 , 07-Sep-2024 , 17-Oct-2024 , 07-Jan-2025 , 13-Feb-2025 , 07-May-2025 , 13-Jun-2025 , 07-Sep-2025 , 15-Oct-2025 , 07-Jan-2026 , 13-Feb-2026 , 07-May-2026 , 15-Jun-2026 , 07-Sep-2026 , 14-Oct-2026 , 07-Jan-2027 , 17-Feb-2027 , 07-May-2027
Synopsis	The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-085 for Clinical Trial Required or for PAR-21-087 for Independent Basic Experimental Studies with Humans Required..

124315	<a href="#">NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-119	18-Jun-2024	375,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Bracie Watson, Jr.
Contact Telephone	301-402-3458

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:watsonb@nidcd.nih.gov">watsonb@nidcd.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 18-Jun-2024 , 17-Oct-2024 , 19-Feb-2025 , 17-Jun-2025 , 17-Oct-2025 , 18-Feb-2026 , 17-Jun-2026 , 19-Oct-2026 , 17-Feb-2027</p> <p>Synopsis The NIDCD Early Career Research (ECR) Award (R21) is intended to support both basic and clinical research from scientists who are beginning to establish an independent research career. It cannot be used for thesis or dissertation research. The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language. The NIDCD ECR Award R21 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. Irrespective of the type of project, the intent of the NIDCD ECR Award R21 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.</p>				
124298	<p><a href="#">NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required)</a></p>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-150	13-Jun-2024	315,000 USD
	<p>Contact Name Alberto L. Rivera-Rentas, Ph.D.</p> <p>Contact Telephone 301-496-1804</p> <p>Contact Email <a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 13-Jun-2024 , 07-Sep-2024 , 17-Oct-2024 , 07-Jan-2025 , 13-Feb-2025 , 07-May-2025 , 13-Jun-2025 , 07-Sep-2025 , 15-Oct-2025 , 07-Jan-2026 , 13-Feb-2026 , 07-May-2026 , 15-Jun-2026 , 07-Sep-2026 , 14-Oct-2026 , 07-Jan-2027 , 17-Feb-2027 , 07-May-2027</p> <p>Synopsis The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-24-159).			
124299	<a href="#">NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Clinical Trial Not Allowed)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-159	13-Jun-2024	315,000 USD
	Contact Name	Alberto L. Rivera-Rentas, Ph.D.			
	Contact Telephone	301-496-1804			
	Contact Email	<a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	13-Jun-2024 , 07-Sep-2024 , 17-Oct-2024 , 07-Jan-2025 , 13-Feb-2025 , 07-May-2025 , 13-Jun-2025 , 07-Sep-2025 , 15-Oct-2025 , 07-Jan-2026 , 13-Feb-2026 , 07-May-2026 , 15-Jun-2026 , 07-Sep-2026 , 14-Oct-2026 , 07-Jan-2027 , 17-Feb-2027 , 07-May-2027			
	Synopsis	The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFOs (PAR-24-149 and PAR-24-150).			
117259	<a href="#">Notice of Special Interest (NOSI): Encouraging Women's Health Research within the NIDCD Mission Areas</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-23-006	07-May-2024	Not Specified
	Contact Name	Christopher Myers			
	Contact Telephone	301-435-0713			
	Contact Email	<a href="mailto:myersc@nidcd.nih.gov">myersc@nidcd.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 25-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 25-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 25-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 25-Feb-2026 , 07-May-2026			
	Synopsis	The National Institute on Deafness and Other Communication Disorders (NIDCD) is issuing this Notice of Special Interest (NOSI) to stimulate research in areas regarding the health of women within the scope of NIDCD's mission. NIDCD's mission is to conduct and support research and research training in the normal and disordered processes of hearing, balance, taste, smell, voice, speech, and language. As noted in the recently issued 2023–2027 NIDCD Strategic Plan (2023-2027 NIDCD Strategic Plan   NIDCD), research projects to improve the health of women covering the lifespan are encouraged across all the NIDCD mission areas. These projects may include biological studies which may incorporate anatomical, structural, hormonal, or genetic aspects, behavioral traits, societal aspects, or healthcare related activities that may benefit a women's quality of life.			
122020	<a href="#">NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-050	27-Jun-2024	Not Specified
	Contact Name	Trinh T. Ly, M.D.			
	Contact Telephone	301-435-4085			
	Contact Email	<a href="mailto:trinh.ly@nih.gov">trinh.ly@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	27-Jun-2024 , 28-Oct-2024 , 27-Feb-2025 , 27-Jun-2025 , 28-Oct-2025 , 27-Feb-2026 , 29-Jun-2026 , 27-Oct-2026			
	Synopsis	The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting well-designed and well-executed clinical trials. This funding opportunity supports a cooperative agreement between an NIDCD Project Scientist and an Investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has potentially higher risks to participants. Clinical trial applications exceeding the annual direct costs of \$700,000 or more, in certain cases, may also be a criterion for this funding opportunity. These investigator-initiated clinical trials are perceived to benefit from close interaction, oversight, and guidance resulting from a cooperative agreement. Only one clinical trial may be proposed per application submitted to this funding opportunity. Low risk clinical trials not meeting any of the criteria above are referred to the companion NIDCD Low Risk Clinical Trials in Communication Disorders (R01-Clinical Trial Required) PAR-24-051. Investigators are strongly encouraged to contact Dr. Trinh Ly, prior to submission, to ensure this is the correct NOFO for their proposed research.			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
102240	<a href="#">Notice of Special Interest (NOSI): Hearing Healthcare for Adults: Improving Access and Affordability</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-21-001	07-May-2024	Not Specified
	<p>Contact Name Kelly King, Au.D, Ph.D.</p> <p>Contact Telephone 301-402-3458</p> <p>Contact Email <a href="mailto:kingke@nidcd.nih.gov">kingke@nidcd.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to encourage applications for research on hearing health care in adults in support of improving access and affordability. Further research is needed to strengthen the evidence base with a goal of delivering better hearing health care outcomes in adults.</p>				
122021	<a href="#">NIDCD Low Risk Clinical Trials in Communication Disorders (R01 Clinical Trial Required)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-051	07-May-2024	2,499,995 USD
	<p>Contact Name Trinh T. Ly, M.D.</p> <p>Contact Telephone 301-435-4085</p> <p>Contact Email <a href="mailto:trinh.ly@nih.gov">trinh.ly@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027</p> <p>Synopsis The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials. This notice of funding opportunity announcement (NOFO) supports investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this NOFO, not require FDA oversight, not an NIH defined Phase III Clinical Trial, have low risks to subjects, and intends to gather scientific data/evidence to inform subsequent studies. This NOFO also supports low risk trials determined to be Basic Science Experimental Studies involving Humans (BESH). These studies fall within the NIH definition of a clinical trial and meet the definition of basic research. It is advisable</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application. High risk clinical trials not meeting all the criteria above are referred to companion U01 NOFO, PAR-24-050, NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders.

106846	<a href="#">NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-22-025	06-Jun-2024	7,500,000 USD
--------	--	---	------------	-------------	---------------

Contact Name	Lana Shekim, Ph.D.
Contact Telephone	301-496-5061
Contact Email	<a href="mailto:shekiml@nidcd.nih.gov">shekiml@nidcd.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	06-Jun-2024 , 09-Oct-2024
Synopsis	The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and amelioration of human communication disorders. For this announcement, Clinical Research is defined as research involving individuals with communication disorders or data/tissues from individuals with a communication disorder. Examples of such research include but are not limited to, studies of the prevention, pathogenesis, pathophysiology, diagnosis, treatment, management or epidemiology of a disease or disorder of hearing, balance, smell, taste, voice, speech, or language. Applications may propose a low risk clinical trial but are not required to (optional).

117406	<a href="#">Notice of Special Interest (NOSI): Promoting Language and Communication in Minimally Verbal/Non-Speaking Individuals with Autism</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-23-009	07-May-2024	Not Specified
--------	--	---	---------------	-------------	---------------

Contact Name	Holly L. Storkel, Ph.D.
Contact Telephone	301-496-5061
Contact Email	<a href="mailto:holly.storkel@nih.gov">holly.storkel@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 05-Apr-2026 , 07-May-2026 , 05-Jun-2026</p> <p>The purpose of this Notice of Special Interest (NOSI) is to encourage applications for research to promote language and communication in autistic individuals who are minimally verbal/non-speaking. Further research is needed to evaluate and tailor existing interventions, develop novel interventions, develop and apply new research designs and methods to intervention efforts, and identify meaningful outcome measures.</p>			
123100	<a href="#">RFA-DA-25-028 -- Development of Clinical Outcome Assessments as New FDA-Qualified Drug Development Tools to Accelerate Therapeutics Development for Opioid and Stimulant Use Disorders (UG3/UH3 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-028	09-Jun-2024 [Optional][LOI/Pre-App]	2,500,000 USD
	Contact Name	Tanya Ramey, M.D., Ph.D.			
	Contact Telephone	301-827-5944			
	Contact Email	<a href="mailto:tanya.ramey@nih.gov">tanya.ramey@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	09-Jun-2024 [Optional][LOI/Pre-App], 09-Jul-2024			
	Synopsis	<p>The purpose of this funding opportunity is to support the development of Clinical Outcome Assessments (COA) for Substance Use Disorders (SUD). The COA development plan is expected to progress into the FDA drug development tool qualification program. This notice of funding opportunity (NOFO) utilizes the UG3/UH3 Phased Innovation Awards Cooperative Agreement grant mechanism that includes two phases. The applications responding to this NOFO should contain a COA development plan that will cover both UG3 and UH3 phases. In the first 2-year UG3 phase the project must have a set of operational milestones to be completed by the end of this period. Once NIDA program has evaluated the progress of the UG3 phase and determined that the UG3 phase has been successfully completed, it transitions to the UH3 phase to be funded for three additional years. The goal of this NOFO is to expand the armamentarium of COA that are FDA qualified as drug development tool (DDT) in the context of use (COI) of a SUD. Achieving this goal will greatly facilitate the development of treatments for SUDs. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>			
101989	<a href="#">Notice of Special Interest (NOSI): Long-Term Neurocognitive</a>	National Institute on Drug	NOT-DA-	07-May-2024	Not

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders</a>	Abuse/NIH/DHHS	21-018		Specified
	<p>Contact Name   Raul Mandler, MD</p> <p>Contact Telephone   301-480-2541</p> <p>Contact Email   <a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   NIDA is interested in receiving research applications focusing on studying the long-term neurocognitive consequences of the COVID-19/HIV/SUDs syndemic.</p>				
103071	<a href="#">Notice of Special Interest (NOSI): Deciphering the Mosaic of Glia in the Addicted Brain</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-001	07-May-2024	Not Specified
	<p>Contact Name   Shang-Yi Anne Tsai, Ph.D</p> <p>Contact Telephone   301-827-5842</p> <p>Contact Email   <a href="mailto:stsai@nih.gov">stsai@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to inform potential applicants of its interest in research project grant submissions that examine the effects of drug use on the structural and functional diversity and plasticity of glia and non-neuronal cells on nervous system process in the context of drug misuse and substance use disorders (SUD). Glial and other non-neuronal cells include astrocytes, microglia, oligodendrocytes and ependymal cells.</p>				
103870	<a href="#">Notice of Special Interest (NOSI): Leveraging Longitudinal Studies in Animal Models to Identify Neural Mechanisms of Vulnerability and Resilience to Substance Use Disorder</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-003	07-May-2024	Not Specified
	<p>Contact Name   Holly Moore</p> <p>Contact Telephone   301-827-7376</p> <p>Contact Email   <a href="mailto:Holly.Moore@nih.gov">Holly.Moore@nih.gov</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024</p> <p>Synopsis NIDA seeks to stimulate research in non-human species aimed at modeling environmental and/or biological risk factors for SUD to elucidate neural and cognitive developmental mechanisms that may mediate, moderate, or predict the effects of these factors on subsequent emergence of SUD-related behaviors. Use of longitudinal designs and developmental-stage-appropriate paradigms are strongly encouraged.</p>				
104862	<p><a href="#">Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience</a></p>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-030	07-May-2024	Not Specified
	<p>Contact Name Yu (Woody) Lin</p> <p>Contact Telephone 301-435-1318</p> <p>Contact Email <a href="mailto:ylin1@mail.nih.gov">ylin1@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024 , 25-Sep-2024 , 12-Oct-2024 , 25-Oct-2024 , 07-Jan-2025</p> <p>Synopsis This Notice of Special Interest [NOSI] is to support computational HIV/AIDS research as it relates to NIDA’s mission through collaborative research between investigators with experimental expertise related to HIV/AIDS and those with computational proficiency, including scientists from statistics, physics, mathematics, engineering, and computer science. The NOSI will support meritorious and innovative research built on well-established computational strategies (theory, models, and methods) to investigate HIV-related neurocognitive deficits and neuropathogenesis in the context of substance use or substance use disorder (SUD). Investigators are expected to have complementary and integrated expertise in their field(s), but an ongoing collaboration or record of co-authorship is not required.</p>				
109484	<p><a href="#">Notice of Special Interest (NOSI): Leveraging Data Science to Bring Actionable Insights for Substance use Prevention and Treatment</a></p>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-23-006	07-May-2024	Not Specified
	<p>Contact Name Janet Kuramoto-Crawford, PhD</p> <p>Contact Telephone 301-443-8856</p> <p>Contact Email <a href="mailto:janet.kuramoto-crawford@nih.gov">janet.kuramoto-crawford@nih.gov</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025</p> <p>Synopsis This Notice encourages research projects that 1) leverage data science to provide actionable insights for substance use prevention and treatment 2) shorten the time between data capture and data availability so that data are available real-time or near real-time, and 3) explore methods and tools that may allow for faster or better localized responses for substance use treatment and prevention. Priority will be given to projects that emphasize the use of existing data streams (e.g., electronic health records, syndromic surveillance, claims data, registry data, pharmacy dispensing, social media, and mortality records).</p>				
109268	<a href="#">Notice of Special Interest (NOSI): Epidemiology of Drug Abuse</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-22-004	07-May-2024	Not Specified
	<p>Contact Name Marsha Lopez, PhD, MHS</p> <p>Contact Telephone 301-443-6504</p> <p>Contact Email <a href="mailto:Marsha.Lopez@nih.gov">Marsha.Lopez@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025</p> <p>Synopsis The purpose of this Notice is to encourage the submission of research project applications that enhance our understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, misuse, and addiction across individuals, families, communities, and diverse population groups. Of interest are applications that address multiple levels of risk, resilience, and causation across scientific disciplines, and that apply novel methods to advance knowledge of the interplay among genetic, environmental, neurobiological, and developmental factors and associated health and disease outcomes. Priority will be given to research with a well described path towards translation and/or public health impact. In addition to novel data collection, approaches are encouraged that build on the research investments of NIH and sister HHS agencies to harness existing data on the epidemiology and etiology of drug misuse to improve public health prevention and treatment programs. The research areas noted below should be considered in the context of topics such as health disparities or inequities, familial/genetic liability, and physical, psychiatric, and polysubstance comorbidities and interactions.</p>				
119295	<a href="#">Substance Use/Substance Use Disorder Dissertation Research Award (R36)</a>	National Institute on Drug	PAR-23-	07-May-2024	100,000



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Clinical Trials Not Allowed</a>		Abuse/NIH/DHHS		194 USD
	<p>Contact Name   Marsha F. Lopez, Ph.D., M.H.S.</p> <p>Contact Telephone   301-443-6504</p> <p>Contact Email   <a href="mailto:marsha.lopez@nih.gov">marsha.lopez@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026</p> <p>Synopsis   The goal of this Notice of Funding Opportunity (NOFO) is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Research projects should align with the NIDA Strategic Plan (2022-2026 NIDA Strategic Plan Director's Message   National Institute on Drug Abuse (NIDA) (nih.gov). This award will facilitate the entry of promising new investigators into the field of substance use/substance use disorder (SU(D) research, enhancing the pool of highly talented SU(D) researchers. Applications are particularly encouraged from individuals from diverse backgrounds, including those from underrepresented groups as described in the Notice of NIH's Interest in Diversity (NOT-OD-20-031). This NOFO is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.</p>				
113995	<a href="#">Notice of Special Interest (NOSI): Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R01, R21, R03)</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-23-012	07-May-2024	Not Specified
	<p>Contact Name   Tisha Wiley, Ph.D.</p> <p>Contact Telephone   301-594-4381</p> <p>Contact Email   <a href="mailto:tisha.wiley@nih.gov">tisha.wiley@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis   The purpose of this Notice is to inform potential applications to the National Institute on Drug Abuse (NIDA) of special interest in grant applications to conduct rigorous health services and economic research to maximize the availability and</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		delivery of efficient, effective drug, alcohol, and tobacco treatment and recovery support services. Examples of such research include: (1) clinical quality improvement; (2) quality improvement in services organization and management; (3) implementation science; (4) availability, demand, access, and financing; (5) effectiveness; and (6) development or improvement of research methodology, analytic approaches, and measurement instrumentation.			
114150	<a href="#">Notice of Special Interest (NOSI): Chemsex and HIV: Prevalence, Medical/Psychosocial Consequences, and Treatment</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-002	07-May-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Raul Mandler, MD 240-281-0569 <a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a>  <a href="#">Link to program URL</a> 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 The purpose of this notice is to support research on the epidemiology, medical/psychosocial impact, and preventive and therapeutic measures for chemsex in people with HIV and HIV-vulnerable populations including sexual minorities (SM) e.g. lesbian, gay, bisexual.			
124184	<a href="#">RFA-DA-25-043 -- Transformative Research on the Basic Mechanisms of Polysubstance use in Addiction (R01 - Clinical Trial Not Allowed)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-015	17-Jun-2024 [Optional][LOI/Pre-App]	1,750,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Sunila Nair, PhD 301-827-6832 <a href="mailto:sunila.nair@mail.nih.gov">sunila.nair@mail.nih.gov</a>  <a href="#">Link to program URL</a> 17-Jun-2024 [Optional][LOI/Pre-App], 17-Jul-2024 This Funding Opportunity Announcement (FOA) will support projects proposing mechanistic studies that will transform our understanding of polysubstance use in addiction. These hypothesis-based, exploratory projects may investigate mechanisms of polysubstance use at the behavioral, cognitive, cellular, circuit, genetic, epigenetic, pharmacological and/or computational			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	levels.				
102446	<a href="#">Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-007	07-May-2024	Not Specified
	<p>Contact Name Richard A. Jenkins PhD</p> <p>Contact Telephone 301-443-1923</p> <p>Contact Email <a href="mailto:jenkinsri@mail.nih.gov">jenkinsri@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The purpose of this Notice is to encourage grant applications proposing research that makes use of available, large data sets with the objective of improving HIV epidemic modeling and service planning, with greater attention to the role of substance use. Data may be from NIDA-funded or co-funded projects as well as from other sources. This Notice is expected to increase the utilization of existing data including epidemiologic and clinic cohorts, longitudinal follow-up studies of interventions, as well as other publicly available data including those provided by government bodies, data warehouses and commercial data sources. Existing data may include data from completed projects as well as those that are ongoing. Results from studies supported by this NOSI are expected to generate knowledge that can be used to answer significant questions about HIV epidemics, promote efficient provision of services, and address limitations of existing models that have guided public policy. NIDA is particularly interested in research that integrates substance use considerations into program planning and policy to increase the quality of HIV services and their responsiveness to substance using populations.</p>				
101829	<a href="#">Notice of Special Interest (NOSI): Effects of Smoking and Vaping on the Risk and Outcome of COVID-19 Infection</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-011	07-May-2024	Not Specified
	<p>Contact Name Raul Mandler, MD; FAAN; FANA</p> <p>Contact Telephone 301-480-2541</p> <p>Contact Email <a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The purpose of this notice is to communicate NIDA’s interest in supporting research on the effects of smoking or vaping</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection. This Notice is a reissuance of NOT-DA-20-084.				
102016	<a href="#">Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-017	07-May-2024	Not Specified
	<p>Contact Name   Raul Mandler, MD</p> <p>Contact Telephone   301-480-2541</p> <p>Contact Email   <a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   NIDA is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19.</p>				
102120	<a href="#">Notice of Special Interest (NOSI): Telehealth Strategies for Individuals with HIV and Substance Use Disorders</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-019	07-May-2024	Not Specified
	<p>Contact Name   Raul Mandler, MD</p> <p>Contact Telephone   301-480-2541</p> <p>Contact Email   <a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   The National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) inviting research applications to explore and develop telehealth methods and strategies for diagnosis, prevention, treatment, and population analysis in individuals living with HIV and Substance Use Disorder (SUD).</p>				
103874	<a href="#">Notice of Special Interest (NOSI): Leveraging Transformative Connectome Resources in Model Organisms to Elucidate the Neurobiology of Substance Abuse Disorders</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-006	07-May-2024	Not Specified
	<p>Contact Name   Olivier Berton, Ph.D.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-827-7771</p> <p>Contact Email   <a href="mailto:olivier.berton@nih.gov">olivier.berton@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   The purpose of this notice is to encourage research project submissionsthat leverage whole-brain or large connectome resources in genetically tractable model organisms to investigate the role of distributed neuronal circuits in behaviors relevant to substance use disorders (SUD).</p>				
104182	<a href="#">Notice of Special Interest (NOSI): Advanced Computational Approaches to Elucidate Disease Pathology and Identify Novel Therapeutics for Addiction</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-004	07-May-2024	Not Specified
	<p>Contact Name   Susan Wright, Ph.D.</p> <p>Contact Telephone   301-402-6683</p> <p>Contact Email   <a href="mailto:susan.wright@nih.gov">susan.wright@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis   The purpose of this Notice is to inform potential applicants to the National Institute on Drug Abuse (NIDA) of NIDA's interest in grant applications that will develop or utilize advanced computational approaches to describe complex drug-disease relationships in ways that will rapidly advance the development of new treatments, allow for targeted funding of substance use disorder (SUD) drug discovery and improve health care. NIDA has a particular interest in applications that include approaches in one or more of the following categories: 1) artificial intelligence, including machine learning and deep learning, 2) supercomputing/parallel computing, and/or 3) quantum computing.</p>				
106007	<a href="#">Notice of Special Interest (NOSI): International Research Collaboration on Drug Abuse and Addiction Research</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-064	07-May-2024	Not Specified
	<p>Contact Name   Steve Gust, Ph.D.</p> <p>Contact Telephone   301-402-1118</p> <p>Contact Email   <a href="mailto:sgust@nida.nih.gov">sgust@nida.nih.gov</a></p> <p>Sponsor Website  </p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The purpose of this notice is to encourage collaborative research applications that take advantage of opportunities outside of the United States. Applications examining all areas of NIDA-supported research addressing the causes, consequences, treatment, recovery, and prevention of drug use, misuse, and addiction are encouraged. Projects may be conducted through newly formed or well-established partnerships between investigators in a U.S.-based institution and scientists working in another country. All NIH grant applications for research to be conducted outside the United States must establish that the proposal takes advantage of unique research opportunities in other countries, speeds scientific discovery, and advances U.S. health science.</p>				
115450	<p><a href="#">Notice of Special Interest (NOSI): Pharmacogenomic Approaches to Enhancing HIV and Substance Use Disorder (SUD) Treatment Strategies, A Jump Into Precision Medicine.</a></p>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-001	07-May-2024	Not Specified
	<p>Contact Name Guifang Lao, Ph.D.</p> <p>Contact Telephone 301-827-5931</p> <p>Contact Email <a href="mailto:laog@nih.gov">laog@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026</p> <p>Synopsis NIDA is interested in receiving research proposals focusing on studying pharmacogenomics in PLWH with SUD as a crucial step in the science of Precision Medicine, in the path of personalized care for HIV and drug abuse..</p>				
123798	<p><a href="#">Notice of Special Interest (NOSI): Strategies to Address Stigmatizing Beliefs and Policies Affecting People Who Use Drugs</a></p>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-25-029	05-Jun-2024	Not Specified
	<p>Contact Name Julia Zur, PhD</p> <p>Contact Telephone 301-443-2261</p> <p>Contact Email <a href="mailto:julia.zur@nih.gov">julia.zur@nih.gov</a></p> <p>Sponsor Website</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2024</p> <p>Synopsis                      People who use drugs experience stigma from different sources and in a variety of contexts, all of which are associated with negative outcomes. Some common stigmatizing beliefs directed toward people who use drugs include the notion that drug use is a personal choice, that people with substance use disorders (SUD) can stop using drugs if they have enough willpower, and that people with SUD are dishonest and immoral. These beliefs can manifest through negative interactions with friends and family members as well as through unpleasant encounters with healthcare providers. Stigma also exists at the structural level, such as through public policies that criminalize people with SUD. People who use drugs may also experience self-stigma, which occurs when they internalize stereotypes associated with substance use and direct these beliefs toward themselves. As a result, they often opt to not disclose to other people that they have SUD.</p>				
102988	<a href="#">Notice of Special Interest (NOSI): Basic Research on Fentanyl and Synthetic Fentanyl Analogs: Signaling, Neurobiology, and Pharmacology</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-033	07-May-2024	Not Specified
	<p>Contact Name Pamela G. Fleming</p> <p>Contact Telephone 301-480-1159</p> <p>Contact Email <a href="mailto:pfleming@nih.gov">pfleming@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Sep-2024</p> <p>Synopsis                      This Notice informs potential applicants to the National Institute on Drug Abuse (NIDA) about a special interest in basic research on fentanyl and synthetic fentanyl analogs. Of particular interest is research that is focused on elucidating chemical, cellular, signaling, and neurobiological mechanisms underlying abuse potential, physical dependence, addiction liability and deaths due to overdose of fentanyl and fentanyl analogs.</p>				
103015	<a href="#">Notice of Special Interest (NOSI): Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-028	07-May-2024	Not Specified
	<p>Contact Name Pamela G. Fleming</p> <p>Contact Telephone 301-480-1159</p> <p>Contact Email <a href="mailto:pfleming@nih.gov">pfleming@nih.gov</a></p> <p>Sponsor Website</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Sep-2024</p> <p>Synopsis This Notice informs potential applicants to the National Institute on Drug Abuse (NIDA) about a special interest in research on chemistry, pharmacology, biological targets and biochemical mechanisms that contribute to the effects of synthetic psychoactive substances.</p>				
123707	<p><a href="#">RFA-DA-25-053 -- Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R41/R42 Clinical Trials Not Allowed)</a></p>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-053	25-Jun-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Tam Nguyen, Ph.D.</p> <p>Contact Telephone 301-451-1203</p> <p>Contact Email <a href="mailto:tam.nguyen@nih.gov">tam.nguyen@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 25-Jun-2024 [Optional][LOI/Pre-App], 25-Jul-2024</p> <p>Synopsis This notice of funding opportunity (NOFO) encourages Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) proposing research projects directed towards commercialization to harness artificial intelligence (AI), including machine learning (ML), tools, and polypharmacology to identify pharmacotherapeutics with lower toxicity and higher efficacy to prevent or treat substance use disorders (SUDs).</p>				
123702	<p><a href="#">RFA-DA-25-054 -- Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)</a></p>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-054	25-Jun-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Tam Nguyen, Ph.D.</p> <p>Contact Telephone 301-451-1203</p> <p>Contact Email <a href="mailto:tam.nguyen@nih.gov">tam.nguyen@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 25-Jun-2024 [Optional][LOI/Pre-App], 25-Jul-2024</p> <p>Synopsis This notice of funding opportunity (NOFO) encourages Small Business Innovation Research (SBIR) grant applications from</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		small business concerns (SBCs) proposing research projects directed towards commercialization to harness artificial intelligence (AI), including machine learning (ML), tools, and polypharmacology to identify pharmacotherapeutics with lower toxicity and higher efficacy to prevent or treat substance use disorders (SUDs).			
111673	<a href="#">Notice of Special Interest (NOSI): High Priority Areas in Integrative Neuroscience Branch in the Division of Neuroscience and Behavior</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-22-058	07-May-2024	Not Specified
	Contact Name	Olivier Berton, Ph.D.			
	Contact Telephone	301-827-7771			
	Contact Email	<a href="mailto:Olivier.berton@nih.gov">Olivier.berton@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026			
	Synopsis	The mission of the Division of Neuroscience and Behavior (DNB) is to facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of substance use and substance use disorders (SUD) across the lifespan and to guide treatment strategies. The Integrative Neuroscience (IN) Branch within DNB supports research on the cellular mechanisms and circuitry that underlie substance use and SUD. Research supported by the Branch covers: 1) the regulation and plasticity of neurotransmitter and neuromodulatory systems induced by chronic or intermittent exposure to, and/or withdrawal from, addictive substances, 2) the study of substance-induced neurotoxicity, 3) neuron-glia interactions and their modification by substance use and SUD 4) neuroendocrine modulation of neural systems in relation to substance use and SUD , and 5) neuroimmune modulation of the brain including the influences of neuroAIDS and substance-induced neuroinflammation.			
114003	<a href="#">Notice of Special Interest (NOSI): Targeting Epigenetic Regulators for Treating Addiction and Substance Use Disorders</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-004	08-Apr-2024	Not Specified
	Contact Name	Sam Ananthan, Ph.D.			
	Contact Telephone	301-435-2199			
	Contact Email	<a href="mailto:sam.ananthan@nih.gov">sam.ananthan@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 08-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 08-Dec-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 08-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 08-Aug-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 08-Dec-2025 , 07-Jan-2026			
	Synopsis	The National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to inform applicants about NIDA's special interest in innovative research that uses chemical and pharmacological approaches to identify and target epigenetic regulators and mechanisms for the treatment of addiction and substance use disorders.			

117589	<a href="#">Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-23-158	20-Jun-2024	Not Specified
--------	--	---	------------	-------------	---------------

	Contact Name	Vani Pariyadath, Ph.D.			
	Contact Telephone	301-443-3209			
	Contact Email	<a href="mailto:vani.pariyadath@nih.gov">vani.pariyadath@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	20-Jun-2024 , 09-Oct-2024 , 13-Mar-2025 , 20-Jun-2025 , 09-Oct-2025 , 13-Mar-2026			
	Synopsis	This Notice of Funding Opportunity (NOFO) uses a R61/R33 Phased Innovation Award activity code to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substance use. This NOFO is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and studies that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the companion NOFO - Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) PAR-23-157. For projects not requiring a phased research approach, applicants are encouraged to apply under a different activity code (e.g., PA-20-184 “Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)”).			

117587	<a href="#">Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-23-157	20-Jun-2024	Not Specified
--------	---	---	------------	-------------	---------------

	Contact Name	Vani Pariyadath, Ph.D.			
--	--------------	------------------------	--	--	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-443-3209</p> <p>Contact Email   <a href="mailto:vani.pariyadath@nih.gov">vani.pariyadath@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   20-Jun-2024 , 09-Oct-2024 , 13-Mar-2025 , 20-Jun-2025 , 09-Oct-2025 , 13-Mar-2026</p> <p>Synopsis   This Notice of Funding Opportunity (NOFO) uses a R61/R33 Phased Innovation Award activity code to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substance use. Note: For basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants” please use the companion NOFO - Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH)) PAR-23-282 For projects not requiring a phased research approach, applicants are encouraged to apply under a different funding activity code (e.g., PA-20-183 “Research Project Grant (Parent R01 Clinical Trial Required)”).</p>				
117405	<a href="#">Notice of Special Interest (NOSI): Liveraging Glial Cells to Treat Addiction</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-006	07-May-2024	Not Specified
	<p>Contact Name   Shang-Yi Anne Tsai, Ph.D.</p> <p>Contact Telephone   301-827-5842</p> <p>Contact Email   <a href="mailto:stsai@nih.gov">stsai@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 12-Feb-2026 [LOI/Pre-App], 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 12-Jun-2026 , 16-Jun-2026 , 07-Sep-2026</p> <p>Synopsis   This Notice of Special Interest (NOSI) encourages studies to exploit the unique properties and functions of glial cells and develop strategies to mitigate Central Nervous System (CNS) damage due to acute or chronic exposure to addictive substances or therapeutic avenues for addiction treatments.</p>				
107619	<a href="#">Notice of Special Interest (NOSI): Research in the Chemistry and Pharmacology of Addictive Drugs</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-23-002	07-May-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Kiran Vemuri, Ph.D.</p> <p>Contact Telephone   301-435-4446</p> <p>Contact Email   <a href="mailto:kiran.vemuri@nih.gov">kiran.vemuri@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 12-Feb-2025</p> <p>Synopsis   The mission of the Division of Neuroscience and Behavior of NIDA is to discover, facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of drug addiction across the lifespan and to guide treatment strategies. As a component of the Division, the Chemistry and Pharmacology Branch supports research on all aspects of the chemistry and pharmacology of addictive drugs. The Branch develops and oversees a broad portfolio encompassing research on substance use disorders (SUD) and overdose designed to: 1) elucidate mechanisms of action, synthetic and biosynthetic methodologies, structure-activity relationships, pharmacology and toxicity of addictive drugs, and determination of 3D structures of ligands bound to biological targets, 2) develop new receptor type and subtype specific agents, and 3) discover and advance the pre-clinical development of new pharmacotherapies for the treatment of SUD and overdose, emphasizing the pre-clinical stages of target identification through hit-to-lead.</p>				
114048	<a href="#">Notice of Special Interest (NOSI): Chemoproteomic Approaches for Discovery of Targets and Therapeutics to Treat Substance Use Disorders</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-005	08-Apr-2024	Not Specified
	<p>Contact Name   Sam Ananthan, Ph.D.</p> <p>Contact Telephone   301-435-2199</p> <p>Contact Email   <a href="mailto:sam.ananthan@nih.gov">sam.ananthan@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 08-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 08-Dec-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 08-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 08-Aug-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 08-Dec-2025 , 07-Jan-2026</p> <p>Synopsis   The purpose of this Notice is to inform potential applicants to the National Institute on Drug Abuse (NIDA) about a special interest in supporting basic research on the application of chemoproteomic approaches for the discovery of targets and for development of drugs to treat addiction and substance use disorders.</p>				
114151	<a href="#">Notice of Special Interest (NOSI): Chemsex and HIV: Prevalence,</a>	National Institute on Drug Abuse	NOT-DA-	07-May-2024	Not

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Medical/Psychosocial Consequences, and Treatment</a>		Abuse/NIH/DHHS	24-002	Specified
	<p>Contact Name   Raul Mandler, MD</p> <p>Contact Telephone   240-281-0569</p> <p>Contact Email   <a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis   The purpose of this notice is to support research on the epidemiology, medical/psychosocial impact, and preventive and therapeutic measures for chemsex in people with HIV and HIV-vulnerable populations including sexual minorities (SM) e.g. lesbian, gay, bisexual.</p>				
104639	<a href="#">NIDA Animal Genomics Program (U01 – Clinical Trial Not Allowed)</a>		National Institute on Drug Abuse/NIH/DHHS	PAR-21-244 27-Jun-2024	Not Specified
	<p>Contact Name   Amy C. Lossie, PhD</p> <p>Contact Telephone   301-827-6092</p> <p>Contact Email   <a href="mailto:lossieac@mail.nih.gov">lossieac@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   27-Jun-2024 , 26-Jul-2024</p> <p>Synopsis   The purpose of the NIDA Animal Genetics Program is to identify genetic, genomic, and molecular (epi)genetic variants that underlie: 1. Phenotypes associated with addictive behaviors and/or vulnerability to distinct stages along the substance use disorder (SUD) trajectory (e.g. initial/acute use, escalation of use, acquisition of tolerance, dependence, uncontrolled use, abstinence and relapse or recovery); 2. Behaviors associated with SUD (e.g. impulsivity, novelty seeking, delayed discounting, and other genetically-associated phenotypes); and 3. Comorbidities that demonstrate genetic correlations with phenotypes and behaviors linked with SUD (e.g. anxiety, stress, poor maternal care, social defeat, and other paradigms). Applications may examine any type of variant, including single nucleotide variants (SNVs), indels, large and small structural variants, and all types of mobile DNA. NIDA encourages applications that take genomics, multi-omics, and/or data-based approaches that integrate multi-level ‘omics data, delineate gene networks, and/or uncover the function of known or newly discovered</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		genetic or epigenetic variants. NIDA expects these studies to uncover novel mechanisms that contribute to SUD and facilitate the discovery of targets for intervention and guide the development of individualized therapeutics to treat these different aspects of SUD.			
105778	<a href="#">Imaging - Science Track Award for Research Transition (I/START) (R03-Basic Experimental Studies with Humans Required)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-21-309	07-May-2024	150,000 USD
	Contact Name	John Fedota, PhD			
	Contact Telephone	301-402-0812			
	Contact Email	<a href="mailto:john.fedota@mail.nih.gov">john.fedota@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025			
	Synopsis	This Funding Opportunity Announcement (FOA) encourages Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both newly independent investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources.			
105780	<a href="#">Imaging - Science Track Award for Research Transition (I/START) (R03-Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-21-310	07-May-2024	150,000 USD
	Contact Name	John Fedota, PhD			
	Contact Telephone	301-402-0812			
	Contact Email	<a href="mailto:john.fedota@mail.nih.gov">john.fedota@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025			
	Synopsis	This Funding Opportunity Announcement (FOA) encourages Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both newly independent investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| limited resources.

115679	<a href="#">NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)</a>	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-23-111	07-May-2024	275,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	
Contact Telephone	301-402-1366
Contact Email	<a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026
Synopsis	NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S.

108296	<a href="#">High-End Instrumentation (HEI) Grant Program (S10 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-079	03-Jun-2024	2,000,000 USD
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Guanghu (Jeff) Wang, PhD
Contact Telephone	301-435-0772
Contact Email	<a href="mailto:HEI@mail.nih.gov">HEI@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	03-Jun-2024
Synopsis	The High-End Instrumentation (HEI) Grant Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-end, specialized, commercially available instruments or integrated systems. The minimum award is \$600,001. There is no maximum price limit for the instrument; however, the maximum award is \$2,000,000. Instruments supported include, but are not limited to, X-ray diffractometers, high throughput robotic screening systems, mass spectrometers, nuclear magnetic resonance spectrometers, DNA and protein sequencers, biosensors, electron

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		and light microscopes, flow cytometers, and biomedical imagers.			
108298	<a href="#">Limited Competition: Basic Instrumentation Grant (BIG) Program (S10 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-081	03-Jun-2024	250,000 USD
	Contact Name	C. Ashley Barnes, PhD			
	Contact Telephone	301-435-0783			
	Contact Email	<a href="mailto:ashley.barnes@nih.gov">ashley.barnes@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	03-Jun-2024			
	Synopsis	<p>The Basic Instrumentation Grant (BIG) Program encourages applications from groups of NIH-supported investigators to purchase a single high-priced, specialized, commercially available instrument or an integrated instrumentation system. The BIG Program is limited to institutions that have not received S10 instrumentation funding of \$250,001 or greater in any of the preceding 3 Federal fiscal years (FY). Use the following to determine applicable funding periods: for application due date of June 1, 2022, consider S10 funding in FYs 2019-2021; for application due date of June 1, 2023, consider S10 funding in FYs 2020-2022; for application due date of June 3, 2024, consider S10 funding in FYs 2021-2023. The minimum award is \$25,000. There is no maximum price limit for the instrument; however, the maximum award is \$250,000. Instruments supported include, but are not limited to, basic cell sorters, confocal microscopes, ultramicrotomes, gel imagers, or computer systems.</p>			
108564	<a href="#">RFA-MH-22-145 -- BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-MH-22-145	15-May-2024 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Ming Zhan, Ph.D.			
	Contact Telephone	301-827-3678			
	Contact Email	<a href="mailto:ming.zhan@nih.gov">ming.zhan@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-May-2024 [Optional][LOI/Pre-App], 14-Jun-2024			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) aims to develop standards that describe experimental protocols conducted as part of the BRAIN Initiative. It is expected that applications will solicit community input at all stages of the process. It is</p>			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					recommended that the first step of standard development will involve sharing data between different key groups in the experimental community in order to ensure that the developing standard will encompass the data collection efforts of those groups. The developed standard is expected to be broadly disseminated for use and widely available.
109721	<a href="#">International Research Ethics Education and Curriculum Development Award (R25 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-118	06-Jun-2024	1,150,000 USD
	Contact Name	Barbara Sina, Ph.D.			
	Contact Telephone	301-402-9467			
	Contact Email	<a href="mailto:sinab@mail.nih.gov">sinab@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	06-Jun-2024			
	Synopsis	<p>The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support "the ethics of" educational activities that foster a better understanding of biomedical, behavioral and clinical research and its implications. (The overarching goal of this R25 program is to support educational activities that foster a better understanding of "the ethics of" biomedical, behavioral and clinical research and its implications.) To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development Mentoring Activities Curriculum or Methods Development Research Experiences</p> <p>The Fogarty International Bioethics Training Program aims to increase the number of research intensive institutions in low- and middle-income countries (LMICs) that can provide advanced education in international research ethics. This FOA will support innovative LMIC master's level research ethics education programs proposing integrated activities to develop culturally appropriate foundational research ethics curriculum, research ethics career skills development courses, ethics research or practicum experiences, and effective mentoring approaches. Education programs supported by this initiative should equip scientists, health professionals and academics in these countries with in-depth knowledge of the ethical principles, processes and policies related to international research. Programs should be designed to strengthen the critical competencies needed to provide research ethics education, ethical review leadership and expert consultation to LMIC researchers, their academic or research institutions, governments and international health research organizations to enhance the application of research ethics principles.</p>			
111746	<a href="#">Notice of Special Interest (NOSI): Availability of Administrative Supplements for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome) Project</a>	National Institutes of Health/DHHS	NOT-OD-22-137	01-Jun-2024	500,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jun-2024 , 01-Jun-2025</p> <p>Synopsis The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). This Notice of Special Interest (NOSI) announces NIH's continued support for administrative supplement applications for actively funded projects to meet NIH Down syndrome research objectives related to the NIH INCLUDE Project as listed below.</p>				
117962	<p><a href="#">RFA-NS-23-028 -- HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional)</a></p>	National Institutes of Health/DHHS	RFA-NS-23-028	11-May-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Eric Hudak, Ph.D.</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email <a href="mailto:NINDS-Devices@nih.gov">NINDS-Devices@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 11-May-2024 [Optional][LOI/Pre-App], 10-Jun-2024 , 10-May-2025 [Optional][LOI/Pre-App], 09-Jun-2025</p> <p>Synopsis This funding opportunity announcement (FOA) is designed to support interdisciplinary research teams of multiple PDs/PIs to investigate the mechanism of action of pain relief by medical devices with the overall goal of optimizing therapeutic outcomes for FDA-approved or -cleared technologies. Teams must leverage appropriate multi-disciplinary expertise to develop new principles and methods for experimentation, analysis, and interpretation. Teams are encouraged to consider objectives that will produce major advances in the understanding of pain relief by medical devices.</p>				
119320	<p><a href="#">RFA-MH-24-280 -- BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)</a></p>	National Institutes of Health/DHHS	RFA-MH-24-280	08-May-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Eunyoung Kim, Ph.D.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-827-3420</p> <p>Contact Email   <a href="mailto:eunyoung.kim@nih.gov">eunyoung.kim@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   08-May-2024 [Optional][LOI/Pre-App], 07-Jun-2024 , 08-Jan-2025 [Optional][LOI/Pre-App], 07-Feb-2025 , 07-Sep-2025 [Optional][LOI/Pre-App], 07-Oct-2025 , 09-May-2026 [Optional][LOI/Pre-App], 08-Jun-2026 , 09-Jan-2027 [Optional][LOI/Pre-App], 08-Feb-2027</p> <p>Synopsis   The purpose of this Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is to encourage research that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged.</p>				
108297	<a href="#">Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-080	03-Jun-2024	750,000 USD
	<p>Contact Name   Guanghu (Jeff) Wang, PhD</p> <p>Contact Telephone   301-435-0772</p> <p>Contact Email   <a href="mailto:SIG@mail.nih.gov">SIG@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   03-Jun-2024</p> <p>Synopsis   The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-priced, specialized, commercially available instruments or integrated instrumentation system. The minimum award is \$50,000. There is no maximum price limit for the instrument; however, the maximum award is \$750,000. Instruments supported include, but are not limited to: X-ray diffractometers, mass spectrometers, nuclear magnetic resonance spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, flow cytometers, and biomedical imagers.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
117915	<a href="#">RFA-NS-23-025 -- BRAIN Initiative: Exploratory Team-Research BRAIN Circuit Programs - eTeamBCP (U01 Clinical Trials Optional)</a>	National Institutes of Health/DHHS	RFA-NS-23-025	15-May-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name   Karen K David, Ph.D.</p> <p>Contact Telephone   301-496-9964</p> <p>Contact Email   <a href="mailto:BRAINcircuits@nih.gov">BRAINcircuits@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-May-2024 [Optional][LOI/Pre-App], 14-Jun-2024</p> <p>Synopsis   This funding opportunity announcement (FOA) is designed to support teams of three or more (up to six) PDs/PIs that seek to cross boundaries of interdisciplinary collaboration to elucidate the contributions of dynamic circuit activity to a specific behavioral or neural system. Applications are encouraged to propose adventurous and challenging goals that can only be tackled by a synergistic team-based approach and have the potential to be transformative and/or to enable significant advances. These studies at the exploratory stage are intended for the development of experimental capabilities and/or theoretical frameworks in preparation for a future competition for larger-scale or extended efforts, including the BRAIN TargetedBCP (R01) or the multi-component, Team-Research BRAIN Circuit Programs (U19). The overall goal of this FOA is to enable a large-scale analysis of neural systems and circuits within the context and during the simultaneous measurement of an ethologically relevant behavior. Toward this end, teams are expected to assemble and leverage multi-disciplinary expertise, and to integrate experimental with computational and theoretical approaches. Teams are expected to bridge fields by incorporating rich information on cell-types, on circuit functionality and connectivity, in conjunction with sophisticated analyses of an ethologically relevant behavior of an organism or a well-defined neural system. Teams are also expected to aim for a mechanistic understanding of the circuits of the central nervous system (CNS) by applying cutting-edge methods such as those for large-scale recording, manipulation, and analysis of neural circuits across multiple regions of the CNS.</p>				
115197	<a href="#">In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-074	05-Jun-2024	2,499,995 USD
	<p>Contact Name   Mahua Mukhopadhyay, PhD</p> <p>Contact Telephone   301-435-6886</p> <p>Contact Email   <a href="mailto:mukhopam@mail.nih.gov">mukhopam@mail.nih.gov</a></p> <p>Sponsor Website  </p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2024 , 05-Oct-2024 , 05-Jun-2025 , 05-Oct-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The mission of IMPC is to generate a comprehensive catalogue of mammalian gene function that will provide the foundation for functional analyses of human genetic variation. The current (July 19, 2022) IMPC data release includes phenotypic data for 8260 knockout genes. Overall, the IMPC hopes to generate a null mutant and undertake broad-based phenotyping for every gene in the mouse genome. About 30% of these strains are expected to be either embryonic or perinatal lethal, or subviable. However, a large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in-depth phenotyping and research.</p>				
113466	<a href="#">Notice of Special Interest (NOSI): BRAIN Initiative: Notice of Support for Research on Interoception Circuits</a>	National Institutes of Health/DHHS	NOT-AT-23-003	14-Jun-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 14-Jun-2024 , 28-Jun-2024 , 13-Sep-2024 , 21-Sep-2024 , 02-Oct-2024</p> <p>Synopsis The purpose of this announcement is to notify the research community that NIH welcomes BRAIN Initiative applications targeting interoceptive processes and circuits, as appropriate to the goals and requirements of specific BRAIN Initiative FOAs.</p>				
116697	<a href="#">RFA-OD-23-013 -- Understanding Chronic Conditions Understudied Among Women (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-OD-23-013	20-May-2024 [Optional][LOI/Pre-App]	275,000 USD
	<p>Contact Name Sarah Temkin, M.D.</p> <p>Contact Telephone 301-402-2168</p> <p>Contact Email <a href="mailto:temkinsm@mail.nih.gov">temkinsm@mail.nih.gov</a></p> <p>Sponsor Website</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 20-May-2024 [Optional][LOI/Pre-App], 20-Jun-2024</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to invite R21 applications on chronic conditions understudied among women and/or that disproportionately affect populations of women who are understudied, underrepresented, and underreported in biomedical Research should align with Goal 1 of the 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing Science for the Health of Women." The awards under this NOFO will be administered by NIH ICs using funds that have been made available through the Office of Research on Women's Health (ORWH) and the scientific partnering Institutes and Centers across NIH.</p>				
110282	<p><a href="#">RFA-OD-22-007 -- Investigation of Co-occurring conditions across the Lifespan to Understand Down syndrome (INCLUDE) Clinical Trial Readiness (R21 Clinical Trial Not Allowed)</a></p>	National Institutes of Health/DHHS	RFA-OD-22-007	01-Jun-2024 [Optional][LOI/Pre-App]	275,000 USD
	<p>Contact Name Laurie M. Ryan, Ph.D.</p> <p>Contact Telephone 301.496.9350</p> <p>Contact Email <a href="mailto:ryanl@mail.nih.gov">ryanl@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jun-2024 [Optional][LOI/Pre-App], 01-Jul-2024</p> <p>Synopsis The NIH Investigation of Co-occurring conditions across the Lifespan to Understand Down syndrome (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in Down syndrome. This initiative seeks applications that are intended to facilitate Down syndrome research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials for Down syndrome and its co-occurring conditions, and to increase their likelihood of success through development and testing of biomarkers and clinical outcome assessment measures, development and testing of novel trial methods and recruitment strategies, or by defining the presentation and course of the co-occurring conditions in individuals with Down syndrome to enable the design of future clinical trials.</p>				
110290	<p><a href="#">RFA-OD-22-010 -- Clinical Trials Development for Co-Occurring Conditions in Individuals with Down syndrome: Phased Awards for INCLUDE (R61/R33 Clinical Trial Required)</a></p>	National Institutes of Health/DHHS	RFA-OD-22-010	01-Jun-2024 [Optional][LOI/Pre-App]	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Laurie M. Ryan, Ph.D.</p> <p>Contact Telephone   301.496.9350</p> <p>Contact Email   <a href="mailto:ryanl@mail.nih.gov">ryanl@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   01-Jun-2024 [Optional][LOI/Pre-App], 01-Jul-2024</p> <p>Synopsis   The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phased Innovation (R61/R33) grant applications to support development of clinical trials to treat critical and co-occurring health conditions in individuals with Down syndrome. The proposed research aims should be milestone-driven. The total project period for an application submitted in response to this FOA may not exceed five years. This FOA provides support for up to two years (R61 phase) for preliminary/developmental/planning studies, followed by possible transition to clinical trial support (R33) of up to three years, although the total duration of the award may not exceed five years. This FOA requires measurable R61 milestones.</p>				
110376	<p><a href="#">RFA-OD-22-008 -- Small Research Grants for Analysis, Curation, and/or Sharing of Down syndrome-related Research Data for the INCLUDE Project (R03 Clinical Trial Not Allowed)</a></p>	National Institutes of Health/DHHS	RFA-OD-22-008	01-Jun-2024 [Optional][LOI/Pre-App]	200,000 USD
	<p>Contact Name   Huiqing Li, PhD</p> <p>Contact Telephone   301-435-0554</p> <p>Contact Email   <a href="mailto:Huiqing.Li@nih.gov">Huiqing.Li@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   01-Jun-2024 [Optional][LOI/Pre-App], 01-Jul-2024</p> <p>Synopsis   The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. This FOA is intended to support meritorious small research projects focused on analyses of genomics other -omics, clinical and phenotypic datasets related to Down syndrome research, with an emphasis on elucidating the underlying etiologies of risk and resiliencies to co-occurring health conditions. Development of approaches, tools, or algorithms appropriate for analyzing data relevant to Down syndrome and facilitating data sharing within the research community through the INCLUDE Data Hub may also be proposed.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
113526	<a href="#">Investigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Clinical Research Short Course (R25 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-195	27-Jun-2024	2,000,000 USD
	<p>Contact Name   Cara Finley, M.P.H.</p> <p>Contact Telephone   202-557-4354</p> <p>Contact Email   <a href="mailto:cara.finley@nih.gov">cara.finley@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   27-Jun-2024 , 27-Jun-2025</p> <p>Synopsis   The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). As part of the INCLUDE Project, NIH is interested in expanding and diversifying the skilled DS clinical research workforce. The intent of this Funding Opportunity Announcement (FOA) is to encourage applications that develop creative and innovative short courses to train the next generation of DS researchers in state-of-the-art clinical research skills that will improve the understanding of the co-occurring clinical features in DS and support development of new treatments for health conditions experienced by those with DS.</p>				
119045	<a href="#">RFA-HG-23-017 -- Investigator-Initiated Research in Genomics and Health Equity (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-HG-23-017	08-Jun-2024 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name   Lucia Hindorff, Ph.D.</p> <p>Contact Telephone   240-271-1509</p> <p>Contact Email   <a href="mailto:hindorffl@mail.nih.gov">hindorffl@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   08-Jun-2024 [Optional][LOI/Pre-App], 08-Jul-2024 , 08-Jun-2025 [Optional][LOI/Pre-App], 08-Jul-2025</p> <p>Synopsis   The purpose of this initiative is to support investigator-initiated research in genomics and health equity, with the ultimate goal of developing approaches, generating and disseminating data, and implementing metrics or interventions that will advance the equitable use of genomics to improve health in U.S. populations. Awardees will conduct innovative and generalizable research in genomics and health equity spanning across genomic research areas and will incorporate a plan for enhancing diverse perspectives. Applications supporting New or Early Stage Investigators from diverse backgrounds,</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

including those from groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce, as described in the NIH Notice of Interest in Diversity (NOT-OD-20-031), are encouraged. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications without a PEDP will not be reviewed.

117935	<a href="#">RFA-NS-23-024 -- BRAIN Initiative: Targeted BRAIN Circuits Projects-TargetedBCP (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-NS-23-024	29-May-2024 [Optional][LOI/Pre-App]	Not Specified
--------	--	------------------------------------	---------------	--	---------------

Contact Name	Karen K David, PhD
Contact Telephone	301-496-9964
Contact Email	<a href="mailto:BRAINCircuits@NIH.GOV">BRAINCircuits@NIH.GOV</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	29-May-2024 [Optional][LOI/Pre-App], 28-Jun-2024 , 02-Sep-2024 [Optional][LOI/Pre-App], 02-Oct-2024
Synopsis	<p>This FOA solicits applications for research projects that seek to understand how circuit activity gives rise to mental experience and behavior using innovative, methodologically-integrated approaches. The goal is to support adventurous projects that can realize a potentially transformative outcome within 5 years. Applications are expected to address circuit function in the context of specific behaviors or neural systems, such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication, or homeostasis. Projects should link theory, data analysis, and/or computational approaches to experimental design and should produce predictive models (conceptual or quantitative). Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Diverse species or experimental systems and a cross-species/comparative approach are welcome and should be chosen based on their power to address the specific question at hand and to reveal generalizable and fundamental neuroscience principles.</p>

117936	<a href="#">RFA-NS-23-023 -- BRAIN Initiative: Targeted BRAIN Circuits Planning Projects – TargetedBCPP (R34 Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	RFA-NS-23-023	29-May-2024 [Optional][LOI/Pre-App]	450,000 USD
--------	---	------------------------------------	---------------	--	-------------

Contact Name	Karen K David, PhD
Contact Telephone	301-496-9964
Contact Email	<a href="mailto:BRAINCircuits@NIH.GOV">BRAINCircuits@NIH.GOV</a>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 29-May-2024 [Optional][LOI/Pre-App], 28-Jun-2024 , 02-Sep-2024 [Optional][LOI/Pre-App], 02-Oct-2024</p> <p>Synopsis This R34 FOA solicits applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying results that, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted BRAIN Circuits Projects - TargetedBCP R01, as described in the companion FOA (RFA-NS-23-024). Applications should be adventurous, exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior.</p>				
117668	<a href="#">RFA-MH-23-270 -- BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-MH-23-270	08-May-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Ming Zhan, Ph.D.</p> <p>Contact Telephone 301-827-3678</p> <p>Contact Email <a href="mailto:ming.zhan@nih.gov">ming.zhan@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 08-May-2024 [Optional][LOI/Pre-App], 07-Jun-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits applications to develop informatics tools for analyzing, visualizing, and integrating data related to the BRAIN Initiative or to enhance our understanding of the brain. As part of programs of building the informatics infrastructure for the BRAIN Initiative, the FOA supports several different, but related activities. These include modifying existing analysis and visualization tools to deal with BRAIN Initiative data and integrating different types of BRAIN Initiative datasets. Proposing the development of new tools to deal with BRAIN Initiative data is also permitted. The tools supported under this FOA will make use of relevant data standards and will be built so that they can be integrated into the data repositories, both of which are created in awards under the other FOAs of the BRAIN initiative informatics program. The tools must be user-friendly in accessing and analyzing data from appropriate data archives, and should analyze/visualize data without requiring users to download data. The tools should also allow data to be combined for analysis/visualization from multiple locations.</p>				
114889	<a href="#">Notice of Special Interest (NOSI): BRAIN Initiative: Developing Data Archive, Informatics Tools and Data Standards for Brain Behavior Quantification and Synchronization (BBQS)</a>	National Institutes of Health/DHHS	NOT-MH-23-115	07-Jun-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Ming Zhan, Ph.D.</p> <p>Contact Telephone   (301) 827-3678</p> <p>Contact Email   <a href="mailto:ming.zhan@nih.gov">ming.zhan@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jun-2024 , 14-Jun-2024</p> <p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to encourage new applications for developing informatics infrastructure for the Brain Behavior Quantification and Synchronization (BBQS) research program of the Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative. Specifically, the NOSI supports a) creation of data archive(s) to store and manage BBQS-relevant data; b) development of computational tools or software for analyzing, visualizing and integrating BBQS-related data, and for predicting and modeling the complex dynamics of the brain-behavior system; and c) establishment of data standards or ontologies that support the BBQS-related studies.</p>				
114327	<a href="#">Research Infrastructure Development for Interdisciplinary Aging Studies (R61/R33 - Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-053	03-Jun-2024	2,499,995 USD
	<p>Contact Name   Dr. Sanoj Suneja</p> <p>Contact Telephone   301-402-7710</p> <p>Contact Email   <a href="mailto:sunejas@mail.nih.gov">sunejas@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   03-Jun-2024 , 04-Oct-2024 , 02-Jun-2025 , 03-Oct-2025</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA utilizes NIH's R61/R33 Exploratory/Developmental Phased Award activity code. The R61 phase provides up to 2 years of support for initial developmental activities. The R33 phase provides up to 3 years of support for expanded activities. Through this award, investigators will endeavor to develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.</p>				
114328	<a href="#">Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-054	03-Jun-2024	2,499,995 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Dr. Sanoj Suneja
Contact Telephone	301-402-7710
Contact Email	<a href="mailto:sunejas@mail.nih.gov">sunejas@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	03-Jun-2024 , 04-Oct-2024 , 02-Jun-2025 , 03-Oct-2025
Synopsis	This Funding Opportunity Announcement (FOA) invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA utilizes NIH's R33 Exploratory/Developmental Grants Phase II activity code to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed with other NIH or non-NIH support. Through this award, investigators will endeavor to develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.

121493	<a href="#">RFA-EY-23-001 -- BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-EY-23-001	18-Jun-2024	400,000 USD
--------	--	------------------------------------	---------------	-------------	-------------

Contact Name	Martha Flanders, PhD
Contact Telephone	301-827-5191
Contact Email	<a href="mailto:BRAIN-FOAs@nih.gov">BRAIN-FOAs@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	18-Jun-2024 , 17-Jun-2025 , 15-Jun-2026
Synopsis	This NOFO seeks applications for unique and innovative recording and/or modulation technologies that are in the earliest stage of development, including new and untested ideas that are in the initial stages of conceptualization. Some projects may aim to increase recording or modulation capabilities by many orders of magnitude, while others may aim to improve the precision and selectivity of recording or modulation (also referred to as stimulation, perturbation, or manipulation). A wide range of modalities are appropriate including acoustic, chemical, electrical, magnetic, and optical, as well as the use of genetic tools. Invasive or non-invasive approaches are sought that will enable large-scale recording and/or precise manipulation of neural activity, and that would ultimately be compatible with experiments in humans or behaving animals. Applications are encouraged from any qualified individual, including chemists, physicists, engineers, theoreticians,

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		materials scientists, and others from fields not typically involved with neuroscience research. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.			
117410	<a href="#">NIH Science Education Partnership Award (SEPA) (R25 - Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-137	07-Jun-2024	1,250,000 USD
	Contact Name	Tony Beck, Ph.D.			
	Contact Telephone	301-480-4623			
	Contact Email	<a href="mailto:beckl@mail.nih.gov">beckl@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jun-2024 , 06-Jun-2025			
	Synopsis	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on: Courses for Skills Development Research Experiences Mentoring Activities Curriculum or Methods Development Outreach			
121099	<a href="#">RFA-HG-23-002 -- Broadening Opportunities for Computational Genomics and Data Science Education (UE5 – Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-HG-23-002	10-Jun-2024	Not Specified
	Contact Name	Shurjo K. Sen, Ph.D.			
	Contact Telephone	301-827-7028			
	Contact Email	<a href="mailto:sensh@mail.nih.gov">sensh@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	10-Jun-2024			
	Synopsis	The NIH Research Education Program (UE5) supports research education activities in the mission areas of the NIH. The overarching goal of this U35 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

studies or careers in research. To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on: Curriculum or Methods Development The NIH Research Education Program (UE5) supports research education activities in the mission areas of the NIH. The overarching goal of this UE5 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in computational genomics and data science research. To accomplish the stated over-arching goal, this funding opportunity will support creative educational activities with a primary focus on: Curriculum or Methods Development Specifically, this UE5 program will support faculty members at institutions which have a documented historical and current mission to educate students from any of the populations that have been identified as underrepresented in biomedical research as defined by the National Science Foundation NSF, see <http://www.nsf.gov/statistics/wmpd/> or have a documented historical record of recruiting, training and/or educating, and graduating underrepresented students as defined by NSF (see above), to develop undergraduate and master’s degree-level educational content in data science and computational genomics. Content developed will be expected to leverage the resources of NIH cloud computing platforms such as NHGRI’s ANVIL and the All of Us Researcher Workbench. This UE5 funding opportunity is a parallel effort to the recently established Educational Hub for Enhancing Diversity in Computational Genomics and Data Science (hereafter called the CGDS Hub) described in detail in RFA-HG-22-002. Awardees of this funding opportunity (hereafter referred to as the CGDS Sites) are expected to make use of educational support resources developed by the CGDS Hub, and the CGDS Hub awardee will provide educational and hands-on research training and resources in CGDS for the future workforce through the establishment of lasting partnerships with the Sites, facilitate faculty development and student educational and research training at the undergraduate and master’s degree levels.

109253	<a href="#">RFA-NS-22-049 -- BRAIN Initiative Connectivity across Scales (BRAIN CONNECTS): Specialized Projects for Scalable Technologies (U01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-NS-22-049	13-Jun-2024 [Optional][LOI/Pre-App]	Not Specified
--------	--	------------------------------------	---------------	--	---------------

Contact Name	Edmund Talley
Contact Telephone	301-496-1917
Contact Email	<a href="mailto:BRAIN-CONNECTS-Inquiries@nih.gov">BRAIN-CONNECTS-Inquiries@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	13-Jun-2024 [Optional][LOI/Pre-App], 13-Jul-2024
Synopsis	This Funding Opportunity Announcement (FOA) supports Specialized Projects to develop current or emerging technologies to generate comprehensive atlases of brain connectivity, with an emphasis on human, non-human primate (NHP), and mouse. Projects using other species are also permitted, if their use is well justified and the goal is test and validate approaches that

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

can be generalized across species. Applications may address any aspect(s) of data collection, reconstruction, analysis, integration, dissemination, and interpretation of brain connectivity and associated data pipelines, to enable faster, more precise, and more cost-effective generation and interpretation of brain-wide wiring diagrams. Proposals are encouraged to develop distinct capabilities and competencies that may be expected to complement Comprehensive Centers solicited by the companion FOAs, with aims of further developing and optimizing current technologies, or proposing entirely new, disruptive, and potentially risky approaches. Funded projects will be integrated into the BRAIN CONNECTS Network, consisting of other Specialized Projects from this FOA, and Comprehensive Centers from its companion announcements, as a coordinated effort aimed at developing the capabilities to generate wiring diagrams that can span entire brains across multiple scales.

118275	<a href="#">RFA-MH-23-295 -- BRAIN Initiative: Development of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in Human and Non-Human Primate Brain (UG3/UH3 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-MH-23-295	07-Jun-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name Douglas S. Kim, Ph.D.  
 Contact Telephone 301-827-6463  
 Contact Email [douglas.kim@nih.gov](mailto:douglas.kim@nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 07-Jun-2024

Synopsis The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative notice of funding opportunity is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis and manipulation of complex circuits in large brains. Critical advances in the treatment of brain disorders in human populations are hindered by our lack of ability to monitor and manipulate circuitry in safe, minimally-invasive ways. Clinical intervention with novel cell- and circuit-specific tools will require extensive focused research designed to remove barriers for targeted circuit manipulation. In addition to identification and removal of barriers, the need to delineate dysfunctional circuitry poses additional challenges. Neuroscience has experienced an impressive influx of exciting new research tools in the past decade, especially since the launch of the BRAIN Initiative. However, the majority of these cell- and circuit-specific mapping, monitoring, and manipulating tools has been developed for use in model organisms, primarily rodents, fish and flies. These cutting-edge tools are increasingly adaptable to larger mammalian brains and, more importantly, are emerging as potential human therapeutic strategies for brain disorders. A pressing need to develop tools for use in large brains or those that are more directly relevant to the human brain is the focus of this initiative. The initiative will support initial proof of principle studies aimed at demonstrating the feasibility of using the cutting-edge approaches in humans and other mammalian species (e.g., non-human primate [NHP]/sheep/pigs).

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

106783	<a href="#">Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PAR-21-349	21-Jun-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

	<p>Contact Name   William Elwood, PhD</p> <p>Contact Telephone   301-402-0116</p> <p>Contact Email   <a href="mailto:william.elwood@nih.gov">william.elwood@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   21-Jun-2024</p> <p>Synopsis   This funding opportunity announcement (FOA) invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. Types of projects submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolation. NIH considers such studies as Basic Experimental Studies with Humans (BESH) that are prospective basic science studies involving human participants that meet the NIH definition of basic research and fall within the NIH definition of clinical trials (see, e.g., NOT-OD-19-024). Applications should not propose a goal of clinical outcomes or products. Applications that propose studies including model animal research or observational studies involving humans should submit under the companion FOA, PAR-21-350 "Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed).</p>
--	--

106784	<a href="#">Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-350	21-Jun-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

	<p>Contact Name   William Elwood, PhD</p> <p>Contact Telephone   301-402-0116</p> <p>Contact Email   <a href="mailto:william.elwood@nih.gov">william.elwood@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p>
--	---



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   21-Jun-2024</p> <p>Synopsis   This funding opportunity announcement (FOA) invites research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. Both animal model and human subjects research projects are welcome; however, clinical trials are not allowed. Researchers proposing Basic Experimental Studies with Humans (BESH) should consider the companion FOA, PAR-21-349, "Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required)".</p>				
106790	<p><a href="#">Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trial Required)</a></p>	National Institutes of Health/DHHS	PAR-21-352	21-Jun-2024	Not Specified
	<p>Contact Name   William Elwood, PhD</p> <p>Contact Telephone   301-402-0116</p> <p>Contact Email   <a href="mailto:william.elwood@nih.gov">william.elwood@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   21-Jun-2024</p> <p>Synopsis   This funding opportunity announcement (FOA) invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. Types of projects submitted under this FOA include mechanistic studies that are classified as clinical trials. Mechanistic studies are defined as studies with the objective to understand the mechanism(s) of action of an intervention, a biological or behavioral process, or the pathophysiology of a disease/condition. See NOT-AT-20-001 and NOT-MH-19-006 for examples of clinical trials that are/are not considered mechanistic studies. Clinical trials that propose to influence a clinical outcome, test safety or feasibility of an intervention, demonstrate the clinical efficacy or effectiveness of an intervention, or analyze the effect size of an intervention on clinical outcomes are ineligible for this FOA. Types of studies that should submit under this FOA include clinical trials that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Researchers proposing basic science experimental studies involving human participants should consider this FOA's companion for basic experimental studies with humans, PAR-21-349, "Research on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required)." Applications proposing studies that include, but are not limited to, model animal research or observational studies involving humans should submit under the companion FOA, PAR-21-350, "Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed).</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
106620	<a href="#">RFA-OD-21-007 -- INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Exploratory/Developmental Research Grant Award (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-OD-21-007	01-Jun-2024 [Optional][LOI/Pre-App]	275,000 USD
	<p>Contact Name   Melissa A. Parisi, M.D., Ph.D.</p> <p>Contact Telephone   301-435-6880</p> <p>Contact Email   <a href="mailto:parisima@mail.nih.gov">parisima@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   01-Jun-2024 [Optional][LOI/Pre-App], 01-Jul-2024</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of new exploratory and developmental research projects that address critical needs for Down syndrome projects, as articulated in the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) project objectives. For example, such projects could assess the feasibility of a novel area of investigation or a new experimental system that has the potential to enhance health-related research. Another example could include the unique and innovative use of an existing methodology to explore a new scientific area. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.</p>				
116668	<a href="#">RFA-OD-23-014 -- Understanding Chronic Conditions Understudied Among Women (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-OD-23-014	20-May-2024 [Optional][LOI/Pre-App]	1,400,000 USD
	<p>Contact Name   Sarah Temkin, M.D.</p> <p>Contact Telephone   301-402-2168</p> <p>Contact Email   <a href="mailto:temkinsm@mail.nih.gov">temkinsm@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   20-May-2024 [Optional][LOI/Pre-App], 20-Jun-2024</p> <p>Synopsis   The purpose of this Notice of Funding Opportunity (NOFO) is to invite R01 applications on chronic conditions understudied among women and/or that disproportionately affect populations of women who are understudied, underrepresented, and underreported in biomedical Research should align with Goal 1 of the 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing Science for the Health of Women." The awards under this NOFO will be administered by NIH ICs</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

using funds that have been made available through the Office of Research on Women’s Health (ORWH) and the scientific partnering Institutes and Centers across NIH.

121738	<a href="#">Advancing Research Careers (ARC) Predoctoral to Postdoctoral Transition Award to Promote Diversity (F99/K00 - Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-222	13-Jun-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Laurie Stepanek, Ph.D.
Contact Telephone	
Contact Email	<a href="mailto:laurie.stepanek@nih.gov">laurie.stepanek@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	13-Jun-2024 , 07-Sep-2024 , 11-Oct-2024 , 07-Jan-2025 , 13-Feb-2025 , 07-May-2025 , 13-Jun-2025 , 07-Sep-2025 , 10-Oct-2025 , 07-Jan-2026 , 13-Feb-2026 , 07-May-2026 , 15-Jun-2026 , 07-Sep-2026 , 14-Oct-2026 , 07-Jan-2027 , 11-Feb-2027 , 07-May-2027
Synopsis	<p>The purpose of the Advancing Research Careers (ARC) Predoctoral to Postdoctoral Transition Award to Promote Diversity (F99/K00) program is to support promising, late-stage graduate students from diverse backgrounds, for example those from underrepresented groups (see Notice of NIH’s Interest in Diversity), to transition into and succeed in mentored postdoctoral research positions. It is anticipated that successful completion of this phased award program will position ARC scholars to advance in impactful careers in the biomedical research workforce that typically require postdoctoral training (e.g., academic research and teaching at a range of institution types, industry or government research). This two-phase award will provide support for late-stage graduate students pursuing research related to the mission areas of participating NIH Institutes, Centers, and Offices (ICOs) to facilitate the completion of doctoral dissertation projects and research training (F99 phase), and to transition into and succeed in postdoctoral biomedical research and career development opportunities (K00 phase). ARC F99 fellows/K00 scholars will be part of organized cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by ARC Institutionally-Focused Research Education Award to Promote Diversity (UE5) recipients. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Candidates to this NOFO are permitted to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>

112126	<a href="#">RFA-TR-22-030 -- Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-TR-22-030	15-Jun-2024 [Optional][LOI/Pre-App]	100,000 USD
--------	--	------------------------------------	---------------	--	-------------

Contact Name	Karlie Sharma, Ph.D.
Contact Telephone	301-451-4965

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:DruggableGenome@mail.nih.gov">DruggableGenome@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jun-2024 [Optional][LOI/Pre-App], 15-Jul-2024</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to solicit applications for pilot projects to elucidate a role for understudied proteins associated with rare diseases. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s). A list of eligible proteins is provided and are members of druggable protein families that have a known association with a rare disease. This FOA is intended to jumpstart research on understudied proteins that are associated with rare diseases and provide applicants with sufficient funding to perform basic biochemical and/or biological work to further the characterization of understudied proteins associated with rare disease.</p>				
117066	<a href="#">Instrumentation Grant Program for Resource-Limited Institutions (S10 - Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-138	03-Jun-2024	250,000 USD
	<p>Contact Name Dorothy Beckett, PhD</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:dorothy.beckett@nih.gov">dorothy.beckett@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 03-Jun-2024 , 02-Jun-2025</p> <p>Synopsis The Instrumentation Grant Program for Resource-limited Institutions supports the purchase of state-of-the-art scientific instruments to enhance the research and educational missions of resource-limited institutions. Requested instruments may support biomedical research and education in basic, translational, biomedically-related behavioral or clinical fields.</p>				
119046	<a href="#">RFA-HG-23-018 --Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-HG-23-018	08-Jun-2024 [Optional][LOI/Pre-App]	400,000 USD
	<p>Contact Name Lucia Hindorff, Ph.D.</p> <p>Contact Telephone 240-271-1509</p> <p>Contact Email <a href="mailto:hindorffl@mail.nih.gov">hindorffl@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   08-Jun-2024 [Optional][LOI/Pre-App], 08-Jul-2024 , 08-Jun-2025 [Optional][LOI/Pre-App], 08-Jul-2025</p> <p>Synopsis   The purpose of this initiative is to support investigator-initiated research in genomics and health equity, with the ultimate goal of developing approaches, generating and disseminating data, and implementing metrics or interventions that will advance the equitable use of genomics to improve health in U.S. populations. Awardees will conduct innovative and generalizable research in genomics and health equity spanning across genomic research areas and will incorporate a plan for enhancing diverse perspectives. This R21 Notice of Funding Opportunity (NOFO) will support small research projects that can be carried out in a short period of time with limited resources. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Applications supporting New or Early Stage Investigators from diverse backgrounds, including those from groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce, as described in the NIH Notice of Interest in Diversity (NOT-OD-20-031), are encouraged. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications without a PEDP will not be reviewed.</p>				
114707	<p><a href="#">RFA-NS-22-023 -- HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research (Independent Basic Experimental Studies with Humans Required)</a></p>	National Institutes of Health/DHHS	RFA-NS-22-023	11-Jun-2024	Not Specified
	<p>Contact Name   DP Mohapatra, Ph.D.</p> <p>Contact Telephone   301-496-9964</p> <p>Contact Email   <a href="mailto:dp.mohapatra@nih.gov">dp.mohapatra@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   11-Jun-2024 , 11-Oct-2024 , 11-Feb-2025</p> <p>Synopsis   The purpose of the NIH HEAL Initiative® Pathway to Independence Award (K99/R00) program is to support a cohort of new and well-trained independent investigators conducting Pain and/or SUD research, in order to increase the independent investigator workforce in research areas supported by the NIH HEAL Initiative®. This program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative®. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

114700	<a href="#">RFA-NS-22-022 -- HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research (K99/R00 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-NS-22-022	11-Jun-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name | DP Mohapatra, Ph.D.  
 Contact Telephone | 301-496-9964  
 Contact Email | [dp.mohapatra@nih.gov](mailto:dp.mohapatra@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 11-Jun-2024 , 11-Oct-2024 , 11-Feb-2025

Synopsis | The purpose of the NIH HEAL Initiative® Pathway to Independence Award (K99/R00) program is to support a cohort of new and well-trained independent investigators conducting Pain and/or SUD research, in order to increase the independent investigator workforce in research areas supported by the NIH HEAL Initiative®. This program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative®. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, an ancillary study to a clinical trial, or an independent Basic Experimental Studies with Humans (BESH). Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing an independent BESH as lead investigator, should apply to the companion FOA (RFA-NS-22-023).

112443	<a href="#">HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required)</a>	National Institutes of Health/DHHS	PAS-22-206	12-Jun-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name | Lori Ducharme, Ph.D.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone | 301-827-6331  
 Contact Email | [Lori.Ducharme@nih.gov](mailto:Lori.Ducharme@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 12-Jun-2024 , 12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025

Synopsis | The purpose of this Mentored Research Scientist Development Award in Implementation Science for Substance Use Prevention and Treatment (K01) is to provide support and “protected time” (3-5 years) for an intensive, supervised career development experience leading to research independence in this area of specialization. Realizing the return on public investment in the development of evidence-based treatments and preventive interventions to address the ongoing overdose crisis depends on a cadre of skilled researchers with expertise in implementation science, who can help move these interventions into routine practice. Implementation science focuses on identifying modifiable barriers to the uptake and sustained use of evidence-based practices in real world settings and developing replicable and scalable strategies to overcome those barriers. While this field has grown rapidly over the past 15 years, there remain a limited number of independent researchers with dual expertise in addiction research and implementation science, constraining the field’s capacity to respond to continued calls for research in this area. There is a pressing need for a deeper bench of researchers who can be called upon to meet ongoing and emerging implementation challenges in the addiction field. This Funding Opportunity Announcement (FOA) will support early career investigators who have foundational training in substance use prevention or treatment research and will provide support and protected time to acquire training and research experience in implementation science. Development and execution of an independent NIH-defined clinical trial applying implementation science methods to one of the four domains of the HHS Overdose Prevention Strategy (prevention; evidence-based addiction treatment; harm reduction; or recovery research) is required. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, should consult the NIH Research Career Development Awards website for alternative funding opportunities.

111464	<a href="#">Notice of Special Interest (NOSI): Mentored Career Development Awards to Foster the Careers of Investigators Pursuing Research Related to Down syndrome as Part of the INCLUDE Project</a>	National Institutes of Health/DHHS	NOT-OD-22-124	07-May-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name | Charlene Schramm, PhD  
 Contact Telephone | 301-402-3793  
 Contact Email | [schrammc@nih.gov](mailto:schrammc@nih.gov)

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024</p> <p>Synopsis The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). This Notice of Special Interest (NOSI) announces NIH support for the professional development of early career scientists aiming to establish a career in DS-related research. By providing these scientists with training, resources, and mentorship, the NIH intends to support the career development of junior investigators in DS who will lead future research to improve the understanding of the biology of DS and support development of new treatments for health conditions experienced by those with DS.</p>				
105002	<a href="#">The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional)</a>	National Institutes of Health/DHHS	PAR-21-275	07-May-2024	Not Specified
	<p>Contact Name Rada K. Dagher, PhD, MPH</p> <p>Contact Telephone 301-451-2187</p> <p>Contact Email <a href="mailto:rada.dagher@nih.gov">rada.dagher@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support innovative population-based research that can contribute to identifying and characterizing pathways and mechanisms through which work or occupation influences health outcomes and health status among populations with health and/or health care disparities, and how work functions as a social determinant of health.</p>				
108364	<a href="#">Health Care Models for Persons with Multiple Chronic Conditions from Populations that Experience Health Disparities: Advancing Health Care towards Health Equity (R01 - Clinical Trials Optional)</a>	National Institutes of Health/DHHS	PAR-22-092	07-May-2024	Not Specified
	<p>Contact Name Larissa Avilés-Santa, MD, MPH</p> <p>Contact Telephone 301-827-6924</p> <p>Contact Email <a href="mailto:avilessantal@nih.gov">avilessantal@nih.gov</a></p> <p>Sponsor Website</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Sep-2024</p> <p>Synopsis This initiative will support innovative, collaborative, and multi-disciplinary research designed to study the effective adaptation, integration, and implementation of recommended guidelines of care of persons with multiple chronic conditions (MCCs) from populations that experience health disparities. Projects would be expected to involve more than one component and/or more than one level of influence within existing or newly proposed health care models. The goal of this initiative is attainment of optimal treatment and health outcomes goals to advance health care towards health equity.</p>				
108571	<p><a href="#">Notice of Special Interest (NOSI): Enhancing Research on Deciphering Mechanisms of COVID-19-Associated Coagulopathy</a></p>	National Institutes of Health/DHHS	NOT-HL-23-003	07-May-2024	Not Specified
	<p>Contact Name Anthony Agresti</p> <p>Contact Telephone 301-827-8014</p> <p>Contact Email <a href="mailto:agrestia@nhlbi.nih.gov">agrestia@nhlbi.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis This Notice of Special Interest (NOSI) aims to accelerate a comprehensive understanding of the mechanisms of COVID-19-Associated Coagulopathy (CAC) which are provoked by vascular endothelial cell injury, hyperimmune responses, and hypercoagulability at genomic, molecular, and cellular levels. Knowledge obtained from such studies may be applied to the future design of early diagnostics and effective treatment for high-risk patients as well as enable CAC research findings to be applied to on-going COVID-19 clinical trials.</p>				
114402	<p><a href="#">Multisite Clinical Research: Leveraging Network Infrastructure to Advance Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities (U01 Clinical Trial Optional)</a></p>	National Institutes of Health/DHHS	PAR-23-037	07-May-2024	Not Specified
	<p>Contact Name Robert Tamburro, MD, MSc</p> <p>Contact Telephone 301-480-2619</p> <p>Contact Email <a href="mailto:NICHD-Network-ClinicalResearch@nih.gov">NICHD-Network-ClinicalResearch@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026</p> <p>Synopsis   The purpose of this funding opportunity announcement (FOA) is to invite applications for multisite clinical trials and observational studies developed in conjunction with NICHD Networks that will be conducted using NICHD-supported Network infrastructure. The goal of this FOA is to operationalize the previously reported NICHD guiding principles for multisite clinical trials delineated in Notice NOT-HD-19-034: To enhance the rigor and reproducibility of clinical trial protocols To promote greater availability of multisite clinical trial infrastructure to support trials from a wider range of investigators To facilitate data sharing and access to biospecimens to efficiently expand research capacity for all investigators To facilitate greater involvement of diverse populations in multisite clinical trials. Consequently, multisite clinical trials and observational studies conducted by and within the participating NICHD-supported Clinical Research Networks will be submitted as investigator-initiated, multi-Principal Investigator (PI) grant applications by any qualified investigator in the extramural community (including NICHD Network investigators) in conjunction with the respective NICHD Network Data Coordinating Center (DCC). It is the intent of this initiative to utilize the NICHD Clinical Research Network infrastructure in a manner that will promote the funding and support of the best science in a timely, transparent, equitable and cost-effective manner.</p>				
119254	<a href="#">Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-207	05-Jun-2024	Not Specified
	<p>Contact Name   Laura M. Rowland, Ph.D.</p> <p>Contact Telephone   301-480-8335</p> <p>Contact Email   <a href="mailto:laura.rowland@nih.gov">laura.rowland@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Synopsis   The goal of this Notice of Funding Opportunity (NOFO) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This NOFO uses the R01 mechanism, while the companion announcement PAR-23-208 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism.</p>				
117793	<a href="#">Interventions to Expand Cancer Screening and Preventive Services to ADVANCE Health in</a>	National Institutes	PAR-23-	05-Jun-2024	Not

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Populations that Experience Health Disparities (R01, Clinical Trial Required)</a>		of Health/DHHS 170		Specified
	<p>Contact Name   JoyAnn Courtney, Ph.D.</p> <p>Contact Telephone   301-402-3911</p> <p>Contact Email   <a href="mailto:joyann.courtney@nih.gov">joyann.courtney@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis   The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this R01 to solicit applications to address barriers and facilitators that impede use or uptake of cancer screening and preventive services in populations that experience health disparities. Interventions should include screening, preventive services, or other healthcare processes, including timely follow-up of abnormal findings, and referral to accessible care. Projects are encouraged to leverage collaborations with community partners and service providers. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community. Specific research interests of participating NIH ICs are detailed within. Projects are encouraged to leverage collaborations with community partners and service providers to promote or enhance existing interventions and/or adapt new combinations of evidence-based strategies. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community.</p>				
106063	<a href="#">Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Required)</a>		National Institutes of Health/DHHS PAR-21-272	07-May-2024	Not Specified
	<p>Contact Name   Lanay M. Mudd, Ph.D., FACSM</p> <p>Contact Telephone   301-594-9346</p> <p>Contact Email   <a href="mailto:lanay.mudd@nih.gov">lanay.mudd@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 12-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this program is to enhance</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

diversity in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see Notice of NIH's Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The MOSAIC K99/R00 program will provide independent NIH research support before and after this transition to help awardees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will be part of organized scientific cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity (UE5) grantees. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA PAR-21-271.

106062	<a href="#">Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-271	07-May-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Kenneth D. Gibbs, Jr., Ph.D.
Contact Telephone	
Contact Email	<a href="mailto:kenneth.gibbs@nih.gov">kenneth.gibbs@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 12-Jun-2024 , 07-Sep-2024
Synopsis	The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this program is to enhance diversity in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see Notice of NIH's Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The MOSAIC K99/R00 program will provide independent NIH research support before and after this transition to help awardees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will be part of organized scientific cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity (UE5) grantees. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA PAR-21-272.			
105617	<a href="#">Effectiveness of School-Based Health Centers to Advance Health Equity (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-21-287	07-May-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025</p> <p>Synopsis</p>	<p>The purpose of this Funding Opportunity Announcement is to support research that investigates the effectiveness of school-based health centers (SBHCs) as a health services care delivery model to address the needs of school-aged children from populations with health disparities (hence, underserved youth). The goals of this FOA are to support multidisciplinary research that investigates the effectiveness of SBHCs as a health services care delivery model to detect, manage, and prevent chronic illnesses that disproportionately burden underserved youth. The mechanisms of impact by which SBHCs improve the health of at-risk populations such as sexual and gender minority youth, immigrant youth, and youth who reside in rural areas are also a relevant focus for understanding effective models of SBHCs. Applications are expected to provide a conceptual model that describes hypothesized causal pathways by which SBHCs engage underserved youth to improve health outcomes and how SBHCs may complement (or reduce) the use of other services. Lessons learned through this initiative can help determine whether SBHCs can be adopted as a best practice care model to address the health services needs of underserved youth and if so, whether SBHCs given their accessibility to students can be an effective site of intervention to address disparities in chronic conditions, and behavioral, oral, and reproductive health of youth from underserved communities who lack access to health care.</p>			
105755	<a href="#">Investigator Initiated Research in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-254	05-Jun-2024	2,500,000 USD
	<p>Contact Name Daniel Gilchrist, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:daniel.gilchrist@nih.gov">daniel.gilchrist@nih.gov</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2024</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research that develops innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems.</p>				
105618	<a href="#">Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-294	05-Jun-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-945-7573</p> <p>Contact Email <a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2024 , 05-Oct-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite research grant applications (R01) for the development and use of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation in vivo. The motivation for this initiative is that much of current imaging research into the role of inflammation in cancer is largely based on in vitro and ex vivo methods with limited utilization of imaging approaches that could lead to significant new insights relevant to dynamic cancer and inflammation interactions. Utilization of molecular imaging probes in pre-clinical and clinical investigations for precise temporal resolution at the molecular and cellular level are valuable approaches for identification and characterization of in vivo inflammatory cellular physiology in cancers and of molecular changes in response to treatment. This FOA encourages applications that focus on developing integrated imaging approaches to interrogate the role of inflammation in cancer through strong cross-field collaboration between cancer basic science researchers and imaging scientists. These collaborations are expected to advance science and understanding of cancer inflammation interactions.</p>				
107429	<a href="#">Patient-Clinician Relationship: Improving Health Outcomes in Populations that Experience Health Care Disparities (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-22-064	05-Jun-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Larissa Aviles-Santa, MD, MPH</p> <p>Contact Telephone   301-827-6924</p> <p>Contact Email   <a href="mailto:avilessantal@nih.gov">avilessantal@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2024 , 05-Oct-2024</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to support innovative multi-disciplinary and multi-level (e.g., patient, clinician, interpersonal, health care system, community) research designed to understand how optimizing patient-clinician communication and relationship affects health care outcomes in patients from populations with health care disparities. In addition, this initiative will support research to (1) gain an understanding of how the Patient-Clinician Relationship (PCR) in the primary care and chronic disease care settings affects clinical and non-clinical health outcomes in populations that experience health disparities, and (2) identify best practices and interventions that build and improve PCR leading to better health outcomes and increased health equity.</p>				
114120	<a href="#">Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-046	07-May-2024	Not Specified
	<p>Contact Name   David M. Panchision, Ph.D.</p> <p>Contact Telephone   301-443-5288</p> <p>Contact Email   <a href="mailto:panchisiond@mail.nih.gov">panchisiond@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function, and aging in healthy and disease states. This FOA is intended to encourage the further development of projects with feasibility support for the line of investigation. Applicants proposing exploratory research at the early and conceptual stages of project development may instead wish to apply to the companion R21 FOA (PAR-23-047).</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
116911	<a href="#">Research With Activities Related to Diversity (ReWARD) (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-122	07-May-2024	Not Specified
	<p>Contact Name Alison Gammie</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:alison.gammie@nih.gov">alison.gammie@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis The NIH Research With Activities Related to Diversity (ReWARD) Program's overarching goal is to enhance the breadth and geographical location of research and research-related activities supported by NIH. The ReWARD program provides support for the health-related research of scientists who are making a significant contribution to Diversity, Equity, Inclusion, and Accessibility (DEIA) and who have no current NIH research project grant funding. The ReWARD program provides funding for both the scientific research and the DEIA activities of investigators. The grant will support scientific research in areas related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) and ongoing DEIA activities focused on enhancing diversity in the biomedical research enterprise within the United States and territories.</p>				
116476	<a href="#">Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-130	05-Jun-2024	Not Specified
	<p>Contact Name Katie M. Vance, Ph.D.</p> <p>Contact Telephone 301-435-6640</p> <p>Contact Email <a href="mailto:Katie.Vance@nih.gov">Katie.Vance@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities.			
116616	<a href="#">Notice of Special Interest (NOSI): Research Project Grants in Valvular Heart Disease (CAROL Act)</a>	National Institutes of Health/DHHS	NOT-HL-23-079	07-May-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Frank Evans, PhD 301-435-0510 <a href="mailto:evansf@nhlbi.nih.gov">evansf@nhlbi.nih.gov</a>  <a href="#">Link to program URL</a> 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 As part of the National Heart, Lung, and Blood Institute’s implementation of the Cardiovascular Advances in Research and Opportunities Legacy (CAROL) Act, this Notice of Special Interest is seeking R01 applications that propose research in valvular heart disease.			
123009	<a href="#">Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-24-088	05-Jun-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Enrique L. Michelotti, Ph.D. 301-443 5415 <a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a>  <a href="#">Link to program URL</a> 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 The purpose of this Notice of Funding Opportunities (NOFOs) is to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds ( validated hits ) for chemical optimization and bioassays for testing new analog compounds. Through this NOFO, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of National Institute of Mental Health (NIMH),			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		National Institute on Drug Abuse (NIDA), National Eye Institute (NEI), and/or National Institute on Aging (NIA) and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes.			
112444	<a href="#">HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K23 - Clinical Trial Required)</a>	National Institutes of Health/DHHS	PAS-22-207	12-Jun-2024	Not Specified

Contact Name | Lori Ducharme, Ph.D.  
 Contact Telephone | 301-827-6331  
 Contact Email | [Lori.Ducharme@nih.gov](mailto:Lori.Ducharme@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 12-Jun-2024 , 12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025

Synopsis | The purpose of this Mentored Patient-Oriented Research Career Development Award in Implementation Science for Substance Use Prevention and Treatment (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research from an implementation science perspective. These awards provide salary and research support for a sustained period of “protected time” (3-5 years) for an intensive, supervised career development experience leading to research independence in this area of specialization. Realizing the return on public investment in the development of evidence-based treatments and preventive interventions to address the ongoing overdose crisis depends on a cadre of skilled clinician researchers with expertise in implementation science, who can help move these interventions into routine clinical practice. Implementation science focuses on identifying modifiable barriers to the uptake and sustained use of evidence-based practices in real world clinical settings, and developing replicable and scalable strategies to overcome those barriers. While this field has grown rapidly over the past 15 years, there remain a limited number of independent clinician researchers with dual expertise in substance use and implementation science, limiting the field’s capacity to address persistent gaps in this area. There is a pressing need for a deeper bench of clinician researchers who can be called upon to meet ongoing and emerging implementation challenges in the substance use field. This Funding Opportunity Announcement (FOA) will support early career investigators who have foundational clinical training in substance use prevention or treatment and/or co-occurring mental illness, and will provide support and protected time to acquire training and research experience in implementation science. Development and execution of an independent NIH-defined clinical trial applying implementation science methods to patient-oriented research in one or more of the four domains of the HHS Overdose Prevention Strategy (prevention; evidence-based addiction treatment; harm reduction; or recovery research) is required. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, should consult the NIH Research Career Development Awards website for alternative funding opportunities.</p>					
120821	<a href="#">RFA-HD-24-007 -- Understanding and Mitigating Health Disparities Experienced by People with Disabilities Caused by Ableism (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-HD-24-007	07-May-2024	2,499,995 USD
	<p>Contact Name   Toyin Ajisafe, PhD</p> <p>Contact Telephone   301-827-9242</p> <p>Contact Email   <a href="mailto:toyin.ajisafe@nih.gov">toyin.ajisafe@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis   The goal of this NOFO is to encourage research to understand the impact of ableism on health outcomes. Research on the underlying mechanisms by which ableism adversely influences the health of persons with disabilities (PWD), as well as developing and/or testing interventions at a community or health systems level to mitigate adverse health effects of ableism are high priority.</p>				
120869	<a href="#">Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for Alcohol, Tobacco, and Other Drugs (ATOD) Use and Misuse in Adult Populations That Experience Health Disparities (R01, Clinical Trial Required)</a>	National Institutes of Health/DHHS	PAR-23-270	05-Jun-2024	Not Specified
	<p>Contact Name   Denise Stredrick, Ph.D.</p> <p>Contact Telephone   301-402-9749</p> <p>Contact Email   <a href="mailto:denise.stredrick@nih.gov">denise.stredrick@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027</p> <p>Synopsis   The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICOs) are issuing this NOFO seeking applications to test innovative approaches to implementing SBIRT/P for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities. SBIRT/P, (a term used for</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>purposes of this funding announcement), involves screening individuals for risk of ATOD use and misuse, briefly intervening with a conversation about harmful substance use, and referring individuals for treatment or preventive services, as needed. Proposed research should include prospective tests of SBIRT/P and should leverage collaborations with healthcare and community partners Specific research interests of participating NIH ICOs are detailed within.</p>			
121246	<a href="#">Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-292	05-Jun-2024	Not Specified
	<p>Contact Name   David Dean Jr., Ph.D., M.S.            Contact Telephone   240-276-8703            Contact Email   <a href="mailto:bconnole@mail.nih.gov">bconnole@mail.nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026            Synopsis   Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) intends to support the rigorous assessment of barriers to quality cancer treatment and follow-up care for sexual and gender minority (SGM) cancer survivors. This funding opportunity is intended to address a critical need for improved care delivery and outcomes for SGM cancer survivors. The goal is to address the disease burden in an underserved and understudied population that is at higher risk of poorer health outcomes. The NCI solicits proposals for observational and/or interventional studies of SGM survivors designed to understand barriers and/or improve care and outcomes for SGM people with cancer, using interoperable sexual orientation and gender identity (SOGI) data collection in cancer care settings, where appropriate.</p>				
120817	<a href="#">Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-244	05-Jun-2024	Not Specified
	<p>Contact Name   David Berrigan            Contact Telephone   240-276-6752            Contact Email   <a href="mailto:berrigad@mail.nih.gov">berrigad@mail.nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026            Synopsis   This Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>increasing awareness of the relationship between alcohol and cancer risk, understanding and changing social norms related to alcohol consumption, developing and/or evaluating alcohol policy approaches, and the development, testing, and implementation of population-level interventions to reduce alcohol-related cancer risk. Applications that address multiple levels of consumption, such as moderate and heavy drinking, are of particular interest, as well as those focusing on alcohol use disorder (AUD) from the perspective of cancer prevention and control. Proposals addressing understudied areas are encouraged, as is attention to underrepresented minority (URM) populations experiencing cancer and alcohol-related disparities such as American Indian, Alaskan Native, and sexual and gender minority populations.</p>				
109791	<a href="#">Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-137	07-May-2024	1,250,000 USD
	<p>Contact Name: Julia Zehr, Ph.D.            Contact Telephone: 301-443-1617            Contact Email: <a href="mailto:Zehrj@mail.nih.gov">Zehrj@mail.nih.gov</a>            Sponsor Website:            Program URL: <a href="#">Link to program URL</a>            Deadline Dates (ALL): 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis: The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (<a href="http://www.abcdstudy.org">www.abcdstudy.org</a>). This FOA uses the R01 grant mechanism, whereas its companion FOA, PAR-22-138, seeks shorter, higher-risk R21 grant applications.</p>				
109941	<a href="#">Focused Technology Research and Development (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-127	07-May-2024	Not Specified
	<p>Contact Name: Fei Wang, Ph.D.            Contact Telephone:            Contact Email: <a href="mailto:wangf@mail.nih.gov">wangf@mail.nih.gov</a>            Sponsor Website:            Program URL: <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL) | 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025

Synopsis | This Funding Opportunity Announcement (FOA) supports projects relevant to the NIGMS mission or those of other NIH institutes or Centers (ICs) participating in the FOA that focus solely on the development of technologies with the potential to enable acquisition of biomedical knowledge. Projects should be justified in terms of technical innovation and utility of such technical innovation for impacting future biomedical research. Outcomes or products of the proposed project should significantly advance the current state of the art and be sufficiently characterized for application in addressing a broad range of biomedical research questions. These outcomes may include, but are not limited to: laboratory instruments and other devices, algorithms and software, chemical reagents and processes, biological molecules or systems that have been modified by human intervention to become research tools. The goal of this FOA is to support the development of technologies with demonstrated proof-of-concept that have remaining significant technical challenges to full implementation and broad utility. As such, applications should not propose to test specific biological questions. Applications proposing to test specific biological questions are not responsive to this FOA and will be administratively withdrawn without review. Applications with a focus on optimization, hardening, or obvious extrapolations of established technology will be a lower priority for funding.

120387	<a href="#">Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-254	05-Jun-2024	1,750,000 USD
--------	--	------------------------------------	------------	-------------	---------------

Contact Name | Melissa Rotunno, Ph.D.  
 Contact Telephone | 240-276-7245  
 Contact Email | [rotunnom@mail.nih.gov](mailto:rotunnom@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)

Deadline Dates (ALL) | 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026

Synopsis | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
120101	<a href="#">Social Disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-238	05-Jun-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Jovier Evans, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-443-6328</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:jevans1@mail.nih.gov">jevans1@mail.nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>05-Jun-2024 , 05-Oct-2024 , 02-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this Notice of Funding Opportunity (NOFO) is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental. This NOFO solicits R01 applications, while the companion announcement PAR-23-239 solicits R21 applications. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 mechanism.</td> </tr> </table>					Contact Name	Jovier Evans, Ph.D.	Contact Telephone	301-443-6328	Contact Email	<a href="mailto:jevans1@mail.nih.gov">jevans1@mail.nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 02-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental. This NOFO solicits R01 applications, while the companion announcement PAR-23-239 solicits R21 applications. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 mechanism.
Contact Name	Jovier Evans, Ph.D.																		
Contact Telephone	301-443-6328																		
Contact Email	<a href="mailto:jevans1@mail.nih.gov">jevans1@mail.nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 02-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026																		
Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental. This NOFO solicits R01 applications, while the companion announcement PAR-23-239 solicits R21 applications. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 mechanism.																		
120715	<a href="#">Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-245	05-Jun-2024	1,000,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Allison Dennis, PhD</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-827-9721</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:allison.dennis@nih.gov">allison.dennis@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this Notice of Funding Opportunity (NOFO) is to advance the development of novel informatics and data science approaches that can help individuals understand and improve their health through actionable insights. The NLM and participating institutes listed in this NOFO seek applications that further the science of personal health informatics by providing meaningful and actionable insights to individuals through innovative personal health data collection, integration, analysis, and personalized risk assessments and interpretation. Applications seeking to advance the understanding of how informatics tools, systems, and platforms can best present the results, interpretation, and limitations of personalized</td> </tr> </table>					Contact Name	Allison Dennis, PhD	Contact Telephone	301-827-9721	Contact Email	<a href="mailto:allison.dennis@nih.gov">allison.dennis@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to advance the development of novel informatics and data science approaches that can help individuals understand and improve their health through actionable insights. The NLM and participating institutes listed in this NOFO seek applications that further the science of personal health informatics by providing meaningful and actionable insights to individuals through innovative personal health data collection, integration, analysis, and personalized risk assessments and interpretation. Applications seeking to advance the understanding of how informatics tools, systems, and platforms can best present the results, interpretation, and limitations of personalized
Contact Name	Allison Dennis, PhD																		
Contact Telephone	301-827-9721																		
Contact Email	<a href="mailto:allison.dennis@nih.gov">allison.dennis@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026																		
Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to advance the development of novel informatics and data science approaches that can help individuals understand and improve their health through actionable insights. The NLM and participating institutes listed in this NOFO seek applications that further the science of personal health informatics by providing meaningful and actionable insights to individuals through innovative personal health data collection, integration, analysis, and personalized risk assessments and interpretation. Applications seeking to advance the understanding of how informatics tools, systems, and platforms can best present the results, interpretation, and limitations of personalized																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		assessments for the benefit of individuals are encouraged. Applications should include end user engaged approaches and real-world evaluation to inform the design of generalizable, reusable, and scalable personal health informatics tools, systems, and platforms for the benefit of individuals in understanding and improving their health.			
110112	<a href="#">Leveraging Health Information Technology (Health IT) to Address and Reduce Health Care Disparities (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-22-145	07-May-2024	Not Specified
	Contact Name	Yewande A. Oladeinde, Ph.D.			
	Contact Telephone	301-402-4307			
	Contact Email	<a href="mailto:beda.jean-francois@nih.gov">beda.jean-francois@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025			
	Synopsis	This funding opportunity announcement (FOA) seeks to support research that examines the impact of leveraging health information technology (health IT) to reduce disparities in access to and utilization of health care services, patient-clinician communication, and health outcomes for populations that experience health disparities in the U.S.			
110794	<a href="#">Notice of Special Interest (NOSI): Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP)</a>	National Institutes of Health/DHHS	NOT-AI-22-042	07-May-2024	Not Specified
	Contact Name	Marina Protopopova, Ph.D.			
	Contact Telephone	301-761-7653			
	Contact Email	<a href="mailto:marina.protopopova@niaid.nih.gov">marina.protopopova@niaid.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025			
	Synopsis	The purpose of this Notice is to encourage new applications to support further development of a diverse and comprehensive portfolio of SR/LA products for prevention and treatment of HIV. SR/LA antiretroviral products will have a minimum window of protection of three (3) months from either a single dosing (injection, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.) to reflect current state of SR/LA drug market for HIV treatment or prevention.			
110513	<a href="#">Notice of Special Interest (NOSI): High Priority Areas in Genetics, Epigenetics, and Developmental Neuroscience Branch in the Division of Neuroscience and Behavior</a>	National Institutes of Health/DHHS	NOT-DA-23-004	07-May-2024	Not Specified



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Jonathan D. Pollock, Ph.D.</p> <p>Contact Telephone   301-435-1309</p> <p>Contact Email   <a href="mailto:jpollock@mail.nih.gov">jpollock@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</p> <p>Synopsis   The mission of the Division of Neuroscience and Behavior (DNB) is to discover, facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of drug addiction across the lifespan and to guide treatment strategies. The Genetics, Epigenetics, and Development (GED) Branch within DNB supports research on the genetics, epigenetics, and developmental mechanisms that underlie addiction and substance use disorders (SUD).</p>				
123847	<a href="#">Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD &amp; other ADRDs (R01 - Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-24-148	04-Jun-2024	2,500,000 USD
	<p>Contact Name   Linda McGavern, PhD</p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:mcgavernlm@ninds.nih.gov">mcgavernlm@ninds.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   04-Jun-2024 , 04-Oct-2024</p> <p>Synopsis   This Notice of Funding Opportunity (NOFO) supports studies establishing deeper mechanistic insights and causal cellular and molecular relationships between TDP-43 pathology and clinical phenotypic outcomes. Additionally, it requires comparisons between at least two TDP-43 proteinopathies, one of which must be an Alzheimer’s Disease-Related Dementia (ADRD), such as, but not limited to, Limbic-predominant Age-related TDP-43 Encephalopathy (LATE), with or without Alzheimer’s disease neuropathological change (AD-NC), or Frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP), to further understand distinct and overlapping mechanisms in these syndromes.</p>				
106925	<a href="#">Notice of Special Interest (NOSI): Promoting Research To Understand Vascular Contributions to Cognitive Impairment and Dementia (VCID)</a>	National Institutes of Health/DHHS	NOT-HL-23-002	07-May-2024	Not Specified
	<p>Contact Name   Jue Chen, Ph.D.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-435-0550</p> <p>Contact Email   <a href="mailto:jue.chen@nih.gov">jue.chen@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis   The purpose of this Notice is to inform potential applicants about an area of special interest to NHLBI, NINDS and NIA in research to understand mechanisms of vascular contributions to cognitive impairment and dementia (VCID) and to develop new approaches for the treatment of VCID.</p>				
111036	<a href="#">Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-22-105	07-May-2024	Not Specified
	<p>Contact Name   Gila Neta, Ph.D.</p> <p>Contact Telephone   240-276-6785</p> <p>Contact Email   <a href="mailto:gila.neta@nih.gov">gila.neta@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.</p>				
111616	<a href="#">Notice of Special Interest (NOSI): NIH Research Project Grants on Down Syndrome (R01 for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome) Project</a>	National Institutes of Health/DHHS	NOT-OD-22-123	07-May-2024	Not Specified
	Contact Name   Charlene Schramm, PhD				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-402-3739</p> <p>Contact Email   <a href="mailto:schrammc@nih.gov">schrammc@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025</p> <p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to support research project grant (R01) applications that are focused on Down syndrome and that meet programmatic objectives for the INCLUDE Project. Sharing of resources and effective communication of outputs of appropriate interest to broader communities are a high priority of the INCLUDE Project. Applicants responding to this NOSI are strongly encouraged to describe plans for rapid sharing of data and results as well as innovative data analytics approaches (see Goal 3, NIH Strategic Plan For Data Science).</p>				
117550	<p><a href="#">Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)</a></p>	National Institutes of Health/DHHS	PAR-23-164	07-May-2024	Not Specified
	<p>Contact Name   Enrique Michelotti, Ph.D.</p> <p>Contact Telephone   301-443-5415</p> <p>Contact Email   <a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis   This Funding Opportunity Announcement (NOFO) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain and the incorporation of pilot or clinical feasibility evaluation from previously collected data in pre-clinical studies. These studies are expected to provide the requisite data needed to advance promising PET ligands for use in clinical research. Projects proposing only preclinical animal studies should consider the companion NOFO (PAR-23-164).</p>				
117551	<p><a href="#">Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)</a></p>	National Institutes of Health/DHHS	PAR-23-165	07-May-2024	Not Specified
	<p>Contact Name   Enrique Michelotti, Ph.D.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-443-5415</p> <p>Contact Email   <a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis   This Notice of Funding Opportunity (NOFO) invites research grant applications that propose the preclinical development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in rodent and nonhuman primate brain and incorporation of pilot or clinical feasibility evaluation in pre-clinical studies and appropriate model development. Projects proposing clinical assessments of novel radioligands should respond to NOFO (PAR-23-164).</p>				
123846	<a href="#">Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-24-147	04-Jun-2024	2,500,000 USD
	<p>Contact Name   Linda McGavern, PhD</p> <p>Contact Telephone</p> <p>Contact Email   <a href="mailto:mcgavernlm@ninds.nih.gov">mcgavernlm@ninds.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   04-Jun-2024 , 04-Oct-2024</p> <p>Synopsis   This Notice of Funding Opportunity (NOFO) supports investigations with a minimum of two Alzheimer’s Disease-Related Dementias (ADRD) co-pathologies (e.g., tau, alpha-synuclein, TDP-43, TMEM106B, vascular), with or without risk factors and co-morbidities, in the same model system to identify interactions and cellular and molecular mechanisms to determine how, whether, and when these interactive multi-pathology mechanisms drive worsening pathophysiology and clinical phenotypic outcomes, such as cognitive, behavioral, or functional impairment.</p>				
099859	<a href="#">Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)</a>	National Institutes of Health/DHHS	NOT-HL-20-814	07-May-2024	Not Specified
	<p>Contact Name   Guofei Zhou, PhD</p> <p>Contact Telephone   301-827-7825</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email [guofei.zhou@nih.gov](mailto:guofei.zhou@nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024  
 Synopsis The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of NHLBI in research to understand host resilience as a critical determinant of outcomes in acute respiratory distress syndrome (ARDS) /acute lung injury (ALI).

109172	<a href="#">Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-085	05-Jun-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name Avi Rasooly, PhD  
 Contact Telephone 240-276-6196  
 Contact Email [rasoolya@mail.nih.gov](mailto:rasoolya@mail.nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025  
 Synopsis This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaeobacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis. This funding opportunity is part of a broader NCI-sponsored research on microbial based cancer therapy.

115307	<a href="#">Notice of Special Interest (NOSI): Understanding Sudden Death in the Young Through Research</a>	National Institutes of Health/DHHS	NOT-HL-22-040	07-May-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name Kristin M. Burns, MD  
 Contact Telephone 301-594-6859

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:kristin.burns@nih.gov">kristin.burns@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</p> <p>Synopsis This Notice of Special Interest (NOSI) highlights interest in receiving grant applications focused on mechanistic, genetic, and other studies to evaluate causes and consequences of, and risk factors for sudden death in the young (SDY). Studies are required to use phenotypic data and/or DNA samples and/or associated sequence data from the NIH/CDC Sudden Death in the Young (SDY) Case Registry as foundations for their research. Studies may use SDY Case Registry phenotypic data and/or samples and/or sequence data alone or in combination with other cohorts. Results of such studies are required to adhere to the NIH Data Sharing Policy so that the data is disseminated widely and provides an evidence base to advance discussions about screening and prevention of SDY.</p>				
116310	<a href="#">Notice of Special Interest (NOSI): Enhancing Research on Deciphering Mechanisms of COVID-19-Associated Coagulopathy</a>	National Institutes of Health/DHHS	NOT-HL-23-003	07-May-2024	Not Specified
	<p>Contact Name Anthony Agresti</p> <p>Contact Telephone 301-827-8014</p> <p>Contact Email <a href="mailto:agrestia@nhlbi.nih.gov">agrestia@nhlbi.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis This Notice of Special Interest (NOSI) aims to accelerate a comprehensive understanding of the mechanisms of COVID-19-Associated Coagulopathy (CAC) which are provoked by vascular endothelial cell injury, hyperimmune responses, and hypercoagulability at genomic, molecular, and cellular levels. Knowledge obtained from such studies may be applied to the future design of early diagnostics and effective treatment for high-risk patients as well as enable CAC research findings to be applied to on-going COVID-19 clinical trials.</p>				
122108	<a href="#">RFA-AI-23-061 -- Long-Acting Drug Delivery Systems for ART Optimization in Children Living with HIV-1 II (LADDS II) (R61/R33 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-AI-23-061	07-May-2024	5,450,000 USD
	Contact Name Tania B. Lombo Rodriguez, Ph.D.				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-761-7612</p> <p>Contact Email   <a href="mailto:tania.lombo@mail.nih.gov">tania.lombo@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis   The purpose of this Notice of Funding Opportunity (NOFO) is to accelerate the development of safe and effective long-acting drug delivery systems for improved, simplified treatment of HIV-1 in children. This NOFO invites applicants engaged in the development of existing long-acting platforms at early stages of development stages to perform specific preclinical activities that enable product optimization and accelerated translation to HIV-infected children. Collaborative research partnerships with industry are required.</p>				
114710	<p><a href="#">RFA-NS-22-024 -- HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research to Promote Diversity (K99/R00 Independent Basic Experimental Studies with Humans Required)</a></p>	National Institutes of Health/DHHS	RFA-NS-22-024	11-Jun-2024	Not Specified
	<p>Contact Name   DP Mohapatra, Ph.D.</p> <p>Contact Telephone   301-496-9964</p> <p>Contact Email   <a href="mailto:dp.mohapatra@nih.gov">dp.mohapatra@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   11-Jun-2024 , 11-Oct-2024 , 11-Feb-2025</p> <p>Synopsis   The purpose of this NIH HEAL Initiative® Pathway to Independence Award (K99/R00) program is to support a cohort of new and well-trained, independent investigators from diverse backgrounds (e.g. see NOT-OD-20-031, Notice of NIH’s Interest in Diversity) conducting Pain and/or SUD research, in order to promote a diverse pool of available independent investigators working in research areas supported by the NIH HEAL Initiative®. This program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative®. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

114711	<a href="#">RFA-NS-22-025 -- HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-NS-22-025	11-Jun-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	DP Mohapatra, Ph.D.
Contact Telephone	301-496-9964
Contact Email	<a href="mailto:dp.mohapatra@nih.gov">dp.mohapatra@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	11-Jun-2024 , 11-Oct-2024 , 11-Feb-2025
Synopsis	The purpose of this NIH HEAL Initiative® Pathway to Independence Award (K99/R00) program is to support a cohort of new and well-trained, independent investigators from diverse backgrounds (e.g. see NOT-OD-20-031, Notice of NIH's Interest in Diversity) conducting Pain and/or SUD research, in order to promote a diverse pool of available independent investigators working in research areas supported by the NIH HEAL Initiative®. This program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative®. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, an ancillary study to a clinical trial, or an independent Basic Experimental Studies with Humans (BESH). Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing an independent BESH as lead investigator, should apply to the companion FOA (RFA-NS-22-024).

106064	<a href="#">Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Basic Experimental Studies with Humans Required (BESH))</a>	National Institutes of Health/DHHS	PAR-21-273	07-May-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Lanay M. Mudd, Ph.D., FACSM
--------------	-----------------------------



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone | 301-594-9346  
 Contact Email | [lanay.mudd@nih.gov](mailto:lanay.mudd@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 07-May-2024 , 12-Jun-2024 , 07-Sep-2024

Synopsis | The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this program is to enhance diversity in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see Notice of NIH's Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The MOSAIC K99/R00 program will provide independent NIH research support before and after this transition to help awardees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will be part of organized scientific cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity (UE5) grantees. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

117692	<a href="#">RFA-MH-23-331 -- BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-MH-23-331	13-Jun-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name | James Churchill, Ph.D.  
 Contact Telephone | 301-326-8800  
 Contact Email | [BRAINDIVERSITYK99R00@nih.gov](mailto:BRAINDIVERSITYK99R00@nih.gov)

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 13-Jun-2024 , 11-Oct-2024 , 13-Feb-2025 , 13-Jun-2025 , 15-Oct-2025 , 13-Feb-2026</p> <p>Synopsis The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds, including those from underrepresented groups in the biomedical and behavioral sciences, in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to assist awardees in launching independent research careers. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this Notice of Funding Opportunity (NOFO) are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (RFA-MH-22-330).</p>				
102740	<a href="#">Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-124	20-Jun-2024	750,000 USD
	<p>Contact Name Becky Roof, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email <a href="mailto:rebecca.roof@nih.gov">rebecca.roof@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 20-Jun-2024 , 21-Oct-2024</p> <p>Synopsis This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.</p>				
110969	<a href="#">National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U19 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-22-144	25-Jun-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Linda Brady, Ph.D. 301-443-3563 <a href="mailto:lbrady@mail.nih.gov">lbrady@mail.nih.gov</a>  <a href="#">Link to program URL</a> 25-Jun-2024 , 25-Oct-2024 , 24-Feb-2025  Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to accelerate innovative drug and device therapies translation from discovery to early human studies. Studies appropriate for this FOA will develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders or alcohol use disorder (AUD); develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative candidates for mental disorders; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders or AUD. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or or AUD, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. Projects seeking support for a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach should consider the companion FOA (PAR-22-143). This FOA will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral vector-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). This FOA supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies.
--	---

110968	<a href="#">National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-22-143	25-Jun-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website	Linda Brady, Ph.D. 301-443-3563 <a href="mailto:lbrady@mail.nih.gov">lbrady@mail.nih.gov</a>  
---	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 25-Jun-2024 , 25-Oct-2024 , 24-Feb-2025</p> <p>Synopsis                      The purpose of this Funding Opportunity Announcement (FOA) is to accelerate innovative drug and device therapies translation from discovery to early human studies. Studies appropriate for this FOA will develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders or alcohol use disorder (AUD); develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative candidates for mental disorders or AUD; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders or AUD. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or AUD, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. Projects seeking support for a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach should consider the companion FOA (PAR-22-144) This FOA will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral vector-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). This FOA supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies.</p>				
110865	<a href="#">Notice of Special Interest (NOSI): Understanding the Basic Mechanisms of Immune-related Adverse Events (irAEs) in Cancer Immunotherapy</a>	National Institutes of Health/DHHS	NOT-CA-22-063	07-May-2024	Not Specified
	<p>Contact Name Yin Liu, Ph.D.</p> <p>Contact Telephone 240-276-6251</p> <p>Contact Email <a href="mailto:liuy@mail.nih.gov">liuy@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024</p> <p>Synopsis                      The overall goal of this Notice of Special Interest (NOSI) is to promote mechanistic research aimed at better understanding the pathophysiology of immune-related adverse events (irAEs). It is anticipated that the mechanistic research supported</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>through this NOSI will build the foundational knowledge which will ultimately lead to better strategies to predict, prevent and/or ameliorate toxicities that can arise as a consequence of current immunotherapeutic regimens, and improve treatment outcomes. The proposed research can be basic or translational but should be focused on revealing the mechanisms underlying irAEs. Single investigators and/or multidisciplinary teams with relevant expertise in the research area proposed and/or patient characterization and selection are encouraged to apply.</p>				
112346	<a href="#">Notice of Special Interest (NOSI): Research on the Health of Sexual and Gender Minority (SGM)</a>	National Institutes of Health/DHHS	NOT-MD-22-012	08-Apr-2024	Not Specified
	<p>Contact Name   Crystal L. Barksdale, PhD MPH            Contact Telephone   301-827-4228            Contact Email   <a href="mailto:crystal.barksdale@nih.gov">crystal.barksdale@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 06-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 20-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 09-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025            Synopsis   This Notice calls for research on the health of sexual and gender minority populations. SGM populations include, but are not limited to, individuals who identify as lesbian, gay, bisexual, asexual, transgender, Two-Spirit, queer, and/or intersex. Individuals with same-sex or -gender attractions or behaviors and those with a difference in sex development are also included. These populations also encompass those who do not self-identify with one of these terms but whose sexual orientation, gender identity or expression, or reproductive development is characterized by non-binary constructs of sexual orientation, gender, and/or sex.</p>				
112751	<a href="#">Notice of Special Interest (NOSI): HEAL Initiative: Clinical Translation of Diagnostic and Therapeutic Devices via Blueprint MedTech</a>	National Institutes of Health/DHHS	NOT-NS-23-002	20-Jun-2024	Not Specified
	<p>Contact Name   Eric Hudak, Ph.D.            Contact Telephone   301-496-1779            Contact Email   <a href="mailto:NINDS-Devices@nih.gov">NINDS-Devices@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   20-Jun-2024</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis	<p>This Notice of Special Interest (NOSI) encourages the translation of the novel neurotechnologies, funded through the Helping to End Addiction Long-Term (HEAL) Initiative and overseen by the NIH Blueprint MedTech program. Academic institutions and Small Business Concerns (SBCs) are encouraged to submit grant applications that propose non-clinical validation for subsequent clinical feasibility studies of medical devices for the diagnosis and treatment of pain and opioid use disorder (OUD). Applications supporting the development and translation of groundbreaking neurotechnologies that fit within the mission of the HEAL Initiative are encouraged.</p>
----------	--

112471	<a href="#">Notice of Special Interest (NOSI): Single-Cell Level Spatiotemporal Mapping of Dental and Craniofacial Embryogenesis</a>	National Institutes of Health/DHHS	NOT-DE-22-003	07-May-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Kathryn Stein, PhD</p> <p>301-827-4653</p> <p><a href="mailto:kathryn.stein@nih.gov">kathryn.stein@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025</p> <p>The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage research that applies cutting edge imaging and high-throughput ‘omics approaches at the single-cell level to understand the complex spatiotemporal context of the developing dental and craniofacial tissues in the embryo.</p>
---	--

122207	<a href="#">Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-293	18-Jun-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Dave Kaufman</p> <p>301-402-4997</p> <p><a href="mailto:dave.kaufman@nih.gov">dave.kaufman@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>18-Jun-2024 , 21-Oct-2024 , 20-Feb-2025 , 17-Jun-2025 , 20-Oct-2025 , 19-Feb-2026 , 18-Jun-2026 , 20-Oct-2026</p> <p>This Notice of Funding Opportunity (NOFO) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genetic or genomic research. Applications may propose studies using</p>
---	---

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

either single or mixed methods. Approaches may include but are not limited to empirical qualitative and quantitative methods, and conceptual, legal, and normative analyses. Applied research designed to address ELSI issues in genetics and genomics will also be considered responsive. Direct engagement with communities and other interested groups is encouraged, but not required. Plan for Enhancing Diverse Perspectives The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: Transdisciplinary research projects and collaborations among researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). Individual applications and partnerships that enhance geographic and regional heterogeneity. Investigators and teams composed of researchers at different career stages. Participation of individuals from diverse backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. Opportunities to enhance the research environment to benefit early- and mid-career investigators. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

122256	<a href="#">Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-294	18-Jun-2024	275,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Dave Kaufman
Contact Telephone	301-402-4997
Contact Email	<a href="mailto:dave.kaufman@nih.gov">dave.kaufman@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	18-Jun-2024 , 21-Oct-2024 , 20-Feb-2025 , 17-Jun-2025 , 20-Oct-2025 , 19-Feb-2026 , 18-Jun-2026 , 20-Oct-2026
Synopsis	This Notice of Funding Opportunity (NOFO) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genetic or genomic research. Applications may

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

propose studies using either single or mixed methods, that break new ground, extend previous discoveries in new directions, or develop preliminary data in preparation for larger studies. Approaches may include but are not limited to empirical qualitative and quantitative methods, and conceptual, legal, and normative analyses. Applied research designed to address ELSI issues in genetics and genomics will also be considered responsive. Direct engagement with communities and other stakeholders is encouraged, but not required.

122258	<a href="#">Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-295	18-Jun-2024	100,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Dave Kaufman
Contact Telephone	301-402-4997
Contact Email	<a href="mailto:dave.kaufman@nih.gov">dave.kaufman@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	18-Jun-2024 , 21-Oct-2024 , 20-Feb-2025 , 17-Jun-2025 , 20-Oct-2025 , 19-Feb-2026 , 18-Jun-2026 , 20-Oct-2026
Synopsis	This Notice of Funding Opportunity (NOFO) invites Small Research Grant (R03) applications that propose to study the ethical, legal and social implications (ELSI) of human genetic or genomic research. These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data. Applications may propose studies using either single or mixed methods. Applied research designed to address ELSI issues in genetics and genomics will also be considered responsive. Direct engagement with communities and other stakeholders is encouraged, but not required.

106107	<a href="#">Blueprint Medtech: Small Business Translator (U44 - Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-21-282	20-Jun-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Leonardo Angelone, Ph.D
Contact Telephone	
Contact Email	<a href="mailto:Blueprint-MedTech@nih.gov">Blueprint-MedTech@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	20-Jun-2024



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	<p>Synopsis</p>	<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from Small Business Concerns (SBCs) to pursue translational activities and limited-size clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities leading to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use.</p> <p>This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Participants in Blueprint MedTech receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants to receive assistance with specialty areas including regulatory, reimbursement, intellectual property, commercialization, and strategic partnerships. Participants can also augment their project with NIH contract research organizations (CROs) that specialize in large animal testing, sterilization testing, biocompatibility assessment, manufacturing, and medical monitoring. SBCs developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or any of the companion opportunities. For more information see BP MedTech website: <a href="https://neuroscienceblueprint.nih.gov/neurotherapeutics/blueprint-medtech">https://neuroscienceblueprint.nih.gov/neurotherapeutics/blueprint-medtech</a></p>			

106116	<a href="#">Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-21-315	20-Jun-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Nick Langhals, PhD
Contact Telephone	301-496-1779
Contact Email	<a href="mailto:NINDS-Devices@nih.gov">NINDS-Devices@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	20-Jun-2024

		<p>Synopsis</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and clinical feasibility studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent clinical feasibility study. The clinical study is expected to provide information about the device</p>			
--	--	---	--	--	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Participants in Blueprint MedTech receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants to receive assistance with specialty areas including regulatory, reimbursement, intellectual property, commercialization, and strategic partnerships. Participants can also augment their project with NIH contract research organizations that specialize in large animal testing, sterilization testing, biocompatibility assessment, manufacturing, and medical monitoring. Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or any of the companion opportunities. For more information see BP MedTech website: <https://neuroscienceblueprint.nih.gov/neurotherapeutics/blueprint-medtech>

108288	<a href="#">Notice of Special Interest (NOSI): BRAIN Initiative: Translation of Groundbreaking Technologies from Early-stage Development through Early Clinical Study via Blueprint MedTech</a>	National Institutes of Health/DHHS	NOT-NS-22-052	20-Jun-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name | Nick Langhals, PhD  
 Contact Telephone | 301-496-1779  
 Contact Email | [NINDS-Devices@nih.gov](mailto:NINDS-Devices@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 20-Jun-2024

Synopsis | This Notice of Special Interest (NOSI) encourages the translation of the novel neurotechnologies, funded through the Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative and overseen by the NIH Blueprint MedTech program. Academic and Small Business Concerns (SBCs) are encouraged to submit grant applications that propose non-clinical validation for subsequent clinical feasibility studies. Applications supporting the development and translation of groundbreaking neurotechnologies that fit within the mission of the BRAIN Initiative are encouraged.

111618	<a href="#">Notice of Special Interest (NOSI): Developing Academic Research Enhancement Award (AREA) and Research Enhancement Award Program (REAP) for Institutions With an Emphasis On Down Syndrome Research (R15 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	NOT-OD-22-136	07-May-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name | Sujata Barhan, Ph.D.  
 Contact Telephone | 301-435-0471

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:sujata.bardhan@nih.gov">sujata.bardhan@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 25-Jun-2024 , 07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The NIH Investigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). This Notice of Special Interest (NOSI) announces NIH support for development of Academic Research Enhancement Award (AREA) and Research Enhancement Award Program (REAP) applications to support small scale basic and translational research grants that meet programmatic objectives of the INCLUDE project at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate and/or graduate students and enhancing the research environment at applicant institutions. Eligible institutions must award NIH-relevant baccalaureate or advanced degrees in health professions and have received less than \$6 million per year of NIH support (total costs) in 4 of the last 7 fiscal years. In this FOA, a college is a stand-alone entity and not a component of a university system. The goal of this NOSI is also to build a pathway of meritorious undergraduate and graduate students engaged in Down syndrome research.</p>				
103023	<a href="#">Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-166	05-Jun-2024	2,495,000 USD
	<p>Contact Name Miguel Ossandon MS</p> <p>Contact Telephone 240-276-5714</p> <p>Contact Email <a href="mailto:ossandom@mail.nih.gov">ossandom@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines "innovation" as likelihood to deliver a new capability to end users.

113804	<a href="#">Notice of Special Interest (NOSI): Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NICHD Populations of Interest</a>	National Institutes of Health/DHHS	NOT-HD-22-038	07-May-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Elyse R. Grossman 240-551-3628 <a href="mailto:elyse.grossman@nih.gov">elyse.grossman@nih.gov</a>  <a href="#">Link to program URL</a> 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 This notice informs applicants of an expansion to the NOT-HD-22-038 "Notice of Special Interest (NOSI): Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NICHD Populations of Interest" to include research priority areas for the National Institute on Drug Abuse (NIDA). The National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to announce that research on the effects of: emerging and evolving public health crises; and/or policy changes on the health, development, and well-being of populations of interest to the NIDA is of high program priority. The NIDA populations of interest include neonates, infants, children, adolescents, young adults, adults, and older adults, people using or misusing substances, people with substance use disorders, as well as the families of these individuals. The NIDA supports research on the impact of policy in understanding and addressing substance use risk and behavior across the life span. For information on the NIDA Strategic Goals and Mission, see <a href="https://nida.nih.gov/about-nida/strategic-plan/nidas-mission">https://nida.nih.gov/about-nida/strategic-plan/nidas-mission</a> .
--	---

116056	<a href="#">Notice of Special Interest (NOSI): Mortality of Adolescents, Young Adults, and Other NICHD Priority Populations in the United States</a>	National Institutes of Health/DHHS	NOT-HD-23-001	07-May-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name Contact Telephone	Juanita J. Chinn, PhD 301-827-4901
-----------------------------------	---------------------------------------

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:juanita.chinn@nih.gov">juanita.chinn@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024</p> <p>Synopsis                      The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is issuing this Notice of Special Interest (NOSI) to invite applications to: Identify mechanisms, causes, correlates, and modifiable risk factors underlying recent trends in mortality during adolescence and young adulthood. Trends to be examined include the growing inequalities in overall mortality and by cause of death and manner of death (natural, unintentional and intentional injuries, including suicide and homicide, and undetermined), with attention to race, ethnicity, sex, gender, age, disability status, as well as family structure and living arrangements, income, education, and geographic location. Examine trends in mortality among individuals with intellectual and physical disabilities with a particular interest in studies that identify mechanisms, explanations, and modifiable risk factors. Improve the accuracy and granularity of cause of death coding, especially for individuals with intellectual and physical disabilities, and to improve the accuracy of manner of death coding, particularly across unintentional and intentional injuries, including suicide and homicide, for adolescents and young adults as well as for individuals with intellectual and physical disabilities. Improve research on mortality among youth populations of all sexual orientations and gender identities –especially for suicide and homicide, and other intentional and unintentional injuries. Examine the impact of rising mortality among adolescents, adolescents transitioning to adulthood and young adults on the health and development of the population, including demographic factors such as fertility and nuptiality, on the health and development of decedents' offspring and other family members, and on the health, development, and well-being of populations of interest to the NICHD is of high program priority. The NICHD populations of interest that are the focus of this Notice are adolescents, young adults, and individuals with intellectual, developmental, or physical disabilities. For information on the NICHD Strategic Plan 2020 (<a href="https://www.nichd.nih.gov/about/org/strategicplan">https://www.nichd.nih.gov/about/org/strategicplan</a>)</p>				
117690	<a href="#">RFA-MH-23-330 -- BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	RFA-MH-23-330	13-Jun-2024	Not Specified
	<p>Contact Name James Churchill, Ph.D.</p> <p>Contact Telephone 301-326-8800</p> <p>Contact Email <a href="mailto:BRAINDIVERSITYK99R00@nih.gov">BRAINDIVERSITYK99R00@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 13-Jun-2024 , 11-Oct-2024 , 13-Feb-2025 , 13-Jun-2025 , 15-Oct-2025 , 13-Feb-2026</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Synopsis	<p>The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds, including those from underrepresented groups in the biomedical and behavioral sciences, in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to assist awardees in launching independent research careers. This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (RFA-MH-22-331).</p>			
--	----------	--	--	--	--

115095	<a href="#">Mentored Career Development Program for Early Stage Investigators Using Nonhuman Primate Research Models (K01 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-073	07-May-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:AITraininghelpdesk@niaid.nih.gov">AITraininghelpdesk@niaid.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to provide early-stage investigators with support and			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

“protected time” (up to five years) for intensive, research-focused career development program activities under the guidance of an experienced mentorship team with expertise in both the preclinical application of nonhuman primate (NHP) models and in translation of the results from such studies to clinical application. The focus of this program is to increase the number of highly skilled scientists using NHP models to address complex translational biomedical research designed to foster translation of outcomes into the clinic. The expectation is that through this sustained period of research career development and training, awardees will launch independent research careers and become competitive for new research project grant (e.g., R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

112644	<a href="#">Notice of Special Interest (NOSI): Promoting Mechanistic Research on Therapeutic and Other Biological Properties of Minor Cannabinoids and Terpenes</a>	National Institutes of Health/DHHS	NOT-AT-22-027	07-May-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name  
 Contact Telephone  
 Contact Email  
 Sponsor Website  
 Program URL  
 Deadline Dates (ALL)

[Link to program URL](#)

07-May-2024 , 05-Jun-2024

Synopsis

This Notice of Special Interest (NOSI) is being issued by the National Center for Complementary and Integrative Health (NCCIH) with participation from multiple NIH Institutes, Centers, and Offices (ICOs). This NOSI aims to promote mechanistic research of therapeutic benefits of minor cannabinoids and terpenes in the cannabis plant. Minor cannabinoids are defined as any and all cannabinoids from the cannabis plant other than Δ9-tetrahydrocannabinol (Δ9-THC). Cannabinoids of particular interest include the following: Δ8-THC, Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC), cannabichromevarin (CBDV), tetrahydrocannabivarin (THCV), Tetrahydrocannabivarin acid (THCVA), tetrahydrocannabinolic acid (THCA), carmagerol, cannabicitran, sesquicannabigerol. Terpenes of particular interest include the following: Myrcene, β-caryophyllene, Limonene, α-terpineol, Linalool, α-phellandrene, α-pinene, β-pinene, β-terpinene, and α-humulene. This NOSI intends to support highly innovative basic and/or mechanistic studies in appropriate model organisms and/or human subjects aiming to investigate the impact of minor cannabinoids and terpenes on mechanisms underlying their therapeutic effects. Preclinical studies of combinations of minor cannabinoids with terpenes or other natural products that may enhance their therapeutic benefits and/or abate unwanted effects are encouraged. The mechanisms and processes underlying potential contribution of minor cannabinoids and terpenes to symptoms relief and functional restoration may be very broad encompassing different pathological conditions and diseases. This NOSI encourages interdisciplinary collaborations among



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		experts from multiple fields, such as pharmacologists, chemists, physicists, physiologists, neuroscientists, psychologists, endocrinologists, immunologists, geneticists, behavioral scientists, clinicians, or others in relevant areas of inquiry.			
112791	<a href="#">Notice of Special Interest (NOSI): Community-Based Participatory Research (CBPR) Initiative in Reducing and Eliminating Health Disparities With a Focus on Addressing Diverse Representation in Research On Down Syndrome (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	NOT-OD-22-142	07-May-2024	Not Specified
	<p>Contact Name: Sujata Bardhan, Ph.D.</p> <p>Contact Telephone: 301-435-0471</p> <p>Contact Email: <a href="mailto:sujata.bardhan@nih.gov">sujata.bardhan@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025</p> <p>Synopsis: The NIH Investigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). This Notice of Special Interest (NOSI) announces NIH support for exploratory/developmental grant (R21) applications that are focused on community-based participatory research (CBPR) in DS to address health disparities and that meet programmatic objectives for the INCLUDE Project.</p>				
121564	<a href="#">Developing Novel Theory and Methods for Understanding the Genetic Architecture of Complex Human Traits (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-301	16-Jun-2024	275,000 USD
	<p>Contact Name: Alexander Arguello, Ph.D.</p> <p>Contact Telephone: 240-731-3753</p> <p>Contact Email: <a href="mailto:alexander.arguello@mail.nih.gov">alexander.arguello@mail.nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026</p> <p>Synopsis: The goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should account for interdependencies across scales of biological, social, and ecological organization, make extensive use of theory, modeling, and validation with available large-scale datasets, and may be interdisciplinary drawing</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	from the natural and social sciences.				
117659	<a href="#">Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-098	10-May-2024 [Optional][LOI/Pre-App]	7,500,000 USD
	Contact Name	Stephanie A. Morris, Ph.D.			
	Contact Telephone	301-435-5738			
	Contact Email	<a href="mailto:morriss2@mail.nih.gov">morriss2@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	10-May-2024 [Optional][LOI/Pre-App], 21-Jun-2024 , 09-May-2025 [Optional][LOI/Pre-App], 24-Jun-2025			
	Synopsis	<p>The Centers of Excellence in Genomic Science (CEGS) program establishes academic Centers for advanced genome research. Each CEGS award supports a multi-investigator, interdisciplinary team to develop integrated, transformative genomic approaches to address a biomedical problem. A CEGS project will address a critical issue in genomic science, genomic medicine, or computational genomics, proposing a highly innovative solution that would be a major advance. The research will entail substantial risk, balanced by outstanding scientific and management plans and very high potential payoff. A CEGS will focus on the development of novel technological or computational methods for the production or analysis of comprehensive data sets, on a genome-scale biomedical problem, or on other ways to develop and use genomic approaches for understanding biological systems or furthering the application of genomic knowledge, data, and methods towards clinical applications. Each CEGS will nurture genomics by facilitating the interaction of investigators from several disciplines. Along with its scientific goals, CEGS will also expand the pool of genomic scientists and engineers that can use and apply the novel methods, concepts, and knowledge developed by the CEGS by providing education and outreach experiences to scientists at all career levels.</p>			
109792	<a href="#">Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-138	07-May-2024	275,000 USD
	Contact Name	Julia Zehr, Ph.D.			
	Contact Telephone	301-443-1617			
	Contact Email	<a href="mailto:Zehrj@mail.nih.gov">Zehrj@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis   The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (<a href="http://www.abcdstudy.org">www.abcdstudy.org</a>). This FOA seeks shorter, higher-risk</p>				
114596	<a href="#">Development of Animal Models and Related Biological Materials for Down Syndrome Research (R21 Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-067	16-Jun-2024	275,000 USD
	<p>Contact Name   Sige Zou, PhD            Contact Telephone   301-435-0749            Contact Email   <a href="mailto:zous@mail.nih.gov">zous@mail.nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025</p> <p>Synopsis   The INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome (INCLUDE) Project encourages exploratory and innovative research to develop, characterize, or improve animal models and related biological materials for Down syndrome (DS) related research and to improve access to information about or from the use of animal models for DS research. The animal models and related biological materials developed must have utility in targeted or basic science studies in areas highly relevant to DS. With this funding opportunity announcement, the INCLUDE Project encourages, but is not limited to, projects focusing on development of various animal models, genetic resources, atlases at a single cell or subcellular level, advanced informatics technologies including artificial intelligence (AI) or machine learning (ML), and integration of multiple animal models and technology platforms for enhancing rigor and reproducibility of preclinical DS research.</p>				
114857	<a href="#">Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-075	16-Jun-2024	200,000 USD
	<p>Contact Name   James N. Coulombe, Ph.D.            Contact Telephone   301-451-1390            Contact Email   <a href="mailto:CoulombeJ@mail.nih.gov">CoulombeJ@mail.nih.gov</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025			
	Synopsis	<p>The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotypic data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. Kids First has established and continues to develop a Data Resource including a collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on analyses of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets. Development of approaches, tools, or algorithms appropriate for analyzing genomic, phenotypic, and/or clinical data relevant to Kids First may also be proposed.</p>			
120393	<a href="#">Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-255	16-Jun-2024	275,000 USD
	Contact Name	Melissa Rotunno, Ph.D.			
	Contact Telephone	240-276-7245			
	Contact Email	<a href="mailto:rotunnom@mail.nih.gov">rotunnom@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026			
	Synopsis	<p>Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
120102	<a href="#">Social disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-239	16-Jun-2024	275,000 USD
	<p>Contact Name   Jovier Evans, Ph.D.</p> <p>Contact Telephone   301-443-6328</p> <p>Contact Email   <a href="mailto:jevans1@mail.nih.gov">jevans1@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026</p> <p>Synopsis   The purpose of this Notice of Funding Opportunity (NOFO) is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental. This NOFO solicits R21 applications, while the companion announcement PAR-23-238 solicits R01 applications. High risk/high payoff projects that lack preliminary data may be most appropriate for this R21 mechanism, while applications with preliminary data should apply to the R01 mechanism, PAR-23-238.</p>				
112267	<a href="#">Notice of Special Interest (NOSI): Advancing Research on Early Pregnancy Loss</a>	National Institutes of Health/DHHS	NOT-HD-22-026	07-May-2024	Not Specified
	<p>Contact Name   Clara Cheng, PhD</p> <p>Contact Telephone   301-435-6992</p> <p>Contact Email   <a href="mailto:clara.cheng@nih.gov">clara.cheng@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025</p> <p>Synopsis   Early Pregnancy loss (EPL), defined as a pregnancy loss occurring up to 20 weeks gestation, is a very common pregnancy complication, occurring in 12-15% of clinically recognized pregnancies, with increased prevalence associated with increasing maternal age. The use of highly sensitive hCG assays allows the detection of pregnancy earlier in gestation than the time of clinical recognition, and gives an even higher estimated loss of 50-70% of conceptions prior to the second trimester. To</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>achieve a successful pregnancy, a series of strict embryonic and maternal conditions must be met, that include high quality embryos, favorable conditions for embryo implantation, receptive maternal endometrium and optimal uterine environment to sustain the conceptus to term. In addition, maternal immune tolerance and hormonal factors play a critical role. While approximately half of all cases of EPL appear to be due to embryonic aneuploidy, very little is known about the physiologic and pathophysiologic processes that underlie non-aneuploid EPL. As a result, there is also a lack of understanding for the underlying causes of recurrent pregnancy loss (RPL). This NOSI seeks to address these critical knowledge gaps by encouraging basic, translational and clinical studies on biological processes that may uncover potential etiologies of EPL and RPL. This includes research to understand implantation mechanistically and identify a range of key factors, involved in implantation and placentation that are important for early pregnancy establishment, including abnormalities that contribute to sporadic EPL and recurrent pregnancy loss.</p>			
123347	<a href="#">Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-24-060	07-May-2024	450,000 USD
	<p>Contact Name   Amy B. Goldstein, PhD</p> <p>Contact Telephone   301-827-4124</p> <p>Contact Email   <a href="mailto:amy.goldstein@nih.gov">amy.goldstein@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027</p> <p>Synopsis   The purpose of this notice of funding opportunity (NOFO) is to encourage theoretically driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. The latter may include pilot studies of strategies or approaches to intervention, and/or other service system-based research to address areas such as economics, funding, service quality and engagement. In addition to the prevention of substance use, misuse and disorder, other outcomes of interest for the research supported through this NOFO include a reduction in negative sequelae of use, such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and substance-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings.</p>				
108483	<a href="#">Notice of Special Interest (NOSI): COVID-19 Pandemic Mental Health Research</a>	National Institutes of Health/DHHS	NOT-MH-22-100	07-May-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Pim Brouwers, Ph.D.</p> <p>Contact Telephone   240-627-3863</p> <p>Contact Email   <a href="mailto:ebrouwer@mail.nih.gov">ebrouwer@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis   NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in basic, translational, intervention and services research relevant to the COVID-19 pandemic. NIMH is especially interested in research to provide an evidence base to understand how mental illness contributes to COVID-19 risk and mortality, how incident mental illness develops with COVID-19, and the development of scalable interventions to meet the public mental health needs during and resulting from the pandemic both specifically related to the virus but also at a broader population level that is impacted by stress, disruptions, and loss of lives in the pandemic. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH. Research is anticipated to focus on particularly vulnerable populations based on existing evidence of increased mental health symptoms and illness and preexisting and worsening health disparities.</p>				
108358	<a href="#">Exploratory/Developmental Bioengineering Research Grants(EBRG) (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-090	16-Jun-2024	275,000 USD
	<p>Contact Name   Miguel R. Ossandon, Ph.D.</p> <p>Contact Telephone   240-276-5714</p> <p>Contact Email   <a href="mailto:ossandom@mail.nih.gov">ossandom@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2024 , 16-Oct-2024</p> <p>Synopsis   The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility</p>				
111039	<a href="#">Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-22-109	07-May-2024	275,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Contact Name	Gila Neta, Ph.D.			
	Contact Telephone	240-276-6785			
	Contact Email	<a href="mailto:gila.neta@nih.gov">gila.neta@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.</p>			

111040	<a href="#">Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-106	07-May-2024	275,000 USD
--------	--	------------------------------------	------------	-------------	-------------

	Contact Name	Gila Neta, Ph.D.			
	Contact Telephone	240-276-6785			
	Contact Email	<a href="mailto:gila.neta@nih.gov">gila.neta@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.

110996	<a href="#">Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-160	07-May-2024	100,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Gila Neta, PhD
Contact Telephone	240-276-6785
Contact Email	<a href="mailto:Gila.Neta@nih.gov">Gila.Neta@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.

119255	<a href="#">Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-208	16-Jun-2024	275,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name	Laura M. Rowland, Ph.D.
Contact Telephone	301-480-8335
Contact Email	<a href="mailto:laura.rowland@nih.gov">laura.rowland@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The goal of this Notice of Funding Opportunity (NOFO) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This NOFO uses the R21 mechanism, while the companion PAR-23-207 uses the R01 grant mechanism. Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism, while applicants with preliminary data who seek longer-term funding should apply using the R01 mechanism.</p>				
110997	<p><a href="#">Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)</a></p>	National Institutes of Health/DHHS	PAR-22-167	18-Jun-2024	3,250,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Soju Chang, M.D., M.P.H.</p> <p>301-827-9206</p> <p><a href="mailto:soju.chang@nih.gov">soju.chang@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>18-Jun-2024 , 17-Oct-2024</p> <p>The Clinical and Translational Science Award (CTSA) Program Collaborative and Innovative Acceleration Award (CCIA) supports synergistic activities that accelerate the translational research process through collaboration and innovation. This funding opportunity announcement (FOA) invites applications to develop, demonstrate and disseminate innovative solutions to transform the field of translational science by addressing the inefficiencies that are common across diseases and bringing more interventions to all people more quickly through collaborative science among the CTSA Program hubs, NIH Institutes, Centers, Offices (ICOs), and/or external stakeholders.</p>			
103168	<p><a href="#">Research on Autism Spectrum Disorders (R01 Clinical Trial Optional)</a></p>	National Institutes of Health/DHHS	PA-21-201	05-Jun-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p>	<p>Lisa Gilotty, Ph.D.</p> <p>301-443-3825</p> <p><a href="mailto:gilottyl@mail.nih.gov">gilottyl@mail.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   05-Jun-2024 , 05-Oct-2024</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). The Research Project Grant (R01) mechanism supports discrete, specified projects based in scientific areas that represent the investigators' specific interests and competencies, and that fall within the mission of the participating NIH Institutes and Centers (ICs). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions, and preliminary data are generally expected. Applicants pursuing exploratory/developmental research to support early and conceptual stages of project development should consider the companion R21 FOA, PA-21-200. Applicants pursuing secondary analysis of existing data, and pilot or feasibility studies that can be completed with limited budgets should consider the companion R03 FOA, PA-21-199.</p>				
108898	<a href="#">Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services</a>	National Institutes of Health/DHHS	NOT-MH-22-110	07-May-2024	Not Specified
	<p>Contact Name   Stephen O'Connor, Ph.D.</p> <p>Contact Telephone   301-480-8366</p> <p>Contact Email   <a href="mailto:stephen.o'connor2@nih.gov">stephen.o'connor2@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis   The National Institutes of Health seeks research conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related (e.g., youth; adult; older adult), geographic (rural/remote settings), cultural considerations, and health disparities influence the types of care that are provided. Examples of NIMH and NIDA studies that are encouraged through this Notice address the continuum of crisis service systems. Applications that include crisis services for children and under-resourced populations are encouraged. Topics of research interest span the crisis care continuum, including the effectiveness of these components: call center capabilities to address distress and coordinate care, deployed mobile crisis outreach and support, and crisis services that can diagnose and provide short term stabilization.</p>				
109173	<a href="#">Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-086	16-Jun-2024	275,000 USD
	Contact Name   Avi Rasooly, PhD				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone | 240-276-6196  
 Contact Email | [rasoolya@mail.nih.gov](mailto:rasoolya@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025

Synopsis | This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaeobacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis This funding opportunity is part of a broader NCI-sponsored research on microbial based cancer therapy.

109181	<a href="#">Notice of Special Interest (NOSI): Public Health Research on Cannabis</a>	National Institutes of Health/DHHS	NOT-DA-22-003	07-May-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name | Marsha Lopez, PhD  
 Contact Telephone | (301) 402-1846  
 Contact Email | [\(301\) 402-1846](tel:(301)402-1846)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025

Synopsis | The National Institute on Drug Abuse (NIDA) is issuing this notice to encourage grant applications on the effects of changing cannabis laws and policies in the US and globally on public health.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
114123	<a href="#">Engineering Next-Generation Human Nervous System Microphysiological</a>	National Institutes of	PAR-23-	07-May-2024	275,000

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<a href="#">Systems (R21 Clinical Trials Not Allowed)</a>		Health/DHHS	047		USD
	<p>Contact Name   David M. Panchision, Ph.D.</p> <p>Contact Telephone   301-443-5288</p> <p>Contact Email   <a href="mailto:panchisiond@mail.nih.gov">panchisiond@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high reward projects that lack preliminary data may be most appropriate for this FOA. Applicants with preliminary data may instead wish to apply to the companion R01 mechanism (PAR-23-046).</p>				
114061	<a href="#">Notice of Special Interest (NOSI): Explainable Artificial Intelligence for Decoding and Modulating Neural Circuit Activity Linked to Behavior</a>	National Institutes of Health/DHHS	NOT-MH-23-110	07-May-2024	Not Specified
	<p>Contact Name   Mauricio Rangel-Gomez, Ph.D.</p> <p>Contact Telephone   301-435-6908</p> <p>Contact Email   <a href="mailto:mauricio.rangel-gomez@nih.gov">mauricio.rangel-gomez@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026</p> <p>Synopsis   This Notice of Special Interest (NOSI) solicits applications in the area of XAI applied to neuroscientific questions of encoding, decoding, and modulation of neural circuits linked to behavior. This NOSI encourages collaborations between computationally and experimentally focused investigators. This NOSI seeks the development of machine learning algorithms that are able to mechanistically explain how experimental manipulations affect cognitive, affective, or social processing in humans or animals. Proof-of-concept applications aimed at improving the current state of the technology that uses XAI to</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		provide unbiased, hierarchical explanations of causal relationships between complex neural and behavioral data are also appropriate.			
115062	<a href="#">Notice of Special Interest (NOSI): argeting the Endocannabinoid System for Brain Health and Acute and Chronic Diseases</a>	National Institutes of Health/DHHS	NOT-DA-22-048	07-May-2024	Not Specified
	Contact Name	Yu (Woody) Lin, PhD			
	Contact Telephone	301-435-1318			
	Contact Email	<a href="mailto:ylin1@mail.nih.gov">ylin1@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 25-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 25-Sep-2024 , 05-Oct-2024 , 10-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 25-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 13-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 25-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 25-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026			
	Synopsis	This Notice of Special Interest (NOSI) encourages studies of the endocannabinoid system (ECS) and its roles in brain health and acute and chronic disease, substance use, and substance use disorder (SUD). The desired outcomes of research will be a mechanistic understanding of how cannabinoids and manipulation of the ECS can elicit both therapeutic and deleterious effects as well as the role of cannabinoids and ECS in symptom management.			
124219	<a href="#">Long-Term Effects of Disasters on Healthcare Systems in Populations with Health Disparities (R01- Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-24-109	06-May-2024 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Carolina Solis-Sanabria, MD, MPH, FACS			
	Contact Telephone	301-827-3460			
	Contact Email	<a href="mailto:carolina.solissanabria@nih.gov">carolina.solissanabria@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	06-May-2024 [Optional][LOI/Pre-App], 05-Jun-2024 , 06-Sep-2024 [Optional][LOI/Pre-App], 07-Sep-2024 , 05-Oct-2024 , 06-Jan-2025 [Optional][LOI/Pre-App], 07-Jan-2025 , 05-Feb-2025 , 06-May-2025 [Optional][LOI/Pre-App], 07-May-2025 , 05-Jun-2025 , 06-Sep-2025 [Optional][LOI/Pre-App], 07-Sep-2025 , 05-Oct-2025 , 06-Jan-2026 [Optional][LOI/Pre-App], 07-Jan-2026 , 05-Feb-2026 , 06-May-2026 [Optional][LOI/Pre-App], 07-May-2026 , 05-Jun-2026 , 06-Sep-2026 [Optional][LOI/Pre-App], 07-			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
				Sep-2026 , 05-Oct-2026 , 06-Jan-2027 [Optional][LOI/Pre-App], 07-Jan-2027 , 05-Feb-2027 , 07-May-2027	
	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to support collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on healthcare systems serving populations that experience health disparities living in the U.S. and its territories.			
103419	<a href="#">Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health</a>	National Institutes of Health/DHHS	NOT-OD-21-100	07-May-2024	Not Specified
	Contact Name	Wendy Nelson, PhD, MPH			
	Contact Telephone	240-276-6971			
	Contact Email	<a href="mailto:nelsonw@mail.nih.gov">nelsonw@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024			
	Synopsis	This Notice of Special Interest (NOSI) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR) with participation from multiple NIH Institutes, Centers, and Offices. This NOSI calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels. The specific research interests of participating NIH Institutes and Centers are detailed within.			
103180	<a href="#">Research on Autism Spectrum Disorders (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PA-21-200	16-Jun-2024	275,000 USD
	Contact Name	Lisa Gilotty, Ph.D.			
	Contact Telephone	301-443-3825			
	Contact Email	<a href="mailto:gilottyl@mail.nih.gov">gilottyl@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. Exploratory, novel studies that break new ground or extend previous discoveries toward new directions are appropriate for this mechanism. No preliminary data are required but may be included if available. Applicants pursuing secondary analysis of existing data, and pilot or feasibility studies that can be completed with limited budgets should consider the companion R03 FOA, PA-21-199 . Applicants pursuing larger studies in established scientific areas where preliminary data are expected should consider the companion R01 FOA, PA-21-201.</p>			
103183	<a href="#">Research on Autism Spectrum Disorders (R03 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PA-21-199	16-Jun-2024	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Lisa Gilotty, Ph.D.</p> <p>301-443-3825</p> <p><a href="mailto:gilottyl@mail.nih.gov">gilottyl@mail.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>16-Jun-2024 , 16-Oct-2024</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). An R03 grant supports small, discrete, well-defined projects that can be completed in two years and that require limited resources. R03 applications may include development of new research methodologies or technology, secondary analysis of existing data, and pilot or feasibility studies. Preliminary data are not required, particularly in applications proposing pilot or feasibility studies. Applicants pursuing exploratory/developmental research to support early and conceptual stages of project development should consider the companion R21 FOA, PA-21-200. Applicants pursuing larger studies in established scientific areas where preliminary data are expected should consider the companion R01 FOA, PA-21-201.</p>			
103732	<a href="#">Notice of Special Interest (NOSI): Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence</a>	National Institutes of Health/DHHS	NOT-DA-21-012	07-May-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p>	<p>Keisher Highsmith, DrPH</p> <p></p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	<a href="mailto:highsmithks@nih.gov">highsmithks@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	<p>The purpose of this Notice is to inform potential applicants of the National Institute on Drug Abuse (NIDA) special interest in grant applications to conduct rigorous basic, translational and/or clinical research to: (1) advance identification of sex and/or gender differences in risk for substance use disorders or the response or medical consequences of alcohol or substance misuse to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research.</p>			
103983	<a href="#">Notice of Special Interest (NOSI): Public Policy Effects on Alcohol-, Cannabis-, Tobacco-, and Other Drug-Related Behaviors and Outcomes</a>	National Institutes of Health/DHHS	NOT-AA-21-028	07-May-2024	Not Specified

	Contact Name	Gregory Bloss, M.A., M.P.P.			
	Contact Telephone				
	Contact Email	<a href="mailto:Gregory.Bloss@nih.gov">Gregory.Bloss@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	<p>This announcement encourages applications to conduct research on the effects of public policies on health-related behaviors and outcomes associated with alcohol, cannabis, tobacco, prescription drugs, and other substances. The purpose of the Notice is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol and other drugs. This Notice is intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health. Research projects that may be supported include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes; studies of disparities in policy effects and the role of policy in exacerbating or potentially reducing health disparities; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes.</p>			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
104057	<a href="#">Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PA-21-219	07-May-2024	275,000 USD
	<p>Contact Name   Karrah Benson</p> <p>Contact Telephone   301-496-0838</p> <p>Contact Email   <a href="mailto:Karrah.benson@nih.gov">Karrah.benson@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis   The Joint NINDS/NIMH Exploratory Neuroscience Research Grant program supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community. While this funding opportunity also accepts clinical trials, only applications proposing “mechanistic clinical trials or studies” (studying pathophysiology or mechanism of action of an intervention, but not safety or efficacy) or basic experimental studies with humans (BESH) will be supported. For information on NIH clinical trial definitions and the types of clinical trials that are within scope of this funding opportunity announcement refer to the NIH Definition of a Clinical Trial page and the Funding Opportunity Description, below, respectively.</p>				
104714	<a href="#">Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAS-21-245	16-Jun-2024	450,000 USD
	<p>Contact Name   Hung Tseng PhD</p> <p>Contact Telephone   301-496-0810</p> <p>Contact Email   <a href="mailto:tsengh@mail.nih.gov">tsengh@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2024</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) is to support applications to a new NIAMS initiative to encourage the skin research community to contribute to basic understanding of skin injuries caused by chemical threats to the civilian population, with an emphasis on investigating the commonalities of such injuries and identifying potential shared signaling</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		pathways and therapeutic targets for countermeasure development.			
105478	<a href="#">Notice of Special Interest (NOSI): Advancing Research in Gastrointestinal Dysfunction in People with Neurodevelopmental Disorders</a>	National Institutes of Health/DHHS	NOT-NS-22-003	07-May-2024	Not Specified
	<p>Contact Name   Adam L. Hartman, MD</p> <p>Contact Telephone   301-496-9135</p> <p>Contact Email   <a href="mailto:adam.hartman@nih.gov">adam.hartman@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 16-Jun-2024</p> <p>Synopsis   The National Institute of Neurological Disorders and Stroke is issuing this Notice to highlight interest in receiving grant applications focused in the following area(s) to support basic, translational, and/or clinical research on the causes, diagnosis, prevention, or treatment of gastrointestinal dysfunction in people with neurodevelopmental disorders.</p>				
105756	<a href="#">Investigator Initiated Research in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-255	16-Jun-2024	275,000 USD
	<p>Contact Name   Daniel Gilchrist, Ph.D.</p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:daniel.gilchrist@nih.gov">daniel.gilchrist@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2024</p> <p>Synopsis   The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research that develops innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems.</p>				
105890	<a href="#">Notice of Special Interest (NOSI): Precision Imaging of Oral Lesions</a>	National Institutes of Health/DHHS	NOT-DE-21-010	07-May-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Zhong Chen, MD, PhD</p> <p>Contact Telephone   301-529-7083</p> <p>Contact Email   <a href="mailto:zhong.chen@nih.gov">zhong.chen@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   Diagnosing and treating lesions of the oral cavity and oropharynx are challenging due to reliance on subjective analyses of clinical features and histopathological diagnostic criteria. High resolution and quantitative tools are needed to enhance the precision of diagnostic approaches for oral pathologies to guide options for treatment. This Notice of Special Interest (NOSI) is to encourage research projects that develop, adapt, optimize, and validate imaging-based applications and data analysis tools to enhance oral disease detection, diagnosis, and treatment. The long-term goal is to facilitate translation of research findings into clinical practice, paving the way for personalized health care through objective measures that promote accurate and timely diagnosis, targeted therapies, and improved patient survival and quality of life.</p>				
105732	<a href="#">Notice of Special Interest (NOSI): Immune Responses to Arthropod Feeding on Vertebrate Hosts</a>	National Institutes of Health/DHHS	NOT-AI-21-059	07-May-2024	Not Specified
	<p>Contact Name   Qian “Joy” Liu, M.D., MSc.</p> <p>Contact Telephone   301-761-6621</p> <p>Contact Email   <a href="mailto:liujoy@niaid.nih.gov">liujoy@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   This Notice of Special Interest (NOSI) solicits transdisciplinary research projects to understand the immunologic events in the vertebrate host that occur at the bite site (skin) and systemically during and after feeding by hematophagous and ectoparasitic arthropods. Exploratory research on arthropod blood feeding was formerly supported by NIAID through the expired FOA, PAR-18-860, “Immune Response to Arthropod Blood Feeding (R21 Clinical Trial Not Allowed). The intent of this NOSI is to indicate continued NIAID support for research in this area as described below through applications to the parent R01 and R21 FOAs.</p>				
106126	<a href="#">Notice of Special Interest (NOSI): Social, Behavioral, and Economic Impact of COVID-19 in Underserved and Vulnerable Populations</a>	National Institutes of Health/DHHS	NOT-MH-21-330	07-May-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Adam Haim, Ph.D.
Contact Telephone	
Contact Email	<a href="mailto:haima@mail.nih.gov">haima@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024
Synopsis	<p>NIH Institutes, Centers, and Offices participating in the Social, Behavioral, and Economic Impacts of COVID-19 in Vulnerable and Health Disparity Populations initiative are issuing this Notice of Special Interest (NOSI) to highlight interest in research to strengthen the understanding and response to the Coronavirus Disease 2019 (COVID-19) pandemic and help us prepare more effectively for future public health emergencies. While research related to the direct clinical effects of COVID-19 are supported by other funding opportunities, there are additional urgent public health needs, particularly in populations who experience health disparities and in vulnerable populations. The purpose of this Notice is to 1) emphasize the roles and impacts of interventions, particularly those under the umbrella of digital health, as well as community-engaged and multi-level interventions in healthcare settings to address access, reach, delivery, engagement, effectiveness, scalability, and sustainability of services that are utilized during and following the pandemic, and 2) encourage the leveraging of existing large-scale data sources with broad population coverage to improve prediction of various mitigation efforts (including vaccinations, masking, and physical distancing to inform the public health response) on transmission reduction and on social and economic impacts, and assess the downstream health and healthcare access effects, with an emphasis on underserved and vulnerable populations. Additionally, the use of large-scale data sources to study the indirect health impacts of the pandemic and subsequent social and economic changes is needed to understand the costs and benefits of various COVID-19 mitigation strategies.</p>

106119	<a href="#">Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-21-313	07-May-2024	375,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Katrina J. Serrano, Ph.D.
Contact Telephone	301-480-7855
Contact Email	<a href="mailto:katrina.serrano@nih.gov">katrina.serrano@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 16-Jun-2024 , 07-Sep-2024

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical, clinical, behavioral and social sciences research, to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Human Genome Research Institute (NHGRI) or the National Institute of Biomedical Imaging and Bioengineering (NIBIB). New investigators at the time of award under this FOA will have had less than \$125,000 direct costs of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate transition to research independence. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.</p>				
106848	<p><a href="#">Notice of Special Interest (NOSI): Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities</a></p>	National Institutes of Health/DHHS	NOT-DE-21-013	07-May-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Hiroko Iida, DDS, MPH</p> <p>301-594-7404</p> <p><a href="mailto:hiroko.iida@nih.gov">hiroko.iida@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage research studies designed to identify and understand the mechanisms by which biologic factors (microbial, immune, genetic) contribute to disparities in dental, oral, and craniofacial disease onset, progression, and persistence.</p>			
107449	<p><a href="#">Notice of Special Interest (NOSI): Reducing Stigma Related to Drug Use in Human Service Settings</a></p>	National Institutes of Health/DHHS	NOT-DA-21-060	07-May-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Richard A. Jenkins PhD</p> <p>301-443-1923</p> <p><a href="mailto:jenkinsri@mail.nih.gov">jenkinsri@mail.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The National Institute on Drug Abuse (NIDA) recognizes that stigma is pervasive in clinic, social service and other settings related to HIV prevention and care. Stigma contributes to a lack of attention to drug use screening, inadequate outreach to people who use drugs (PWUD) and insufficient uptake of services to prevent, treat, or mitigate HIV infection (and related consequences of drug use) among PWUD. Stigmas of interest include: internalized stigma among drug users, stigma associated with providing services to PWUD, and stigma toward PWUD by providers or service settings. Policies and practices that create or augment stigma also are of interest here, as well as stigma experienced by providers who might otherwise broaden their services to PWUD. Stigma reduction interventions for HIV service settings have been developed and, in some cases, implemented on a wide scale, but generally target sexual transmission as the primary behavioral risk; however, knowledge from this work can inform stigma among PWUD. Large literatures on stigma also exist in a variety of other conditions (e.g., cancer, mental illness) which also can provide conceptual and programmatic bases to speed the development of new interventions addressing PWUD.</p>			
106966	<a href="#">Notice of Special Interest (NOSI): Somatic Cell Gene Editing Therapies To Improve Transplantation Outcomes</a>	National Institutes of Health/DHHS	NOT-AI-21-080	07-May-2024	Not Specified
	Contact Name	Nasrin Nabavi, Ph.D.			
	Contact Telephone	240-627-3538			
	Contact Email	<a href="mailto:nnabavi@mail.nih.gov">nnabavi@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025			
	Synopsis	<p>The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting research that applies somatic cell gene editing (SCGE) approaches to improve graft survival and outcomes for recipients of allogenic solid organ, pancreatic islet, or vascularized composite allograft (VCA) transplants in animal models or human tissues or organs excluded from clinical use.</p>			
107609	<a href="#">Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-032	16-Jun-2024	275,000 USD
	Contact Name	Enrique Michelotti, PhD			
	Contact Telephone	301-443-5415			
	Contact Email	<a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a>			
	Sponsor Website				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2024 , 16-Oct-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH, NIA, NIAAA and NIDA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents. This FOA will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies).</p>				
107543	<p><a href="#">Notice of Special Interest (NOSI): Accelerating Progress in Celiac Disease Research</a></p>	National Institutes of Health/DHHS	NOT-AI-22-004	07-May-2024	Not Specified
	<p>Contact Name Annette L. Rothermel, Ph.D.</p> <p>Contact Telephone 240-627-3477</p> <p>Contact Email <a href="mailto:arothermel@niaid.nih.gov">arothermel@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 25-Sep-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants to the National Institutes of Health (NIH) of special interest in research on the etiology and pathogenesis of celiac disease, identification of therapeutic targets, and development of preventative or disease ameliorating therapies/strategies.</p>				
107545	<p><a href="#">Notice of Special Interest (NOSI): Expanding the Otitis Media Research Workforce: Focus on Early Stage Investigators</a></p>	National Institutes of Health/DHHS	NOT-DC-22-001	07-May-2024	Not Specified
	<p>Contact Name Bracie Watson, Jr., Ph.D.</p> <p>Contact Telephone 301-402-3458</p> <p>Contact Email <a href="mailto:watsonb@nidcd.nih.gov">watsonb@nidcd.nih.gov</a></p> <p>Sponsor Website</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 20-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025
Synopsis	The National Institute on Deafness and Other Communication Disorderse (NIDCD) is interested in expanding the cadre of basic and clinical scientists who conduct research on otitis media (OM). The purpose of this Notice of Special Interest (NOSI) is to invite Early Stage Investigators (ESIs), as defined by the NIH <a href="https://grants.nih.gov/grants/new_investigators/index.htm#earlystage">https://grants.nih.gov/grants/new_investigators/index.htm#earlystage</a> , to submit research applications that focus on OM—commonly known as ear infections. There is a critical need for focused, novel, creative and innovative research approaches that accelerate the development of effective ways to prevent and treat OM.

107483	<a href="#">Notice of Special Interest (NOSI): Mechanistic Studies on the Impact of Substance Use in Sex and Gender Differences in HIV-Associated Neurocognitive Disorders</a>	National Institutes of Health/DHHS	NOT-DA-22-047	07-May-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025
Synopsis	Compared to men, women are often more likely to develop HIV-associated neurocognitive impairments. The purpose of this notice is to inform potential applicants of NIDA’s special interest in understanding the neurobiological bases for sex or gender-specific differences in HIV-associated neurocognitive disorders. This information can be used for targeted therapeutics and optimization of treatment options in HIV positive individuals with substance use disorders.

107484	<a href="#">Notice of Special Interest (NOSI): The Functional Oral Microbiome</a>	National Institutes of Health/DHHS	NOT-DE-21-015	07-May-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Tamara McNealy, PhD.
Contact Telephone	202-430-1474
Contact Email	<a href="mailto:tamara.mcnealy@nih.gov">tamara.mcnealy@nih.gov</a>
Sponsor Website	



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025</p> <p>Synopsis The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage research studies that focus beyond the bacteria to the multispecies communities making up the oral microbiome.</p>				
108065	<a href="#">Notice of Special Interest (NOSI): Pediatric COVID-19 and Respiratory Viral Co-infection</a>	National Institutes of Health/DHHS	NOT-HL-22-004	07-May-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</p> <p>Synopsis This NOSI is intended to support projects that will employ existing and new clinical trial cohorts/observational cohorts to screen for co-infection, phenotype and collect biospecimens to answer some of these questions and to encourage investigator-initiated applications for basic, translational and human subject research (not clinical trials) in this space.</p>				
115289	<a href="#">Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services</a>	National Institutes of Health/DHHS	NOT-MH-23-140	07-May-2024	Not Specified
	<p>Contact Name Stephen O'Connor, Ph.D.</p> <p>Contact Telephone 301-480-8366</p> <p>Contact Email <a href="mailto:stephen.o'connor2@nih.gov">stephen.o'connor2@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis The National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), and Office of Research on Women's Health (ORWH) are issuing this Notice of Special Interest (NOSI) to outline priorities for research in crisis response services.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Research is sought that is conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related (e.g., youth; adult; older adult), geographic (rural/remote settings), cultural considerations, and health disparities influence the types of care that are provided. Studies are encouraged that address the continuum of crisis service systems, as well as applications that address crisis services for children and under-resourced populations.

110102	<a href="#">Notice of Special Interest (NOSI): Dissemination and Implementation Research to Advance Mental, Emotional, and Behavioral Health Preventive Interventions in School Settings</a>	National Institutes of Health/DHHS	NOT-AT-22-004	07-May-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name | Beda Jean-Francois, Ph.D.  
 Contact Telephone | 202-313-2144  
 Contact Email | [Beda.Jean-Francois@nih.gov](mailto:Beda.Jean-Francois@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 07-May-2024 , 05-Jun-2024

Synopsis | The purpose of this Notice of Special Interest (NOSI) is to stimulate dissemination and implementation research to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based preventive interventions to support children’s mental, emotional, and behavioral (MEB) health in school settings. This NOSI encourages applications which focus on dissemination and implementation research to deliver interventions in the school setting that will promote healthy MEB development and/or prevent MEB disorders. Applications should include a focus on one of the following: (1) primary/universal prevention MEB programs designed to promote healthy MEB development by decreasing risk factors and increasing protective factors to prevent onset of an MEB disorder; or (2) secondary/selective prevention programs designed to support screening and early identification of MEB disorders to slow progression with early intervention. Applications focused on tertiary/indicated treatment of MEB disorders will be considered non-responsive to this Notice.

110578	<a href="#">Notice of Special Interest (NOSI): Administrative Supplements for Research of Emerging and Existing Issues of COVID-19 Related to the Health and Well-Being of Women, Children and Individuals with Physical and/or Intellectual Disabilities</a>	National Institutes of Health/DHHS	NOT-HD-22-003	07-May-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name | Robert Tamburro, MD, MSc  
 Contact Telephone | 301-480-2619

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:robert.tamburro@nih.gov">robert.tamburro@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024</p> <p>Synopsis The purpose of this funding opportunity is to provide an opportunity for funded researchers in these various fields to pursue supplemental funding to conduct research addressing these emerging and other existing COVID-related issues among pregnant and lactating people, infants, children and adolescents, and individuals with physical and/or intellectual disabilities. The goal of this NOSI is to not replace or to compete with the various COVID-related funding opportunities currently available. Instead, the purpose is to complement them by offering a funding opportunity for currently funded investigators to address key issues not currently covered by available COVID-related funding announcements among these populations. It is hoped that the use of administrative supplements will foster research in these key areas in the most timely manner. Research projects addressing issues that are the focus of currently available or future COVID funding opportunity announcements will be encouraged to submit to those announcements. Also, applicants responding to this NOSI are strongly encouraged to describe plans for the rapid sharing of data and results as well as innovative data analytics approaches. The sharing of COVID-related data and resources and the effective communication of results are a high priority of the NIH.</p>				
110057	<p><a href="#">Notice of Special Interest (NOSI): Emerging and Existing Issues of Coronavirus Disease 2019 (COVID-19) Research Related to the Health and Well-Being of Women, Children and Individuals with Physical and/or Intellectual Disabilities</a></p>	National Institutes of Health/DHHS	NOT-HD-22-002	07-May-2024	Not Specified
	<p>Contact Name Robert Tamburro, MD, MSc</p> <p>Contact Telephone 301-480-2619</p> <p>Contact Email <a href="mailto:robert.tamburro@nih.gov">robert.tamburro@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024</p> <p>Synopsis The purpose of this funding opportunity is to provide an avenue for researchers to pursue funding to conduct research addressing these and other emerging and existing COVID-related issues among pregnant and lactating people, infants, children and adolescents, and individuals with physical and/or intellectual disabilities.</p>				
109942	<p><a href="#">Technology Development Research for Establishing Feasibility and Proof of</a></p>	National Institutes of	PAR-22-	07-May-2024	275,000

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Concept (R21 - Clinical Trial Not Allowed)</a>		Health/DHHS	126	USD
	<p>Contact Name: Fei Wang, Ph.D.</p> <p>Contact Telephone:</p> <p>Contact Email: <a href="mailto:wangf@mail.nih.gov">wangf@mail.nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis: This Funding Opportunity Announcement (FOA) supports exploratory research leading to the development of innovative technologies for biomedical research that is relevant to the NIGMS mission or that of other NIH Institutes or Centers (ICs) participating in this FOA. Projects should entail a high degree of risk and/or novelty, which will be offset by a high future potential impact in biomedical research. Outcomes or products of the proposed project, which should significantly advance the current state of the art, may include, but are not limited to: laboratory instruments and other devices, algorithms and software, chemical reagents and processes, biological molecules or systems that have been modified by human intervention to become research tools. The goal of this FOA is to support proof of concept, high-risk and potentially high-reward studies for feasibility and exploratory technology development. Due to the constraints that would be imposed on broad utility, this FOA does not support technology development that is narrowly focused on addressing specific biological questions. Rather, applications should propose development of innovative tools that can potentially benefit a broad spectrum of biomedical research. Moreover, feasibility of the proposed technology must not have already been established in the literature or with preliminary data. Applications that are focused on technology development to address specific biological questions and/or include unpublished or published data that provide proof of concept are not responsive to this FOA and will be administratively withdrawn without review.</p>				
110034	<p><a href="#">Notice of Special Interest (NOSI): Research Using Implementation Science To Support the Delivery of Evidence-Based Practices in Community-Based Mental or General Medical Healthcare Settings</a></p>	National Institutes of Health/DHHS	NOT-MH-22-170	07-May-2024	Not Specified
	<p>Contact Name:</p> <p>Contact Telephone:</p> <p>Contact Email:</p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025			
	Synopsis	This Notice of Special Interest (NOSI) highlights interest in mental health services and implementation science research to support the adoption and sustainability of evidence-based practices (EBPs) in community-based settings that deliver care to people with mental illness. These settings could include, but are not limited to, Certified Community Behavioral Health Clinics (CCBHCs) funded through the Substance Abuse and Mental Health Services Administration (SAMHSA) Certified Community Behavioral Health Clinic-Expansion (CCBHC-E) grant program.			
116487	<a href="#">Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-131	16-Jun-2024	275,000 USD
	Contact Name	Katie M. Vance, Ph.D.			
	Contact Telephone	301-435-6640			
	Contact Email	<a href="mailto:Katie.Vance@nih.gov">Katie.Vance@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026			
	Synopsis	The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities.			
107841	<a href="#">Risk and Protective Factors of Family Health and Family Level Interventions (R01 - Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-21-358	07-May-2024	Not Specified
	Contact Name	Deborah E. Linares, PhD, MA			
	Contact Telephone	301-402-2516			
	Contact Email	<a href="mailto:Deborah.Linares@nih.gov">Deborah.Linares@nih.gov</a>			
	Sponsor Website				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis The purpose of this initiative is to advance the science of minority health and health disparities by supporting research on family health and well-being and resilience. The NIMHD Research Framework recognizes family health, family well-being, and family resilience as critically important areas of research to decrease disparities and promote equity.</p>				
107608	<a href="#">Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-031	05-Jun-2024	Not Specified
	<p>Contact Name Enrique Michelotti, PhD</p> <p>Contact Telephone 301-443-5415</p> <p>Contact Email <a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2024 , 05-Oct-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA, NIMH, NIAAA, NIDA and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.</p>				
121868	<a href="#">Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-303	07-May-2024	Not Specified
	<p>Contact Name Larissa Avilés-Santa, MD, MPH, Director</p> <p>Contact Telephone 301-827-6924</p> <p>Contact Email <a href="mailto:avilessantal@nih.gov">avilessantal@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	<p>Synopsis</p>	2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 This Notice of Funding Opportunity (NOFO) will support innovative, collaborative, and interdisciplinary research focused on clinical epidemiology, evaluation of public and/or health care policies, and validation of measurements that address health and healthcare disparities related to non-communicable and chronic diseases (NCDs) with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos.			
121869	<p><a href="#">Interventions on Health and Healthcare Disparities on Non-Communicable and Chronic Diseases in Latin America: Improving Health Outcomes Across the Hemisphere (R01 - Clinical Trial Required)</a></p>	National Institutes of Health/DHHS	PAR-23-304	07-May-2024	Not Specified

	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	Larissa Avilés-Santa, MD, MPH, Director 301-827-6924 <a href="mailto:avilessantal@nih.gov">avilessantal@nih.gov</a>  <a href="#">Link to program URL</a> 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 The purpose of this Notice of Funding Opportunity (NOFO) is to support innovative and interdisciplinary team research focused on clinical, health services, and/or community-based interventions that address health and healthcare disparities related to non-communicable and chronic diseases (NCDs) with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos.			
121337	<p><a href="#">NIAID and NIDDK Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)</a></p>	National Institutes of Health/DHHS	PAR-23-275	07-May-2024	Not Specified

	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	Diane Adger-Johnson, MPH 240-669-2924 <a href="mailto:Altraininghelpdesk@niaid.nih.gov">Altraininghelpdesk@niaid.nih.gov</a>  <a href="#">Link to program URL</a> 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025			
--	---	--	--	--	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this notice of funding opportunity (NOFO) is to encourage researchers from diverse backgrounds to work with their institutions to submit applications for research projects within the mission of either NIAID or NIDDK. This NOFO seeks to support either (a) a New Investigator (NI), who has not previously competed successfully for substantial, independent funding from NIH, or (b) an 'At-Risk' investigator, who had prior support as a PD/PI on a substantial independent research award and unless successful in securing a substantial research grant award in the current fiscal year, will have no substantial research grant funding in the following fiscal year.			
121563	<a href="#">Developing Novel Theory and Methods for Understanding the Genetic Architecture of Complex Human Traits (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-302	05-Jun-2024	Not Specified
	Contact Name	Alexander Arguello, Ph.D.			
	Contact Telephone	240-731-3753			
	Contact Email	<a href="mailto:alexander.arguello@mail.nih.gov">alexander.arguello@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026			
	Synopsis	The goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should be interdisciplinary drawing from the natural and social sciences, account for interdependencies across scales of biological, social, and ecological organization, and make extensive use of theory, modeling, and validation with available large-scale datasets.			
122024	<a href="#">Understanding the Impact of Healthcare System and Clinician Factors on Disparities in Maternal Morbidity and Mortality (R01 - Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-24-059	05-Jun-2024	Not Specified
	Contact Name	Rada K. Dagher, PhD, MPH			
	Contact Telephone	301-451-2187			
	Contact Email	<a href="mailto:rada.dagher@nih.gov">rada.dagher@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis					
104359	<a href="#">Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PA-21-232	07-May-2024	2,500,000 USD
	<p>Contact Name   Larissa Aviles-Santa, MD, MPH</p> <p>Contact Telephone   301-827-6924</p> <p>Contact Email   <a href="mailto:avilessantal@mail.nih.gov">avilessantal@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   This initiative will support innovative research to develop, test and evaluate multi-level/multi-component strategies (including models of health care) to effectively adapt and implement comprehensive clinical care for individuals with Type 2 diabetes mellitus from populations with health disparities concordant with recommended and evidence-based guidelines.</p>				
103967	<a href="#">Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-229	05-Jun-2024	2,499,995 USD
	<p>Contact Name   Mahua Mukhopadhyay, Ph.D.</p> <p>Contact Telephone   301-435-6886</p> <p>Contact Email   <a href="mailto:mukhopam@mail.nih.gov">mukhopam@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2024 , 05-Feb-2025</p> <p>Synopsis   Rapid advances in genotyping and next generation sequencing technologies have led to the identification of genetic variants that are associated with a wide variety of congenital defects including structural birth defects (SBDs), intellectual developmental disabilities (IDDs) and inborn errors of metabolism (IEMs). Large quantities of genomic data collected from pediatric birth defects cohorts are available to the research community through several databases such as the Database of Genotypes and Phenotypes (dbGaP), the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive and Clinical Genome Resource (ClinGen). The purpose of this initiative is to promote the screening, functional validation and characterization of birth defects-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches. This initiative</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest.

104500	<a href="#">Notice of Special Interest (NOSI): Behavioral Economics for Implementation Research (BEIR) to Improve Use of Evidence-Based Practices for HLBS Conditions</a>	National Institutes of Health/DHHS	NOT-HL-21-010	07-May-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Rebecca A. Roper, MS, MPH
Contact Telephone	301-496-1051
Contact Email	<a href="mailto:Rebecca.Roper@nih.gov">Rebecca.Roper@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Sep-2024
Synopsis	This Notice of Special Interest (NOSI) is intended to stimulate the use of behavioral economics strategies for implementation research (BEIR) in order to develop more effective strategies for implementation of evidence-based practices (EBP) to address heart, lung, blood, and sleep (HLBS) conditions. NHLBI encourages applications that recognize the importance of cultural context, patterns of behavior change, and motivators for change across decision-making levels, including individuals (e.g., patients, parents, clinicians, others), groups, healthcare systems and/or communities. Applications that focus on the use of behavioral economics to develop implementation strategies for user-driven, sustainable interventions that may be simplified and minimally disruptive when possible are encouraged. Applications may propose either a clinical trial or non-clinical trial design, as appropriate to the research objectives.

108001	<a href="#">Notice of Special Interest (NOSI): Epidemiologic studies in Asian Americans, Native Hawaiians, and Pacific Islanders (Parent R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	NOT-HL-23-001	07-May-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Robb Rowley, MD
Contact Telephone	301-827-9126
Contact Email	<a href="mailto:Robb.Rowley@nih.gov">Robb.Rowley@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The purpose of this Notice of Special Interest (NOSI) is to stimulate novel epidemiological research to address key knowledge gaps within and between subpopulations of Asian Americans, Native Hawaiians, and Pacific Islanders. These populations are frequently aggregated in research, potentially masking important social and health differences. Given clear heterogeneity in ancestry, culture, immigration patterns among Asian Americans, socioeconomic position, and acculturation into American life, a critical need exists for epidemiological research to enhance our understanding of the interplay of environmental exposures, lifestyle, behavioral, genomics, social, neighborhood, and biological factors that impact the health of Asian American, Native Hawaiian, and Pacific Islander subpopulations.</p>			
112441	<a href="#">Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-22-210	05-Jun-2024	2,500,000 USD
	Contact Name	Liam O'Fallon			
	Contact Telephone	984-287-3298			
	Contact Email	<a href="mailto:ofallon@niehs.nih.gov">ofallon@niehs.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages multidisciplinary projects to investigate the potential health risks of environmental exposures of concern to a community and to develop and implement an environmental public health action plan based on research findings. Projects supported under this program will employ community-engaged research methods to conduct research and to translate research findings into public health action. This announcement reflects NIEHS' and NIMHD's commitment to environmental health disparities and environmental justice research. This FOA also advances efforts to nurture and sustain trust and bi-directional communication between academic researchers and affected communities. The Research to Action program is part of the National Institute of Environmental Health Sciences (NIEHS) "Partnerships for Environmental Public Health" (PEPH) network (<a href="https://www.niehs.nih.gov/research/supported/translational/peph/index.cfm">https://www.niehs.nih.gov/research/supported/translational/peph/index.cfm</a>).</p>			
112472	<a href="#">Notice of Special Interest (NOSI): Respiratory Complications of the Muscular Dystrophies (R01)</a>	National Institutes of Health/DHHS	NOT-HL-22-025	07-May-2024	Not Specified
	Contact Name	Aruna Natarajan, MD, PhD			
	Contact Telephone	301-827-0180			
	Contact Email	<a href="mailto:aruna.natarajan@nih.gov">aruna.natarajan@nih.gov</a>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of this NOSI is to encourage research grant applications focused on respiratory complications of the muscular dystrophies. This includes further elucidation of respiratory phenotypes in humans; research to optimize pulmonary function testing and existing respiratory therapies in humans; and mechanistic and translational research, including in vitro and in animal models, that examines respiratory muscle response to gene therapies and other therapeutic strategies in the muscular dystrophies.</p>				
120789	<a href="#">RFA-NS-24-021 -- HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-NS-24-021	06-Jun-2024	3,250,000 USD
	<p>Contact Name D.P. Mohapatra, Ph.D.</p> <p>Contact Telephone 301-496-9964</p> <p>Contact Email <a href="mailto:dp.mohapatra@nih.gov">dp.mohapatra@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 06-Jun-2024 , 08-Oct-2024 , 06-Feb-2025</p> <p>Synopsis This notice of funding opportunity (NOFO) seeks to support research aimed at holistic understanding of inter-individual or between-person differences in human pain conditions, focusing on 'Whole Person Health' and enhancing pain treatment and management strategies towards personalized pain medicine. The goal of this NOFO is to support studies that focus on the collection of clinical and/or preclinical data to enable evidence-based modeling and understanding of inter-individual differences and/or heterogeneity of pain occurring with use of pain therapy/management, or with conditions such as a second pain condition, a comorbid health condition, a comorbid mental health condition, or conditions of use / misuse of opioids, alcohol or other substances. Applicants are encouraged to develop and implement novel, multidisciplinary research approaches, and include investigators with complementary expertise to fulfill the project and program goals. Input from patients and caregivers on the goals of the project is highly encouraged. Rigorous data-driven and evidence-based research approaches supported under this NOFO are expected to provide better understanding of biological and/or biopsychosocial underpinnings of inter-individual differences, heterogeneity, and stratification of persons with lived pain experience, which would accelerate the development of evidence-based solutions toward precision pain medicine.</p>				
122946	<a href="#">Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-24-092	07-May-2024	275,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Ann Namkung, MPH</p> <p>Contact Telephone   301-496-6838</p> <p>Contact Email   <a href="mailto:ann.namkung@nih.gov">ann.namkung@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027</p> <p>Synopsis   This NOFO invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches. Proposed research must be consistent with the HIV/AIDS Research Priorities outlined by NIH s Office of AIDS Research (OAR) as described in NOT-OD-20-018.</p>				
122945	<a href="#">Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-24-091	07-May-2024	Not Specified
	<p>Contact Name   Ann Namkung, MPH</p> <p>Contact Telephone   301-496-6838</p> <p>Contact Email   <a href="mailto:ann.namkung@nih.gov">ann.namkung@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027</p> <p>Synopsis   This NOFO invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches. Proposed research must be consistent with the HIV/AIDS Research Priorities outlined by NIH s Office of AIDS Research (OAR), as described in NOT-OD-20-018.</p>				
107248	<a href="#">Notice of Special Interest (NOSI): Improving Outcomes in Cancer</a>	National Institutes of	NOT-CA-	07-May-2024	Not

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Treatment-Related Cardiotoxicity</a>		Health/DHHS	22-001	Specified
	Contact Name	Crystal Wolfrey			
	Contact Telephone	240-276-6277			
	Contact Email	<a href="mailto:wolfreyc@mail.nih.gov">wolfreyc@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 08-Oct-2024			
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to encourage collaborative and innovative approaches to mitigate cardiovascular dysfunction while optimizing cancer outcomes by understanding the mechanisms of cancer treatment-related cardiotoxicity and translating the findings to improve risk stratification, early detection, prevention, and management.			
111641	<a href="#">Notice of Special Interest (NOSI): Climate Change and Health</a>		National Institutes of Health/DHHS	NOT-ES-22-006 08-Apr-2024	Not Specified
	Contact Name	Claudia L. Thompson			
	Contact Telephone	984-287-3330			
	Contact Email	<a href="mailto:thomps1@niehs.nih.gov">thomps1@niehs.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 25-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 19-Jun-2024 , 09-Jul-2024 , 15-Jul-2024 , 08-Aug-2024 , 07-Sep-2024 , 25-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 21-Oct-2024 , 12-Nov-2024 , 15-Nov-2024 , 08-Dec-2024 , 09-Dec-2024 , 07-Jan-2025 , 25-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 19-Feb-2025 , 08-Apr-2025 , 07-May-2025			
	Synopsis	The National Institute of Environmental Health Science (NIEHS), in partnership with Fogarty International Center (FIC), National Institute of Minority Health and Health Disparities (NIMHD), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Heart Blood and Lung Institute (NHBLI) and National Institute of Allergy and Infectious Disease (NIAID) is leading an NIH-wide Climate Change and Health Initiative (CCHI) with the goals of: reducing the health threats posed by climate change across the lifespan; improving the health of people who are at increased risk from or disparately affected by climate change impacts; and building health resilience among individuals, communities, nations around the world, thereby increasing health equity. As a part of this CCHI, this NOSI encourages applications that address the impact of climate change			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	on health and well-being over the life course, including the health implications of climate change in the United States and globally.																		
111858	<a href="#">Notice of Special Interest (NOSI): Preventive Interventions to Address Cardiometabolic Risk Factors in Populations that Experience Health Disparities</a>	National Institutes of Health/DHHS	NOT-OD-22-154	07-May-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Jennifer Alvidrez, PhD</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-827-0071</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td><a href="mailto:Jennifer.alvidrez@nih.gov">Jennifer.alvidrez@nih.gov</a></td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>07-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The purpose of this NOSI is to solicit projects on preventive interventions that address cardiometabolic risk factors in populations that experience health disparities.</td> </tr> </table>					Contact Name	Jennifer Alvidrez, PhD	Contact Telephone	301-827-0071	Contact Email	<a href="mailto:Jennifer.alvidrez@nih.gov">Jennifer.alvidrez@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025	Synopsis	The purpose of this NOSI is to solicit projects on preventive interventions that address cardiometabolic risk factors in populations that experience health disparities.
Contact Name	Jennifer Alvidrez, PhD																		
Contact Telephone	301-827-0071																		
Contact Email	<a href="mailto:Jennifer.alvidrez@nih.gov">Jennifer.alvidrez@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025																		
Synopsis	The purpose of this NOSI is to solicit projects on preventive interventions that address cardiometabolic risk factors in populations that experience health disparities.																		
117360	<a href="#">Notice of Special Interest (NOSI): Research to Address Vaccine Uptake and Implementation among Populations Experiencing Health Disparities</a>	National Institutes of Health/DHHS	NOT-MD-23-008	05-Jun-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Deborah E. Linares, Ph.D., M.A.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-402-2516</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td><a href="mailto:deborah.linares@nih.gov">deborah.linares@nih.gov</a></td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024 , 07-Nov-2024 , 05-Feb-2025 , 16-Feb-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Feb-2026 , 16-Feb-2026 , 05-Jun-2026</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>This Notice of Special Interest (NOSI) highlights the need for research on strategies and interventions to increase vaccine uptake and implementation among populations experiencing health disparities in the United States (U.S.) and its territories. Research is needed to understand and address misinformation, uncertainty, distrust, and hesitancy regarding uptake of vaccines (e.g., SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV), varicella, tetanus, diphtheria, and pertussis [Tdap]) among individuals in the U.S. and its territories, especially in populations at increased risk for morbidity</td> </tr> </table>					Contact Name	Deborah E. Linares, Ph.D., M.A.	Contact Telephone	301-402-2516	Contact Email	<a href="mailto:deborah.linares@nih.gov">deborah.linares@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024 , 07-Nov-2024 , 05-Feb-2025 , 16-Feb-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Feb-2026 , 16-Feb-2026 , 05-Jun-2026	Synopsis	This Notice of Special Interest (NOSI) highlights the need for research on strategies and interventions to increase vaccine uptake and implementation among populations experiencing health disparities in the United States (U.S.) and its territories. Research is needed to understand and address misinformation, uncertainty, distrust, and hesitancy regarding uptake of vaccines (e.g., SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV), varicella, tetanus, diphtheria, and pertussis [Tdap]) among individuals in the U.S. and its territories, especially in populations at increased risk for morbidity
Contact Name	Deborah E. Linares, Ph.D., M.A.																		
Contact Telephone	301-402-2516																		
Contact Email	<a href="mailto:deborah.linares@nih.gov">deborah.linares@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024 , 07-Nov-2024 , 05-Feb-2025 , 16-Feb-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Feb-2026 , 16-Feb-2026 , 05-Jun-2026																		
Synopsis	This Notice of Special Interest (NOSI) highlights the need for research on strategies and interventions to increase vaccine uptake and implementation among populations experiencing health disparities in the United States (U.S.) and its territories. Research is needed to understand and address misinformation, uncertainty, distrust, and hesitancy regarding uptake of vaccines (e.g., SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV), varicella, tetanus, diphtheria, and pertussis [Tdap]) among individuals in the U.S. and its territories, especially in populations at increased risk for morbidity																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>and mortality due to long-standing systemic health and social inequities, as well as chronic medical conditions. This NOSI is focused on individuals across the life span (i.e., all ages). The purpose of this NOSI is to solicit research that will: 1) understand and address barriers to increasing reach, access, and uptake of vaccinations among populations experiencing health disparities; 2) evaluate organizational, local, state, and federal policies and initiatives that mitigate or exacerbate disparities in vaccine access, uptake, and series completion, and 3) evaluate community-engaged interventions (e.g., expand reach, address psychosocial barriers, and social determinants of health [SDOH]) to facilitate vaccination uptake in clinical and community contexts.</p>			
112904	<a href="#">Notice of Special Interest (NOSI): Research on the Health of Bisexual and Bisexual+ People</a>	National Institutes of Health/DHHS	NOT-OD-22-166	07-May-2024	Not Specified
	Contact Name	Christopher Barnhart, PhD			
	Contact Telephone	301-594-8983			
	Contact Email	<a href="mailto:christopher.barnhart@nih.gov">christopher.barnhart@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 21-Jun-2024 , 25-Jun-2024 , 09-Jul-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025			
	Synopsis	<p>This Notice of Special Interest (NOSI) solicits research, research training, and research career development on the health and well-being of people who identify as bisexual or bisexual+. “Bisexual” or “bi” in this NOSI may describe those with the potential to be attracted, romantically and/or sexually, to people of more than one sex or gender, not necessarily at the same time, not necessarily in the same way, and not necessarily to the same degree. “Bisexual+” or “bi+” in this NOSI is an umbrella term that is intended to encompass non-monosexual identities, including but not limited to bisexual, pansexual, sexually fluid, and queer.</p>			
114765	<a href="#">Notice of Special Interest (NOSI): Firearm Injury and Mortality Prevention Research</a>	National Institutes of Health/DHHS	NOT-OD-23-039	03-May-2024	Not Specified
	Contact Name	Dara R. Blachman, Ph.D.			
	Contact Telephone				
	Contact Email	<a href="mailto:Dara.blachman-demner@nih.gov">Dara.blachman-demner@nih.gov</a>			
	Sponsor Website				
	Program URL				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	03-May-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 21-Jun-2024 , 09-Jul-2024 , 07-Sep-2024 , 08-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026			
	Synopsis	The purpose of this Notice is to highlight interest in research to improve understanding of the determinants of firearm injury, the identification of those at risk of firearm injury (including self- and other-directed, victims and perpetrators, accidental injury), the development, piloting, and testing of innovative interventions to prevent firearm injury and mortality, and the examination of approaches to improve the implementation of existing, evidence-based interventions to prevent firearm injury and mortality.			
112420	<a href="#">Notice of Special Interest (NOSI): Increasing Uptake of Evidence-Based Screening in Diverse Populations Across the Lifespan</a>	National Institutes of Health/DHHS	NOT-OD-22-178	07-May-2024	Not Specified
	Contact Name	Melissa C. Green Parker, PhD			
	Contact Telephone	301-480-1161			
	Contact Email	<a href="mailto:melissa.greenparker@nih.gov">melissa.greenparker@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025			
	Synopsis	The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this Notice of Special Interest (NOSI) to encourage applications proposing to test multilevel strategies and interventions to improve the uptake of evidence-based screening services across the lifespan and in populations including, but not limited to, those experiencing health disparities and those that are underserved. Studies addressing efficacy, effectiveness, dissemination and implementation research, as well as studies seeking to understand and address barriers to screening are encouraged.			
112421	<a href="#">Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening</a>	National Institutes of Health/DHHS	NOT-OD-22-179	07-May-2024	Not Specified
	Contact Name	Melissa C. Green Parker, PhD			
	Contact Telephone	301-480-1161			
	Contact Email	<a href="mailto:melissa.greenparker@nih.gov">melissa.greenparker@nih.gov</a>			
	Sponsor Website				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this Notice of Special Interest (NOSI) to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and harms cannot be determined. This NOSI encourages the development and use of innovative and rigorous methods and approaches to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation.</p>				
111986	<a href="#">Notice of Special Interest (NOSI): Stimulating Research to Understand and Address Hunger, Food and Nutrition Insecurity</a>	National Institutes of Health/DHHS	NOT-OD-22-135	07-May-2024	Not Specified
	<p>Contact Name Marya Levintova, PhD</p> <p>Contact Telephone 301-496-9535</p> <p>Contact Email <a href="mailto:marya.levintova@nih.gov">marya.levintova@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024</p> <p>Synopsis The purpose of this NOSI is to encourage research on the efficacy of interventions that address nutrition security and the mechanisms of food insecurity on a variety of health outcomes. It also calls for the development of new measures for nutrition security and assessment of food insecurity that are broadly applicable. . It was developed by the Office of Nutrition Research (ONR) Implementation Working Group on Nutrition and Health Disparities in collaboration with NIH Institutes and Centers (ICs) and Offices in support of the goals and objectives of the Strategic Plan for NIH Nutrition Research.</p>				
112325	<a href="#">Notice of Special Interest (NOSI): Research on Addressing Violence to Improve Health Outcomes</a>	National Institutes of Health/DHHS	NOT-OD-22-167	07-May-2024	Not Specified
	<p>Contact Name Dara R. Blachman, Ph.D.</p> <p>Contact Telephone 301-496-8522</p> <p>Contact Email <a href="mailto:Dara.blachman-demner@nih.gov">Dara.blachman-demner@nih.gov</a></p> <p>Sponsor Website</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 09-Jul-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025</p> <p>Synopsis The purpose of this Notice is to highlight interest in addressing the role of violence in health outcomes and integrating violence-related screening and interventions into health care settings. This Notice is to encourage intervention research focused on addressing exposure to violence - including but not limited to child maltreatment, intimate partner violence/teen dating violence, elder mistreatment, peer violence/bullying, and community violence – to improve individual-level health processes and outcomes.</p>				
124566	<p><a href="#">RFA-MD-24-006 -- Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)</a></p>	National Institutes of Health/DHHS	RFA-MD-24-006	10-Jun-2024	Not Specified
	<p>Contact Name LCDR Michael Banyas, USPHS, MPA</p> <p>Contact Telephone 240-619-9483</p> <p>Contact Email <a href="mailto:nimhdsbirsttr@mail.nih.gov">nimhdsbirsttr@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 10-Jun-2024 , 05-Aug-2024 , 10-Dec-2024 , 10-Jun-2025 , 04-Aug-2025 , 09-Dec-2025 , 10-Jun-2026 , 03-Aug-2026 , 09-Dec-2026</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications that propose to develop a product, process or service for commercialization with the aim of improving minority health and/or reducing and ultimately eliminating health disparities in one or more populations that experience health disparities. Appropriate technologies should be effective, affordable, and culturally acceptable.</p>				
124567	<p><a href="#">RFA-MD-2D-24-007 -- Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional)</a></p>	National Institutes of Health/DHHS	RFA-MD-24-007	11-May-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name LCDR Michael Banyas, USPHS, MPA</p> <p>Contact Telephone 240-619-9483</p> <p>Contact Email <a href="mailto:nimhdsbirsttr@mail.nih.gov">nimhdsbirsttr@mail.nih.gov</a></p> <p>Sponsor Website</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 11-May-2024 [Optional][LOI/Pre-App], 10-Jun-2024 , 08-Jul-2024 , 11-Nov-2024 [Optional][LOI/Pre-App], 10-Dec-2024 , 11-May-2025 [Optional][LOI/Pre-App], 10-Jun-2025 , 07-Jul-2025 , 10-Nov-2025 [Optional][LOI/Pre-App], 09-Dec-2025 , 11-May-2026 [Optional][LOI/Pre-App], 10-Jun-2026 , 06-Jul-2026 , 10-Nov-2026 [Optional][LOI/Pre-App], 09-Dec-2026</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications that propose to develop a product, process or service for commercialization with the aim of improving minority health and/or reducing and ultimately eliminating health disparities in one or more NIH-defined populations that experience health disparities. Appropriate technologies should be effective, affordable, and culturally acceptable.</p>				
102069	<a href="#">Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-21-115	05-Jun-2024	Not Specified
	<p>Contact Name Melissa Parisi, MD, PhD</p> <p>Contact Telephone 301-435-6880</p> <p>Contact Email <a href="mailto:parisima@mail.nih.gov">parisima@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2024 , 05-Oct-2024</p> <p>Synopsis This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening. By defining the sequence and timing of the onset of symptoms and complications of a disorder, a valuable resource will be developed for the field. In addition, for some disorders, specific genotype-phenotype correlations may allow prediction of the clinical course, and for other disorders, identification of modifying genetic, epigenetic, or environmental factors will enhance an understanding of the clinical outcomes for an individual with such a condition. Comprehensive data on natural history will facilitate the field's ability to: 1) accurately diagnose the disorder; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the disorder; 3) identify underlying mechanisms related to basic defects; 4) potentially prevent, manage, and treat symptoms and complications of the disorder; and 5) provide children and their families with needed support and predictive information about the disorder.</p>				
114250	<a href="#">Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial)</a>	National Institutes of Health	PAR-24-	07-May-2024	400,000

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Optional</a>		Health/DHHS	022	USD
	Contact Name	Randy King, Ph.D.			
	Contact Telephone	301-451-0707			
	Contact Email	<a href="mailto:Randy.King@nih.gov">Randy.King@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 16-Jun-2024 , 16-Jul-2024 , 07-Sep-2024 , 16-Oct-2024 , 16-Nov-2024 , 07-Jan-2025 , 16-Feb-2025 , 16-Mar-2025 , 07-May-2025 , 16-Jun-2025 , 16-Jul-2025 , 07-Sep-2025 , 16-Oct-2025 , 16-Nov-2025 , 07-Jan-2026			
	Synopsis	<p>This Trailblazer Award is an opportunity for NIH-defined New and Early Stage Investigators (<a href="https://grants.nih.gov/policy/early-investigators/index.htm">https://grants.nih.gov/policy/early-investigators/index.htm</a>) to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal or no preliminary data. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal. All preliminary data should be clearly marked and limited to one-half page, which may include one figure. Applications including data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review.</p>			
121565	<a href="#">Health and Health Care Disparities Among Persons Living with Disabilities (R01 - Clinical Trials Optional)</a>	National Institutes of Health/DHHS	PAR-23-309	05-Jun-2024	Not Specified
	Contact Name	Sundania J. W. Wonnum, PhD, LCSW			
	Contact Telephone				
	Contact Email	<a href="mailto:sundania.wonnum@nih.gov">sundania.wonnum@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026			
	Synopsis	<p>The purpose of this Notice of Funding Opportunity (NOFO) is to support novel and innovative research that examines and/or intervenes on the underlying and multilevel causes, pathways, and factors adversely impacting the health and well-being of persons with disabilities at the intersections of race and ethnicity, and socioeconomic status.</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
122756	<a href="#">Addressing Health and Health Care Disparities among Sexual and Gender Minority Populations (R01 - Clinical Trials Optional)</a>	National Institutes of Health/DHHS	PAR-24-077	07-May-2024	2,500,000 USD
	<p>Contact Name   Rada K. Dagher, Ph.D., M.P.H.</p> <p>Contact Telephone   301-451-2187</p> <p>Contact Email   <a href="mailto:ada.dagher@nih.gov">ada.dagher@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027</p> <p>Synopsis   The purpose of this Notice of Funding Opportunity (NOFO) is to support innovative observational and intervention-based research to identify and characterize the pathways and mechanisms through which health and health care disparities occur among sexual and gender minority populations of minoritized racial/ethnic and socio-economic statuses. Per Notice Number: NOT-MH-24-170: Research Priorities The National Institute of Mental Health (NIMH) will only accept nonclinical trials applications that reflect the mission and scientific priorities as identified in the strategic plan NIMH » The National Institute of Mental Health Strategic Plan (nih.gov) and also NIMH’s Approach to Mental Health Disparities Research. Clinical trial applications will not be accepted under this notice. Per NOT-MH-20-067, NIMH expects that grant applications involving human research participants will collect a minimum set of Common Data Elements.</p>				
114589	<a href="#">Notice of Special Interest (NOSI): Research to Address ‘Ending the HIV Epidemic’ Initiative Goals Relevant to Substance Using Populations At-Risk for or Living with HIV</a>	National Institutes of Health/DHHS	NOT-DA-23-013	07-May-2024	Not Specified
	<p>Contact Name   Vasundhara Varthakavi, PhD</p> <p>Contact Telephone   301-443-2146</p> <p>Contact Email   <a href="mailto:vasundhara.varthakavi@nih.gov">vasundhara.varthakavi@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 09-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 14-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 21-Mar-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 16-Oct-2026 , 07-Oct-2027</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this NOSI is to support a broad spectrum of multi-disciplinary, substance use research to address the goals of the four pillars, including Diagnose, Treat, Prevent, and Respond of the 'Ending the HIV Epidemic in the U.S. (EHE)' initiative. Projects proposed in response to this NOSI are required to meet the needs of the substance using populations who are at high risk for contracting HIV or living with HIV in the geographically defined EHE priority areas within the U.S.			
124951	<a href="#">Notice of Special Interest (NOSI): Supporting the Exploration of Cloud in NIH-supported Research</a>	National Institutes of Health/DHHS	NOT-OD-24-078	18-Jun-2024	200,000 USD
	Contact Name	Fenglou Mao			
	Contact Telephone	301-451-9389			
	Contact Email	<a href="mailto:cloudsupport@nih.gov">cloudsupport@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	18-Jun-2024 , 18-Jun-2025 , 18-Jun-2026			
	Synopsis	This notice announces the availability of funds from the Office of Data Science Strategy (ODSS) to NIH-managed or NIH-majority-funded projects that may benefit from using the cloud. The purpose of this announcement is to explore and test potential opportunities for leveraging cloud solutions to enhance existing NIH activities. Projects already using cloud may apply to explore and test cloud capabilities not yet leveraged. This initiative is aligned with the NIH Strategic Plan for Data Science, which describes actions aimed at building a better data infrastructure and a modernized data ecosystem.			
105957	<a href="#">Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-305	09-Apr-2024	Not Specified
	Contact Name	Mary Evans, Ph.D.			
	Contact Telephone	301-594-4578			
	Contact Email	<a href="mailto:evansmary@mail.nih.gov">evansmary@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	09-Apr-2024 , 08-May-2024 , 10-Jun-2024 , 09-Aug-2024 , 10-Sep-2024 , 09-Oct-2024 , 07-Nov-2024 , 10-Dec-2024 , 09-Jan-2025			
	Synopsis	This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>activity, sedentary behavior, and/or sleep) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity-related policy or program offers an uncommon and scientifically-compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date; however, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.</p>				
112749	<a href="#">Notice of Special Interest (NOSI): HEAL Initiative: Opioid Use Disorder Care Pathways for Individuals with Histories of Exposure to Violence</a>	National Institutes of Health/DHHS	NOT-DA-23-007	12-Jun-2024	Not Specified
	<p>Contact Name: Carrie Mulford            Contact Telephone: 301-827-6473            Contact Email: <a href="mailto:Carrie.Mulford@nih.gov">Carrie.Mulford@nih.gov</a>            Sponsor Website:            Program URL: <a href="#">Link to program URL</a>            Deadline Dates (ALL): 12-Jun-2024 , 12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025            Synopsis: The proposed initiative seeks to test innovative models of service delivery to improve substance use and mental health outcomes for individuals who have actionable needs following exposure to violence.</p>				
108327	<a href="#">Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)</a>	National Institutes of Health/DHHS	PAR-21-357	07-May-2024	375,000 USD
	<p>Contact Name: Mahua Mukhopadhyay, Ph.D.            Contact Telephone: 301-435-6886            Contact Email: <a href="mailto:mukhopam@mail.nih.gov">mukhopam@mail.nih.gov</a>            Sponsor Website:            Program URL: <a href="#">Link to program URL</a>            Deadline Dates (ALL): 07-May-2024 , 25-Jun-2024 , 07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025            Synopsis: The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>providing biomedical research experiences primarily for health professional, undergraduate and graduate students and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate or advanced science degrees and have received no more than \$6 million dollars per year of NIH support (in both direct and F&amp;A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the schools and colleges within the institution as a whole. Help determining the Organization Funding Level can be found here or <a href="https://grants.nih.gov/grants/funding/r15.htm">https://grants.nih.gov/grants/funding/r15.htm</a>. This REAP funding opportunity announcement (FOA) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. For purposes of this FOA, minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.</p>			
108357	<a href="#">Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-060	07-May-2024	375,000 USD
	Contact Name	Lisa Chadwick			
	Contact Telephone	301-435-7275			
	Contact Email	<a href="mailto:lisa.chadwick@nih.gov">lisa.chadwick@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 25-Jun-2024 , 07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025			
	Synopsis	<p>The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for health professional, undergraduate and graduate students and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate or advanced science degrees and have received no more than \$6 million dollars per year of NIH support (in both direct and F&amp;A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the schools and colleges within the institution as a whole. Help determining the Organization Funding Level can be found here or <a href="https://grants.nih.gov/grants/funding/r15.htm">https://grants.nih.gov/grants/funding/r15.htm</a>.</p>			
109009	<a href="#">Notice of Special Interest (NOSI): Research Addressing Eye and Vision Health Equity/Health Disparities</a>	National Institutes of Health/DHHS	NOT-EY-22-004	08-Apr-2024	Not Specified
	Contact Name	Jimmy Le, Sc.D.			
	Contact Telephone	301-435-8160			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:Jimmy.Le@nih.gov">Jimmy.Le@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 08-Aug-2024 , 05-Sep-2024 , 07-Sep-2024 , 25-Sep-2024 , 08-Dec-2024 , 05-Jan-2025 , 07-Jan-2025 , 25-Jan-2025</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to highlight interest in supporting research that aims to promote health equity in the prevention, treatment, and management of eye and vision conditions. Applications that target reduction of health disparities experienced by people who are visually impaired or blind are encouraged, as well as applications that investigate the impact of bias, structural racism, and discrimination in causing or sustaining eye or vision health inequities.</p>				
110813	<a href="#">Notice of Special Interest (NOSI): Towards Developing a Cure for HBV in HIV/HBV Co-Infection</a>	National Institutes of Health/DHHS	NOT-AI-22-043	07-May-2024	Not Specified
	<p>Contact Name Chris Lambros, PhD</p> <p>Contact Telephone 240-627-3093</p> <p>Contact Email <a href="mailto:clambros@niaid.nih.gov">clambros@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025</p> <p>Synopsis The purpose of this NOSI is to encourage applications for support of innovative basic, translational, and clinical research to identify and address the unique challenges to achieving HBV cure in the presence of HIV. Research on HIV/HBV co-infection relating to the following areas will be encouraged: (1) immunology; (2) virology; and (3) therapeutics.</p>				
108347	<a href="#">Notice of Special Interest (NOSI): Advancing NEI AGI Research on newly Identified Factors Into Models of Visual System Regeneration</a>	National Institutes of Health/DHHS	NOT-EY-22-002	07-May-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024</p> <p>Synopsis The National Eye Institute (NEI) is issuing this Notice of Special Interest (NOSI) to encourage novel research that incorporates newly identified factors into new or existing models of visual system regeneration. These factors were identified by a consortium of research teams as part of the Audacious Goal Initiative (AGI) and are being shared broadly with the research community. Applicants beyond the original consortium are strongly encouraged to apply.</p>				
104784	<a href="#">Notice of Special Interest (NOSI): HIV Drug Resistance Assays and Actionable Data Dissemination Strategies</a>	National Institutes of Health/DHHS	NOT-AI-21-056	07-May-2024	Not Specified
	<p>Contact Name Usha Sharma, PhD</p> <p>Contact Telephone 240-292-4809</p> <p>Contact Email <a href="mailto:usharma@niaid.nih.gov">usharma@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis This Notice of Special Interest (NOSI) is to inform potential applicants of NIAID's interest in the development and optimization of next generation methodologies for HIV-1 drug resistance (DR) mutation detection and reporting. This is needed to improve the guidance available to treatment and prevention programs for both individuals and populations. Research responsive to this NOSI could include the development of: (i) highly sensitive mutation detection technologies that can be integrated into multiplex assay systems capable of simultaneous assessment of large numbers of potential mutations (ii) point of care (POC) DR assays, or (iii) strategies for rapid acquisition, curation and analysis of these HIV DR data and timely dissemination to healthcare providers and public health decision makers. Strategies applicable to low and middle income countries as defined by the World Bank are especially encouraged.</p>				
111805	<a href="#">Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-22-181	06-May-2024	Not Specified
	<p>Contact Name Albert Avila, Ph.D.</p> <p>Contact Telephone 301-496-8804</p> <p>Contact Email <a href="mailto:aavila@nida.nih.gov">aavila@nida.nih.gov</a></p> <p>Sponsor Website</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 06-May-2024 , 07-May-2024 , 06-Jun-2024 , 06-Sep-2024 , 07-Sep-2024 , 08-Oct-2024 , 07-Jan-2025 , 08-Jan-2025 , 06-Feb-2025 , 05-May-2025 , 07-May-2025 , 06-Jun-2025 , 07-Sep-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the participating NIH Institutes or Centers. This program is intended to support New Investigators and At-Risk Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences. Investigators from diverse backgrounds, including those from underrepresented groups (e.g., see NOT-OD-20-031, Notice of NIH’s Interest in Diversity), are encouraged to work with their institutions to apply for support under this program. Investigators from categories A and B are particularly encouraged to work with their institutions to apply.</p>				
114377	<a href="#">Notice of Special Interest (NOSI): Advancing Research for Tickborne Diseases (TBDs)</a>	National Institutes of Health/DHHS	NOT-AI-23-013	07-May-2024	Not Specified

Contact Name	Samuel Perdue, Ph.D.
Contact Telephone	240-627-3341
Contact Email	<a href="mailto:sperdue@nih.gov">sperdue@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to announce that the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Mental Health (NIMH), and the National Institute of Neurological Disorders and Stroke (NINDS), encourage applications to advance research activities relevant to the five strategic priorities identified in the recently released NIH Strategic Plan for Tickborne Disease Research: Improve fundamental knowledge of Tickborne Diseases (TBDs) to understand the host, vector, and pathogen factors that drive TBD pathogenesis and transmission. Elucidate the host immune mechanisms in response to and exploited by TBD pathogens. Advance research to improve the diagnosis of TBDs using both host- and pathogen-targeted approaches, including research for rapid diagnostics and multiplex platform approaches that detect multiple tickborne pathogens. Accelerate research to improve TBD prevention by supporting science to design, develop, and evaluate vaccines, vector control strategies, and other prevention approaches. Promote research to improve treatment for all forms of TBDs,

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

including studies to develop effective therapies to treat symptoms that persist after TBD treatment, therapies for non-infectious TBDs, and new antimicrobials. Support tools and resources to advance research in understanding, preventing, diagnosing, and treating TBDs, including repositories, genomic resources, animal models, and preclinical services to aid the development and assessment of diagnostic, vaccine, and therapeutic candidates.

114675	<a href="#">Notice of Special Interest (NOSI): Optimization of Data Storage and Utilization for the Sequence Read Archive (SRA)</a>	National Institutes of Health/DHHS	NOT-GM-23-015	08-Apr-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 16-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 08-Aug-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 08-Dec-2024 , 05-Jan-2025 , 07-Jan-2025 , 16-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 25-Feb-2025 , 05-Apr-2025 , 12-Apr-2025 , 07-May-2025 , 16-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 25-Jun-2025 , 08-Aug-2025 , 05-Sep-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 25-Oct-2025 , 08-Dec-2025
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to inform the scientific community of the interest of NIGMS, NLM, and ODSS in supporting efficiency optimization and cost reduction for Sequence Read Archive (SRA) data storage and utilization.

114367	<a href="#">Notice of Special Interest (NOSI): Advancing Development of Rapid Point-of-Care Hepatitis C Virus Diagnostics</a>	National Institutes of Health/DHHS	NOT-AI-23-001	07-May-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Julie Dyll, PhD
Contact Telephone	301-631-7296
Contact Email	<a href="mailto:dyallj@niaid.nih.gov">dyallj@niaid.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Notice of Special Interest is to announce that the National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) and the National Cancer Institute (NCI) are encouraging applications in the area of translational research and development of rapid Point-of-Care diagnostics that will diagnose active viremic HCV infections.			
113609	<a href="#">NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)</a>	National Library of Medicine/NIH/DHHS	PAR-23-034	07-May-2024	1,000,000 USD
	Contact Name	Meryl Sufian, PhD			
	Contact Telephone	301-496-4671			
	Contact Email	<a href="mailto:sufianm@mail.nih.gov">sufianm@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026			
	Synopsis	The National Library of Medicine (NLM) supports innovative research and development in biomedical informatics and data science. This funding opportunity focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. The scope of NLM's interest in these research domains is broad, with emphasis on new and innovative methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, scalable, and reusable/reproducible approaches to discovery, curation, analysis, organization, and management of health-related digital objects.			
115310	<a href="#">Notice of Special Interest (NOSI): Computational and Statistical Methods to Enhance Discovery from Health Data</a>	National Library of Medicine/NIH/DHHS	NOT-LM-23-001	07-May-2024	Not Specified
	Contact Name	Meryl Sufian, PhD			
	Contact Telephone	301-496-4671			
	Contact Email	<a href="mailto:sufianm@mail.nih.gov">sufianm@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The National Library of Medicine is issuing this Notice to highlight its interest in receiving grant applications focused on research that aims to reduce or mitigate gaps and errors in health data sets.</p>				
113256	<p><a href="#">Notice of Special Interest (NOSI): Development and Preliminary Testing of Health-related Behavioral Interventions</a></p>	Office of Behavioral and Social Sciences Research/NIH/DHHS	NOT-OD-22-203	07-May-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>William Elwood, PhD</p> <p>301-402-0116</p> <p><a href="mailto:william.elwood@nih.gov">william.elwood@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-May-2024 , 13-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 18-Jun-2024 , 09-Jul-2024 , 07-Sep-2024 , 13-Sep-2024</p> <p>To achieve more potent strategies to promote sustained health-related behavior change, there is a need for intentional and methodical translation of foundational behavioral and social science discoveries into new or improved interventions. The Office of Behavioral and Social Sciences Research (OBSSR) and participating ICOs are issuing this Notice to highlight interest in the systematic development of original health-related behavioral interventions that test hypotheses that draw on basic behavioral and social sciences research (bBSSR) findings that posit causal or processual mechanisms of action of healthier behavior change. This includes research that focuses on use-inspired bBSSR, understanding of mechanisms of action underlying initial and sustained behavior change, and systematic development and testing of health-related behavioral interventions and their components.</p>			
124675	<p><a href="#">RFA-OD-24-014 -- Botanical Dietary Supplements Translational Research Teams (RM1 Clinical Trial Required)</a></p>	Office of Dietary Supplements/NIH/DHHS	RFA-OD-24-014	09-Jun-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Barbara C. Sorkin, Ph.D.</p> <p></p> <p><a href="mailto:sorkinb@mail.nih.gov">sorkinb@mail.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>09-Jun-2024 [Optional][LOI/Pre-App], 08-Jul-2024</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Synopsis	<p>The purpose of this Notice of Funding Opportunity (NOFO) is to support trans-disciplinary, translational research on chemically complex botanical products or natural products traditionally used as dietary components, to inform future clinical trials of the efficacy of exceptionally promising dietary supplements for improving resilience. Clinical efficacy trials of such products are often challenged by gaps in understanding that critically affect the design and/or interpretation of a clinical trial. For example, the molecular mechanism(s) of action of a botanical dietary supplement might not be well established and thus the optimal product chemistry, for a given health outcome may not be known; in the absence of such information to guide product specifications, stability testing and assessments of bioavailability and absorption kinetics a clinical trial might not provide a good test of the effect of that botanical on the health outcome(s) assessed. Similarly, the best outcome measure for a trial of a product reputed to have many different health effects, or to have effects where many different quantitative outcomes might be relevant might benefit from deeper understanding of the biological structure(s) and/or system(s) affected by the product, and the health outcomes expected from modulating those targets. Interpretation of a clinical trial of an ingested product will benefit from the availability of methods to assess bioavailability of active constituents of the product or target engagement by those constituents. Clinical trial design will benefit from an understanding of the ways in which trial participant characteristics, whether genetics, background diet, epigenomics, gut microbiota, or health history, for example, may influence the effect of the intervention tested. The forgoing are examples of the types of knowledge gaps of interest for this NOFO.</p>			
--	----------	---	--	--	--

113926	<a href="#">Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research (R01)</a>	Office of Research Infrastructure Programs/NIH/DHHS	PAR-23-040	05-Jun-2024	Not Specified
--------	---	---	------------	-------------	---------------

	Contact Name	Sige Zou, Ph.D.			
	Contact Telephone	301-435-0749			
	Contact Email	<a href="mailto:zous@mail.nih.gov">zous@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025			
	Synopsis	<p>The Office of Research Infrastructure Programs (ORIP) encourages research project grant applications aimed at developing and implementing broadly applicable technologies, tools, and resources for validating animal models and enhancing rigor, reproducibility, and translatability of animal research. Research projects submitted under this Funding Opportunity Announcement (FOA) should be hypothesis driven with strong preliminary data. Proposed studies, models, resources, or technologies under this FOA must either address research interests of multiple NIH Institutes and Centers (ICs), explore multiple organ systems, or be applicable to diseases and processes that impact multiple organ systems in order to align</p>			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		with ORIP’s NIH-wide mission and programs. Applications should aim to enhance the rigor, reproducibility, and translatability of animal research through the development and implementation of technologies, tools, and resources that have significant impact across a broad range of research areas using animal models. Applications must demonstrate how the proposed resources and technologies impact rigor and reproducibility of animal studies.			
102835	<a href="#">Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)</a>	Office of Research Infrastructure Programs/NIH/DHHS	PAR-21-167	07-May-2024	275,000 USD
	Contact Name	Sige Zou, Ph.D.			
	Contact Telephone	301-435-0749			
	Contact Email	<a href="mailto:zous@mail.nih.gov">zous@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025			
	Synopsis	This funding opportunity announcement (FOA) encourages innovative research to develop, characterize, and improve animal models, biological materials, and novel technologies to better understand human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed project must have broad application to multiple NIH Institutes or Centers (ICs) to align with the Office of Research Infrastructure Programs’ (ORIP) trans-NIH mission. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC, will be considered not acceptable to this FOA and will be withdrawn.			
123592	<a href="#">RFA-OD-24-009 -- Data Coordinating and Operations Center for the ECHO IDeA States Pediatric Clinical Trials Network - 3 (U24 Clinical Trial Required—Infrastructure)</a>	Office of the Director, National Institutes of Health/NIH/DHHS	RFA-OD-24-009	14-Jun-2024	26,250,000 USD
	Contact Name	Tonse N.K. Raju, MD Program Officer			
	Contact Telephone	301-435-5236			
	Contact Email	<a href="mailto:Tonse.raj@nih.gov">Tonse.raj@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	14-Jun-2024			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis

This Notice of Funding Opportunity (NOFO), issued by the Office of the Director (OD), National Institutes of Health (NIH), invites applications from entities/institutions in Institutional Development Award (IDeA)-eligible states to participate as the Data Coordinating and Operations Center (DCOC) in the Environmental influences on Child Health Outcomes IDeA States Pediatric Clinical Trials Network (ECHO ISPCTN). This RFA runs in parallel with companion RFA (Clinical Sites RFA-OD-24-008) that will solicit applications for ECHO ISPCTN Clinical Sites. The ECHO ISPCTN DCOC and Clinical Sites together will form the ECHO ISPCTN. The ECHO ISPCTN is the intervention component of the ECHO Program and supports its overall mission to enhance the health of children for generations to come. The DCOC award budget will fund approximately five multicenter pediatric clinical trials with each trial related to prevention or treatment of one or more of ECHO’s five outcome areas of interest: pre-, peri-, and postnatal outcomes; upper and lower airways; obesity; neurodevelopment; and positive health. Overall, the five trials should address at least two of the five areas. The DCOC will support the ECHO ISPCTN Clinical Sites to Develop, conduct, and disseminate findings from multicenter clinical trials research, assuring the participation of children living in rural or underserved communities in IDeA states Build pediatric clinical trial research capacity in IDeA states funded by the ECHO ISPCTN Engage interested parties such as community members, nonprofit organizations, and professional societies to enhance ECHO ISPCTN clinical trial impact, transferability, rigor, and feasibility Through the rigorous use of appropriate scientific methodology and by recruiting and retaining the numbers of participants that justify multicenter trials, the ECHO ISPCTN aims to provide valid and generalizable answers to intervention research questions relevant to the health of children from rural or underserved backgrounds. The ECHO ISPCTN awardees will be primarily responsible for initiating and conducting clinical trials, although they may collaborate with other NIH research networks or subject matter experts outside the network. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

## National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
120039	<a href="#">NSF National Quantum Virtual Laboratory</a>	National Science Foundation	23-604	09-Apr-2024 [LOI/Pre-App]	1,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone 703-292-8235</p> <p>Contact Email <a href="mailto:NQVL@nsf.gov">NQVL@nsf.gov</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 09-Apr-2024 [LOI/Pre-App], 11-Jun-2024</p> <p>Synopsis</p>	<p>The National Quantum Initiative (NQI) Act1 aims to ensure the continuing leadership of the United States (U.S.) in quantum information science and technology. In conformance with the NQI goals, an argument was set forth for a renewed emphasis on identifying and fostering early adoption of quantum technologies to transform the field of Quantum Information Science and Engineering (QISE) and to accelerate broader impacts on society. A systematic approach to maturing quantum technology platforms by integrating end-users and potential customers from other fields of science and engineering and other sectors of the economy into cycles of research, development, and demonstration should result in lowering the barriers for end-users to pioneer new applications. NSF support for use-inspired and translational research in QISE, combined with its existing strength in support of the underlying foundational research, is anticipated to accelerate development of a market for quantum technologies. With this program solicitation, the Foundation is introducing the National Quantum Virtual Laboratory (NQVL) concept as an overarching shared infrastructure designed to facilitate the translation from basic science and engineering to the resultant technology, while at the same time emphasizing and advancing its scientific and technical value. The NQVL aims to develop and utilize use-inspired and application-oriented quantum technologies. In the process, NQVL researchers will explore quantum frontiers6, foster QISE workforce education and training, engage in outreach activities at all levels, and promote broadening participation, diversity, equity, and inclusion in QISE, thereby lowering barriers at all entry points of the research enterprise. The engagement of the entire United States (U.S.) QISE community will be necessary for this initiative to succeed, and, indeed, the project is designed to include participation from a full spectrum of organizations who have expertise to contribute. In particular, NSF recognizes that the involvement of industry partners is essential and will welcome these to be a part of the overall structure. Partnerships with other U.S. Federal agencies under the NQI umbrella are also encouraged. This solicitation lays out a vision for the entire NQVL program that includes Quantum Science and Technology Demonstration (QSTD) projects, support for enabling technologies through Transformative Advances in Quantum Systems (TAQS), as well as a central coordination hub. Proposals for Pilot phase QSTDs are solicited at this time.</p>			
124484	<a href="#">Artificial Intelligence, Formal Methods, and Mathematical Reasoning</a>	National Science	24-554	03-Jun-2024	1,200,000 USD

## National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Foundation					
	<p>Contact Name   Tomek Bartoszynski</p> <p>Contact Telephone   703-292-4885</p> <p>Contact Email   <a href="mailto:tbartosz@nsf.gov">tbartosz@nsf.gov</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   03-Jun-2024 , 05-Feb-2025 , 05-Feb-2026</p> <p>Synopsis   The Artificial Intelligence, Formal Methods, and Mathematical Reasoning (AIMing) program seeks to support research at the interface of innovative computational and artificial intelligence (AI) technologies and new strategies/technologies in mathematical reasoning to automate knowledge discovery. Mathematical reasoning is a central ability of human intelligence that plays an important role in knowledge discovery. In the last decades, both the mathematics and computer science communities have contributed to research in machine-assisted mathematical reasoning, encompassing conjecture, proof, and verification. This has been in the form of both formal methods and interactive theorem provers, as well as using techniques from artificial intelligence. Recent technological advances have led to a surge of interest in machine-assisted mathematical reasoning from the mathematical sciences, formal methods, and AI communities. In turn, advances in this field have potential impact on research in AI.</p>				
124523	<a href="#">Computer Science for All</a>	National Science Foundation	24-555	04-Jun-2024	Not Specified
	<p>Contact Name   Allyson Kennedy</p> <p>Contact Telephone   703-292-8950</p> <p>Contact Email   <a href="mailto:aykenned@nsf.gov">aykenned@nsf.gov</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   04-Jun-2024 , 12-Feb-2025</p> <p>Synopsis   This program aims to provide all U.S. students with the opportunity to participate in computer science (CS) and computational thinking (CT) education in their schools at the preK-12 levels. With this solicitation, the National Science Foundation (NSF) focuses on both research and research-practice partnerships (RPPs) that foster the research and development needed to bring CS and CT to all schools. Specifically, this solicitation aims to provide (1) high school teachers</p>				

## National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		with the preparation, professional development (PD) and ongoing support they need to teach rigorous computer science courses; (2) preK-8 teachers with the instructional materials and preparation they need to integrate CS and CT into their teaching; and (3) schools and districts with the resources needed to define and evaluate multi-grade pathways in CS and CT.			
124892	<a href="#">Dear Colleague Letter: Nordic-U.S. Research Collaboration on Sustainable Development of the Arctic</a>	National Science Foundation	NSF 24-070	04-Jun-2024 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	703-292-5111			
	Contact Email	<a href="mailto:NSF-NordForsk@nsf.gov">NSF-NordForsk@nsf.gov</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	04-Jun-2024 [LOI/Pre-App]			
	Synopsis	<p>The U.S. National Science Foundation (NSF) and NordForsk, the science funding body of the Nordic Council of Ministers, have signed a Memorandum of Understanding (MOU) on Research Cooperation. The MOU provides an overarching framework to encourage collaboration among U.S., Nordic, and Canadian research communities and sets out the principles by which jointly supported activities might be developed. NordForsk and NSF are pleased to announce support for interdisciplinary research to bring forward new knowledge on how to ensure sustainable development of the Arctic. This funding opportunity is designed to support interdisciplinary research projects of the highest international quality and potential for societal impact with clear added value from multilateral collaboration. Only interdisciplinary research will be funded that integrates skills from multiple disciplines to contribute new and groundbreaking knowledge for the sustainable development of the Arctic.</p>			
124652	<a href="#">Global Centers</a>	National Science Foundation	24-556	11-Jun-2024	5,000,000 USD
	Contact Name	Karen R. Lips			
	Contact Telephone	703-292-5133			
	Contact Email	<a href="mailto:globalcenters@nsf.gov">globalcenters@nsf.gov</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	11-Jun-2024			
	Synopsis	This solicitation describes an ambitious program to fund international, interdisciplinary collaborative research centers that			

## National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>will apply best practices of broadening participation and community engagement to develop use-inspired bioeconomy research to address one or more global challenges identified by the scientific community. Here, the "used-inspired" nature of the research refers to project outcomes leading to foreseeable benefits to society. This program will prioritize research collaborations that foster team science and community-engaged research, use knowledge-to-action frameworks whose rationale, conceptualization, and research directions are driven by the potential use of the results as illustrated by Pasteur's Quadrant (see Stokes, Donald E. (1997), "Pasteur's Quadrant - Basic Science and Technological Innovation," Brookings Institution Press, p.196. ISBN 9780815781776). Proposals should also indicate how research will be co-generated with communities and stakeholders identified in the proposal. The proposed research should maximize the benefits of international, interdisciplinary collaborations, and describe the roles and responsibilities of each national team in achieving the goals of the proposed Global Center. Global Centers projects involving partnership between the U.S. and two or more partner countries are strongly encouraged. Global challenges must be addressed through international collaboration and researchers are encouraged to develop international teams to address research questions that can only be addressed through multilateral efforts.</p>			
109414	<a href="#">Industry-University Cooperative Research Centers Program</a>	National Science Foundation	20-570	12-Jun-2024	Not Specified
	<p>Contact Name   Prakash G. Balan</p> <p>Contact Telephone   703-292-5341</p> <p>Contact Email   <a href="mailto:pbalan@nsf.gov">pbalan@nsf.gov</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Jun-2024</p> <p>Synopsis   The IUCRC program catalyzes breakthrough pre-competitive research by enabling close and sustained engagement between industry innovators, world-class academic teams, and government agencies. IUCRCs help industry partners and government agencies connect directly and efficiently with university researchers to achieve three primary objectives: 1) Conduct high-impact research to meet shared and critical industrial needs in companies of all sizes; 2) Enhance U.S. global leadership in driving innovative technology development, and 3) Identify, mentor and develop a diverse, highly skilled science and engineering workforce.</p>				
124885	<a href="#">Mathematical Foundations of Digital Twins</a>	National Science Foundation	24-559	20-Jun-2024	5,000,000 USD

## National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Yuliya Gorb</p> <p>Contact Telephone   703-292-2113</p> <p>Contact Email   <a href="mailto:ygorb@nsf.gov">ygorb@nsf.gov</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   20-Jun-2024 , 17-Mar-2025</p> <p>Synopsis   The Division of Mathematical Sciences (DMS) in the Directorate for Mathematical and Physical Sciences (MPS) at the National Science Foundation (NSF) and the Air Force Office of Scientific Research (AFOSR) plan to jointly support foundational mathematical and statistical research on Digital Twins in applied sciences. Recent years have witnessed a significant increase in the demand and interest in applications that involve collaborative teams developing and analyzing Digital Twins to support decision making in various fields, including science, engineering, medicine, urban planning, and more. Both agencies recognize the need to promote research aiming to stimulate an interplay between mathematics/statistics/computation and practical applications in the realm of Digital Twins. This program encourages new collaborative efforts within the realm of Digital Twins, aiming at stimulating fundamental research innovation, pushing, and expanding the boundaries of knowledge, and exploring new frontiers in mathematics and computation for Digital Twin development, and its applications. By leveraging this synergy, the program aims to harness science, technology, and innovation to address some of our Society's most pressing challenges.</p>				
124924	<a href="#">Foundations for Digital Twins as Catalyzers of Biomedical Technological Innovation</a>	National Science Foundation	24-561	21-Jun-2024	Not Specified
	<p>Contact Name   Yulia R. Gel</p> <p>Contact Telephone   703-292-7888</p> <p>Contact Email   <a href="mailto:ygel@nsf.gov">ygel@nsf.gov</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL  </p> <p>Deadline Dates (ALL)   21-Jun-2024 , 05-May-2025</p> <p>Synopsis   The Foundations for Digital Twins as Catalyzers of Biomedical Technological Innovation (FDT-BioTech) program supports inherently interdisciplinary research projects that underpin the mathematical and engineering foundations behind the development and use of digital twins and synthetic data in biomedical and healthcare applications, with a particular focus on digital, in silico models used in the evaluation of medical devices and the relevance of the developed models in addressing</p>				

## National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		current and emerging challenges affecting the development and assessment of biomedical technologies. The goal of the FDT-BioTech initiative is to catalyze biomedical technological innovation through new foundational development of methods and algorithms relevant to digital twins and synthetic humans.			
124963	<a href="#">Data Science Corps</a>	National Science Foundation	24-560	21-Jun-2024	1,200,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Stephanie D. Teasley</p> <p>703-292-8752</p> <p><a href="mailto:steasley@nsf.gov">steasley@nsf.gov</a></p> <p><a href="#">Link to sponsor website</a></p> <p><a href="#">Link to program URL</a></p> <p>21-Jun-2024</p>			
	Synopsis	<p>The objective of the Data Science Corps program is to help build a strong national data science infrastructure and workforce. The Data Science Corps program seeks to engage data science students in real-world data science implementation projects. This engagement will help bridge the data-to-knowledge gap in organizations and communities at all levels, including local, state, and national, and will empower better use of data for more effective decision making. Data Science Corps participants will be able to sharpen their skills in data science by working on real-world projects focused on specific community needs, including rural communities, urban communities, academia, industry, or government. This partnership between communities and data scientists will serve the nation by helping produce a workforce-ready cohort of data scientists and technologists, who have experience with data science in action in real-world settings. The program welcomes proposals that seek to broaden participation in science, technology, engineering and mathematics (STEM) and STEM education. This solicitation prompts the community to respond to one or more mechanisms by which to provide students with data science education and training, including in data science issues related to knowledge representation and creation and use of knowledge graphs. The solicitation supports opportunities for undergraduates (including students from community colleges, Minority Serving Institutions, other emerging research institutions as defined in the CHIPS and Science Act, <a href="https://www.congress.gov/bill/117th-congress/house-bill/4346">https://www.congress.gov/bill/117th-congress/house-bill/4346</a>, and institutions in EPSCoR jurisdictions), and grade 6-12 teachers and students.</p>			
113761	<a href="#">Expanding AI Innovation through Capacity Building and Partnerships</a>	National Science Foundation	23-506	24-Jun-2024	Not Specified
	Contact Name				



## National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	703-292-5111
Contact Email	<a href="mailto:ExpandAIProgram@nsf.gov">ExpandAIProgram@nsf.gov</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	24-Jun-2024 , 18-Oct-2024 , 10-Mar-2025 , 23-Jun-2025
Synopsis	<p>The National Science Foundation and its partners support the continued growth of a broad and diverse interdisciplinary research community for the advancement of AI and AI-powered innovation, providing a unique opportunity to broadly promote the NSF vision and core values, especially inclusion and collaboration. The Expanding AI Innovation through Capacity Building and Partnerships (ExpandAI) program aims to significantly broaden participation in AI research, education, and workforce development through capacity development projects and through partnerships within the National AI Research Institutes ecosystem.</p>

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
115139	<a href="#">Special Emphasis Notice (SEN): Research on Climate Change and Healthcare</a>	Agency for Healthcare Research and Quality/DHHS	NOT-HS-23-006	08-Apr-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Brent Sandmeyer, MPH 301-427-1441 <a href="mailto:Brent.sandmeyer@ahrq.hhs.gov">Brent.sandmeyer@ahrq.hhs.gov</a>  <a href="#">Link to program URL</a> 12-Apr-2024 , 25-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 26-Jun-2024 , 08-Aug-2024 , 12-Aug-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 26-Oct-2024 , 08-Dec-2024 , 12-Dec-2024 , 25-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 26-Feb-2025 , 08-Apr-2025 , 12-Apr-2025 , 25-May-2025 , 12-Jun-2025 , 08-Aug-2025 , 12-Aug-2025 , 25-Sep-2025 , 25-Sep-2025 , 12-Oct-2025 , 12-Dec-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027 This Special Emphasis Notice (SEN) announces AHRQ's interest in receiving health services research grant applications that address the intersection of climate change and healthcare.			
109186	<a href="#">Notice of Special Interest (NOSI): Health Services Research on Health System and Healthcare Professional Responsiveness to COVID-19</a>	Agency for Healthcare Research and Quality/DHHS	NOT-HS-22-010	25-May-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Leeann Comfort, PhD, MPP  <a href="mailto:Leeann.Comfort@ahrq.hhs.gov">Leeann.Comfort@ahrq.hhs.gov</a>  <a href="#">Link to program URL</a> 25-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Jan-2025 , 05-Feb-2025 This Special Emphasis Notice (SEN) informs the research community that the Agency for Healthcare Research and Quality (AHRQ) is interested in receiving health services research grant applications to develop models of care that improve access, quality, and outcomes of care related to COVID-19 and post-acute sequelae from COVID-19 (PASC).			
123850	<a href="#">AHRQ Small Health Services Research Grant Program (R03)</a>	Agency for Healthcare Research and Quality/DHHS	PA-24-155	16-Jun-2024	100,000 USD
	Contact Name				

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-427-1025</p> <p>Contact Email <a href="mailto:kathryn.woolridge@ahrq.hhs.gov">kathryn.woolridge@ahrq.hhs.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026 , 16-Feb-2027 , 16-Jun-2027 , 16-Oct-2027 , 16-Feb-2028 , 16-Jun-2028 , 16-Oct-2028 , 16-Feb-2029 , 16-Jun-2029</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to seek health services research grant applications focused on AHRQ research priorities, including improving healthcare quality and patient safety, improving healthcare delivery and practice improvement, and enhancing whole-person healthcare delivery. AHRQ supports research in all healthcare settings, including the hospital, long-term care, ambulatory care, home healthcare, pharmacy, and care transitions between settings. Research may involve many partners and other groups, including patients, families, clinicians, non-clinical healthcare staff, policymakers, payers, healthcare organizations, providers and accreditors, local and State governments, the Federal Government, and others.</p>				
123849	<a href="#">AHRQ Health Services Research Projects (R01)</a>	Agency for Healthcare Research and Quality/DHHS	PA-24-154	05-Jun-2024	2,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone 301-427-1025</p> <p>Contact Email <a href="mailto:kathryn.woolridge@ahrq.hhs.gov">kathryn.woolridge@ahrq.hhs.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027 , 05-Jun-2027 , 05-Oct-2027 , 05-Feb-2028 , 05-Jun-2028 , 05-Oct-2028 , 05-Feb-2029 , 05-Jun-2029</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to seek health services research grant applications focused on AHRQ research priorities, including improving healthcare quality and patient safety, improving healthcare delivery and practice improvement, and enhancing whole-person healthcare delivery. AHRQ supports research in all healthcare settings, including the hospital, long-term care, ambulatory care, home healthcare, pharmacy, and care transitions between settings. Research may involve many partners and other groups, including patients, families, clinicians, non-clinical healthcare staff, policymakers, payers, healthcare organizations, providers and accreditors, local and State governments, the Federal Government, and others.</p>				

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
114270	<a href="#">Special Emphasis Notice (SEN): Interest in Healthcare Associated Infections and Combating Antibiotic Resistant Bacteria Research</a>	Agency for Healthcare Research and Quality/DHHS	NOT-HS-23-003	25-May-2024	Not Specified
	<p>Contact Name   Leyi Lin, MD</p> <p>Contact Telephone   301-427-1333</p> <p>Contact Email   <a href="mailto:leyi.lin@ahrq.hhs.gov">leyi.lin@ahrq.hhs.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   25-May-2024 , 05-Jun-2024 , 25-Sep-2024 , 05-Oct-2024 , 25-Jan-2025 , 05-Feb-2025 , 25-May-2025 , 05-Jun-2025 , 25-Sep-2025 , 25-Jan-2026 , 05-Feb-2026 , 25-May-2026 , 05-Jun-2026 , 25-Sep-2026 , 05-Oct-2026 , 05-Oct-2026</p> <p>Synopsis   The purpose of this Special Emphasis Notice (SEN) is to inform the research community of the Agency for Healthcare Research and Quality (AHRQ) continued interest in, and available funding for, supporting innovative research seeking to reduce the burden of healthcare-associated infections (HAIs) and to address the growing threat posed by antimicrobial resistant organisms. HAIs continue to cause significant patient harm and are also associated with considerable financial consequences for healthcare facilities and for patients. Unfortunately, the COVID-19 pandemic has been associated with observed increases of several types of HAIs as well as increases in antimicrobial resistance, highlighting the importance of developing and studying resilient and adaptable countermeasures.</p>				
107009	<a href="#">Large Research Projects for Combating Antibiotic-Resistant Bacteria (CARB) (R01)</a>	Agency for Healthcare Research and Quality/DHHS	PA-22-047	05-Jun-2024	2,500,000 USD
	<p>Contact Name   James Cleeman, MD</p> <p>Contact Telephone   301-427-1330</p> <p>Contact Email   <a href="mailto:james.cleeman@ahrq.hhs.gov">james.cleeman@ahrq.hhs.gov</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis   Agency for Healthcare Research and Quality (AHRQ) invites applications to conduct Large Health Services Research Demonstration and Dissemination Projects (R18) focused on Combating Antibiotic-Resistant Bacteria (CARB). This FOA will use the R01 Research Project Grant award mechanism.</p>				

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
119452	<a href="#">Biological Technologies</a>	Defense Advanced Research Projects Agency/Department of Defense	HR001123S0045	20-Jun-2024 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:BTOBAA2023@darpa.mil">BTOBAA2023@darpa.mil</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	20-Jun-2024 [LOI/Pre-App], 20-Jun-2024			
	Synopsis	<p>BTO's mission is to develop capabilities that leverage the unique properties of biology - adaption, replication, resilience and complexity, to revolutionize how the United States defends the homeland and prepares and protects its Warfighters.</p> <p>Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness.</p>			
123396	<a href="#">Accelerating STEM and Climate Ambitions</a>	Department of State	LUXEM-PDS-FY24-01	05-May-2024 [LOI/Pre-App]	15,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:LuxembourgGrants@state.gov">LuxembourgGrants@state.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-May-2024 [LOI/Pre-App], 09-Jun-2024			
	Synopsis	<p>The Public Diplomacy Section (PD) of the U.S. Embassy in Luxembourg, U.S. Department of State, announces an open competition for organizations to submit applications to carry out programs strengthening bilateral ties between the United States and Luxembourg on Accelerating STEM and Climate Ambitions. Awards may range from \$3,000 to \$15,000.</p>			
125081	<a href="#">Space Experiential Learning Center (SELC)</a>	Department of State	ND-NOFO-24-104	03-Jun-2024	100,000 USD
	Contact Name				

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email <a href="mailto:ND_GrantApplications@state.gov">ND_GrantApplications@state.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 03-Jun-2024</p> <p>Synopsis The U.S. Department of State’s Public Diplomacy Section in New Delhi invites proposals for the operation and demonstration of experiences at American Center New Delhi (ACND). The ACND will establish a Space Experiential Learning Center (SELC) to enable next generation space enthusiasts to participate in space exploration studies, education, experiential learning activities, and networking to incline them towards pursuing higher education and a career in space science, innovation, technology, and applications. This NOFO solicits proposals for running and showcasing experiences at ACND. Funding for one award may range from \$75,000 to \$100,000.</p>				
119530	<a href="#">Naval Air Warfare Center Aircraft Division (NAWCAD) Office-Wide Broad Agency Announcement</a>	Department of the Navy/Department of Defense	N00421-23-S-0001	22-Jun-2024 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:NAWCAD_PAXR_OfficeWide_BAA@us.navy.mil">NAWCAD_PAXR_OfficeWide_BAA@us.navy.mil</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 22-Jun-2024 [LOI/Pre-App]</p> <p>Synopsis The Naval Air Warfare Center Aircraft Division (NAWCAD) is interested in receiving white papers for Research and Development projects which offer potential for advancement and improvement of NAWCAD operations.</p>				
125167	<a href="#">Centers of Excellence to Enhance Disease Detection in Newborns</a>	National Center for Environmental Health/CDC/DHHS	CDC-RFA-EH-24-0044	26-Apr-2024 [Optional][LOI/Pre-App]	4,000,000 USD
	<p>Contact Name Cynthia Hinton, Project Officer</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:ceh9@cdc.gov">ceh9@cdc.gov</a></p> <p>Sponsor Website</p>				

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	26-Apr-2024 [Optional][LOI/Pre-App], 04-Jun-2024
Synopsis	This funding opportunity will establish a newborn screening (NBS) Center of Excellence that will work collaboratively with CDC’s Newborn Screening and Molecular Biology Branch (NSMBB), partner jurisdictions, and other relevant partners, to: Develop infrastructure to implement advanced technologies to expand NBS system capacity. Use advanced technologies as first and/or higher tier testing platforms to optimize screening performance. Incorporate bioinformatics to analyze complex biochemical and molecular NBS data.

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
124816	<a href="#">Global Centres (GC) Addressing Global Challenges Through Bioeconomy</a>	Biotechnology and Biological Sciences Research Council (BBSRC)		11-Jun-2024	2,683,800 USD
	Contact Name Contact Telephone Contact Email <a href="mailto:global.centres.bioeconomy@bbsrc.ukri.org">global.centres.bioeconomy@bbsrc.ukri.org</a> Sponsor Website Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 11-Jun-2024 Synopsis Funding is available to support large-scale international research projects to address global challenges through the bioeconomy. BBSRC will support Global Centres that facilitate international, interdisciplinary collaborations and workforce training with diverse stakeholders. BBSRC funding is available for UK eligible researchers for partnerships which must include a US partner and encouraged to include partners in one or more participating countries. The full economic cost (FEC) of a project can be up to £2.13 million. BBSRC will fund 80% of the FEC for projects of up to five years in duration. Applicant Types Funding Limit 2,130,000.00 maximum Limited Submission No				
115901	<a href="#">R Accelerated Award Grant</a>	Alex's Lemonade Stand		06-Jun-2024	800,000 USD
	Contact Name Contact Telephone 866-333-1213 Contact Email <a href="mailto:Grants@AlexsLemonade.org">Grants@AlexsLemonade.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a>				



## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 06-Jun-2024</p> <p>Synopsis The purpose of the R Accelerated Award Grant is to advance ALSF’s mission to find cures and better treatments for childhood cancers by providing support to scientists focused on pediatric oncology research. Applicants must have an original project that is not currently being funded that has a clear focus on accelerating the discovery of more effective, less toxic therapies for childhood cancers. Research projects should address a testable hypothesis based on strong scientific rationale. Applicants must be first-time recipients of a pediatric cancer research focused NIH R01 award or equivalent independent award. Demonstration of continued commitment to pediatric cancer investigation as well as institutional support are critical components of a successful application. The R Accelerated Award is a four-year grant.</p> <p>Applicant Types</p> <p>Funding Limit 200,000.00 per year</p> <p>Limited Submission No</p>				

053763	<a href="#">Innovation Grants (Building Trust Through DEI)</a>	Alliance for Academic Internal Medicine		07-Jun-2024	Not Specified
--------	--	---	--	-------------	---------------

Contact Name	
Contact Telephone	703-341-4540
Contact Email	<a href="mailto:innovationgrants@im.org">innovationgrants@im.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jun-2024
Synopsis	The Building Trust through Diversity, Health Care Equity, & Inclusion in Internal Medicine Training program supports projects that will integrate diversity, equity, and inclusion (DEI) into the fabric of internal medicine education and training. Funding totals \$400,000 and is designated to support inter-professional projects that are led by internal medicine residents and faculty focused on improving trust and advancing health equity in the health care system. Of this funding, \$100,000 is specifically allocated for grants supporting projects designed to enhance diagnostic

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types   excellence and address disparities based on factors such as race, ethnicity, gender, sexual orientation, geography, age, and disability.</p> <p>Funding Limit   0.00 see detail</p> <p>Limited Submission   No</p>				
110437	<a href="#">Seed Grants</a>	ALS Association		09-Apr-2024 [LOI/Pre-App]	50,000 USD
	<p>Contact Name  </p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:researchgrants@alsa-national.org">researchgrants@alsa-national.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   09-Apr-2024 [LOI/Pre-App], 20-Jun-2024</p> <p>Synopsis   The ALS Association’s Seed Grant program seeks to fund research with a strong scientific rationale and potential for significant impact in ALS but limited preliminary data. These 1-year awards with a maximum budget of \$50,000 should be used to gather preliminary data that will support future applications to larger grant award programs.</p> <p>Applicant Types  </p> <p>Funding Limit   50,000.00 maximum</p> <p>Limited Submission   No</p>				
059708	<a href="#">ADDF-Harrington Scholar Program</a>	Alzheimer's Drug Discovery Foundation		03-Jun-2024 [LOI/Pre-App]	600,000 USD
	<p>Contact Name  </p> <p>Contact Telephone  </p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email	<a href="mailto:grants@alzdiscovery.org">grants@alzdiscovery.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	03-Jun-2024 [LOI/Pre-App], 26-Aug-2024
Synopsis	The ADDF-Harrington Scholar Program is dedicated to advancing academic discoveries into medicines for Alzheimer’s disease and related dementias. This unique award provides funding and project support by a team of pharmaceutical industry experts through a collaboration with the Alzheimer’s Drug Discovery Foundation (ADDF) and the Brain Health Medicines Centers of the Harrington Discovery Institute.
Applicant Types	
Funding Limit	600,000.00 maximum
Limited Submission	No

115885	<a href="#">Global Program to Help Customers Develop Cloud Solutions to Advance Health Equity</a>	Amazon Web Services	30-Jun-2024	Not Specified
--------	---	---------------------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	<a href="mailto:aws-pr@amazon.com">aws-pr@amazon.com</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	30-Jun-2024 , 15-Nov-2024
Synopsis	AWS is committing \$40.0 million to harness the power of the cloud to advance health equity globally. Amazon Web Services (AWS) is offering AWS Promotional Credit and technical expertise to selected institutions and companies addressing health disparities that impact underserved or underrepresented communities around the world. The program will support applications that develop culturally responsive solutions to: 1) increase access to health

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>services, 2) reduce disparities by addressing social determinants of health, and 3) leverage data to promote equitable and inclusive systems of care.</p> <p>0.00 see detail</p> <p>No</p>			
064670	<a href="#">SkinCare for Developing Countries Program</a>	American Academy of Dermatology		30-Jun-2024	5,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p><a href="#">RIGNAHS@aad.org</a></p> <p><a href="#">Link to sponsor website</a></p> <p><a href="#">Link to program URL</a></p> <p>30-Jun-2024</p> <p>The American Academy of Dermatology offers grants to individuals and organizations to fund international volunteer and humanitarian projects under the Skin Care for Developing Countries program. Grants vary between \$2,500 and \$5,000 depending on the proposal, scope of the project, and availability of funds.</p> <p>5,000.00 maximum</p> <p>No</p>			
042399	<a href="#">Research Grants</a>	American Academy of Otolaryngic Allergy Foundation		01-Jun-2024	10,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p>	<p>Kate Chenal</p> <p>202-955-5010 x 600</p> <p><a href="mailto:foundation@aaoallergy.org">foundation@aaoallergy.org</a></p>			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2024			
	Synopsis	The American Academy of Otolaryngic Allergy (AAOA) Foundation seeks to advance allergy research and knowledge for the treatment of otolaryngic conditions by inviting applications for grants to conduct research in the pathogenesis, pathophysiology, diagnosis, prevention, or treatment of otolaryngic allergy. Funds are available to support multiple projects each year; each project may have total direct costs of \$10,000.			
	Applicant Types				
	Funding Limit	10,000.00 maximum			
	Limited Submission	No			

115487	<a href="#">Patty and Paul Levi Research Award</a>	American Academy of Periodontology Foundation		01-Jun-2024	5,000 USD
--------	--	--	--	-------------	-----------

	Contact Name	Ariel A. Medoff			
	Contact Telephone	312-573-3254			
	Contact Email	<a href="mailto:ariel@perio.org">ariel@perio.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2024			
	Synopsis	The Patty and Paul Levi Research Award provides an annual \$5,000 award to a predoctoral student doing research related to preventative periodontology and being mentored by a periodontal faculty member. The award should be considered a supplement to any salary, stipend or research support.			
	Applicant Types				
	Funding Limit	5,000.00 maximum			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
115485	<a href="#">Dr. Colin Richman and Family Perio-Ortho Interface Award</a>	American Academy of Periodontology Foundation		01-Jun-2024	20,000 USD
	Contact Name	Ariel A. Medoff			
	Contact Telephone	312-573-3254			
	Contact Email	<a href="mailto:ariel@perio.org">ariel@perio.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2024			
	Synopsis	The Dr. Colin Richman and Family Perio-Ortho Interface Award will be made to an individual performing clinical or basic science research related to the orthodontic/periodontal interface. A \$20,000 fellowship will be awarded annually to one or more individuals.			
	Applicant Types				
	Funding Limit	20,000.00 maximum			
	Limited Submission	No			
124908	<a href="#">Dr. Mark K. Setter Leadership in Periodontology and Dental Implantology Award</a>	American Academy of Periodontology Foundation		01-Jun-2024	10,000 USD
	Contact Name	Ariel A. Medoff			
	Contact Telephone	312-573-3254			
	Contact Email	<a href="mailto:ariel@perio.org">ariel@perio.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2024			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis The Dr. Mark K. Setter Leadership in Periodontology and Dental Implantology Award is presented annually in the amount of \$10,000 to recognize a periodontal resident who exemplifies the leadership qualities that Dr. Setter lived and encouraged throughout his lifetime.</p> <p>Applicant Types</p> <p>Funding Limit 10,000.00 maximum</p> <p>Limited Submission No</p>				
014713	<a href="#">Gertrude B. Elion Cancer Research Award</a>	American Association for Cancer Research		03-Jun-2024	225,000 USD
	<p>Contact Name</p> <p>Contact Telephone 215-446-7280</p> <p>Contact Email <a href="mailto:grants@aacr.org">grants@aacr.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 03-Jun-2024</p> <p>Synopsis The AACR Gertrude B. Elion Cancer Research Award is intended to encourage and support tenure-eligible junior faculty. The research proposed for funding must focus on cancer etiology, diagnosis, treatment, or prevention and may be basic, translational, or clinical in nature. The award provides a one-year grant of \$225,000 for expenses related to the research project</p> <p>Applicant Types</p> <p>Funding Limit 225,000.00 maximum</p> <p>Limited Submission Yes</p>				
071222	<a href="#">General and Dedicated Research Grants</a>	American Association of Nurse Anesthetists Foundation		30-Jun-2024	Not Specified
	Contact Name				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone 847-692-7050 Contact Email <a href="mailto:foundation@aana.com">foundation@aana.com</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 30-Jun-2024 , 30-Sep-2024 , 31-Dec-2024 Synopsis The American Association of Nurse Anesthetists Foundation's mission is to advance the science of anesthesia through education and research. One of the goals of the AANA Foundation is to support new and seasoned investigators in nurse anesthesia through grants. Programs are designed to develop researchers in nurse anesthesia. Only AANA member CRNAs (clinical or research) are appropriate for application. Applicant Types Funding Limit 0.00 see detail Limited Submission No				

032751	<a href="#">Eva King Killiam Research Award</a>	American College of Neuropsychopharmacology		20-Jun-2024	Not Specified
--------	---	---	--	-------------	---------------

	Contact Name Contact Telephone 615-324-2360 Contact Email <a href="mailto:acnp@acnp.org">acnp@acnp.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 20-Jun-2024 Synopsis The American College of Neuropsychopharmacology (ACNP) presents the Eva King Killiam Research Award to an early career researcher on the basis of outstanding translational research contributions to neuropsychopharmacology. Applicant Types				
--	--	--	--	--	--



## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	0.00 see detail			
	Limited Submission	No			
072617	<a href="#">Joel Elkes Research Award</a>	American College of Neuropsychopharmacology		20-Jun-2024	Not Specified
	Contact Name				
	Contact Telephone	615-324-2360			
	Contact Email	<a href="mailto:ancp@acnp.org">ancp@acnp.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	20-Jun-2024			
	Synopsis	The American College of Neuropsychopharmacology (ACNP) presents the Joel Elkes Research Award to a young scientist in recognition of an outstanding clinical contribution to neuropsychopharmacology. Award recipients will receive a monetary award and a plaque to be given at the ACNP Annual Meeting.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
103871	<a href="#">Barbara Fish Memorial Award</a>	American College of Neuropsychopharmacology		20-Jun-2024	Not Specified
	Contact Name				
	Contact Telephone	615-324-2360			
	Contact Email	<a href="mailto:acnp@acnp.org">acnp@acnp.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 20-Jun-2024</p> <p>Synopsis The American College of Neuropsychopharmacology (ACNP) presents the Barbara Fish Memorial Award to an ACNP member who has made an outstanding contribution to basic, translational or clinical neuroscience. Award recipients will receive a monetary award and a plaque to be given at the ACNP Annual Meeting.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
095617	<a href="#">Media Award</a>	American College of Neuropsychopharmacology		20-Jun-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 615-324-2360</p> <p>Contact Email <a href="mailto:acnp@acnp.org">acnp@acnp.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 20-Jun-2024</p> <p>Synopsis The ACNP Media Award was established to recognize major contributions to the education of the public about mental illness and substance abuse research and the positive impact of research on treatment. The Media Award consists of an expense paid trip to the ACNP Annual Meeting and a plaque to be presented at the Annual Meeting.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
023798	<a href="#">Elizabeth Barrett-Connor Research Award for Young Investigators</a>	American Heart Association		06-Jun-2024	1,000 USD

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 800-242-8721</p> <p>Contact Email <a href="mailto:council.awards@heart.org">council.awards@heart.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 06-Jun-2024 , 10-Jun-2024</p> <p>Synopsis The Elizabeth Barrett-Connor Research Award in Epidemiology and Prevention for Investigators in Training recognizes excellence in research by early career investigators and trainees and encourages continued biomedical research careers broadly related to cardiovascular function and diseases, including basic science, integrated physiology, and clinical problems.</p> <p>Applicant Types</p> <p>Funding Limit 1,000.00 see detail</p> <p>Limited Submission No</p>				
023802	<a href="#">Melvin Judkins Young Clinical Investigator Award</a>	American Heart Association		06-Jun-2024	1,000 USD
	<p>Contact Name</p> <p>Contact Telephone 214-570-5978</p> <p>Contact Email <a href="mailto:council.awards@heart.org">council.awards@heart.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 06-Jun-2024 , 10-Jun-2024</p> <p>Synopsis The Melvin Judkins Young Clinical Investigator Award recognizes meritorious research from early career investigators and promotes careers in cardiovascular radiology.</p> <p>Applicant Types</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit   1,000.00 see detail Limited Submission   Yes				
023809	<a href="#">Vivien Thomas Young Investigator Award</a>	American Heart Association		06-Jun-2024	Not Specified
	Contact Name Contact Telephone Contact Email   <a href="mailto:council.awards@heart.org">council.awards@heart.org</a> Sponsor Website   <a href="#">Link to sponsor website</a> Program URL   <a href="#">Link to program URL</a> Deadline Dates (ALL)   06-Jun-2024 , 10-Jun-2024 Synopsis   The Vivien Thomas Early Career Investigator Award acknowledges the accomplishments of early career investigator members of the Council on Cardiovascular Surgery and Anesthesia (CVSA) who are focusing on fundamental and applied surgical research. Applicant Types Funding Limit   0.00 see detail Limited Submission   Yes				
079306	<a href="#">Lifestyle and Cardiometabolic Health Early Career Investigator Award</a>	American Heart Association		31-May-2024	Not Specified
	Contact Name Contact Telephone Contact Email   <a href="mailto:council.awards@heart.org">council.awards@heart.org</a> Sponsor Website   <a href="#">Link to sponsor website</a> Program URL   <a href="#">Link to program URL</a>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   31-May-2024 , 06-Jun-2024 , 10-Jun-2024</p> <p>Synopsis   The Council on Lifestyle and Cardiometabolic Health Early Career Investigator Award recognizes and awards early career investigator and trainee council members for their achievements and their continuing research. The award also encourages young scientists to become involved in the Council on Lifestyle and Cardiometabolic Health and to develop and maintain productive careers.</p> <p>Applicant Types  </p> <p>Funding Limit   0.00 see detail</p> <p>Limited Submission   Yes</p>				
080457	<a href="#">Award for Outstanding Doctoral Thesis Research in Biological Physics</a>	American Physical Society		03-Jun-2024	Not Specified
	<p>Contact Name  </p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:honors@aps.org">honors@aps.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   03-Jun-2024</p> <p>Synopsis   The Award for Outstanding Doctoral Thesis Research in Biological Physics recognizes doctoral thesis research of outstanding quality and achievement in any area of experimental, computational, engineering, or theoretical Biological Physics, broadly construed, and to encourage effective written and oral presentation of research results.</p> <p>Applicant Types  </p> <p>Funding Limit   0.00 see detail</p> <p>Limited Submission   Yes</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
035693	<a href="#">ASRM/NIH/Duke Clinical Research/Reproductive Scientist Training (CREST) Program</a>	American Society for Reproductive Medicine (ASRM)		15-Jun-2024	Not Specified
	Contact Name				
	Contact Telephone	202-863-4985			
	Contact Email	<a href="mailto:Nicole.Goetz@cuanschutz.edu">Nicole.Goetz@cuanschutz.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Jun-2024			
	Synopsis	The CREST training program is offered by the NICHD, the Clinical Research Training Program (CRTP) at Duke University, and ASRM. This 2-year program meets an existing need for physicians in private or academic clinical practice to obtain formalized academic training in the quantitative and methodological principles of clinical research in reproductive medicine.			
	Applicant Types				
	Funding Limit	0.00 not provided			
	Limited Submission	No			
065121	<a href="#">Research Grants</a>	American Society of PeriAnesthesia Nurses		15-Jun-2024	10,000 USD
	Contact Name	Amy Berardinelli, ASPAN Director for Clinical Inquiry			
	Contact Telephone	877-737-9696			
	Contact Email	<a href="mailto:aberardinelli@aspan.org">aberardinelli@aspan.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Jun-2024			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis The Nursing Research Grants Program is designed to support active American Society of PeriAnesthesia Nurses (ASPAN) members seeking to conduct research that contributes to the advancement of perianesthesia nursing science and the improvement of patient care. This support may be in the form of peer review, thoughtful critique, and recommendations, as well as financial support. A beginning nurse researcher can expect between \$500-\$5,000. An experienced nurse researcher can expect between \$3,000-\$10,000.</p> <p>Applicant Types</p> <p>Funding Limit 10,000.00 maximum</p> <p>Limited Submission No</p>				
011252	<a href="#">Fellowship Research Awards</a>	American Surgical Association Foundation		15-Jun-2024	75,000 USD
	<p>Contact Name</p> <p>Contact Telephone 978-927-8330</p> <p>Contact Email</p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jun-2024</p> <p>Synopsis The purpose of the American Surgical Association Foundation Fellowship is to support and encourage gifted young surgeons who choose careers in investigation and academic surgery. Fellows will be supported in an initial year; the Fellowship can be renewed by review of the Fellowship Committee for a succeeding one-year period. During the Fellowship years, the Awardee should have a primary role in research and teaching. It is expected that the Fellow will have a faculty position following the Fellowship in the Department of Surgery of the sponsoring institution.</p> <p>Applicant Types</p> <p>Funding Limit 75,000.00 per year</p> <p>Limited Submission No</p>				
116899	<a href="#">APSR Multi-Society Research Project</a>	Asian Pacific Society of Respirology		30-Jun-2024	100,000 USD

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone +81-3-5684-3370</p> <p>Contact Email <a href="mailto:research@theapsr.org">research@theapsr.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 30-Jun-2024</p> <p>Synopsis The Asian Pacific Society of Respiriology (APSR) annually offers one Multi-Society Research Project grant of up to US\$100,000 for a duration of two years.</p> <p>Applicant Types</p> <p>Funding Limit 50,000.00 per year</p> <p>Limited Submission No</p>				
015721	<a href="#">Broadley Scholarship</a>	Association for Medical Imaging Management (AHRA)		18-Jun-2024	2,500 USD
	<p>Contact Name</p> <p>Contact Telephone 978-235-5594</p> <p>Contact Email <a href="mailto:memberservices@ahra.org">memberservices@ahra.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 18-Jun-2024</p> <p>Synopsis This program provides scholarship support to imaging administrators seeking to enhance their careers through formal education. The AHRA Education Foundation awards up to two Broadley Scholarships yearly at \$2,500 each.</p> <p>Applicant Types</p> <p>Funding Limit 2,500.00 maximum</p>				



## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
116615	<a href="#">Collaborative ARN and Agnes Marshall Walker Foundation Research Grant</a>	Association of Rehabilitation Nurses		01-Jun-2024	10,000 USD
	Contact Name				
	Contact Telephone	847-375-6356			
	Contact Email	<a href="mailto:info@rehabnurse.org">info@rehabnurse.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2024			
	Synopsis	The Association of Rehabilitation Nurses (ARN) Advancing Science and Practice Committee and the Agnes Marshall Walker Foundation (AMWF) requests applications for grant support for research studies that aim to advance the science and practice of neuroscience rehabilitation nursing. Grants may be up to \$10,000.			
	Applicant Types				
	Funding Limit	10,000.00 maximum			
	Limited Submission	No			
018455	<a href="#">Sir Harcourt Caughey Award</a>	Auckland Medical Research Foundation		26-Jun-2024	15,000 USD
	Contact Name	Research Programme Manager			
	Contact Telephone	+64 9 923 1701			
	Contact Email	<a href="mailto:amrf@medicalresearch.org.nz">amrf@medicalresearch.org.nz</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	26-Jun-2024			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>The Auckland Medical Research Foundation’s (AMRF) vision is to improve the health and quality of life for all New Zealanders. The Foundation aim to achieve this by providing genuine advances in health, science and medicine through funding the highest quality medical research of all kinds. As a part of this, the Sir Harcourt Caughey Awards of up to \$25,000 are offered in three categories.</p> <p>25,000.00 maximum</p> <p>No</p>			
089931	<a href="#">PhD Fellowships</a>	Boehringer Ingelheim Fonds		01-Jun-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>+49 (0)6131 2750 80</p> <p><a href="mailto:secretariat@bifonds.de">secretariat@bifonds.de</a></p> <p><a href="#">Link to sponsor website</a></p> <p><a href="#">Link to program URL</a></p> <p>01-Jun-2024 , 01-Oct-2024</p> <p>The Boehringer Ingelheim Fonds (BIF) awards PhD fellowships of 2 to 3.5 years to outstanding junior scientists worldwide who wish to pursue an ambitious PhD project in basic biomedical research in an internationally leading laboratory.</p> <p>0.00 see detail</p> <p>No</p>			
098358	<a href="#">Catalyst Award</a>	Citizens United for Research in Epilepsy (CURE Epilepsy)		11-Jun-2024 [LOI/Pre-App]	250,000 USD
	<p>Contact Name</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 312-255-1801</p> <p>Contact Email <a href="mailto:research@cureepilepsy.org">research@cureepilepsy.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 11-Jun-2024 [LOI/Pre-App], 28-Aug-2024</p> <p>Synopsis CURE Epilepsy funds research that has the potential to truly transform and save lives. The purpose of this funding opportunity is to stimulate and accelerate discovery and development of new, transformative therapies for epilepsy, moving promising, well-supported preclinical and/or clinical research closer to clinical application. Requests may be made for up to a total of \$250,000 paid over 2 years.</p> <p>Applicant Types</p> <p>Funding Limit 250,000.00 maximum</p> <p>Limited Submission No</p>				
071029	<a href="#">Evert Clark/Seth Payne Award for Young Science Journalists</a>	Council for the Advancement of Science Writing		30-Jun-2024	1,000 USD
	<p>Contact Name Laura Dattaro</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:ldattaro@casw.org">ldattaro@casw.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 30-Jun-2024</p> <p>Synopsis The Evert Clark/Seth Payne Award for Young Science Journalists is intended to encourage young science writers by recognizing outstanding reporting and writing in any field of science. The 2024 winner will receive \$1,000 and expenses to attend the ScienceWriters2024 conference to receive the award.</p> <p>Applicant Types</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	1,000.00 see detail			
	Limited Submission	No			
022157	<a href="#">Victor Cohn Prize for Excellence in Medical Science Reporting</a>	Council for the Advancement of Science Writing		30-Jun-2024	5,000 USD
	Contact Name	Laura Dattaro			
	Contact Telephone	206-880-0177			
	Contact Email	<a href="mailto:ldattaro@casw.org">ldattaro@casw.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	30-Jun-2024			
	Synopsis	The Victor Cohn Prize for Excellence in Medical Science Reporting is given annually, and seeks to honor a writer for a body of work published or broadcast within the last five years which, for reasons of uncommon clarity, accuracy, breadth of coverage, enterprise, originality, insight and narrative power, has made a profound and lasting contribution to public awareness and understanding of critical advances in medical science and their impact on human health and well-being.			
	Applicant Types				
	Funding Limit	5,000.00 see detail			
	Limited Submission	No			
002586	<a href="#">Grants Program</a>	Cure Parkinsons Trust		08-Apr-2024	315,000 USD
	Contact Name	Rosie Fuest, Research Manager			
	Contact Telephone	0207 487 3892			
	Contact Email	<a href="mailto:Rosie@cureparkinsons.org.uk">Rosie@cureparkinsons.org.uk</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 24-Jun-2024 , 21-Oct-2024</p> <p>Synopsis This programme primarily funds preclinical and clinical research focused on slowing, stopping, or reversing Parkinson's. For preclinical research, the sponsor funds grants up to £250,000 (GBP) and prioritise projects that are likely to lead to clinical trials in people with Parkinson's within 5 years. For clinical research, the sponsor funds clinical trials and sub-studies of trials in people with Parkinson's.</p> <p>Applicant Types</p> <p>Funding Limit 250,000.00 see detail</p> <p>Limited Submission No</p>				
074665	<a href="#">Clinical Research Scholars Program Award</a>	Cystic Fibrosis Foundation		12-Jun-2024	Not Specified

Contact Name	Elizabeth Yu
Contact Telephone	301-841-2614
Contact Email	<a href="mailto:eyu@cff.org">eyu@cff.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	12-Jun-2024
Synopsis	The Cystic Fibrosis Clinical Research Scholars Program (CRSP) Award is designed to enable promising early-career physician scientists to enhance their clinical research proficiency and support their development of the necessary clinical research capabilities to become independent investigators who formulate and lead multi-center, clinical research studies.
Applicant Types	
Funding Limit	0.00 see detail
Limited Submission	No

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
052754	<a href="#">Ian McHarg Medal</a>	European Geosciences Union		15-Jun-2024	Not Specified
	Contact Name				
	Contact Telephone	+49-89-2050-76300			
	Contact Email	<a href="mailto:awards-medals@egu.eu">awards-medals@egu.eu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Jun-2024			
	Synopsis	The Ian McHarg Medal is reserved for distinguished research in information technology applied to Earth and space sciences. The award consists of a medal.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
006925	<a href="#">Study Visit Grants</a>	Experimental Psychology Society		01-Jun-2024	4,536 USD
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:expsychsoc@kent.ac.uk">expsychsoc@kent.ac.uk</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2024 , 01-Sep-2024 , 01-Dec-2024			
	Synopsis	The Experimental Psychology Society (EPS) offers Study Visits Grants with the aim of helping finance postgraduate and postdoctoral research in experimental psychology (as defined by the content of The Quarterly Journal of Experimental Psychology). Awards will pay for travel to and accommodation at another institution outside an			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types individual's academic base. Either the researcher's home institution or the institution to be visited, or both, must be in the UK.</p> <p>Funding Limit 3,600.00 see detail</p> <p>Limited Submission No</p>				
014105	<a href="#">H. Thomas Austern Writing Competition</a>	Food and Drug Law Institute		03-Jun-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 202-371-1420</p> <p>Contact Email <a href="mailto:info@fdli.org">info@fdli.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 03-Jun-2024</p> <p>Synopsis The H. Thomas Austern Writing Competition is intended to encourage law students interested in the areas of law affecting FDA-regulated industries: food, drugs, medical devices, biologics, dietary supplements, cosmetics, veterinary, cannabis, or tobacco and nicotine products. Winners are awarded: \$750 for first place, \$500 for second, and \$250 for third. Top papers will be considered for publication in the Food and Drug Law Journal.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
089587	<a href="#">Research Grant Program</a>	Foundation for Ichthyosis & Related Skin Types		14-Apr-2024 [LOI/Pre-App]	50,000 USD
	<p>Contact Name Christine Wassel, Community Engagement Director</p> <p>Contact Telephone 215-997-9400</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:cwassel@firstskinfoundation.org">cwassel@firstskinfoundation.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 14-Apr-2024 [LOI/Pre-App], 16-Jun-2024</p> <p>Synopsis Foundation for Ichthyosis &amp; Related Skin Types (FIRST) offers a research grants to promote and strengthen investigation into the causes, treatments, and potential cures for ichthyosis.</p> <p>Applicant Types</p> <p>Funding Limit 50,000.00 see detail</p> <p>Limited Submission No</p>				
123800	<a href="#">GenScript Life Science Research Grant Program</a>	GenScript Biotech Corporation		15-Jun-2024	100,000 USD

Contact Name	
Contact Telephone	
Contact Email	<a href="mailto:LSRgrant@genscript.com">LSRgrant@genscript.com</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	15-Jun-2024 , 15-Sep-2024 , 15-Nov-2024
Synopsis	This research grant is an initiative dedicated to supporting breakthroughs in life science research areas including but not limited to gene and cell therapy development, antibody drug discovery, vaccine development, diagnostics, and plant sciences. This program is designed to empower researchers by providing grant funding specifically earmarked for purchasing GenScript reagents and services.
Applicant Types	
Funding Limit	100,000.00 maximum
Limited Submission	Yes



## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
032594	<a href="#">Harrington Scholar-Innovators</a>	Harrington Discovery Institute		05-Jun-2024	Not Specified
	Contact Name				
	Contact Telephone	216-983-3472			
	Contact Email	<a href="mailto:Questions@HarringtonDiscovery.org">Questions@HarringtonDiscovery.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2024			
	Synopsis	The Harrington Scholar-Innovator Award is issuing a call for proposals for the flagship Harrington ScholarInnovator program to recognize physician-scientists whose research has the potential to advance the standard of care. This program provides dedicated support from a project management team and pharmaceutical industry experts, as well as funding of \$100,000 for 2 years.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
092434	<a href="#">UJA - Federation Selim and Rachel Benin Scholarship</a>	Hebrew Free Loan Society		02-Jun-2024	Not Specified
	Contact Name				
	Contact Telephone	212-687-0188			
	Contact Email	<a href="mailto:scholarship@hfls.org">scholarship@hfls.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	02-Jun-2024			
	Synopsis	The UJA - Federation Selim and Rachel Benin Scholarships are provided to exceptional Israeli Jewish graduate students studying in certain STEM fields.			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit 0.00 see detail Limited Submission No				
117549	<a href="#">Transformative Research Award Program</a>	Hereditary Disease Foundation		14-Jun-2024	1,000,000 USD
	Contact Name Contact Telephone 212-928-2121 Contact Email <a href="mailto:cures@hdfoundation.org">cures@hdfoundation.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 14-Jun-2024 Synopsis The HDF Transformative Research Award program developed by the Hereditary Disease Foundation will make funds available to advance transformational collaborative projects that will provide new insights into disease mechanisms or create or implement tools and technologies not previously applied to Huntington's disease (HD) research for the advancement of therapeutics. Applicant Types Funding Limit 500,000.00 per year Limited Submission No				
070207	<a href="#">Michelson Prizes</a>	Human Immunome Project		09-Jun-2024	150,000 USD
	Contact Name Contact Telephone Contact Email <a href="mailto:michelsonprizes@humanimmunomeproject.org">michelsonprizes@humanimmunomeproject.org</a> Sponsor Website <a href="#">Link to sponsor website</a>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 09-Jun-2024</p> <p>Synopsis The Michelson Medical Research Foundation (MMRF) and the Human Immunome Project (HIP) are accepting applications for the 2024 Michelson Prizes: Next Generation Grants. The annual prizes award \$150,000 research grants to early-career scientists advancing human immunology, vaccine discovery, and immunotherapy research for major global diseases.</p> <p>Applicant Types</p> <p>Funding Limit 150,000.00 maximum</p> <p>Limited Submission No</p>				
010629	<a href="#">IEEE Medal for Innovations in Healthcare Technology</a>	Institute of Electrical and Electronics Engineers (IEEE)		15-Jun-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 732-562-3844</p> <p>Contact Email <a href="mailto:awards@ieee.org">awards@ieee.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jun-2024 , 01-Jul-2024</p> <p>Synopsis The IEEE Medal for Innovations in Healthcare Technology is presented for exceptional contributions to technologies and applications benefiting healthcare, medicine, and the health sciences. In the evaluation process, the following criteria are considered: impact on the profession and/or society; succession of significant technical or other contributions; leadership in accomplishing worthwhile goal(s); previous honors; other achievements as evidenced by publications or patents or other evidence; and quality of nomination. The award consists of a bronze medal, certificate, and cash honorarium.</p> <p>Applicant Types</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit   0.00 see detail Limited Submission   No				
125035	<a href="#">Bronchoscopy Research Grant</a>	Intuitive Foundation		07-Jun-2024 [LOI/Pre-App]	75,000 USD
	Contact Name Contact Telephone Contact Email   <a href="mailto:grants@intuitive-foundation.org">grants@intuitive-foundation.org</a> Sponsor Website   <a href="#">Link to sponsor website</a> Program URL   <a href="#">Link to program URL</a> Deadline Dates (ALL)   07-Jun-2024 [LOI/Pre-App], 30-Aug-2024 Synopsis   The Intuitive Foundation grant program is accepting applications for Clinical Research Grants for related to the impact of robotic-assisted bronchoscopy on clinical care in 2024-2025. The purpose of these grants is to support clinical research at non-profit institutions worldwide focused on the effect of robotic-assisted bronchoscopy in the clinical care of patients with pulmonary disease. Successful proposals will study important questions related to the impacts robotic-assisted bronchoscopy disease and patient outcomes. Applicants may apply for grant funding total costs up to \$75,000 (US) per project. Applicant Types Funding Limit   75,000.00 maximum Limited Submission   No				
125066	<a href="#">Training and Human Performance Research Grants</a>	Intuitive Foundation		07-Jun-2024 [LOI/Pre-App]	75,000 USD
	Contact Name Contact Telephone				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:grants@intuitive-foundation.org">grants@intuitive-foundation.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jun-2024 [LOI/Pre-App], 30-Aug-2024</p> <p>Synopsis The Intuitive Foundation grant program is active and is accepting applications for grant funding to support Training and Human Performance Research Grants for Robotic-assisted Surgery in 2024-2025. The purpose of these grants is to support training and human performance research in the field of robotic-assisted surgery. Successful proposals will address important questions about assessing intraoperative performance, accelerating skill acquisition while preserving patient safety, and maintaining skill proficiency of surgical team members. Applicants may apply for total costs up to \$75,000 (US) per grant.</p> <p>Applicant Types</p> <p>Funding Limit 75,000.00 maximum</p> <p>Limited Submission No</p>				
066688	<a href="#">Clinical Research Grants for Robotic-Assisted Surgery</a>	Intuitive Foundation		07-Jun-2024 [LOI/Pre-App]	75,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grants@intuitive-foundation.org">grants@intuitive-foundation.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jun-2024 [LOI/Pre-App], 30-Aug-2024</p> <p>Synopsis The Intuitive Foundation's Clinical Research Grants support clinical research at non-profit institutions worldwide focused on the field of robotic-assisted surgery. Successful proposals will study important questions related to surgical care and patient outcomes. Applicants may apply for grant funding total costs up to \$75,000 (US) per project.</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit 75,000.00 maximum Limited Submission No				
000221	<a href="#">Postdoctoral Fellowships for Research in Japan (Short-term)</a>	Japan Society for the Promotion of Science		07-Jun-2024	Not Specified
	Contact Name Contact Telephone +81-3-3263-3810 Contact Email <a href="mailto:postdoc-short@jsps.go.jp">postdoc-short@jsps.go.jp</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 07-Jun-2024 Synopsis The Japan Society for the Promotion of Science (JSPS) offers short-term Postdoctoral Fellowships for Research in Japan in all fields of the humanities, social sciences and natural sciences. Researchers from the US, Canada and Europe may conduct cooperative research under the guidance of their hosts with leading research groups in universities and other Japanese institutions. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
016198	<a href="#">Grants Program</a>	Johnson Controls Foundation		01-Jun-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website <a href="#">Link to sponsor website</a>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jun-2024</p> <p>Synopsis The Johnson Controls Foundation makes charitable contributions to nonprofit organizations, primarily in communities where Johnson Controls has a presence. The Foundation is organized and directed to be operated for charitable purposes which include the distribution and application of financial support to soundly managed and operated organizations or causes which are fundamentally philanthropic. The Foundation contributes to organizations in the United States that operate not for profit and are recognized by the Internal Revenue Service as tax-exempt institutions.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 not provided</p> <p>Limited Submission No</p>				
036282	<a href="#">LEO Foundation Awards</a>	LEO Foundation		27-Jun-2024	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone + 45 32 72 51 10</p> <p>Contact Email <a href="mailto:applications@leo-foundation.org">applications@leo-foundation.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 27-Jun-2024</p> <p>Synopsis The LEO Foundation Awards constitute global recognitions of individual scientists who represents excellence and advance our understanding of skin and skin diseases. Regional awards of USD 100,000 each are given annually to outstanding young scientists within regions Americas, EMEA and Asia-Pacific, whose work represent extraordinary contributions to dermatology research.</p> <p>Applicant Types</p> <p>Funding Limit 100,000.00 maximum</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
109989	<a href="#">Minority Career Development Award (CDA) in Lung Cancer</a>	Lung Cancer Research Foundation		10-Jun-2024	150,000 USD
	Contact Name				
	Contact Telephone	+1-212-588-1580			
	Contact Email	<a href="mailto:grants@lcrf.org">grants@lcrf.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	10-Jun-2024			
	Synopsis	The Minority Career Development Award (CDA) in Lung Cancer provides protected time and mentoring to minority Postdoctoral/Clinical Fellows and Assistant Professors within 10 years of completing their MD training and/or PhD degrees. This program aims to close the gap between the mortality rates and representation in lung cancer research by funding minority researchers with \$150,000 over a period of two years.			
	Applicant Types				
	Funding Limit	75,000.00 per year			
	Limited Submission	No			
118890	<a href="#">Leading Edge Research Grant Program</a>	Lung Cancer Research Foundation		10-Jun-2024	150,000 USD
	Contact Name				
	Contact Telephone	+1-212-588-1580			
	Contact Email	<a href="mailto:grants@lcrf.org">grants@lcrf.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	10-Jun-2024			



## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>The Lung Cancer Research Foundation (LCRF) Leading Edge Research Grant Program will fund innovative projects across the full spectrum of basic, translational, clinical, epidemiological, health services, early detection, disparities, and social determinants of health research.</p> <p>150,000.00 maximum</p> <p>No</p>			
123721	<a href="#">Research Grants on Understanding Resistance in Lung Cancer</a>	Lung Cancer Research Foundation		10-Jun-2024	150,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>+1-212-588-1580</p> <p><a href="mailto:grants@lcrf.org">grants@lcrf.org</a></p> <p><a href="#">Link to sponsor website</a></p> <p><a href="#">Link to program URL</a></p> <p>10-Jun-2024</p> <p>The Lung Cancer Research Foundation (LCRF) Research Grants on Understanding Resistance in Lung Cancer focuses on understanding the development, prevention, and therapy of resistance by supporting research projects that are identifying, characterizing, treating, or preventing resistance to therapies in lung tumor cells, tissues, mouse models, and/or patients. These awards provide a maximum of \$150,000 in funding over a period of two years to post-doctoral researchers, clinical fellows, or investigators with less than 10 years of experience since their initial faculty appointment.</p> <p>150,000.00 maximum</p> <p>No</p>			
109988	<a href="#">Research Grant on Early Detection and Pre-Neoplasia in Lung Cancer</a>	Lung Cancer Research Foundation		10-Jun-2024	150,000 USD

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 212-588-1580</p> <p>Contact Email <a href="mailto:grants@lcrf.org">grants@lcrf.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 10-Jun-2024</p> <p>Synopsis LCRF is offering this funding mechanism to support research projects that facilitate or advance the understanding and characterization of pre-neoplasia or approaches for early detection of lung cancer. Work supported through this mechanism addresses important questions in non-small cell and small cell lung cancer.</p> <p>Applicant Types</p> <p>Funding Limit 75,000.00 per year</p> <p>Limited Submission No</p>				
108503	<a href="#">Grant Program</a>	Mathers (G.Harold and Leila Y.) Foundation		07-Jun-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grants@mathersfoundation.org">grants@mathersfoundation.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jun-2024 , 20-Sep-2024 , 04-Oct-2024 [LOI/Pre-App], 06-Dec-2024</p> <p>Synopsis The G. Harold and Leila Y. Mathers Foundation's mission is to advance knowledge in the life sciences by sponsoring scientific research that will benefit mankind. Basic scientific research, with potential translational application, is central to this goal, and fundamental to the Foundation's operating principles.</p> <p>Applicant Types</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	0.00 not provided			
	Limited Submission	Yes			
022414	<a href="#">Fellowship Program</a>	Matsumae International Foundation		30-Jun-2024	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:application@mif-japan.org">application@mif-japan.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	30-Jun-2024			
	Synopsis	The Matsumae International Foundation offers fellowships of six months in duration to provide overseas researchers who possess excellent academic ability, regardless of race, sex, religion, or ideology, with opportunities to carry out research activities in Japan, thereby contributing to academic development in Japan as well as international friendship and goodwill. Fields of research such as natural science, engineering, and medicine are given first priority.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
013058	<a href="#">Neurology - Clinical Neurophysiology, Electromyography Fellowship - (Florida)</a>	Mayo Clinic College of Medicine and Science		01-Jun-2024	Not Specified
	Contact Name	Devon Rubin, M.D., Program Director			
	Contact Telephone	904-953-0110			
	Contact Email	<a href="mailto:rubin.devon@mayo.edu">rubin.devon@mayo.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 01-Jun-2024</p> <p>Synopsis The Clinical Neurophysiology Program at Mayo Clinic in Jacksonville has been accredited as a one-year fellowship by the ACGME. Those fellows who meet the requirements, including a broad experience in clinical neurophysiology, will be eligible to take the Subspecialty Certification Examination in Clinical Neurophysiology given by the American Board of Psychiatry and Neurology. This one-year fellowship program will prepare fellows to establish and supervise an electromyography laboratory in an academic center or integrated group practice. Training emphasis is on EMG, including single fiber EMG, nerve conduction techniques, evoked potentials, surgical monitoring and related clinical disorders.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission No</p>				
012311	<a href="#">Gastrointestinal &amp; Hepatobiliary Pathology Fellowship - Minnesota</a>	Mayo Clinic College of Medicine and Science		30-Jun-2024	Not Specified
	<p>Contact Name Courtney Schraufnagel, Education Coordinator</p> <p>Contact Telephone 507-422-6123</p> <p>Contact Email <a href="mailto:schraufnagel.courtney@mayo.edu">schraufnagel.courtney@mayo.edu</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 30-Jun-2024</p> <p>Synopsis The one-year Gastrointestinal and Hepatobiliary Pathology Fellowship at Mayo Clinic in Rochester, Minnesota, offers exposure to a broad spectrum of biopsy material and surgical specimens relating to gastrointestinal and hepatobiliary disease.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
013262	<a href="#">Minimally Invasive Gynecologic Surgery Fellowship (Arizona)</a>	Mayo Clinic College of Medicine and Science		30-Jun-2024	Not Specified
	Contact Name	Treene Vito, Education Coordinator			
	Contact Telephone	480-574-1194			
	Contact Email	<a href="mailto:vito.treene@mayo.edu">vito.treene@mayo.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	30-Jun-2024			
	Synopsis	Two positions are available on a competitive basis each year in the Minimally Invasive Gynecologic Surgery Fellowship at Mayo Clinic's campus in Arizona.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
058805	<a href="#">Investigator Studies Program (MISP) -- Anesthesia</a>	Merck		01-Jun-2024	Not Specified
	Contact Name	Lisa Mount			
	Contact Telephone	267-305-1258			
	Contact Email	<a href="mailto:lisa_mount@merck.com">lisa_mount@merck.com</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2024			
	Synopsis	The Investigator Studies Program aims to advance science and improve patient care by supporting, through the provision of drug/vaccine and/or total/partial funding, high-quality research that is initiated, designed, implemented			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>and sponsored by external investigators. Results will be generated and properly disseminated in peer-reviewed publications.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 not provided</p> <p>Limited Submission No</p>				
064085	<a href="#">Lloyd V. Berkner Space Policy Internships</a>	National Academies		03-Jun-2024	Not Specified

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>David H. Smith</p> <p>202-334-3477</p> <p><a href="mailto:dsmith@nas.edu">dsmith@nas.edu</a></p> <p><a href="#">Link to sponsor website</a></p> <p><a href="#">Link to program URL</a></p> <p>03-Jun-2024</p> <p>The goal of the program is to provide promising undergraduate and graduate students with the opportunity to work in the area of civil space research policy in the Nation's capital, under the aegis of the SSB. The Lloyd V. Berkner Space Policy Internships are offered twice annually. Interns typically undertake one or more short-term research projects designed to assist with or to enhance ongoing study projects. The projects undertaken by the SSB standing committees and ad hoc task groups are in constant flux, with studies being completed and new studies beginning on a regular basis. Although this makes it difficult to predict just what the interns will get to work on, it also ensures their exposure to the different stages of the study process –from project initiation, through the committee process, and the final publication of committee reports - as several studies are being undertaken simultaneously.</p> <p></p> <p>0.00 see detail</p> <p>No</p>
---	--

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
002024	<a href="#">Judith Graham Pool Postdoctoral Research Fellowships</a>	National Bleeding Disorders Foundation		06-May-2024 [LOI/Pre-App]	104,000 USD
	Contact Name	Samantha Carlson, LMSW, Director of Research			
	Contact Telephone	212-328-3765			
	Contact Email	<a href="mailto:scarlson@hemophilia.org">scarlson@hemophilia.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	06-May-2024 [LOI/Pre-App], 03-Jun-2024			
	Synopsis	The National Hemophilia Foundation (NHF) offers the Judith Graham Pool (JGP) Postdoctoral Research Fellowships, providing support for basic science and pre-clinical research in bleeding disorders.			
	Applicant Types				
	Funding Limit	52,000.00 per year			
	Limited Submission	No			
116579	<a href="#">Grace Wall Barreda Memorial Scholarship</a>	Native Forward Scholars Fund		01-Jun-2024	Not Specified
	Contact Name				
	Contact Telephone	505-881-4584			
	Contact Email	<a href="mailto:scholarships@nativeforward.org">scholarships@nativeforward.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2024			
	Synopsis	Native Forward Scholars Fund offers the Grace Wall Barreda Scholarship program to provide financial assistance to eligible American Indian and Alaska Native graduate students pursuing degrees full-time at an accredited institution in Public Health or Environmental Science/Studies. This opportunity is a need-based award.			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit 0.00 not provided Limited Submission No				
091882	<a href="#">Spinal Cord Injury Research on the Translational Spectrum</a>	Neilsen (Craig H.) Foundation		07-Jun-2024 [LOI/Pre-App]	Not Specified
	Contact Name Tracey Wheeler Contact Telephone 818-925-1245 Contact Email <a href="mailto:tracey@chnfoundation.org">tracey@chnfoundation.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 07-Jun-2024 [LOI/Pre-App], 08-Nov-2024 Synopsis The Spinal Cord Injury Research on the Translational Spectrum (SCIRTS) grants Portfolio is intended to advance novel approaches to improving function and developing curative therapies after spinal cord injury (SCI). This portfolio emphasizes SCI (vs. spinal cord disease or related disorders) and is intended to fill gaps in the field and to further develop new strategies to restore function resulting from SCI. The Neilsen Foundation does not intend to provide continuous funding to individual labs but to fund novel research throughout the translational spectrum. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
082654	<a href="#">Mentored Research Award</a>	Neuroendocrine Tumor Research Foundation		24-Jun-2024	100,000 USD
	Contact Name Contact Telephone 617-946-1780 Contact Email <a href="mailto:grants@netrf.org">grants@netrf.org</a>				



## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 24-Jun-2024</p> <p>Synopsis The Neuroendocrine Tumor Research Foundation (NETRF) Mentored Award is designed to encourage early career investigators to pursue neuroendocrine tumor research and make a commitment to the field. Mentored Research Awards are in the amount of \$100,000 over two years. These proposals typically have two aims that provide work requiring two years to complete. They have one PI with or without collaborators.</p> <p>Applicant Types</p> <p>Funding Limit 100,000.00 maximum</p> <p>Limited Submission No</p>				
024601	<a href="#">Resident Research Project Grant</a>	Orthopaedic Research & Education Foundation (OREF)		08-Apr-2024 [LOI/Pre-App]	5,000 USD
	<p>Contact Name</p> <p>Contact Telephone 847-430-5109</p> <p>Contact Email <a href="mailto:grants@oref.org">grants@oref.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 20-Jun-2024</p> <p>Synopsis The Resident Research Project Grant provides up to \$5,000 to residents who are interested in research.</p> <p>Applicant Types</p> <p>Funding Limit 5,000.00 maximum</p> <p>Limited Submission No</p>				
083547	<a href="#">Collaborative Research Development Grant</a>	Ovarian Cancer Research Alliance		13-Jun-2024	900,000 USD

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Kristin McGowan</p> <p>Contact Telephone   212-268-1002</p> <p>Contact Email   <a href="mailto:grants@ocrahope.org">grants@ocrahope.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   13-Jun-2024</p> <p>Synopsis   Ovarian Cancer Research Alliance is requesting Letters of Intent for the 2025 Collaborative Research Development Grant (CRDG). The purpose of this grantmaking program is to provide funds for ovarian cancer and/or related gynecologic cancers research projects that may involve several investigators within one institution or collaborations between groups in multiple institutions. Interdisciplinary collaborations are encouraged.</p> <p>Applicant Types  </p> <p>Funding Limit   300,000.00 per year</p> <p>Limited Submission   No</p>				
078435	<a href="#">Early Career Investigator Grant</a>	Ovarian Cancer Research Alliance		13-Jun-2024	450,000 USD

	<p>Contact Name   Kristin McGowan</p> <p>Contact Telephone   212-268-1002</p> <p>Contact Email   <a href="mailto:grants@ocrahope.org">grants@ocrahope.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   13-Jun-2024</p> <p>Synopsis   Ovarian Cancer Research Alliance is requesting Letters of Intent for the 2025 Early Career Investigator Grant (formerly called the Liz Tilberis Early Career Award). The Early Career Investigator Grant (ECIG) is for junior faculty with a strong</p>				
--	---	--	--	--	--

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>commitment to an investigative career in the field of ovarian cancer research. The intent of these grants is to support a substantial time commitment to research and academic endeavors in ovarian cancer.</p> <p>150,000.00 per year</p> <p>No</p>			
124390	<a href="#">Health Equity Research Grant</a>	Ovarian Cancer Research Alliance		13-Jun-2024	200,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>212-268-1002</p> <p><a href="mailto:grants@ocrahope.org">grants@ocrahope.org</a></p> <p><a href="#">Link to sponsor website</a></p> <p><a href="#">Link to program URL</a></p> <p>13-Jun-2024</p> <p>Ovarian Cancer Research Alliance (OCRA) is requesting Letters of Intent (LOI) for the 2025 Health Equity Research Grant. The grant will support t research projects that promote equity, inclusivity, and evidence-based approaches to overcome the barriers faced by marginalized communities with a focus on ovarian cancers and/or related gynecologic cancers. The grant will provide \$100,000 per year for two years.</p> <p></p> <p>100,000.00 per year</p> <p>No</p>			
089498	<a href="#">Emerging Investigator Fellowship Grant</a>	Pediatric Cancer Research Foundation		01-Jun-2024	60,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p>	<p></p> <p></p> <p><a href="mailto:jwilson@pcrf-kids.org">jwilson@pcrf-kids.org</a></p>			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 01-Jun-2024 Synopsis Emerging Investigator Fellowship Grants are designed to support Post-Doctoral Fellowships and Clinical Investigator training for emerging pediatric cancer researchers to pursue exciting research ideas. Applicant Types Funding Limit 60,000.00 per year Limited Submission No				
089497	<a href="#">Translational Research Grant</a>	Pediatric Cancer Research Foundation		01-Jun-2024	200,000 USD
	Contact Name Contact Telephone Contact Email <a href="mailto:jwilson@pcrf-kids.org">jwilson@pcrf-kids.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 01-Jun-2024 Synopsis Translational Research Grants are given to single or multi-institutional programs that involve open, cancer clinical trials or consortia, and implement new approaches to therapy. These grants support “bench to bedside” research, whose endpoint is often the planning or initiation of a clinical trial. Funding is up to \$100,00 per year, for up to 2 years. Applicant Types Funding Limit 100,000.00 per year Limited Submission No				
089495	<a href="#">Basic Research Science Grant</a>	Pediatric Cancer Research Foundation		01-Jun-2024	450,000 USD

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:jwilson@pcrf-kids.org">jwilson@pcrf-kids.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jun-2024</p> <p>Synopsis Basic Science Research Grants fund work that is the basis for childhood cancer research, helping to move science in the direction of improved treatments and eventually finding a cure. These projects help move hypothesis-driven research into the clinic by providing support for important preclinical projects. Funding is up to \$150,000 per year, for up to 3 years.</p> <p>Applicant Types</p> <p>Funding Limit 150,000.00 per year</p> <p>Limited Submission No</p>				

---

102068	<a href="#">Competitive Grant Program: Transthyretin Cardiac Amyloidosis Fellowship</a>	Pfizer Pharmaceuticals		20-Jun-2024	80,000 USD
--------	---	------------------------	--	-------------	------------

	<p>Contact Name Amanda Stein, Grant Officer</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:amanda.j.stein@pfizer.com">amanda.j.stein@pfizer.com</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 20-Jun-2024</p>				
--	--	--	--	--	--

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis Pfizer is accepting applications to support institutions with fellowship programs for Cardiologists that have a strong focus on clinical practice, research, and education to further the understanding of transthyretin cardiac amyloidosis. Grant funding is available to support one fellow for up to a year at \$80,000.</p> <p>Applicant Types</p> <p>Funding Limit 80,000.00 maximum</p> <p>Limited Submission No</p>				
125033	<a href="#">Competitive Grant Program: Quality Improvement Grants to Support Development of Cardiac Amyloid Centers</a>	Pfizer Pharmaceuticals		03-Jun-2024	50,000 USD
	<p>Contact Name Amanda Stein, Grant Officer</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:amanda.j.stein@pfizer.com">amanda.j.stein@pfizer.com</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 03-Jun-2024</p> <p>Synopsis Pfizer is issuing this Request for Proposals (RFP) to support the development of emerging cardiac amyloid centers through funding healthcare quality improvement initiatives in areas of higher need. Individual projects requesting up to \$50,000 will be considered.</p> <p>Applicant Types</p> <p>Funding Limit 50,000.00 maximum</p> <p>Limited Submission No</p>				
035362	<a href="#">PCF Challenge Award</a>	Prostate Cancer Foundation		08-Apr-2024 [LOI/Pre-App]	1,000,000 USD
	Contact Name				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 310-570-4700</p> <p>Contact Email <a href="mailto:applications@pcf.org">applications@pcf.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 17-Jun-2024</p> <p>Synopsis The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Team Science Applications for PCF Challenge Awards for novel investigator-initiated clinical investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world.</p> <p>Applicant Types</p> <p>Funding Limit 1,000,000.00 maximum</p> <p>Limited Submission No</p>				
070888	<a href="#">RPB Stein Innovation Awards</a>	Research to Prevent Blindness		15-Jun-2024	300,000 USD
	<p>Contact Name Pattie Moran</p> <p>Contact Telephone 646-892-9566</p> <p>Contact Email <a href="mailto:pmoran@rpbusa.org">pmoran@rpbusa.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jun-2024 , 01-Jul-2024</p> <p>Synopsis The RPB Stein Innovation (SI) Awards provide funds to two groups of researchers, both with a common goal of understanding the visual system and the diseases that compromise its function. These SI Awards are intended to provide seed money to proposed high-risk/high-gain vision science research which is innovative, cutting-edge, and demonstrates out-of-the-box thinking.</p> <p>Applicant Types</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	300,000.00 maximum			
	Limited Submission	No			
006942	<a href="#">Career Development Awards</a>	Research to Prevent Blindness		15-Jun-2024 [LOI/Pre-App]	350,000 USD
	Contact Name	Pattie Moran, Director of Grants Administration			
	Contact Telephone	646-892-9566			
	Contact Email	<a href="mailto:pmoran@rpbusa.org">pmoran@rpbusa.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Jun-2024 [LOI/Pre-App], 01-Jul-2024			
	Synopsis	The RPB Career Development Award will not have a specific focus and is open to any topic within vision research. Candidates (MDs, PhDs, or MD/PhDs) must have primary appointments in ophthalmology with academic positions up to and including Assistant Professor. Candidate's first full-time ophthalmology faculty appointment must have been within three years of the application deadline. Awardees will be required to expend the award within four years if granted the full \$350,000. Otherwise, the awardee is required to expend the initial \$150,000 within three years.			
	Applicant Types				
	Funding Limit	350,000.00 maximum			
	Limited Submission	Yes			
070892	<a href="#">RPB International Research Collaborators Award</a>	Research to Prevent Blindness		15-Jun-2024 [LOI/Pre-App]	75,000 USD
	Contact Name	Pattie Moran			
	Contact Telephone	646-892-9566			
	Contact Email	<a href="mailto:pmoran@rpbusa.org">pmoran@rpbusa.org</a>			



## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jun-2024 [LOI/Pre-App], 01-Jul-2024</p> <p>Synopsis The RPB International Research Collaborators Award promotes international collaborations through which collaborating researchers in the U.S. and outside the U.S. gain new knowledge and skills. These international collaborations have the potential to accelerate the development of treatments for blinding disorders, positively affecting large populations worldwide for years to come. This award of up to \$75,000 is available to researchers from any institution of higher education in the United States. A three- to six-month stay in the other country is expected by each researcher, with a minimum stay of three months.</p> <p>Applicant Types</p> <p>Funding Limit 75,000.00 maximum</p> <p>Limited Submission Yes</p>				
006943	<a href="#">Medical Student Fellowships</a>	Research to Prevent Blindness		15-Jun-2024 [LOI/Pre-App]	30,000 USD
	<p>Contact Name Pattie Moran</p> <p>Contact Telephone 646-892-9566</p> <p>Contact Email <a href="mailto:pmoran@rpbusa.org">pmoran@rpbusa.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jun-2024 [LOI/Pre-App], 01-Jul-2024</p> <p>Synopsis The Medical Student Eye Research Fellowships allow gifted students to take a year off from allopathic or osteopathic medical school and devote time to the pursuit of a research project within an RPB-supported department of ophthalmology. Research to Prevent Blindness (RPB) is partnering with the American Osteopathic Colleges of Ophthalmology &amp; Otolaryngology-Head and Neck Surgery Foundation (AOCOO-HNS) to offer one (1) award</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>specifically targeted to a student of osteopathic medicine. The remaining Fellowships, targeted to students of allopathic medicine, will not have a specific discipline criteria or scientific focus and will be open to any topic within vision research.</p> <p>Applicant Types</p> <p>Funding Limit 30,000.00 see detail</p> <p>Limited Submission Yes</p>				
093261	<a href="#">Fellowship Training Award</a>	Rheumatology Research Foundation		03-Jun-2024	150,000 USD
	<p>Contact Name</p> <p>Contact Telephone 404-365-1373</p> <p>Contact Email <a href="mailto:foundation@rheumatology.org">foundation@rheumatology.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 03-Jun-2024</p> <p>Synopsis The Amgen Fellowship Training Award helps ensure an adequate supply of (a) rheumatology providers meeting the needs of children and adults with rheumatic diseases in all areas of the country and (b) rheumatology educators and investigators to train future clinicians and advance research in rheumatic and musculoskeletal diseases. The Fellowship Training Award may be used to support the salary of any fellow in an ACGME-accredited rheumatology fellowship training program.</p> <p>Applicant Types</p> <p>Funding Limit 50,000.00 per year</p> <p>Limited Submission Yes</p>				
027718	<a href="#">International Exchanges Scheme</a>	Royal Society		05-Jun-2024	15,120 USD
	Contact Name				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   +44 20 7451 2666</p> <p>Contact Email   <a href="mailto:international.exchanges@royalsociety.org">international.exchanges@royalsociety.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2024 , 26-Sep-2024</p> <p>Synopsis   These schemes are for scientists based in the UK who want to stimulate collaborations with leading scientists overseas through either a one-off visit or bilateral travel.</p> <p>Applicant Types  </p> <p>Funding Limit   12,000.00 maximum</p> <p>Limited Submission   No</p>				

---

000657	<a href="#">Visiting Scholar Program</a>	Sage (Russell) Foundation		25-Jun-2024	Not Specified
--------	--	---------------------------	--	-------------	---------------

---

Contact Name	
Contact Telephone	212-750-6000
Contact Email	<a href="mailto:programs@rsage.org">programs@rsage.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	25-Jun-2024
Synopsis	The Russell Sage Foundation’s Visiting Scholars Program provides a unique opportunity for select scholars in the social, economic, political and behavioral sciences to pursue their data analysis and writing while in residence at the foundation’s headquarters in New York City. The foundation annually awards 15 to 17 Visiting Scholar fellowships. Applicants must be at least two years beyond the Ph.D. when applying, and if selected, typically work on projects related to the foundation’s core programs (Behavioral Science and Decision Making in Context; Future of Work; Race, Ethnicity and Immigration; Social, Political and Economic Inequality) and special initiatives.

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																																																												
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%;">Applicant Types</td> <td colspan="5"></td> </tr> <tr> <td>Funding Limit</td> <td colspan="5">0.00 see detail</td> </tr> <tr> <td>Limited Submission</td> <td colspan="5">No</td> </tr> </table>						Applicant Types						Funding Limit	0.00 see detail					Limited Submission	No																																														
Applicant Types																																																																	
Funding Limit	0.00 see detail																																																																
Limited Submission	No																																																																
049628	<a href="#">Stanley Smith Horticultural Trust Grants</a>	Smith (Stanley) Horticultural Trust		14-Jun-2024 [LOI/Pre-App]	25,000 USD																																																												
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%;">Contact Name</td> <td colspan="5"></td> </tr> <tr> <td>Contact Telephone</td> <td colspan="5">415-332-0166</td> </tr> <tr> <td>Contact Email</td> <td colspan="5"><a href="mailto:grants@smithct.org">grants@smithct.org</a></td> </tr> <tr> <td>Sponsor Website</td> <td colspan="5"><a href="#">Link to sponsor website</a></td> </tr> <tr> <td>Program URL</td> <td colspan="5"><a href="#">Link to program URL</a></td> </tr> <tr> <td>Deadline Dates (ALL)</td> <td colspan="5">14-Jun-2024 [LOI/Pre-App], 15-Jul-2024</td> </tr> <tr> <td>Synopsis</td> <td colspan="5">The Stanley Smith Horticultural Trust supports education and research in ornamental horticulture through grants to botanical gardens, arboreta, universities, and other charitable organizations strongly-aligned with its funding interests. The maximum grant awarded by the Trust is \$25,000, however, grants normally do not exceed \$20,000.</td> </tr> <tr> <td>Applicant Types</td> <td colspan="5"></td> </tr> <tr> <td>Funding Limit</td> <td colspan="5">25,000.00 maximum</td> </tr> <tr> <td>Limited Submission</td> <td colspan="5">Yes</td> </tr> </table>						Contact Name						Contact Telephone	415-332-0166					Contact Email	<a href="mailto:grants@smithct.org">grants@smithct.org</a>					Sponsor Website	<a href="#">Link to sponsor website</a>					Program URL	<a href="#">Link to program URL</a>					Deadline Dates (ALL)	14-Jun-2024 [LOI/Pre-App], 15-Jul-2024					Synopsis	The Stanley Smith Horticultural Trust supports education and research in ornamental horticulture through grants to botanical gardens, arboreta, universities, and other charitable organizations strongly-aligned with its funding interests. The maximum grant awarded by the Trust is \$25,000, however, grants normally do not exceed \$20,000.					Applicant Types						Funding Limit	25,000.00 maximum					Limited Submission	Yes				
Contact Name																																																																	
Contact Telephone	415-332-0166																																																																
Contact Email	<a href="mailto:grants@smithct.org">grants@smithct.org</a>																																																																
Sponsor Website	<a href="#">Link to sponsor website</a>																																																																
Program URL	<a href="#">Link to program URL</a>																																																																
Deadline Dates (ALL)	14-Jun-2024 [LOI/Pre-App], 15-Jul-2024																																																																
Synopsis	The Stanley Smith Horticultural Trust supports education and research in ornamental horticulture through grants to botanical gardens, arboreta, universities, and other charitable organizations strongly-aligned with its funding interests. The maximum grant awarded by the Trust is \$25,000, however, grants normally do not exceed \$20,000.																																																																
Applicant Types																																																																	
Funding Limit	25,000.00 maximum																																																																
Limited Submission	Yes																																																																
095262	<a href="#">Humanitarian Award</a>	Society for Industrial & Organizational Psychology (SIOP)		30-Jun-2024	1,500 USD																																																												
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%;">Contact Name</td> <td colspan="5"></td> </tr> <tr> <td>Contact Telephone</td> <td colspan="5">419-353-0032</td> </tr> <tr> <td>Contact Email</td> <td colspan="5"><a href="mailto:SIOP@siop.org">SIOP@siop.org</a></td> </tr> <tr> <td>Sponsor Website</td> <td colspan="5"><a href="#">Link to sponsor website</a></td> </tr> </table>						Contact Name						Contact Telephone	419-353-0032					Contact Email	<a href="mailto:SIOP@siop.org">SIOP@siop.org</a>					Sponsor Website	<a href="#">Link to sponsor website</a>																																								
Contact Name																																																																	
Contact Telephone	419-353-0032																																																																
Contact Email	<a href="mailto:SIOP@siop.org">SIOP@siop.org</a>																																																																
Sponsor Website	<a href="#">Link to sponsor website</a>																																																																

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	30-Jun-2024
Synopsis	The SIOP Humanitarian Award is given for sustained, significant, and outstanding humanitarian contributions related to I-O psychology. The recipient of the award is given a plaque and a cash prize of \$1,500 (or a donation of the same amount donated to the charity/foundation of the recipient's choice).
Applicant Types	
Funding Limit	1,500.00 see detail
Limited Submission	No

066849	<a href="#">Mentored Clinical Scientist Research Career Development Award (K08)</a>	Society for Vascular Surgery		12-Jun-2024	Not Specified
--------	---	------------------------------	--	-------------	---------------

Contact Name	
Contact Telephone	800-258-7188
Contact Email	<a href="mailto:svsfoundation@vascularsociety.org">svsfoundation@vascularsociety.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	12-Jun-2024 , 12-Jul-2024 , 12-Oct-2024 , 12-Nov-2024
Synopsis	The Mentored Clinical Scientist Research Career Development Award (K08) will prepare clinically trained individuals for careers that have a significant impact on the health-related research needs of the Nation. This program provides support and protected time for an intensive, supervised research career development experience in the fields of biomedical, behavioral, or clinical research, including translational research.
Applicant Types	
Funding Limit	50,000.00 per year
Limited Submission	No

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
091553	<a href="#">Student Scholarship Program</a>	Society of Diagnostic Medical Sonography Foundation		30-Jun-2024	2,500 USD
	Contact Name				
	Contact Telephone	214-473-8057			
	Contact Email	<a href="mailto:scholarship@sdmsfoundation.org">scholarship@sdmsfoundation.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	30-Jun-2024 , 31-Dec-2024			
	Synopsis	The SDMS Foundation Sonography Student Scholarship provides provides a \$2,500 scholarship to a deserving sonography student who has been accepted or is currently enrolled in an educational program in diagnostic medical sonography or cardiovascular technology which has been accredited by the Commission on Accreditation of Allied Health Educational Programs (CAAHEP).			
	Applicant Types				
	Funding Limit	2,500.00 maximum			
	Limited Submission	No			
067272	<a href="#">Grants Program</a>	Sorenson Legacy Foundation		01-Jun-2024	Not Specified
	Contact Name	Lisa Meiling			
	Contact Telephone	801-461-9700			
	Contact Email	<a href="mailto:lisa@sorensonlegacyfoundation.org">lisa@sorensonlegacyfoundation.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2024 , 01-Sep-2024			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Sorenson Legacy Foundation was created to improve the lives of others and the world in which we live. Founded by the late biotechnology pioneer and entrepreneur James LeVoy Sorenson and his wife, education philanthropist Beverley Taylor Sorenson, the foundation provides support for a wide range of endeavors, from community development and education to health care, scientific and artistic pursuits.			
	Applicant Types				
	Funding Limit	0.00 not provided			
	Limited Submission	No			
003009	<a href="#">Vatican Film Library Mellon Fellowship Program</a>	Vatican Microfilm Library		01-Jun-2024	4,500 USD
	Contact Name				
	Contact Telephone	314-977-3096			
	Contact Email	<a href="mailto:vfl@slu.edu">vfl@slu.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2024 , 01-Oct-2024			
	Synopsis	Short-term research fellowships are available for periods between two and eight weeks in length to support research utilizing the collections of the Vatican Film Library. Applications must demonstrate need to consult the primary source materials of the library. All topics will be considered that are served by the collections, such as history, philosophy, theology, literature, art, science, paleography, codicology, illumination, text editing, library history, etc.			
	Applicant Types				
	Funding Limit	2,250.00 per month			
	Limited Submission	No			
009730	<a href="#">Grants-in-Aid</a>	Whitehall Foundation, Inc.		15-Apr-2024 [LOI/Pre-App]	30,000 USD

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 561-655-4474</p> <p>Contact Email <a href="mailto:email@whitehall.org">email@whitehall.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Apr-2024 [LOI/Pre-App], 01-Jun-2024 , 02-Sep-2024 , 01-Oct-2024 [LOI/Pre-App]</p> <p>Synopsis The Whitehall Foundation, through its program of grants and grants-in-aid, assists scholarly research in the life sciences. It is the Foundation's policy to assist those dynamic areas of basic biological research that are not heavily supported by Federal Agencies or other foundations with specialized missions. The Foundation is currently interested in basic research in neurobiology. The Grants-in-Aid program is designed for researchers at the assistant professor level who experience difficulty in competing for research funds because they have not yet become firmly established. Grants-in-Aid can also be made to senior scientists. All applications will be judged on the scientific merit and innovative aspects of the proposal, as well as on past performance and evidence of the applicant's continued productivity. Grants-in-Aid are awarded for a one-year period and do not exceed \$30,000.</p> <p>Applicant Types</p> <p>Funding Limit 30,000.00 maximum</p> <p>Limited Submission No</p>				
001018	<a href="#">Research Grants</a>	Whitehall Foundation, Inc.		15-Apr-2024 [LOI/Pre-App]	300,000 USD
	<p>Contact Name</p> <p>Contact Telephone 561-655-4474</p> <p>Contact Email <a href="mailto:email@whitehall.org">email@whitehall.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p>				



## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   15-Apr-2024 [LOI/Pre-App], 03-Jun-2024 , 01-Sep-2024 , 01-Oct-2024 [LOI/Pre-App]</p> <p>Synopsis   The Whitehall Foundation is focused exclusively on assisting basic research in vertebrate (excluding clinical) and invertebrate neurobiology. They offer research grants to established scientists of all ages working at accredited institutions in the United States. Research grants of up to three years are available. A renewal grant with a maximum of two years is possible, but it will be awarded on a competitive basis.</p> <p>Applicant Types  </p> <p>Funding Limit   100,000.00 per year</p> <p>Limited Submission   No</p>				
071378	<a href="#">Norman Borlaug Award for Field Research and Application</a>	World Food Prize Foundation		15-Jun-2024	10,000 USD
	<p>Contact Name   Ms.Ellen Franzenburg, Director of Secretariat Operations</p> <p>Contact Telephone   515-245-3783</p> <p>Contact Email   <a href="mailto:efranzenburg@worldfoodprize.org">efranzenburg@worldfoodprize.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-Jun-2024</p> <p>Synopsis   The Norman Borlaug Award for Field Research and Application is presented annually in the amount of \$10,000 to recognize exceptional, science-based achievement in international agriculture and food production by an individual under 40 who has clearly demonstrated intellectual courage, stamina, and determination in the fight to eliminate global hunger and poverty.</p> <p>Applicant Types  </p> <p>Funding Limit   10,000.00 maximum</p> <p>Limited Submission   No</p>				
024760	<a href="#">Sustainability Prize</a>	Zayed Sustainability Prize		23-Jun-2024	Not Specified

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	 +971 2 653 3333 <a href="mailto:info@zayedsustainabilityprize.com">info@zayedsustainabilityprize.com</a> <a href="#">Link to sponsor website</a> <a href="#">Link to program URL</a> 23-Jun-2024
Synopsis	The Zayed Sustainability Prize recognises nonprofit organisations (NPOs), small and medium sized enterprises (SMEs) and high schools for their impactful, innovative and inspiring sustainable solutions across the categories of Health, Food, Energy, Water and Global High Schools. In response to the pressing climate crisis, and to further support the UAE’s efforts to accelerate practical solutions needed to drive climate action and uplift vulnerable communities around the world, the Prize has increased its funds from US \$3.6 million to US \$5.9 million. The Prize will reward US \$1 million to each winner in the organisational categories of Health, Food, Energy, Water and Climate Action. Within the Global High Schools category, which is split into six world regions, each school can claim up to US \$150,000 to start or further expand their project. The six world regions of the Global High Schools category are The Americas, Europe & Central Asia, Middle East & North Africa, Sub-Saharan Africa, South Asia, and East Asia & Pacific. The most recent Zayed Sustainability Prize winners were recognised at an Awards Ceremony held during COP28 UAE.
Applicant Types Funding Limit Limited Submission	   0.00 see detail No